


Patrick J. McCarthy
Tel 202.533.2386
Fax 202.331.3101
mccarthyp@gtlaw.com

March 27, 2018

VIA HAND DELIVERY

The Honorable Lisa Barton
Secretary
U.S. INTERNATIONAL TRADE COMMISSION
500 E Street, S.W., Room 112
Washington, D.C. 20436



Re: In the Matter of Certain Strontium-Rubidium Radioisotope Infusion Systems, and Components Thereof Including Generators
U.S. ITC Inv. No. 337-TA-

Dear Secretary Barton,

Enclosed for filing on behalf of Complainant Bracco Diagnostics Inc. ("Bracco" or "Complainant") against the proposed Respondents Jubilant DraxImage Inc., Jubilant Pharma Limited, and Jubilant Life Sciences (collectively, the "Proposed Respondents") are documents in support of Bracco's request that the Commission commence an investigation pursuant to Section 337 of the Tariff Act of 1930, as amended. A request for confidential treatment of Confidential Exhibit 22 and the Complaint is included with this letter.

Accordingly, Complainant submits the following documents for filing:

1. An original and eight (8) paper copies of the verified Non-Confidential Complaint and the Public Interest Statement. (19 CFR § § 210.8(a)(1)(i), 210.8(b).)
2. An original and eight (8) paper copies of the verified Confidential Complaint and the Public Interest Statement. (19 CFR § § 210.8(a)(1)(i), 210.8(b).)
3. One (1) copy, on CD of the accompanying Non-Confidential exhibits 1-21 and 23-28 and public version of Confidential Exhibit 22. (19 CFR §210.8(a)(1)(i).)
4. One (1) copy, on CD with Confidential Exhibit 22. (19 CFR §§ 201.6(c).)
5. One (1) copy, on CD of Physical Exhibit 1. (19 CFR §210.8(a)(1)(i).)
6. Six (6) additional copies of the verified Non-Confidential Complaint and the Public Interest Statement and three (3) CDs of the Non-Confidential exhibits, one (1) of each for service upon each of the Proposed Respondents. (19 CFR §§ 210.8(a)(1)(iii) and 210.11(a).)

ALBANY
AMSTERDAM
ATLANTA
AUSTIN
BOSTON
CHICAGO
DALLAS
DELAWARE
DENVER
FORT LAUDERDALE
HOUSTON
LAS VEGAS
LONDON*
LOS ANGELES
MEXICO CITY*
MIAMI
MILAN*
NEW JERSEY
NEW YORK
ORANGE COUNTY
ORLANDO
PALM BEACH COUNTY
PHILADELPHIA
PHOENIX
ROME*
SACRAMENTO
SAN FRANCISCO
SEOUL*
SHANGHAI
SILICON VALLEY
TALLAHASSEE
TAMPA
TEL AVIV*
TYSONS CORNER
WARSAW-
WASHINGTON, D.C.
WHITE PLAINS


* OPERATES AS GREENBERG TRAUIG/MAHER LLP
* OPERATES AS GREENBERG TRAUIG, S.C.
* A BRANCH OF GREENBERG TRAUIG, P.A. FLORIDA, USA
* OPERATES AS GREENBERG TRAUIG GRZESIAK LLP
* OPERATES AS GREENBERG TRAUIG LLP FOREIGN LEGAL CONSULTANT OFFICE
** STRATEGIC ALLIANCE

Honorable Secretary Barton
March 27, 2018
Page 2

7. Three (3) CDs of Confidential Exhibit 22, one (1) of each for service upon each of the Proposed Respondents. (19 CFR §§ 210.8(a)(1)(iii) and 210.11(a).)
8. Three (3) CDs of Physical Exhibit 1, one (1) of each for service upon each of the Proposed Respondents. (19 CFR §§ 210.8(a)(1)(iii) and 210.11(a).)
9. Certified copies of United States Patent Nos. 9,814,826 (“the ‘826 Patent”); 9,750,869 (“the ‘869 Patent”); and 9,750,870 (“the ‘870 Patent”), included in the Complaint as Exhibits, 1, 3, and 5. (19 CFR §§ 210.8(a)(1)(iii) and 210.12(a)(9)(i).)
10. Certified copies of the assignments for the ‘826, ‘869, and ‘870 patents included in the Complaint as Exhibits 2, 4, and 6. (19 CFR §§ 210.8(a)(1)(iii) and 210.12(a)(9)(ii).)
11. Certified copies of the prosecution histories of the ‘826, ‘869, and ‘870 patents, included in the Complaint as Appendices 1, 3, and 5, and three (3) additional copies of each on separate CDs. (19 CFR §210.12(c)(1)).
12. Four (4) copies on separate CDs of patent and technical reference documents identified in the each of the prosecution histories of the ‘826, ‘869, and ‘870 patents, included in the Complaint as Appendices 2, 4, and 6. (19 CFR §210.12(c)(2)).

Thank you for your attention to this matter. Please contact me if you have any questions.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "P. McCarthy", with a large, sweeping flourish at the end.

Patrick J. McCarthy



Patrick J. McCarthy
Tel 202.533.2386
Fax 202.331.3101
mccarthyp@gtlaw.com

March 27, 2018

VIA HAND DELIVERY

The Honorable Lisa Barton
Secretary
U.S. INTERNATIONAL TRADE COMMISSION
500 E Street, S.W., Room 112
Washington, D.C. 20436

**Re: In the Matter of Certain Strontium-Rubidium Radioisotope Infusion Systems,
and Components Thereof Including Generators
U.S. ITC Inv. No. 337-TA-**

Dear Secretary Barton,

In accordance with Commission Rules 201.6 and 210.5, Complainant Bracco Diagnostics Inc. ("Bracco") requests confidential treatment of the business information contained in the Complaint and Confidential Exhibit 22.

The information for which confidential treatment is sought is proprietary commercial information not otherwise publicly available. Specifically, these exhibits contain proprietary commercial information concerning Bracco's business records, trade secrets, processes, sales, licenses, expenditures and/or other information of commercial value.

The information described above qualifies as confidential business information pursuant to Commission Rule 201.6(a) because:

1. It is not available to the public;
2. unauthorized disclosure of such information could cause substantial harm to the competitive position of Bracco and/or a third party;
3. Its disclosure could impair the Commission's ability to obtain information necessary to perform its statutory function.


ALBANY
AMSTERDAM
ATLANTA
AUSTIN
BOSTON
CHICAGO
DALLAS
DELAWARE
DENVER
FORT LAUDERDALE
HOUSTON
LAS VEGAS
LONDON*
LOS ANGELES
MEXICO CITY*
MIAMI
MILAN*
NEW JERSEY
NEW YORK
ORANGE COUNTY
ORLANDO
PALM BEACH COUNTY
PHILADELPHIA
PHOENIX
ROME*
SACRAMENTO
SAN FRANCISCO
SEOUL*
SHANGHAI
SILICON VALLEY
TALLAHASSEE
TAMPA
TEL AVIV*
TYSONS CORNER
WARSAW-
WASHINGTON, D.C.
WHITE PLAINS

* OPERATES AS GREENBERG TRAUIG MAHER LLP
* OPERATES AS GREENBERG TRAUIG, S.C.
* A BRANCH OF GREENBERG TRAUIG, P.A. FLORIDA, USA
* OPERATES AS GREENBERG TRAUIG GRZESIAK sp. z o.o.
* OPERATES AS GREENBERG TRAUIG LLP FOREIGN LEGAL CONSULTANT OFFICE
** STRATEGIC ALLIANCE

Honorable Secretary Barton
March 27, 2018
Page 2

If you have any questions, please do not hesitate to contact me at (202) 533-2386.

Sincerely,

A handwritten signature in black ink, appearing to read 'P. J. McCarthy', with a large, sweeping flourish at the end.

Patrick J. McCarthy

**UNITED STATES INTERNATIONAL TRADE COMMISSION
WASHINGTON, D.C.**

In the Matter of

**CERTAIN STRONTIUM-RUBIDIUM
RADIOISOTOPE INFUSION
SYSTEMS, AND COMPONENTS
THEREOF INCLUDING
GENERATORS**

Investigation No. 337-TA-_____

STATEMENT REGARDING THE PUBLIC INTEREST

Complainant Bracco Diagnostics Inc. (“Bracco” or “Complainant”) submits this public-interest statement pursuant to Commission Rule 210.8(b), 19 C.F.R. § 210.8(b). As discussed below, the remedies sought against Jubilant DraxImage Inc., Jubilant Pharma Limited, and Jubilant Life Sciences (collectively, the “Proposed Respondents” or “Jubilant”) will not have an adverse effect on public health and welfare in the United States, competitive conditions in the United States economy, the production of competitive articles in the United States, or U.S. consumers.

The products at issue in this Investigation are strontium-rubidium radioisotope infusion systems and component thereof that infringe one or more claims of the Asserted Patents: U.S. Patent No. 9,814,826 (“the ’826 patent”); U.S. Patent No. 9,750,869 (“the ’869 patent”); and U.S. Patent No. 9,750,870 (“the ’870 patent”). Bracco seeks a limited exclusion order barring from entry into the United States all infringing strontium-rubidium radioisotope infusion systems and components thereof sold for importation, imported, or sold within the United States after importation by the Proposed Respondents. Bracco also seeks a cease and desist order prohibiting the Proposed Respondents from engaging in the unlawful sale for importation into the United

States, importation into the United States, and/or the sale within the United States after importation of infringing strontium-rubidium radioisotope infusion systems and components thereof. These requested remedies do not and will not adversely affect the public interest.

I. HOW THE ARTICLES SUBJECT TO THE PROPOSED REMEDIAL ORDERS ARE USED IN THE UNITED STATES

The Accused Product is a strontium-rubidium radioisotope infusion system, including rubidium generator, sold under the tradename Ruby-Fill[®]. Ruby-Fill[®] and/or components thereof are imported into the United States and/or sold in the United States after importation, at least, by the Proposed Respondents. The Ruby-Fill[®] system is used in the medical field to produce rubidium Rb 82 chloride injection for intravenous administration. Rubidium Rb 82 chloride injection is indicated by the U.S. Food and Drug Administration (“FDA”) for Positron Emission Tomography (“PET”) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease. The resulting images allow a physician to evaluate the blood flow (perfusion) through the coronary arteries to the heart muscle, and thus diagnose whether any heart disease exists.

II. IDENTIFY AND PUBLIC HEALTH, SAFETY, OR WELFARE CONCERNS RELATING TO THE REQUESTED REMEDIAL ORDERS

The ITC has made clear that the public interest rests in the protection of intellectual property rights.¹ The question with respect to public interest, then, is not whether a “balancing” of factors merely favors a remedy, but rather whether competing interests exist of so great a significance with regard to only the Accused Products that the strong public policy of protecting

¹ See, e.g., *Certain Digital Television Prods. & Certain Prods. Containing Same & Methods of Using Same*, Inv. No. 337-TA-617, Comm’n Op., at 9 (Aug. 23, 2009) (“*Digital TV Products*”).

intellectual property rights must give way. As shown below, any public interest concerns invoked by this Investigation pales in comparison to this countervailing interest.

Issuance of the requested relief, a limited exclusion order and/or a cease and desist order will have no adverse effect on the public health, safety or welfare in the United States. Bracco's CardioGen-82[®] is the first FDA-approved radioimaging agent dedicated to cardiac PET, and is available today for patients in need of cardiac PET exams, including patients in the United States. Proposed Respondents submitted an abbreviated new drug application ("ANDA") to the U.S. Food and Drug Administration on June 18, 2010 to market a system Proposed Respondents described as the *equivalent* of Bracco's CardioGen-82[®]. Due to variations in administration rates, the FDA reclassified the ANDA application as a 505(b)(2) NDA application. However, Proposed Respondents still stated that since "both generators are systems for the production of rubidium 82, *equal utility is expected* from Ruby-Fill." Thus, an alternative system, which Proposed Respondents represented to the FDA is *equivalent* to the Ruby-Fill[®] system, is readily available to the public.

III. IDENTIFY LIKE OR DIRECTLY COMPETITIVE ARTICLES THAT COMPLAINANTS, THEIR LICENSEES, OR THIRD PARTIES MAKE WHICH COULD REPLACE THE SUBJECT ARTICLE IF THEY WERE TO BE EXCLUDED

As set out in the Complaint, Bracco manufactures CardioGen-82[®] which is like or directly competitive with the Ruby-Fill[®] system and could seamlessly replace it. Thus, any U.S. consumer with a desire to purchase or use a strontium-rubidium radioisotope infusion system can purchase or use the existing CardioGen-82[®] immediately. Proposed Respondents have a relatively small portion of the U.S. market for strontium-rubidium radioisotope infusion systems. Accordingly, Bracco would easily be able to fill the demand gap, if any, felt by the requested remedies.

IV. IDENTIFY WHETHER COMPLAINANTS, COMPLAINANTS' LICENSEES, AND/OR THIRD PARTY SUPPLIERS HAVE THE CAPACITY TO REPLACE THE VOLUME OF ARTICLES SUBJECT TO THE REQUESTED REMEDIAL ORDERS IN A COMMERCIALY REASONABLE TIME

There is no question that Bracco has the capacity to replace the volume of Accused Products subject to the requested remedial orders within a commercially reasonable time. As stated above, Proposed Respondents have a relatively low market share. Thus, there is no indication that excluding the Accused Products will harm the public interest via unmet demand.


V. STATE HOW THE REQUESTED REMEDIAL ORDER WOULD IMPACT CONSUMERS

As discussed above, even after the requested remedy is issued, customers may purchase and consumers will have access to strontium-rubidium radioisotope infusion systems, namely CardioGen-82[®]. Proposed Respondents represented to the FDA that the Accused Product (Ruby-Fill[®]) is *equivalent* to CardioGen-82[®]. Accordingly, the issuance of such relief will have no relevant public interest impact on U.S. consumers.

For the foregoing reasons, no public-interest concerns preclude the issuance of the proposed remedies against the Proposed Respondents in this matter.

Dated: March 27, 2018

By:

A handwritten signature in black ink, appearing to be 'M. Davis', written over a horizontal line.

GREENBERG TRAURIG, LLP

Mark Davis

Patrick J. McCarthy

2101 L Street, NW

Washington, DC 20037

Tel: (202) 331-3100

Email: davisma@gtlaw.com

Email: mccarthyp@gtlaw.com

Scott Bornstein

Brian J. Prew

MetLife Building

200 Park Avenue

New York, NY 10166

Tel: (212) 801-9200

Email: bornsteins@gtlaw.com

Email: prewb@gtlaw.com

Attorneys for Complainant

UNITED STATES INTERNATIONAL TRADE COMMISSION
WASHINGTON, D.C.

In the Matter of

**CERTAIN STRONTIUM-RUBIDIUM
RADIOISOTOPE INFUSION
SYSTEMS, AND COMPONENTS
THEREOF INCLUDING
GENERATORS**

Investigation No. 337-TA-_____

**COMPLAINT UNDER SECTION 337
OF THE TARIFF ACT OF 1930, AS AMENDED**

COMPLAINANT:

Bracco Diagnostics Inc.
259 Prospect Plains Road
Building H,
Monroe Township, NJ 08831
Telephone: (800) 631-5245

COUNSEL FOR COMPLAINANT:

GREENBERG TRAURIG, LLP
Scott J. Bornstein
Brian J. Prew
MetLife Building
200 Park Avenue
New York, NY 10166
Telephone: (212) 801-9200

Mark G. Davis
Patrick J. McCarthy
2101 L Street, N.W., Suite 1000
Washington, D.C. 20037
Telephone: (202) 331-3100

PROPOSED RESPONDENTS:

Jubilant DraxImage Inc.
16751 TransCanada Highway
Kirkland, Québec, Canada
H9H 4J4

Jubilant Pharma Limited
6 Temasek Boulevard, #20-06 Suntec City
Tower Four,
Singapore 038986

Jubilant Life Sciences
Plot 1-A Sector 16-A Institutional Area
Noida, Uttar Pradesh, 201301 India

TABLE OF CONTENTS

I.	Introduction.....	1
	A. Complainant.....	2
	B. Proposed Respondents	4
II.	Technology and Products-At-Issue.....	6
	A. Bracco’s Products	6
	B. Jubilant’s Ruby-Fill Is Manufactured And/Or Imported by Jubilant.....	9
III.	The Asserted Patents and Non-Technical Description	11
	A. The ’826 Patent.....	11
	B. The ’869 Patent.....	12
	C. The ’870 Patent.....	13
	D. Foreign Patents and Applications Corresponding to the Asserted Patents	14
	E. Licensees to the Asserted Patents	14
IV.	Unlawful and Unfair Acts of the Proposed Respondents	14
V.	Specific Acts of Unfair Importation and Sale.....	16
VI.	Harmonized Tariff Schedule Information.....	19
VII.	Related Litigation.....	19
VIII.	Domestic Industry	19
	A. The Economic Prong.....	19
	B. The Technical Prong	21
IX.	Request for Relief.....	22

EXHIBIT LIST

Exhibit Number	Description
Exhibit No. 1	Certified Copy of U.S. Patent No. 9,814,826
Exhibit No. 2	Certified Copy of the assignment for U.S. Patent No. 9,814,826
Exhibit No. 3	Certified Copy of U.S. Patent No. 9,750,869
Exhibit No. 4	Certified Copy of the assignment for U.S. Patent No. 9,750,869
Exhibit No. 5	Certified Copy of U.S. Patent No. 9,750,870
Exhibit No. 6	Certified Copy of the assignment for U.S. Patent No. 9,750,870
Exhibit No. 7	Westlaw Company Investigator Report for Jubilant DraxImage Inc.
Exhibit No. 8	Westlaw Company Investigator Report for Jubilant Pharma Limited
Exhibit No. 9	Jubilant DraxImage website
Exhibit No. 10	Jubilant DraxImage Oct. 3, 2016 press release
Exhibit No. 11	May 28, 2005 Bracco Press Release
Exhibit No. 12	Prescribing Information for Ruby-Fill®
Exhibit No. 13	January 18, 2018 Earnings Call summary by Prabhudas Lilladher
Exhibit No. 14	ASNC 2017 Final Program
Exhibit No. 15	List of Foreign Counterparts to the Asserted Patents
Exhibit No. 16	Mo-99 2017 Technical Program, Sept. 10-13, 2017
Exhibit No. 17	Claim Chart showing infringement of U.S. Patent No. 9,814,826
Exhibit No. 18	Claim Chart showing infringement of U.S. Patent No. 9,750,869
Exhibit No. 19	Claim Chart showing infringement of U.S. Patent No. 9,750,870
Exhibit No. 20	FDA Approval Package for Application No. 202153
Exhibit No. 21	Ruby-Fill® User Manual
Exhibit No. 22	Declaration of Ken Troger (Confidential)
Exhibit No. 23	Domestic Industry chart regarding U.S. Patent No. 9,814,826
Exhibit No. 24	Domestic Industry chart regarding U.S. Patent No. 9,750,869
Exhibit No. 25	Domestic Industry chart regarding U.S. Patent No. 9,750,870
Exhibit No. 26	INTENTIONALLY LEFT BLANK
Exhibit No. 27	INTENTIONALLY LEFT BLANK
Exhibit No. 28	Westlaw Company Investigator Report for Jubilant Life Sciences

PHYSICAL EXHIBIT LIST

Physical Exhibit Number	Description
Physical Exhibit No. 1	Ruby-Fill® video file, previously available at http://www.draximage.com/

APPENDICES

Appendix Number	Description
Appendix No. 1	Certified copy of Prosecution History of U.S. Patent No. 9,814,826
Appendix No. 2	Cited references for Prosecution History of U.S. Patent No. 9,814,826
Appendix No. 3	Certified copy of Prosecution History of U.S. Patent No. 9,750,869
Appendix No. 4	Cited references for Prosecution History of U.S. Patent No. 9,750,869
Appendix No. 5	Certified copy of Prosecution History of U.S. Patent No. 9,750,870
Appendix No. 6	Cited references for Prosecution History of U.S. Patent No. 9,750,870

I. Introduction

1. This Complaint is filed by Bracco Diagnostics Inc. (“Bracco” or “Complainant”), pursuant to Section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. § 1337 (“Section 1337”), against the proposed Respondents Jubilant DraxImage Inc., Jubilant Pharma Limited, and Jubilant Life Sciences (collectively, the “Proposed Respondents” or “Jubilant”). Bracco respectfully requests that the United States International Trade Commission (the “Commission”) institute an investigation relating to the unlawful sale for importation into the United States, importation into the United States, and/or the sale within the United States after importation of certain strontium-rubidium radioisotope infusion systems and/or components thereof, including but not limited to rubidium-82 generators.

2. The Proposed Respondents have engaged in unfair acts in violation of Section 337(a)(1)(B) through and in connection with the unlicensed importation into the United States, sale for importation, and/or sale within the United States after importation of the Proposed Respondent’s strontium-rubidium radioisotope infusion systems and components thereof, that infringe one or more of the following U.S. patents owned by Bracco (collectively, “the Asserted Patents”): 9,814,826 (“the ’826 patent”) (Exhibit No. 1); 9,750,869 (“the ’869 patent”) (Exhibit No. 3); and 9,750,870 (“the ’870 patent”) (Exhibit No. 5). The non-exclusive list of claims that the Proposed Respondents infringe, and/or induce or contribute to the infringement of is as follows:

Infringing Product	Asserted Claims of the ’826 Patent	Asserted Claims of the ’869 Patent	Asserted Claims of the ’870 Patents
Ruby-Fill®	1, 2, 3, 5, 9, 10, 11, 12, 13, 14, 17, 18, 19, 26, and 28	1, 2, 3, 4, 5, 8, 14, 24, 27, 28, 29, and 30	1, 2, 8, 9, 10, 11, 12, 13, 16, 17, 22, and 27

3. The Proposed Respondents have violated and continue to violate Section 337 to the detriment of the domestic industry of Bracco that exists or is in the process of being established in the United States relating to the Asserted Patents.

4. To remedy the Proposed Respondents' continuing and unlawful violation of Section 337, Bracco hereby states pursuant to Commission Rule 210.12(a)(11) that it seeks, as permanent relief, a limited exclusion order, pursuant to 19 U.S.C. § 1337(d), barring from entry into the United States all infringing strontium-rubidium radioisotope infusion systems and components thereof sold for importation, imported, or sold within the United States after importation by the Proposed Respondents. Bracco also seeks cease and desist orders, pursuant to 19 U.S.C. § 1337(f), prohibiting the Proposed Respondents from engaging in the unlawful sale for importation into the United States, importation into the United States, and/or the sale within the United States after importation of infringing strontium-rubidium radioisotope infusion systems and components thereof that infringe, induce or contribute to the infringement of one or more claims of the Asserted Patents. Further, Bracco requests that the Commission impose a bond upon Proposed Respondents' importation of infringing strontium-rubidium radioisotope infusion systems and components thereof during the 60-day Presidential review period, pursuant to 19 U.S.C. § 1337(j), to prevent further injury to the domestic industry that exists or is in the process of being established in the United States relating to the Asserted Patents.

A. Complainant

5. Bracco Diagnostics Inc. is a corporation organized and existing under the laws of the State of Delaware, with a principal place of business at 259 Prospect Plains Road, Monroe Township, New Jersey 08831.

6. Bracco Diagnostics Inc., the U.S.-based subsidiary of Bracco Imaging SpA, was established in 1994 and has since become a leader in the U.S. in innovative contrast imaging agents. Bracco Diagnostics Inc., with headquarters and research offices in Monroe Township, New Jersey, offers a product and solution portfolio for all key diagnostic imaging modalities: X-Ray Imaging (including Computed Tomography, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers.

7. Bracco Diagnostics Inc. is committed to the discovery, development, manufacturing and marketing of imaging agents and solutions aimed at providing quality solutions in terms of diagnostic efficacy, patient safety and cost effectiveness.

8. Bracco's innovative and impressive product portfolio includes Bracco's nuclear medicine and radiopharmaceuticals, such as strontium-rubidium radioisotope infusion systems and rubidium-82 generators that are used with such systems. Bracco's strontium-rubidium radioisotope infusion system is sold under the trade name CardioGen-82[®].

9. CardioGen-82[®] is a closed system used to produce rubidium Rb 82 chloride injection for intravenous administration. Rubidium Rb 82 chloride injection is indicated by the U.S. Food and Drug Administration ("FDA") for Positron Emission Tomography ("PET") imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease. The resulting images allow a physician to evaluate the blood flow (perfusion) through the coronary arteries to the heart muscle, and thus diagnose whether any heart disease exists.

10. PET is an imaging technique that uses small amounts of a radioactive tracer to help in the diagnosis of heart disease. The tracer is introduced into the body, by IV injection

directly from a small and portable generator (e.g., CardioGen-82[®]), and a PET scanner is used to produce an image showing the distribution of the tracer in the heart.

11. In 1989, Bracco's CardioGen-82[®] became the first FDA-approved radioimaging agent dedicated to cardiac PET, and it is available today for patients in need of cardiac PET exams, including patients in the United States.

12. As a pioneer in the field of cardiac PET imaging, Bracco has enjoyed tremendous success based on its innovative strontium-rubidium radioisotope infusion system. Bracco's initial and continued success is based on extensive domestic research and development efforts.

B. Proposed Respondents

13. Jubilant DraxImage Inc. is a corporation organized and existing under the laws of Canada with its principal place of business at 16751 TransCanada Highway Kirkland, Québec, Canada H9H 4J4.¹ *See Exhibit No. 7.*

14. Jubilant DraxImage Inc. received FDA approval for Ruby-Fill[®] rubidium-82 generator and elution system on September 30, 2016. *See Exhibit No. 20.*

15. Jubilant Pharma Limited is a corporation organized and existing under the laws of Singapore with its principal place of business at 6 Temasek Boulevard, #20-06 Suntec City Tower Four, Singapore 038986. *See Exhibit No. 8.*

16. Jubilant Life Sciences is a corporation existing under the laws of India with its principal place of business at Plot 1-A Sector 16-A Institutional Area Noida, Uttar Pradesh, 201301 India. *See Exhibit No. 28.*

17. Jubilant DraxImage Inc. is a subsidiary of Jubilant Pharma Limited. *See Exhibit No. 9.*

¹ <http://www.draximage.com/>

18. Jubilant Pharma Limited is a subsidiary of Jubilant Life Sciences.

19. Jubilant DraxImage Inc. is the manufacturer of the infringing strontium-rubidium radioisotope infusion system, which it sells under the tradename Ruby-Fill[®]. *See, e.g., Exhibit Nos. 12 and 21.* Jubilant DraxImage Inc. also filed 505(b)(2) New Drug Application (NDA or 505(b)(2) NDA) to market and sell the infringing strontium-rubidium radioisotope infusion system (Ruby-Fill[®]) in the United States. **Exhibit No. 20.**

20. At least Jubilant Pharma Limited and Jubilant DraxImage Inc. actively participated in the development and regulatory approval process for the infringing strontium-rubidium radioisotope infusion system (Ruby-Fill[®]). **Exhibit No. 20** at 436-38, 449-50, 461-62, 473-74 (identifying employees from each company that participated in meetings with the FDA to discuss NDA No. 202153).

21. On October 3, 2016, after the 505(b)(2) NDA was approved by the FDA, Jubilant Pharma Limited's CEO (GP Singh) commented "*we* are proud to bring to the US market" the Ruby-Fill[®] system. **Exhibit No. 10** (emphasis added).

22. In recent earnings calls, Jubilant Life Sciences stated that it had completed installation of Ruby-Fill[®] systems in the United States. **Exhibit No. 13.**

23. Thus, upon information and belief, Jubilant Pharma Limited, Jubilant Life Sciences, and Jubilant DraxImage Inc. direct the manufacture and development of the Ruby-Fill[®] system that is the subject of NDA No. 202153, and directly or indirectly, derive substantial revenue from the sale of the Ruby-Fill[®] system and its components thereof.

24. Furthermore, upon information and belief, Jubilant Pharma Limited, Jubilant Life Sciences, and Jubilant DraxImage Inc. are agents of each other and/or work in concert with each other with respect to the development, regulatory approval, marketing, sale, importation, and

distribution of the infringing strontium-rubidium radioisotope infusion system (Ruby-Fill[®]) and/or components thereof throughout the United States.


II. Technology and Products-At-Issue

A. Bracco's Products


25. Heart disease is the number one killer of American men and women. Approximately 650,000 Americans die each year from heart disease related illness. Early detection is critical to effectively treat the disease. Tools for evaluating heart disease include treadmill evaluation, stress echocardiogram, perfusion imaging, coronary calcium screening, and coronary angiography.

26. As a pioneer in the strontium-rubidium radioisotope infusion systems market, Bracco is an industry leader for such devices. The existing CardioGen-82[®] system was the first FDA approved generator-based PET perfusion agent reimbursed for the evaluation of coronary artery disease. *See Exhibit No. 11.*


27. The existing CardioGen-82[®] system infuses a radioactive nuclear medicine agent, rubidium-82 which is produced from its precursor strontium-82, for the purpose of imaging the heart to determine if the heart's blood supply is normal or not. By way of example, the existing CardioGen-82[®] system can be seen below (the actual generator is housed underneath in lead shielding):



28. Contained inside this cart is the rubidium generator:



29. Continuing with its strong tradition of providing strontium-rubidium radioisotope infusion systems for the U.S. Market, Bracco has developed the next generation CardioGen-82[®] Infusion System, Model 1700 (hereinafter "Model 1700") for the U.S. Market.



30. The development of the Model 1700 system [REDACTED]

[REDACTED]

See


Confidential Exhibit No. 22.

31. The Model 1700 system is and will be manufactured using Bracco's proprietary processes and equipment, and practices one or more claims of the Asserted Patents. Likewise,

the Model 1700 system and the use thereof also practices one or more of the Asserted Patents, as explained below.

B. Jubilant's Ruby-Fill Is Manufactured And/Or Imported by Jubilant.

32. Jubilant DraxImage Inc. manufactures and/or imports strontium-rubidium radioisotope infusion systems and/or components thereof, including but not limited to rubidium-82 generators, under the tradename Ruby-Fill[®], which are sold in the United States. *See Exhibit No. 12* (stating Ruby-Fill[®] system is manufactured by Jubilant DraxImage Inc. with an address in Canada). The Ruby-Fill[®] system is pictured below:



See <http://www.draximage.com/products/us/ruby-fill/>.

33. The 2017 Mo-99 Topical Meeting presented by Argonne National Laboratory in Montreal included a “technical tour” of the Jubilant DraxImage Inc. facilities. **Exhibit No. 16.** On September 14, 2017 the participants took a “technical tour of Jubilant DraxImage Inc. I-131 solutions/capsules, I-131 mIBG and *Rb-82 generator manufacturing at its site in Montreal.*” *Id.* (emphasis added).

34. It has been reported that Jubilant “soft launched” a purported equivalent to the CardioGen-82[®] system (branded as Ruby-Fill[®]) and “completed its installation at three sites is (sic) USA.” *See Exhibit No. 13.* Jubilant further reported that they expect the Ruby-Fill[®] system to reach \$250 million in sales and achieve “at least 30-40% market share” over 5 years. *Id.*

35. The Ruby-Fill[®] system utilizes a rubidium (Rb 82) generator. *See Exhibit No. 21.* The Ruby-Fill[®] system pumps saline through the generator to elute rubidium-82 for injection into the patient. *Id.* Jubilant’s rubidium (Rb 82) generator is a critical component to the overall Ruby-Fill[®] system, because it is the source of the rubidium-82. There is no use for Jubilant’s rubidium (Rb 82) generator other than with the Ruby-Fill[®] system. Jubilant’s rubidium (Rb 82) generator is manufactured outside of the United States. *See Exhibit No. 20.* The following is a picture of Jubilant’s rubidium (Rb 82) generator:




Figure 3, Generator, Generator Handle & Lead Cover

See Exhibit No. 21.

36. Jubilant provided a “live demo” of the Ruby-Fill[®] system at the 22nd Annual Scientific Session of the American Society of Nuclear Cardiology on September 14-17, 2017 in Kansas City Missouri. *See Exhibit No. 14.* As explained below in further detail, Ruby-Fill[®], its use, and the processes of manufacturing Ruby-Fill[®] infringe upon Bracco’s patented technology.

III. The Asserted Patents and Non-Technical Description²

37. The Asserted Patents teach novel and nonobvious technology related to strontium-rubidium radioisotope infusion systems and methods for making and using such infusion systems. As explained below, Bracco owns by assignment the entire right, title, and interest in each of the Asserted Patents. Also explained below, Bracco's Model 1700 system, as well as manufacturing and the use thereof, practices the Asserted Patents. Bracco's relevant domestic operations include significant investment in plant and equipment, significant employment of labor and capital, and substantial investment in engineering, research and development.

A. The '826 Patent

38. The '826 patent is entitled "Integrated strontium-rubidium radioisotope infusion systems," and names Stephen E. Hidem, Aaron M. Fontaine, Janet L. Gelbach, Patrick M. McDonald, Kathryn M. Hunter, Rolf E. Swenson, and Julius P. Zodda as inventors. The '826 patent was filed on June 12, 2017 as a continuation of U.S. Patent Application No. 15/389,200, filed Dec. 22, 2016, which is a continuation of U.S. Patent Application No. 12/808,467, filed Jun. 16, 2010 (now U.S. Pat. No. 9,607,722), which is a National Stage of Int'l Application No. PCT/US09/47031, filed Jun. 11, 2009, which in turn is a continuation of the following four patent applications: U.S. Patent Application No. 12/137,356, filed Jun. 11, 2008 (now U.S. Pat. No. 8,317,674); U.S. Patent Application No. 12/137,363, filed Jun. 11, 2008 (now U.S. Pat. No. 7,862,534); U.S. Patent Application No. 12/137,364, filed Jun. 11, 2008 (now U.S. Pat. No. 9,597,053); and U.S. Patent Application No. 12/137,377, filed Jun. 11, 2008 (now U.S. Pat. No.

² This Complaint and the included non-technical descriptions are not intended to and do not construe either the specification or the claims of the Asserted Patents.

8,708,352). The '826 patent has twenty-nine claims – one independent and twenty-eight dependent. A certified copy of the '826 patent is attached to the Complaint as **Exhibit No. 1**.

39. The '826 patent was legally and duly issued on November 14, 2017.

40. Bracco owns by assignment the entire right, title, and interest in the '826 patent.

A certified copy of the assignment is attached as **Exhibit No. 2**.

41. Together with this Complaint, Bracco has filed a copy and three (3) additional copies of the prosecution history of the '826 patent as **Appendix No. 1**. Bracco has also filed four (4) copies of each patent and technical reference identified in the prosecution history of the application leading to the issuance of the '826 Patent as **Appendix No. 2**.

B. The '869 Patent

42. The '869 patent is entitled “Integrated strontium-rubidium radioisotope infusion systems,” and names Stephen E. Hidem, Aaron M. Fontaine, Janet L. Gelbach, Patrick M. McDonald, Kathryn M. Hunter, Rolf E. Swenson, and Julius P. Zodda as inventors. The '869 patent was filed on December 22, 2016 as a continuation of U.S. Patent Application No. 12/808,467, filed Jun. 16, 2010 (now U.S. Pat. No. 9,607,722), which is a National Stage of Int'l Application No. PCT/US09/47031, filed Jun. 11, 2009, which in turn is a continuation of the following four patent applications: U.S. Patent Application No. 12/137,356, filed Jun. 11, 2008 (now U.S. Pat. No. 8,317,674); U.S. Patent Application No. 12/137,363, filed Jun. 11, 2008 (now U.S. Pat. No. 7,862,534); U.S. Patent Application No. 12/137,364, filed Jun. 11, 2008 (now U.S. Pat. No. 9,597,053); and U.S. Patent Application No. 12/137,377, filed Jun. 11, 2008 (now U.S. Pat. No. 8,708,352). The '869 patent has thirty claims – one independent and twenty-nine dependent. A certified copy of the '869 patent is attached to the Complaint as **Exhibit No. 3**.

43. The '869 patent was legally and duly issued on September 5, 2017.

44. Bracco owns by assignment the entire right, title, and interest in the '869 patent. A certified copy of the assignment is attached as **Exhibit No. 4**.

45. Together with this Complaint, Bracco has filed a copy and three (3) additional copies of the prosecution history of the '869 patent as **Appendix No. 3**. Bracco has also filed four (4) copies of each patent and technical reference identified in the prosecution history of the application leading to the issuance of the '869 Patent as **Appendix No. 4**.

C. The '870 Patent

46. The '870 patent is entitled "Integrated strontium-rubidium radioisotope infusion systems," and names Stephen E. Hidem, Aaron M. Fontaine, Janet L. Gelbach, Patrick M. McDonald, Kathryn M. Hunter, Rolf E. Swenson, and Julius P. Zodda as inventors. The '870 patent was filed on April 18, 2017 as a continuation of U.S. Patent Application No. 15/389,200, filed Dec. 22, 2016, which is a continuation of U.S. Patent Application No. 12/808,467, filed Jun. 16, 2010 (now U.S. Pat. No. 9,607,722), which is a National Stage of Int'l Application No. PCT/US09/47031, filed Jun. 11, 2009, which in turn is a continuation of the following four patent applications: U.S. Patent Application No. 12/137,356, filed Jun. 11, 2008 (now U.S. Pat. No. 8,317,674); U.S. Patent Application No. 12/137,363, filed Jun. 11, 2008 (now U.S. Pat. No. 7,862,534); U.S. Patent Application No. 12/137,364, filed Jun. 11, 2008 (now U.S. Pat. No. 9,597,053); and U.S. Patent Application No. 12/137,377, filed Jun. 11, 2008 (now U.S. Pat. No. 8,708,352). The '870 patent has thirty claims – one independent and twenty-nine dependent. A certified copy of the '870 patent is attached to the Complaint as **Exhibit No. 5**.

47. The '870 patent was legally and duly issued on September 5, 2017.

48. Bracco owns by assignment the entire right, title, and interest in the '870 patent. A certified copy of the assignment is attached as **Exhibit No. 6**.

49. Together with this Complaint, Bracco has filed a copy and three (3) additional copies of the prosecution history of the '870 patent as **Appendix No. 5**. Bracco has also filed four (4) copies of each patent and technical reference identified in the prosecution history of the application leading to the issuance of the '870 Patent as **Appendix No. 6**.

D. Foreign Patents and Applications Corresponding to the Asserted Patents

50. A listing of all foreign patents and foreign patent applications corresponding to the respective Asserted Patents can be found as **Exhibit No. 15**.

E. Licensees to the Asserted Patents

51. There are no licensees to the Asserted Patents.

IV. Unlawful and Unfair Acts of the Proposed Respondents

52. Proposed Respondents submitted an abbreviated new drug application (“ANDA”) to the U.S. Food and Drug Administration on June 18, 2010 to market a system Proposed Respondents described as the *equivalent* of CardioGen-82[®]. **Exhibit No. 20**. Due to variations in administration rates, the FDA reclassified the ANDA application as a 505(b)(2) application. *Id.* However, Proposed Respondents still relied on clinical studies that Bracco performed in submitting its proposed equivalent version of Bracco’s product. *Id.* Proposed Respondents stated that since “both generators are systems for the production of rubidium 82, equal utility is expected from Ruby-Fill.” *Id.*

53. Proposed Respondents represented to the FDA that the Ruby-Fill[®] system is a “pharmaceutical equivalent” to Bracco’s CardioGen-82[®]. *Id.* Pharmaceutical equivalents are drug products in identical dosage forms intended for the same route of administration that: (1) contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified release dosage forms that require a reservoir

or overage or such forms as prefilled syringes where residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; (2) do not necessarily contain the same inactive ingredients; and (3) meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates. *See* 21 C.F.R. § 320.1(c).

54. Proposed Respondents received FDA approval for the Ruby-Fill[®] rubidium-82 generator and elution system on September 30, 2016 (*See Exhibit No. 20*) and began selling such units in the United States immediately thereafter.

55. The Proposed Respondents unlawfully sell for importation, import, and/or sell after importation into the United States strontium-rubidium radioisotope infusion systems and components thereof that infringe the Asserted Patents. **Exhibits 17, 18, and 19** contain claim charts that detail examples of how the asserted independent claims of the Asserted Patents read on the Proposed Respondents' Ruby-Fill[®] product, based on information discovered through Bracco's investigation to date.

56. The infringement at issue in this Complaint includes infringement (either literally or under the doctrine of equivalents) under 35 U.S.C. § 271, including without limitation, sections (a)-(c) and (g).

57. Contemporaneously with the filing of this Complaint, Bracco has provided the Proposed Respondents with a copy of the Complaint and the non-confidential exhibits to the Complaint. As a result, the Proposed Respondents received notice of the Asserted Patents and the infringement at issue no later than the filing of this Complaint.

V. Specific Acts of Unfair Importation and Sale

58. Proposed Respondents sell for importation into the United States, import into the United States, and/or sell after importation into the United States at least non-staple components of the Accused Product, including for example the rubidium-82 generator that is used specifically and exclusively with the Ruby-Fill[®] system, which infringes the Asserted Patents in violation of Section 337.


59. Bracco has obtained in the United States a user manual of the Proposed Respondents' Accused Product that infringes the Asserted Patents. **Exhibit No. 21.**

60. Proposed Respondents' Accused Product and/or non-staple components of the Accused Product, including for example the rubidium-82 generator, are manufactured in Canada, sold for importation into the United States, imported into the United States, and/or sold after importation into the United States by Proposed Respondents and/or its authorized agents. **Exhibit Nos. 12, 16, 20, and 21.**

61. As discussed above, Proposed Respondents manufacture the rubidium-82 generator outside of the United States. This generator is an essential component of the Ruby-Fill[®] system as it is the source of the rubidium-82 that is used in the rubidium-82 chloride for injection into patients. The FDA approved labeling for Ruby-Fill[®] states that this generator may be used "only with an appropriate, properly calibrated Elution System (RUBY Rubidium Elution System) labeled for use with the generator." **Exhibit No. 20.** Proposed Respondents understands and intends that the rubidium-82 generator that it imports into the United States from Canada has no other approved use except as part of the infringing Ruby-Fill[®] system. Thus, Proposed Respondents encourages, recommends, and promotes the use of its rubidium-82 generators as part of the infringing Ruby-Fill[®] system.

62. The Accused Product bearing the brand name Ruby-Fill[®], as identified in the claim charts, infringes one or more of the Asserted Patents and is imported and/or sold after importation from Canada within the United States by the Proposed Respondents who manufacture and supply this system for use in the United States to, for example, the radiopharmacy, hospital and/or imaging center.

63. On information and belief, the Ruby-Fill[®] system and/or rubidium-82 generators are manufactured by Proposed Respondents and/or its authorized agents in Canada. For example, the FDA approved labeling clearly identifies Proposed Respondents' address in Canada as the manufacturer:



See Exhibit No. 20.

64. Proposed Respondents' 505(b)(2) NDA No. 202153, which was submitted to the FDA, also clearly identifies the location of manufacturing as Canada:

Product Quality Microbiology Data Sheet

- A. 1. **TYPE OF SUBMISSION** NDA Resubmission
2. **SUBMISSION PROVIDES FOR:** Response to CMC deficiencies in Agency's Complete Response letter
3. **MANUFACTURING SITE:**
Jubilant DraxImage Inc.
16751 TransCanada Highway
Kirkland, QC
Canada H9H4J4

4. **MANUFACTURING FACILITY OF FINISHED DOSAGE FORM**
DRAXIMAGE, (a division of DRAXIS Specialty Pharmaceuticals Inc.)
16751 TransCanada Highway
Kirkland, Quebec
Canada H9H 4J4

See Exhibit No. 20.

65. Moreover, as part of a recent technical conference in Canada hosted by Argonne National Laboratory, Jubilant DraxImage provided a "technical tour" of its manufacturing facilities "in Montreal" for its "Rb-82 generator." *See Exhibit No. 16.*

66. The Ruby-Fill[®] system has been imported, sold and installed in the United States at a minimum of "three sites." *See Exhibit No. 13.* The Ruby-Fill[®] system has been offered for importation into the United States after September -November, 2017 (*i.e.*, after the patents-in-suit issued). Proposed Respondents induce and contribute to the infringement of the patents-in-suit by importing into the United States replacement rubidium 82 generators for use in infringing Ruby-Fill[®] system, including after November 2017. **Exhibit Nos. 21.** As shown in Exhibit 12, rubidium 82 generators must be replaced at least every 60 days. Accordingly, such generators

must have been imported to each location using the Ruby-Fill[®] system after November 14, 2017 (*i.e.*, the issue date of the latest Asserted Patent).

VI. Harmonized Tariff Schedule Information

67. On information and belief, the articles subject to this Complaint are classifiable under at least the following headings and subheadings of the Harmonized Tariff Schedule (“HTS”) of the United States: 9022.14.00.00; 9022.21.00.00; and 9022.90.05.00.

68. These classifications are intended for illustration only and are not intended to restrict the scope of this investigation.

VII. Related Litigation

69. Bracco is not aware of any court or agency actions previously filed involving the Asserted Patents or in any way related to the proposed investigation.

70. Concurrently with the filing of this complaint, Bracco will file a complaint in the U.S. District Court for the District of New Jersey alleging infringement of at least the Asserted Patents against Jubilant DraxImage Inc., Jubilant Pharma Limited, and Jubilant Life Sciences.

VIII. Domestic Industry

71. A domestic industry, as required and defined by 19 U.S.C. § 1337(a)(2)-(3), exists or is in the process of being established by virtue of significant investment in plant and equipment, significant employment of labor or capital, and substantial investment in engineering, research, and development, all related to the Asserted Patents.

A. The Economic Prong

72. An industry, as defined in Section 337(a)(3), exists in the United States by virtue of Bracco’s significant and substantial investments directed to Bracco’s strontium-rubidium radioisotope infusion systems and manufacturing equipment and processes therefore, each of

which is protected by one or more of the Asserted Patents. Bracco has [REDACTED]

[REDACTED]
[REDACTED]
[REDACTED] More information showing Bracco has an existing domestic industry can be found in **Confidential Exhibit No. 22.**

73. Bracco conducts significant, substantial, and extensive activities in the United States related to its strontium-rubidium radioisotope infusion system domestic industry. These activities include, but are not limited to significant domestic investment in employees and labor related to the engineering, research, and development and manufacturing of strontium-rubidium radioisotope infusion systems. Further included are Bracco's significant domestic investment in plant and equipment related to Bracco's engineering, research, and development and manufacturing of strontium-rubidium radioisotope infusion systems. Additionally, Bracco's domestic investment in engineering and research and development for strontium-rubidium radioisotope infusion systems is substantial.

74. In addition to the domestic industry that exists because of the numerous Model 1700 systems that have already been produced, a domestic industry is in the process of being established [REDACTED]

[REDACTED]. Bracco is taking the necessary and tangible steps to establish such an industry, to the extent it does not already exist, in the United States, and there is a significant likelihood that the Model 1700 system will be available in the United States in the near future. For example, [REDACTED]

[REDACTED] From this work, [REDACTED]

[REDACTED]

[REDACTED] The Model 1700 system will be manufactured in the United States [REDACTED]

[REDACTED]

Bracco's Model 1700 system and the use thereof, practices the Asserted Patents (as shown in the attached claim charts related to the technical prong of the domestic industry requirement). Moreover, Bracco has a substantial research and development presence in the United States related to its systems that practice the Asserted Patents. More information showing Bracco has a domestic industry that is in the process of being established can be found in **Confidential Exhibit No. 22.**

B. The Technical Prong

75. Bracco practices the Asserted Patents in the United States through at least the Model 1700 system. [REDACTED]

[REDACTED] The Model

1700 system is an infusion system as recited in the claims of the '869 patent. In addition, the Model 1700 system is used in a manner recited in the claims of the '870 patent, and the Model 1700 system is made using the methods recited in the claims of the '826 patent.

76. The Model 1700 system practices at least claim 1 of the '826 patent, claim 1 of the '869 patent, and claim 1 of the '870 patent.

77. A chart applying the claims of the '869 patent to the Model 1700 system is attached as **Exhibit No. 23.**

78. A chart applying the claims of the '870 patent to the use of the Model 1700 system is attached as **Exhibit No. 24.**

79. A chart applying the claims of the '869 patent to the manufacture of the Model 1700 system is attached as **Exhibit No. 25**.

IX. Request for Relief

WHEREFORE, Bracco respectfully requests that the United States International Trade Commission:

80. Institute an immediate investigation pursuant to Section 337(b)(1) of the Tariff Act of 1930, as amended, 19 U.S.C. § 1337, into the violation by Proposed Respondents of Section 337 arising from the importation into the United States and/or sale within the United States after the importation of Proposed Respondents' products and/or components that infringe or induce or contribute to the infringement of one or more claims of the Asserted Patents;

81. Schedule and conduct a hearing pursuant to Section 337(c), for purposes of receiving evidence and hearing argument concerning whether there has been a violation of Section 337 and, following the hearing, determine that there has been a violation of Section 337;

82. Issue a permanent limited exclusion order pursuant to 19 U.S.C. § 1337 (d) forbidding entry into the United States of Proposed Respondents' products or components that infringe or induce or contribute to the infringement of one or more claims of the Asserted Patents;

83. Issue a permanent cease and desist order, pursuant to 19 U.S.C. § 1337(f), directing Proposed Respondents to cease and desist from the importation, sale, offer for sale, advertising, packaging or solicitation of any sale by Proposed Respondents of products or components that infringe or induce or contribute to the infringement of one or more claims of the Asserted Patents;


84. Issue a permanent cease and desist order, pursuant to 19 U.S.C. § 1337(f), directing Proposed Respondents to cease and desist from inducing or contributing to infringement of the Asserted Patents by providing maintenance, service, direction, training, or instruction of any kind to the existing users of the Proposed Respondents products or components that infringe or induce or contribute to the infringement of one or more claims of the Asserted Patents.

85. Impose a bond upon Proposed Respondents who continue to import infringing articles during the 60-day Presidential review period per 19 U.S.C. § 1337(j); and

86. Grant all such other and further relief as it deems appropriate under the law, based upon the facts complained of herein and as determined by the investigation.

Dated: March 27, 2018

By:

A handwritten signature in black ink, appearing to be 'M. Davis', written over a horizontal line.

GREENBERG TRAUIG, LLP
Mark Davis
Patrick J. McCarthy
2101 L Street, NW, Suite 1000
Washington, DC 20037
Tel: (202) 331-3100
Email: davisma@gtlaw.com
Email: mccarthyp@gtlaw.com

Scott Bornstein
Brian J. Prew
MetLife Building
200 Park Avenue
New York, NY 10166
Tel: (212) 801-9200
Email: bornsteins@gtlaw.com
Email: prewb@gtlaw.com

Attorneys for Complainant

VERIFICATION OF COMPLAINT

I, Vito DeBari, declare, in accordance with 19 CFR §§ 210.4 and 210.12(a), under penalty of perjury that the following statements are true:

1. I am Vice President and General Counsel at Bracco Diagnostics Inc., and am duly authorized to sign this complaint on behalf of the Complainants.
2. I have read the Complaint and am aware of its contents;
3. The Complaint is not being presented for any improper purpose, such as to harass or to cause unnecessary delay or needless increase in the cost of litigation;
4. To the best of my knowledge founded upon reasonable inquiry, the claims and legal contentions of this Complaint are warranted by existing law or a good faith argument for the extension, modification, or reversal of existing law;
5. The allegations and other factual contentions in the Complaint have evidentiary support or are likely to have evidentiary support after a reasonable opportunity for further investigation or discovery.



Executed on March 27, 2018

EXHIBIT 1

U 7667315



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

February 12, 2018

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THIS OFFICE OF:

U.S. PATENT: 9,814,826
ISSUE DATE: November 14, 2017

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office




P. R. GRANT
Certifying Officer



US009814826B2

(12) **United States Patent**
Hidem et al.

(10) **Patent No.:** **US 9,814,826 B2**
(45) **Date of Patent:** ***Nov. 14, 2017**

(54) **INTEGRATED STRONTIUM-RUBIDIUM RADIOISOTOPE INFUSION SYSTEMS**

(71) Applicant: **Bracco Diagnostics Inc.**, Monroe Township, NJ (US)

(72) Inventors: **Stephen E. Hidem**, Edina, MN (US); **Aaron M. Fontaine**, Minneapolis, MN (US); **Janet L. Gelbach**, Schaumburg, IL (US); **Patrick M. McDonald**, Omaha, NE (US); **Kathryn M. Hunter**, Knoxville, TN (US); **Rolf E. Swenson**, Silver Spring, MD (US); **Julius P. Zodda**, Mercerville, NJ (US)

(73) Assignee: **Bracco Diagnostics Inc.**, Monroe Township, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/620,320**

(22) Filed: **Jun. 12, 2017**

(65) **Prior Publication Data**
US 2017/0274138 A1 Sep. 28, 2017

Related U.S. Application Data

(63) Continuation of application No. 15/389,200, filed on Dec. 22, 2016, now Pat. No. 9,750,869, which is a (Continued)

(51) **Int. Cl.**
A61M 5/00 (2006.01)
A61M 5/14 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC **A61M 5/007** (2013.01); **A61B 6/037** (2013.01); **A61B 6/107** (2013.01); **A61B 6/481** (2013.01);
(Continued)

(58) **Field of Classification Search**
CPC .. A61M 5/007; A61M 5/1001; A61M 5/1002; A61M 5/1007;
(Continued)

(56) **References Cited**
U.S. PATENT DOCUMENTS

3,483,867 A 12/1969 Markovitz
3,535,085 A 10/1970 Shumate
(Continued)

FOREIGN PATENT DOCUMENTS

CA 2913373 A1 4/2008
CN 1968653 A 5/2007
(Continued)

OTHER PUBLICATIONS



Alvarez-Diez et al. "Manufacture of strontium-82/rubidium-82 generators and quality control of rubidium-82 chloride for myocardial perfusion imaging in patients using positron emission tomography," Applied Radiation and Isotopes, 1999, pp. 1015-1023.
(Continued)

Primary Examiner — Charles A Marmor, II
Assistant Examiner — Carrie R Dorna
(74) *Attorney, Agent, or Firm* — Fredrikson & Byron, P.A.

(57) **ABSTRACT**

Methods for setting up, maintaining and operating a radio-pharmaceutical infusion system, that includes a radioisotope generator, are facilitated by a computer of the system. The computer may include pre-programmed instructions and a computer interface, for interaction with a user of the system, for example, in order to track contained volumes of eluant and/or eluate, and/or to track time from completion of an elution performed by the system, and/or to calculate one or more system and/or injection parameters for quality control, and/or to perform purges of the system, and/or to facilitate diagnostic imaging.

30 Claims, 27 Drawing Sheets



Related U.S. Application Data

continuation of application No. 12/808,467, filed as application No. PCT/US2009/047031 on Jun. 11, 2009, now Pat. No. 9,607,722, which is a continuation of application No. 12/137,377, filed on Jun. 11, 2008, now Pat. No. 8,708,352, and a continuation of application No. 12/137,363, filed on Jun. 11, 2008, now Pat. No. 7,862,534, and a continuation of application No. 12/137,356, filed on Jun. 11, 2008, now Pat. No. 8,317,674, and a continuation of application No. 12/137,364, filed on Jun. 11, 2008, now Pat. No. 9,597,053.

(51) Int. Cl.

A61B 90/00 (2016.01)
A61M 5/145 (2006.01)
G21F 3/00 (2006.01)
A61M 5/158 (2006.01)
G21F 7/00 (2006.01)
A61M 5/168 (2006.01)
G21G 1/00 (2006.01)
A61B 6/00 (2006.01)
A61B 6/03 (2006.01)
G21G 4/08 (2006.01)
A61B 50/13 (2016.01)
A61M 5/142 (2006.01)
A61K 51/00 (2006.01)
G06F 21/31 (2013.01)
A61B 6/10 (2006.01)
A61B 50/10 (2016.01)
A61N 5/10 (2006.01)
B62B 3/00 (2006.01)

(52) U.S. Cl.

CPC *A61B 6/507* (2013.01); *A61B 50/13* (2016.02); *A61B 90/39* (2016.02); *A61K 51/00* (2013.01); *A61M 5/14* (2013.01); *A61M 5/142* (2013.01); *A61M 5/1409* (2013.01); *A61M 5/1452* (2013.01); *A61M 5/158* (2013.01); *A61M 5/16854* (2013.01); *A61M 5/16881* (2013.01); *A61N 5/1001* (2013.01); *A61N 5/1007* (2013.01); *A61N 5/1075* (2013.01); *G06F 21/31* (2013.01); *G21F 3/00* (2013.01); *G21F 7/00* (2013.01); *G21G 1/001* (2013.01); *G21G 1/0005* (2013.01); *G21G 4/08* (2013.01); *A61B 2050/105* (2016.02); *A61B 2090/392* (2016.02); *A61M 2005/1403* (2013.01); *A61M 2205/18* (2013.01); *A61M 2205/276* (2013.01); *A61M 2205/50* (2013.01); *A61M 2205/505* (2013.01); *A61M 2205/52* (2013.01); *A61M 2209/084* (2013.01); *A61N 2005/1021* (2013.01); *A61N 2005/1022* (2013.01); *A61N 2005/1074* (2013.01); *A61N 2005/1094* (2013.01); *B62B 3/005* (2013.01); *G21G 2001/0031* (2013.01)

(58) Field of Classification Search

CPC *A61M 5/1014-5/1017*; *A61M 5/1027*; *A61M 5/1028*; *A61M 5/1071*; *A61M 5/14*; *A61M 5/142*; *A61M 2005/1021*; *G21G 4/08*; *G21G 1/0005*; *G06F 19/3468*; *A61B 2050/105*

See application file for complete search history.

(56)

References Cited

U.S. PATENT DOCUMENTS

3,543,752 A 12/1970 Hesse et al.
 3,565,376 A 2/1971 Viers
 3,576,998 A 5/1971 Deutsch et al.
 3,710,118 A 1/1973 Holgate et al.
 3,714,429 A 1/1973 McAfee et al.
 3,774,036 A 11/1973 Gerhart
 3,847,138 A 11/1974 Gollub
 3,861,380 A 1/1975 Chassagne et al.
 3,953,567 A 4/1976 Grant et al.
 3,991,960 A 11/1976 Tanaka
 3,997,784 A 12/1976 Picunko et al.
 4,096,859 A 6/1978 Agarwal et al.
 4,160,910 A 7/1979 Thornton et al.
 4,212,303 A 7/1980 Nolan
 4,241,728 A 12/1980 Mirrell
 4,286,169 A 8/1981 Rossem
 4,336,036 A 6/1982 Leeke et al.
 4,406,877 A 9/1983 Neirinckx et al.
 4,466,888 A 8/1984 Verkaart
 4,562,829 A 1/1986 Bergner
 4,585,009 A 4/1986 Barker et al.
 4,585,941 A 4/1986 Bergner
 4,597,951 A 7/1986 Gennaro et al.
 4,623,102 A 11/1986 Hough et al.
 4,625,118 A 11/1986 Kriwetz et al.
 4,656,697 A 4/1987 Naslund
 4,674,403 A 6/1987 Bryant et al.
 4,679,142 A 7/1987 Lee
 4,755,679 A 7/1988 Wong
 4,759,345 A 7/1988 Mistry
 4,769,008 A 9/1988 Hessel
 4,853,546 A 8/1989 Abe et al.
 4,994,056 A 2/1991 Ikeda
 5,039,863 A 8/1991 Matsuno et al.
 5,092,834 A 3/1992 Bradshaw et al.
 5,166,526 A 11/1992 Dietzel
 5,254,328 A 10/1993 Herscheid
 5,258,906 A 11/1993 Kroll et al.
 5,274,239 A 12/1993 Lane et al.
 5,395,320 A 3/1995 Padda et al.
 5,468,355 A 11/1995 Shefer et al.
 5,475,232 A 12/1995 Powers et al.
 5,485,831 A 1/1996 Holdsworth et al.
 5,580,541 A 12/1996 Wells et al.
 5,590,648 A 1/1997 Mitchell et al.
 5,674,404 A 10/1997 Kenley et al.
 5,681,285 A 10/1997 Ford et al.
 5,702,115 A 12/1997 Pool et al.
 5,739,508 A 4/1998 Uber et al.
 5,765,842 A 6/1998 Phaneuf
 5,827,429 A 10/1998 Ruschke et al.
 5,840,026 A 11/1998 Uber, III et al.
 5,885,216 A 3/1999 Evans, III et al.
 6,058,718 A 5/2000 Forsberg et al.
 6,157,036 A 12/2000 Whiting et al.
 6,220,554 B1 4/2001 Daoud
 6,267,717 B1 7/2001 Stoll et al.
 6,269,810 B1 8/2001 Brooker et al.
 6,327,895 B1 12/2001 Jeppsson et al.
 6,347,711 B1 2/2002 Goebel et al.
 6,442,418 B1 8/2002 Evans, III et al.
 6,450,936 B1 9/2002 Smith, III et al.
 6,454,460 B1 9/2002 Ramanathan et al.
 6,558,125 B1 5/2003 Futterknecht
 6,626,862 B1 9/2003 Duchon et al.
 6,639,237 B2 10/2003 Pedersen et al.
 6,758,975 B2 7/2004 Peabody et al.
 6,767,319 B2 7/2004 Reilly et al.
 6,773,686 B1 8/2004 Herscheid et al.
 6,870,175 B2 3/2005 Dell
 6,901,283 B2 5/2005 Evans, III et al.
 6,908,598 B2 6/2005 Sylvester
 6,931,327 B2 8/2005 Goode et al.
 7,091,494 B2 8/2006 Weisner et al.
 7,125,166 B2 10/2006 Eck et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

7,163,031 B2 1/2007 Graves et al.
 7,169,135 B2 1/2007 Duchon et al.
 7,204,797 B2 4/2007 Reilly et al.
 7,256,888 B2 8/2007 Stachr et al.
 7,286,867 B2 10/2007 Schlyer et al.
 7,413,123 B2 8/2008 Ortenzi
 7,476,377 B2 1/2009 Moller et al.
 7,504,646 B2 3/2009 Balestracci et al.
 7,522,952 B2 4/2009 Krieg et al.
 7,586,102 B2 9/2009 Mourtada et al.
 7,605,384 B2 10/2009 Sonnenhol et al.
 7,608,831 B2 10/2009 Lamb et al.
 7,612,999 B2 11/2009 Clark et al.
 7,712,491 B2 5/2010 Tochon-Danguy et al.
 7,734,331 B2 6/2010 Dhawale et al.
 7,737,415 B2 6/2010 Casale et al.
 7,780,352 B2 8/2010 Fox et al.
 7,813,841 B2 10/2010 deKemp et al.
 7,825,372 B2 11/2010 Allberg
 7,862,534 B2 1/2011 Quirico et al.
 7,996,068 B2 8/2011 Telischak et al.
 8,058,632 B2 11/2011 Balestracci et al.
 8,071,959 B2 12/2011 deKemp
 8,198,599 B2 6/2012 Bouton et al.
 8,216,181 B2 7/2012 Balestracci
 8,216,184 B2 7/2012 Balestracci
 8,295,916 B2 10/2012 Shimchuk et al.
 8,317,674 B2 11/2012 Quirico et al.
 8,431,909 B2 4/2013 Horton et al.
 8,439,815 B2 5/2013 Lemer
 8,442,803 B2 5/2013 Chen et al.
 8,708,352 B2 4/2014 Quirico et al.
 2002/0128594 A1 9/2002 Das et al.
 2002/0129471 A1 9/2002 Wang
 2003/0139640 A1 7/2003 Whittacre et al.
 2003/0194894 A1 10/2003 Wariar et al.
 2004/0054319 A1 3/2004 Langley et al.
 2004/0104160 A1 6/2004 Scagliarini et al.
 2004/0260143 A1 12/2004 Reilly et al.
 2005/0085682 A1 4/2005 Sasaki et al.
 2005/0187515 A1 8/2005 Varrichio et al.
 2005/0277833 A1 12/2005 Williams
 2005/0278066 A1 12/2005 Graves et al.
 2006/0015056 A1 1/2006 Ellingboe et al.
 2006/0151048 A1 7/2006 Tochon-Danguy et al.
 2006/0164093 A1 7/2006 Ooe et al.
 2006/0173419 A1 8/2006 Malcolm
 2007/0080223 A1 4/2007 Japuntich
 2007/0140958 A1 6/2007 deKemp
 2007/0226175 A1 9/2007 Resnic et al.
 2007/0232980 A1 10/2007 Felt et al.
 2007/0260213 A1 11/2007 Williams et al.
 2007/0282263 A1 12/2007 Kalafut et al.
 2008/0015794 A1 1/2008 Eiler et al.
 2008/0071219 A1 3/2008 Rhinehart et al.
 2008/0093564 A1 4/2008 Tartaglia et al.
 2008/0166292 A1 7/2008 Levin et al.
 2008/0177126 A1 7/2008 Tate et al.
 2008/0191148 A1 8/2008 Gibson
 2008/0200747 A1 8/2008 Wagner et al.
 2008/0203318 A1 8/2008 Wagner et al.
 2008/0237502 A1 10/2008 Fago
 2008/0242915 A1 10/2008 Jackson et al.
 2008/0260580 A1 10/2008 Helle et al.
 2009/0112478 A1 4/2009 Mueller, Jr. et al.
 2009/0155167 A1 6/2009 Powell et al.
 2009/0224171 A1 9/2009 Verbokkem
 2009/0312630 A1 12/2009 Hidem et al.
 2010/0312039 A1 12/2010 Quirico et al.
 2011/0071392 A1 3/2011 Quirico et al.
 2011/0172524 A1 7/2011 Hidem et al.
 2011/0178359 A1 7/2011 Hirschman et al.
 2011/0209764 A1 9/2011 Uber et al.
 2012/0098671 A1 4/2012 Wieczorek et al.
 2012/0305730 A1 12/2012 Balestracci

2012/0310031 A1 12/2012 Quirico et al.
 2012/0312980 A1 12/2012 Whitehouse
 2013/0300109 A1 11/2013 Balestracci et al.
 2014/0084187 A1 3/2014 Quirico et al.
 2014/0175959 A1 6/2014 Quirico et al.
 2014/0343418 A1 11/2014 Quirico et al.
 2014/0374614 A1 12/2014 Hidem et al.
 2014/0374615 A1 12/2014 Hidem et al.
 2015/0260855 A1 9/2015 McQuaid et al.

FOREIGN PATENT DOCUMENTS

EP 102121 A1 3/1984
 EP 310148 A2 4/1989
 EP 317114 A1 5/1989
 EP 160303 A2 2/1991
 EP 319148 A2 2/1994
 EP 1421960 A1 5/2004
 EP 919249 A1 1/2005
 EP 1772157 A1 4/2007
 EP 1820730 A1 8/2007
 EP 2011126 A2 1/2009
 EP 2492920 A2 8/2012
 FR 2867084 A1 9/2005
 JP 2000350783 A 12/2000
 JP 2003520780 A 7/2003
 JP 2006325826 A 12/2006
 KR 960003726 B1 3/1996
 RU 2131273 C1 6/1999
 RU 2288755 C1 12/2006
 SU 244513 A1 12/1969
 WO 9615337 A1 5/1996
 WO 9956117 A1 11/1999
 WO 02096335 A2 12/2002
 WO 03034444 A1 4/2003
 WO 2004004787 A2 1/2004
 WO 2004059661 A1 7/2004
 WO 2004080523 A2 9/2004
 WO 2005002971 A1 1/2005
 WO 2006007750 A1 1/2006
 WO 2006026603 A2 3/2006
 WO 2006074473 A2 7/2006
 WO 2006129301 A2 12/2006
 WO 2006135374 A2 12/2006
 WO 2007016170 A1 2/2007
 WO 2007016173 A1 2/2007
 WO 2007030249 A2 3/2007
 WO 2007041017 A1 4/2007
 WO 2007071022 A1 6/2007
 WO 2007082093 A2 7/2007
 WO 2007104133 A1 9/2007
 WO 2007149108 A2 12/2007
 WO 2008028165 A2 3/2008
 WO 2008037939 A2 4/2008
 WO 2008066586 A2 6/2008
 WO 2008082966 A2 7/2008
 WO 2008140351 A1 11/2008
 WO 2009152320 A2 12/2009
 WO 2010020596 A1 2/2010
 WO 2011126522 A2 10/2011

OTHER PUBLICATIONS

Brochure, "IV and Liquid Filters: Speedflow Adult 0.2 um Positive", <http://www.gvs.it/flex/FixedPages/UK/LiquidFilters.php/L/UK/ID/Speedflow%20Adjust%...> Retrieved from URL on Nov. 11, 2008.

Bracco Brochure, "Rubidium '82 Infusion System, Easy to Operate... Automated... Complete", © Bracco Diagnostics, Inc., 0605-002NA, Jun. 2001, (2 pages).

"CardioGen-82 Infusion System User's Guide," Medical Product Service GmbH, Jul. 3, 2007, 53 pages.

Imaging Technology News, web exclusive: "FDG-PET Injector Thrusts New Life into Molecular Imaging", Apr. 2008, 2 pages.

Neil J. Epstein, "A Rb82 infusion system for quantitative perfusion imaging with 3D PET" Applied Radiation and Isotopes, vol. 60,

(56)

References Cited

OTHER PUBLICATIONS

Feb. 9, 2004, pp. 921-927, XP002557544 DOI:10.1016/j.apradiso.2004.02.002.

R. Klein, "Precision controlled elution of a Sr82/Rb82 generator for cardiac perfusion imaging with positron emission tomography" *Physics in Medicine and Biology*, vol. 52, Jan. 11, 2007, pp. 659-673, XP002557545 DOI:10.1088/0031-9155/52/3/009.

International Search Report and Written Opinion for International Patent Application No. PCT/US2009/047030, dated Feb. 25, 2010, 22 pages.

International Search Report and Written Opinion for International Patent Application No. PCT/US2009/047030, dated Feb. 17, 2010, 17 pages.

International Search Report and Written Opinion for International Patent Application No. PCT/US2009/047031, dated Mar. 1, 2010, 20 pages.

International Search Report and Written Opinion for International Patent Application No. PCT/US2009/047034, dated Feb. 25, 2010, 15 pages.

International Search Report and Written Opinion for International Patent Application No. PCT/US2009/063788, dated Apr. 1, 2010, 13 pages.

LEMER PAX, POSIJET® Integrated FDG dispensing and infusion system, www.lernerpax.com (copyright date May 2008).

R. Klein, "Precise 82RB infusion system for cardiac perfusion measurement using 3D positron emission tomography", Ottawa-Carleton Institute for Electrical and Computer Engineering School of Information Technology and Engineering (Electrical & Computer Engineering), Feb. 2005, 147 pages.

R. Klein, "Precision control of eluted activity from a Sr/Rb generator for cardiac positron emission tomography", Proceedings of the 26th Annual International Conference of the IEEE EMBS San Francisco, CA, USA, Sep. 1-5, 2004, 4 pages.

Machine translation of abstract of RU2307378 published Sep. 27, 2007.

Kost, "Preventing Medical Errors in Point-of-Care Testing," *Archives of Pathology & Laboratory Medicine*, vol. 125, No. 10, Oct. 2001, pp. 1307-1315.

Leveson, "Medical Devices: The Therac-25*," Appendix of: *Safeware: System Safety and Computers*, 1995, 49 pages.

"Medfusion 3000 Series Technical Service Manual," Smiths Medical, 2010, 184 pages.

"BodyGuard 323 Infusion Pump System Operator Manual," Caesarea Medical Electronics Ltd, Mar. 2009, 81 pages.

"Alaris GH Syringe Pump Directions for Use," Cardinal Health, Oct. 2005, 34 pages.

"Auto Syringe AS40A: Model AS40A Infusion Pump Operation Manual," Baxter, Aug. 1993, 84 pages.

"CardioGen-82 Rubidium Rb 82 Generator for Elution of Rubidium Chloride Rb 82 Injection," Bracco Diagnostics, May 2000, 13 pages.

Fig. 1A




Fig. 1B




Fig. 1D




Fig. 1E





Fig. 2A







Fig. 3A




Fig. 4




Fig. 5A




Fig. 5B





Fig. 5C






Fig. 7A




Fig. 7B





Fig. 7C








Fig. 8A








Fig. 9B




Fig. 9C




Fig. 11

CARADIOGEN-82 GENERATOR MONTHLY RECEIPT/RETURN WORKSHEET																							
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">GENERATOR RECEIPT</th> </tr> <tr> <td style="padding: 2px;">DATE OF DELIVERY:</td> <td style="padding: 2px;">11/9/2008</td> </tr> <tr> <td style="padding: 2px;">DATE OF CALIBRATION:</td> <td style="padding: 2px;">11/10/2008</td> </tr> <tr> <td style="padding: 2px;">LOT NUMBER:</td> <td style="padding: 2px;"></td> </tr> <tr> <td style="padding: 2px;">Sr-82 ACTIVITY:</td> <td style="padding: 2px;">100 mCi</td> </tr> <tr> <td style="padding: 2px;">TOTAL ACTIVITY:</td> <td style="padding: 2px;">256 mCi</td> </tr> <tr> <td style="padding: 2px;">Sr-85 ACTIVITY:</td> <td style="padding: 2px;">156 mCi</td> </tr> </table>	GENERATOR RECEIPT		DATE OF DELIVERY:	11/9/2008	DATE OF CALIBRATION:	11/10/2008	LOT NUMBER:		Sr-82 ACTIVITY:	100 mCi	TOTAL ACTIVITY:	256 mCi	Sr-85 ACTIVITY:	156 mCi	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">RECEIPT SURVEY</th> </tr> <tr> <td style="padding: 2px;">SURFACE:</td> <td style="padding: 2px;">10.0 mrem/hr (MUST BE < 50 mrem/hr)</td> </tr> <tr> <td style="padding: 2px;">1 METER:</td> <td style="padding: 2px;">0.6 mrem/hr (MUST BE < 1 mrem/hr)</td> </tr> <tr> <td style="padding: 2px;">SURFACE WIPE:</td> <td style="padding: 2px;">1599 dpm (MUST BE < 2200 dpm/100 cm²)</td> </tr> </table>	RECEIPT SURVEY		SURFACE:	10.0 mrem/hr (MUST BE < 50 mrem/hr)	1 METER:	0.6 mrem/hr (MUST BE < 1 mrem/hr)	SURFACE WIPE:	1599 dpm (MUST BE < 2200 dpm/100 cm ²)
GENERATOR RECEIPT																							
DATE OF DELIVERY:	11/9/2008																						
DATE OF CALIBRATION:	11/10/2008																						
LOT NUMBER:																							
Sr-82 ACTIVITY:	100 mCi																						
TOTAL ACTIVITY:	256 mCi																						
Sr-85 ACTIVITY:	156 mCi																						
RECEIPT SURVEY																							
SURFACE:	10.0 mrem/hr (MUST BE < 50 mrem/hr)																						
1 METER:	0.6 mrem/hr (MUST BE < 1 mrem/hr)																						
SURFACE WIPE:	1599 dpm (MUST BE < 2200 dpm/100 cm ²)																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">GENERATOR RETURN</th> </tr> <tr> <td style="padding: 2px;">DATE OF RETURN:</td> <td style="padding: 2px;">12/27/2008</td> </tr> <tr> <td style="padding: 2px;">DAYS SINCE CALIBRATION DATE:</td> <td style="padding: 2px;">47</td> </tr> </table>	GENERATOR RETURN		DATE OF RETURN:	12/27/2008	DAYS SINCE CALIBRATION DATE:	47	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">RETURN SURVEY</th> </tr> <tr> <td style="padding: 2px;">SURFACE:</td> <td style="padding: 2px;">5.6 mrem/hr (MUST BE < 50 mrem/hr)</td> </tr> <tr> <td style="padding: 2px;">1 METER:</td> <td style="padding: 2px;">0.2 mrem/hr (MUST BE < 1 mrem/hr)</td> </tr> <tr> <td style="padding: 2px;">SURFACE WIPE:</td> <td style="padding: 2px;">1278 dpm (MUST BE < 2200 dpm/100 cm²)</td> </tr> </table>	RETURN SURVEY		SURFACE:	5.6 mrem/hr (MUST BE < 50 mrem/hr)	1 METER:	0.2 mrem/hr (MUST BE < 1 mrem/hr)	SURFACE WIPE:	1278 dpm (MUST BE < 2200 dpm/100 cm ²)								
GENERATOR RETURN																							
DATE OF RETURN:	12/27/2008																						
DAYS SINCE CALIBRATION DATE:	47																						
RETURN SURVEY																							
SURFACE:	5.6 mrem/hr (MUST BE < 50 mrem/hr)																						
1 METER:	0.2 mrem/hr (MUST BE < 1 mrem/hr)																						
SURFACE WIPE:	1278 dpm (MUST BE < 2200 dpm/100 cm ²)																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">Sr-82 RETURN CALCULATIONS</th> </tr> <tr> <td style="padding: 2px;">INITIAL Sr-82 ACTIVITY:</td> <td style="padding: 2px;">100 mCi</td> </tr> <tr> <td style="padding: 2px;">DECAY FACTOR:</td> <td style="padding: 2px;">0.2718</td> </tr> <tr> <td style="padding: 2px;">REMAINING Sr-82 IN mCi:</td> <td style="padding: 2px;">27.18 mCi</td> </tr> <tr> <td style="padding: 2px;">REMAINING Sr-82 IN GBq:</td> <td style="padding: 2px;">1.01 GBq</td> </tr> </table>	Sr-82 RETURN CALCULATIONS		INITIAL Sr-82 ACTIVITY:	100 mCi	DECAY FACTOR:	0.2718	REMAINING Sr-82 IN mCi:	27.18 mCi	REMAINING Sr-82 IN GBq:	1.01 GBq	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">SUMMARY</th> </tr> <tr> <td style="padding: 2px;">TOTAL Sr-82/Sr-85 ACTIVITY:</td> <td style="padding: 2px;">120.95 mCi</td> </tr> <tr> <td style="padding: 2px;">TOTAL Sr-82/Sr-85 ACTIVITY:</td> <td style="padding: 2px;">4.48 GBq</td> </tr> <tr> <td style="padding: 2px;">TRANSPORT INDEX:</td> <td style="padding: 2px;">0.2</td> </tr> </table>	SUMMARY		TOTAL Sr-82/Sr-85 ACTIVITY:	120.95 mCi	TOTAL Sr-82/Sr-85 ACTIVITY:	4.48 GBq	TRANSPORT INDEX:	0.2				
Sr-82 RETURN CALCULATIONS																							
INITIAL Sr-82 ACTIVITY:	100 mCi																						
DECAY FACTOR:	0.2718																						
REMAINING Sr-82 IN mCi:	27.18 mCi																						
REMAINING Sr-82 IN GBq:	1.01 GBq																						
SUMMARY																							
TOTAL Sr-82/Sr-85 ACTIVITY:	120.95 mCi																						
TOTAL Sr-82/Sr-85 ACTIVITY:	4.48 GBq																						
TRANSPORT INDEX:	0.2																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">Sr-85 RETURN CALCULATIONS</th> </tr> <tr> <td style="padding: 2px;">INITIAL Sr-85 ACTIVITY:</td> <td style="padding: 2px;">156 mCi</td> </tr> <tr> <td style="padding: 2px;">DECAY FACTOR:</td> <td style="padding: 2px;">0.6011</td> </tr> <tr> <td style="padding: 2px;">REMAINING Sr-85 IN mCi:</td> <td style="padding: 2px;">93.77 mCi</td> </tr> <tr> <td style="padding: 2px;">REMAINING Sr-85 IN GBq:</td> <td style="padding: 2px;">3.47 GBq</td> </tr> </table>	Sr-85 RETURN CALCULATIONS		INITIAL Sr-85 ACTIVITY:	156 mCi	DECAY FACTOR:	0.6011	REMAINING Sr-85 IN mCi:	93.77 mCi	REMAINING Sr-85 IN GBq:	3.47 GBq													
Sr-85 RETURN CALCULATIONS																							
INITIAL Sr-85 ACTIVITY:	156 mCi																						
DECAY FACTOR:	0.6011																						
REMAINING Sr-85 IN mCi:	93.77 mCi																						
REMAINING Sr-85 IN GBq:	3.47 GBq																						

Fig. 12A




Fig. 12B





Fig. 12C



INTEGRATED STRONTIUM-RUBIDIUM RADIOISOTOPE INFUSION SYSTEMS

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/389,200, filed Dec. 22, 2016, which is a continuation of U.S. patent application Ser. No. 12/808,467, filed Jun. 16, 2010, now U.S. Pat. No. 9,607,722, issued Mar. 28, 2017, which is a 371 National Stage of International Application No. PCT/US09/47031, filed Jun. 11, 2009, which in turn is a continuation of the following four patent applications: U.S. patent application Ser. No. 12/137,356, filed Jun. 11, 2008, now U.S. Pat. No. 8,317,674, issued Nov. 27, 2012; U.S. patent application Ser. No. 12/137,363, filed Jun. 11, 2008, now U.S. Pat. No. 7,862,534, issued Jan. 4, 2011; U.S. patent application Ser. No. 12/137,364, filed Jun. 11, 2008, now U.S. Pat. No. 9,597,053, issued Mar. 21, 2017; and U.S. patent application Ser. No. 12/137,377, filed Jun. 11, 2008, now U.S. Pat. No. 8,708,352, issued Apr. 29, 2014. The entire contents of all of these applications are incorporated herein by reference.

TECHNICAL FIELD

The present invention pertains to systems that generate and infuse radiopharmaceuticals, and, more particularly, to systems including computer-facilitated maintenance and/or operation.

BACKGROUND

Nuclear medicine employs radioactive material for therapy and diagnostic imaging. Positron emission tomography (PET) is one type of diagnostic imaging, which utilizes doses of radiopharmaceuticals, for example, generated by elution within a radioisotope generator, that are injected, or infused into a patient. The infused dose of radiopharmaceutical is absorbed by cells of a target organ, of the patient, and emits radiation, which is detected by a PET scanner, in order to generate an image of the organ. An example of a radioactive isotope, which may be used for PET, is Rubidium-82 (produced by the decay of Strontium-82); and an example of a radioisotope generator, which yields a saline solution of Rubidium-82, via elution, is the CardioGen-82® available from Bracco Diagnostics Inc. (Princeton, N.J.). A PET scanner in combination with infused doses of radiopharmaceuticals may also be employed to quantify blood flow rate, for example, through the coronary arteries of a patient.

Set up, maintenance and operational procedures for infusion systems that both generate and inject doses of radiopharmaceuticals are relatively involved in order to assure the safety and efficacy of each injected dose for the patient. Efficiency in carrying out these procedures is highly desirable for technical personnel, who work with these systems on a routine basis and would like to avoid unnecessarily prolonged exposure to radioactive radiation. Thus there is a need for new system configurations that facilitate more efficient set up, maintenance and operation.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings are illustrative of particular embodiments of the present invention and therefore do not limit the scope of the invention. The drawings are not to

scale (unless so stated) and are intended for use in conjunction with the explanations in the following detailed description. Embodiments of the present invention will hereinafter be described in conjunction with the appended drawings, wherein like numerals denote like elements.

FIG. 1A is a first perspective view of an infusion system, according to some embodiments of the present invention.

FIG. 1B is another perspective view of a portion of a cabinet structure of the system shown in FIG. 1A, according to some embodiments.

FIG. 1C is a second perspective view of the system shown in FIG. 1A, according to some embodiments.

FIG. 1D is a schematic of an infusion circuit, according to some embodiments of the present invention.

FIG. 1E is a perspective view of exemplary sample vial shielding that may be employed in conjunction with the infusion system of FIG. 1A.

FIG. 2A is a perspective view of a shielding assembly for an infusion system, such as that shown in FIGS. 1A-C, according to some embodiments of the present invention.

FIG. 2B is a perspective view of a framework of the system, according to some embodiments, and FIG. 2B-1 is an enlarged detailed view of a component of the system, according to some embodiments.

FIG. 3A is another perspective view of the shielding assembly shown in FIG. 2A.

FIG. 3B is a perspective view of the infusion circuit, shown in FIG. 1C, configured and routed, according to some embodiments.

FIG. 3C is a perspective view of a disposable infusion circuit subassembly, according to some embodiments.

FIG. 3D is a frame for the subassembly shown in FIG. 3C, according to some embodiments.

FIG. 4 is a main menu screen shot from an interface of a computer, which may be included in systems of the present invention, according to some embodiments.

FIG. 5A is a schematic showing a first group of successive screen shots from the computer interface, according to some embodiments.

FIG. 5B is a pair of screen shots from the computer interface, which provide indications related to eluant volume levels in a reservoir of the system, according to some embodiments.

FIG. 5C is a schematic showing a second group of successive screen shots from the computer interface, according to some embodiments.

FIG. 6 is a schematic showing a third group of successive screen shots from the computer interface, according to some embodiments.

FIGS. 7A-C are schematics showing a fourth group of successive screen shots from the computer interface, according to some embodiments.

FIGS. 8A-B are schematics showing a fifth group of successive screen shots from the computer interface, according to some embodiments.

FIGS. 9A-C are schematics showing a sixth group of successive screen shots from the computer interface, according to some embodiments.

FIG. 10 is a schematic showing a seventh group of successive screen shots from the computer interface, according to some embodiments.

FIG. 11 is an exemplary report which may be generated by the computer included in infusion systems, according to some embodiments.

FIGS. 12A-B are schematics of alternative infusion circuits that may be employed by embodiments of the present invention.

FIG. 12C is a schematic illustrating exemplary activity profiles of injected doses of a radiopharmaceutical.

DETAILED DESCRIPTION

The following detailed description is exemplary in nature and is not intended to limit the scope, applicability, or configuration of the invention in any way. Rather, the following description provides practical illustrations for implementing exemplary embodiments. Utilizing the teaching provided herein, those skilled in the art will recognize that many of the examples have suitable alternatives that can be utilized.

FIG. 1A is a first perspective view of an infusion system 10, according to some embodiments of the present invention, wherein system 10 is shown supported by a cabinet structure, which includes a platform 113 (seen better in FIG. 2B) and a shell 13; shell 13 extends upward from a skirt 11, that surrounds platform 113, to surround an interior space in which a portion of infusion system 10 is contained (seen in FIG. 1C). Shell 13 may be formed from panels of injection-molded polyurethane fitted together according to methods known to those skilled in the art. FIG. 1A illustrates the cabinet structure of system 10 including a grip or handle 14, which extends laterally from shell 13, in proximity to an upper surface 131 thereof, and a post 142, which extends upward from shell 13, and to which a work surface, or tray 16 and a computer 17 are, preferably, attached, via an ergonomic, positionable mount. According to some embodiments, computer 17 is coupled to a controller of system 10, which is mounted within the interior space surrounded by shell 13; and, a monitor 172 of computer 17 not only displays indications of system operation for a user of system 10, but also serves as a device for user input (e.g. touch screen input). However, according to alternate embodiments, another type of user input device, known to those skilled in the art, may be employed by computer 17. Other types of user input devices may be included, for example, a keyboard, a series of control buttons or levers, a bar code reader (or other reader of encoded information), a scanner, a computer readable medium containing pertinent data, etc. The user input device may be mounted on the cabinet structure of system 10, as shown, or may be tethered thereto; alternatively the user input device may be remote from system 10, for example, located in a separate control room. According to some additional embodiments, another user input device, for example, in addition to a touch screen of computer 17, may be remote from system 10 and used to start and stop infusions, as well as to monitor system operation both during quality control infusions and during patient infusions. Operation of system 10, which is facilitated by computer 17, will be described below, in conjunction with FIGS. 4-9C.

FIG. 1A further illustrates two pairs of wheels 121, 122, mounted to an underside of platform 113, to make system 10 mobile; handle 14 is shown located at an elevation suitable for a person to grasp in order to maneuver system 10, from one location to another, upon pairs of wheels 121, 122. According to some preferred embodiments, one or both pairs of wheels 121, 122, are casters, allowing for rotation in a horizontal plane (swivel), in order to provide additional flexibility for maneuvering system 10 in relatively tight spaces.

FIG. 1B is a perspective view of a portion of system 10, on a side 111 of the cabinet structure, which is in proximity to wheels 121, 122. FIG. 1B illustrates a lever or pedal 125, which is located for activation by a foot of the person, who

grasps handle 14 to maneuver system 10. In a neutral position, pedal 125 allows wheels 121, 122 to rotate, and, if embodied as casters, to swivel freely. Pedal 125 may be depressed to a first position which prevents a swiveling of wheels 121, 122, according to those embodiments in which wheels 121, 122 are casters, and may be further depressed to brake wheels 121, 122 from rolling and swiveling, upon reaching a desired location. According to some embodiments, braking may be designed to slow system 10, for example, when rolling down an incline, and, according to yet further embodiments, system 10 may include a motor to power movement thereof.

FIG. 1B further illustrates: a rear access panel 174 of shell 13, for example, providing access to circuit boards of the aforementioned controller contained within the interior space that is surrounded by shell 13; an optional lock 184, to secure panel 174; a power jack 118, for connecting system 10 to a power source; and a printer 117 for providing documentation of each patient infusion carried out by system 10, and of system quality control test results. In some embodiments, system 10 may further include a power strip by which auxiliary equipment may be powered, and one or more additional electrical connectors, or ports (not shown), which are supported by platform 113 and may be integrated into shell 13, for example, in proximity to jack 118 or printer 117; these electrical connectors/ports allow system 10 to communicate with, other devices used for nuclear imaging procedures, for example, a PET scanner/camera, and/or for coupling to an intranet network, and/or to the internet, for example, to link up with software programs for various types of data analysis, and/or to link to computers of consulting clinicians/physicians, and/or to link into service providers and/or component suppliers data bases for enhanced maintenance and inventory management.

FIG. 1A further illustrates upper surface 131 of shell 13 including several openings 133, 135, 139 formed therein. FIG. 1C is a partially exploded perspective view of system 10, wherein a removable access panel 132 is shown as a contoured portion of upper surface 131, which, when exposed, by lifting away a bin 18, that mates therewith, may be removed from another opening 137 formed in upper surface 131. FIG. 1C also provides a better view of another panel 134 which may be lifted away from opening 139. According to the illustrated embodiment, openings 139 and 137 provide a user of system 10 with independent access to separate portions of infusion system 10, which are contained within shell 13, for example, to set up and maintain system 10; and openings 133 and 135 provide passageways for tubing lines to pass through shell 13. FIG. 1C further illustrates an optional switch 102, which in case of an emergency, may be activated to abort function of system 10. With reference to FIGS. 1A and 1C, it may be appreciated that an arrangement of features formed in upper surface 131 of shell 13, in conjunction with bin 18, tray 16 and computer 17, provide a relatively ergonomic and organized work area for technical personnel who operate system 10.

Turning now to FIG. 1D, a schematic of an infusion circuit 300, which may be incorporated by system 10, is shown. FIG. 1D illustrates circuit 300 generally divided into a first part 300A, which includes components mounted outside shell 13, and a second part 300B, which includes components mounted within the interior space surrounded by shell 13. (Parts 300A and 300B are delineated by dotted lines in FIG. 1D.) FIG. 1D further illustrates second part 300B of circuit 300 including a portion contained within a shielding assembly 200, which is designated schematically as a dashed line. Some embodiments of shielding assembly

200 will be described in greater detail, in conjunction with FIGS. 2A-B and 3A-B, below.

According to the illustrated embodiment, circuit 300 includes: an eluant reservoir 15, for example, a bag, bottle or other container, containing saline as the eluant, which is shown hanging from a post, or hanger 141 above upper surface 131 of shell 13 in FIG. 1A; a syringe pump 33, for pumping the eluant from reservoir 15, and a pressure syringe 34 (or other device or sensor), for monitoring pumping pressure; a filter 37, which may also serve as a bubble trap, for the pumped eluant; a radioisotope generator 21, through which the filtered eluant is pumped to create a radioactive eluate, for example an eluate carrying Rubidium-82 that is generated by the decay of Strontium-82, via elution, within a column of generator 21; and an activity detector 25, for measuring the activity of the eluate discharged from generator 21, in order to provide feedback for directing the flow of the eluate, via a divergence valve 35WP, either to a waste bottle 23 or through a patient line 305_p, for example, to inject a dose of the radiopharmaceutical eluate into a patient. With reference back to FIG. 1A, patient line 305_p is shown extending out from shell 13, through opening 135, to a distal end thereof, which, according to some embodiments, includes a filter. Patient line 305_p may be coupled to another line that includes a patient injection needle (not shown). Alternatively, patient line 305_p may be coupled to another line (not shown), which extends from a source of another active substance, for example, a stress agent; the other line is coupled to the line that includes the patient injection needle, in order to permit injection of the additional active substance.

FIG. 1D illustrates an eluant tubing line 301 coupled to reservoir 15 and to pump 33, and, with reference to FIGS. 1A-B, it may be appreciated that opening 133 provides the passageway for tubing line 301 to enter the interior space surrounded by shell 13. According to some preferred embodiments, opening 133 includes a grommet-type seal that prevents leakage of eluant, which may spill from reservoir 15, into the interior space through opening 133, while allowing a user to assemble tubing line 301 through opening 133. Likewise opening 135, which provides a passageway for patient line 305_p, may include a grommet-type seal. According to some embodiments, shell 13 further supports holders to safely hold, for example, during transport of system 10, portions of tubing lines that extend outward therefrom, for example, line 301 and/or line 305_p.

FIG. 1D further illustrates another eluant tubing line 302 coupled to pump 33 and a divergence valve 35BG, which may either direct pumped eluant through a tubing line 304, to generator 21, or direct the pumped eluant through a by-pass tubing line 303, directly to patient line 305_p. Divergence valve 35BG, as well as divergence valve 35WP, which directs eluate from an eluate tubing line 305 either to a waste line 305_w or to patient line 305_p, may each be automatically operated by a corresponding servomotor (not shown), coupled to the controller (not shown) of system 10, which controller receives feedback from activity detector 25. When system 10 is operating for automatic infusion, to deliver a dose of radiopharmaceutical to a patient, for example, Rubidium-82 for diagnostic imaging, divergence valve 35BG is initially set to direct eluant to generator 21 and divergence valve 35WP is set to direct eluate from the generator into waste bottle 23, until activity detector 25 detects the desired activity of the eluate, at which time the feedback from activity detector 25 causes the controller to direct the corresponding servo-motor to re-set valve 35WP for diverting the flow of eluate into patient line 305_p.

According to some embodiments, once a prescribed volume of the eluate has passed through patient line 305_p, the controller directs the corresponding servomotor to re-set divergence valve 35BG for diverting the flow of eluate through by-pass line 303 and into patient line 305_p in order to flush, or push any eluate remaining in patient line 305_p into the patient. According to some embodiments, the controller may also direct the corresponding servomotor to re-set divergence valve 35WP back toward waste bottle 23, prior to the flush through by-pass line 303, in order to prevent back flow of eluant, through line 305, toward generator 21. According to some preferred methods of operation, in certain situations, which will be described in greater detail below, eluant is pumped through by-pass line 303 immediately following the flow of the prescribed volume of eluate into patient line 305_p, at a higher speed, in order to push the eluate in patient line 305, thereby increasing a flow rate of the injection of eluate out from patient line 305_p and into the patient. For example, once the prescribed volume of eluate has flowed into patient line 305_p, and once divergence valve 35BG is set to divert-flow through by-pass line 303, the speed of pump 33 may be adjusted to increase the flow rate of eluant to between approximately 70 mL/min and approximately 100 mL/min. This method for increasing the injection flow rate, is desirable, if a relatively high flow rate is desired for patient injection and a flow rate through generator 21 is limited, for example, to below approximately 70 mL/min, maximum (typical flow rate may be approximately 50 mL/min), in order to avoid an excessive back pressure created by the column of generator 21 in upstream portions of tubing circuit 300; the excessive back pressure could damage filter 37 or otherwise impede flow through eluant tubing line 302.

Although not shown in FIG. 1D, a number of sensors, for example, to measure pressure and/or flow velocity, may be incorporated into circuit 300, according to some alternate embodiments, in order to monitor for flow anomalies, for example, related to occlusions/plugs in circuit 300 and/or leaks, and/or to provide feedback for control of an activity level of infused doses of radiopharmaceutical. Suitable sensors for any of the above purposes are known to those skilled in the art. Examples of flow meters that may be incorporated into circuit 300, include the Innova-Sonic® Model 205 Transit-Time Ultrasonic Liquid Flow Meter that employs digital signal processing (available from Sierra Instruments, Inc.) and the Flocat LA10-C differential pressure flow meter. One example of a pressure sensor that may be employed to detect infusion circuit occlusions is the PRO/Pressure-Occlusion Detector (available from INTROTEK® of Edgewood, N.Y., a subsidiary of Magnetrol of Downers Grove, Ill.), which employs pulse-type ultrasound; this sensor detects subtle changes in positive and negative air pressure and produces a corresponding passive resistive output signal, which may be routed to the system controller and/or computer 17. One or more of this type of sensor may be incorporated into infusion circuit 300 by simply fitting the sensor around any of the tubing lines of infusion circuit 300; in fact, the PRO/Pressure-Occlusion Detector may be a suitable alternative to pressure syringe 34 of circuit 300. Other types of pressure sensors, for example, similar to those known in the art for blood pressure monitoring, may be employed in infusion circuit 300.

System 10 may further include sensors to detect fluid levels in eluant reservoir 15 and waste bottle 23. Some examples of such sensors, which also employ the aforementioned pulse-type ultrasound, are the Drip Chamber Liquid Level Sensor and the CLD/Continuous Level Detector (both

available from INTROTEK®); alternatively, for example, an HPQ-T pipe mounted, self-contained liquid sensor (available from Yamatake Sensing Control, Ltd.), or an SL-630 Non-Invasive Disposable/Reusable Level Switch (available from Cosense, Inc. of Hauppauge, N.Y.) may be employed to detect the fluid levels. Alternately or in addition, system 10 can include additional radiation and/or moisture detection sensors, which can detect leaks. With reference to FIG. 1D, such sensors are preferably located in proximity to fittings 311, 312, 313, 314 and 315 that join portions of circuit 300 to one another. Some examples of leak detection sensors include, without limitation, those in the HPQ-D leak detection sensor family, and the HPF-D040 fiberoptic leak detector (all available from Yamatake Sensing Control, Ltd.). System 10 may further include additional sensors to detect contaminants and/or air bubbles within the tubing lines of circuit; examples of such sensors include the Point-air Detection (PAD) Sensor, that employs pulse-type ultrasound for air bubble detection, and the Blood Component Detector that employs optical sensing technology to perform Colorimetry-based fluid detection of unwanted elements in the tubing lines (both available from INTROTEK®).

According to those embodiments that include any of the above sensors, the sensors are linked into the controller of system 10 and/or computer 17, either of which may provide a signal to a user of system 10, when a flow anomaly is detected, and/or information to the user, via monitor 172, concerning fluid levels, pressure and/or flow through circuit 300. Computer 17 may be pre-programmed to display, for example, on monitor 172, a graphic of infusion circuit 300 wherein each zone of the circuit, where an anomaly has been detected, is highlighted, and/or to provide guidance, to the system user, for correcting the anomaly. It should be noted that the alternative infusion circuits illustrated in FIGS. 12A-B, which will be described below, may also include any or all of these types of sensors.

With further reference to FIG. 1D, it may be appreciated that shielding assembly 200 encloses those portions of circuit 300 from which radioactive radiation may emanate, with the exception of that portion of patient line 305p, which must extend out from shielding assembly 200 in order to be coupled to the patient for injection, or in order to be coupled to shielded sample vials, as will be described below. Thus, technical personnel, who operate system 10, are protected from radiation by shielding assembly 200, except at those times when an infusion is taking place, or when quality control tests require collection of eluate into sample vials. During infusions and quality control test sample collection, all technical personnel are typically in another room, or otherwise distanced from system 10, in order to avoid exposure to radiation during the infusion, and, according to some preferred embodiments of the present invention, system 10 includes at least one means for informing technical personnel that an infusion is about to take place or is taking place. With reference back to FIGS. 1A and 1C, system 10 is shown including a light projector 100, mounted on post 142. According to the illustrated embodiment, projector 100, projects a light signal upward, for maximum visibility, when pump 33 is pumping eluant and elution is taking place within generator 21, or at all times when pump 33 is pumping eluant. According to some embodiments, the light signal flashes on and off when the eluate is being diverted from generator 21 into waste bottle 23, and the light signal shines steadily when the eluate is being diverted through patient line 305p, or visa versa. According to other embodiments, a projector 100 shines a light having a first color, to indicate that eluate is being diverted to waste bottle 23, and then

shines a light having a second, different color, to indicate that eluate is being directed to patient line 305p for infusion. Light projector 100 may further project a more rapidly flashing light, for example, for approximately five seconds, once a peak bolus of radioactivity is detected in the eluate, to provide further information to technical personnel. Alternative means of informing technical personnel that an infusion is taking place may also be incorporated by system 10, for example, including audible alarms or other types of visible or readable signals that are apparent at a distance from system 10, including in the control room.

It should be noted that, according to alternate embodiments, system 10 includes an 'on board' dose calibrator for quality control tests, and circuit 300 is expanded to include elements for an automated collection of eluate samples for activity measurements, via the on board dose calibrator. According to a first set of these alternate embodiments, a sample collection reservoir is integrated into circuit 300, downstream of divergence valve 35WP and in communication with tubing line 305P, in order to receive quality control test samples of eluate, via tubing line 305P, and both the reservoir and the dose calibrator are located in a separate shielded well. According to a second set of these alternate embodiments, waste bottle 23 is configured to receive the quality control test samples of eluate, via tubing line 305W, and a dose calibrator is integrated into shielding assembly 200. Quality control procedures will be described in greater detail below, in conjunction with FIGS. 6-8B.

When maintenance of system 10 requires the emptying waste bottle 23, relatively easy access to waste bottle 23 is provided through opening 139 in top surface 131 of shell 13. It should be noted that technical personnel are preferably trained to empty waste bottle 23 at times when the eluate, contained in waste bottle 23, has decayed sufficiently to ensure that the radioactivity thereof has fallen below a threshold to be safe. Opening 139 is preferably located at an elevation of between approximately 2 feet and approximately 3 feet; for example, opening 139 may be at an elevation of approximately 24 inches, with respect to a lower surface of platform 113, or at an elevation of approximately 32 inches, with respect to a ground surface upon which wheels 121, 122 rest. According to the illustrated embodiment, opening 139 is accessed by lifting panel 134; just within opening 139, a shielded lid or door 223 (FIG. 2A) may be lifted away from a compartment of shielding assembly 200 that contains waste bottle 23. With further reference to FIG. 1C, it may be appreciated that opening 137 provides access to other portions of circuit 300 for additional maintenance procedures, such as changing out generator 21 and/or other components of circuit 300, as will be described below.

For those embodiments of system 10 in which automated quality control tests are performed and/or when system 10 is employed for relatively high volume operation, management of waste may become burdensome, even though access to waste bottle 23 is greatly facilitated, as described above. Thus, in order to facilitate waste management, some embodiments of system 10 may employ a separation system to separate salts, including radioactive elements, from water, for example, via evaporation or reverse osmosis. In an evaporation type system, the water component of the waste is evaporated, while in a reverse osmosis type system the water is separated from the salts, and, then, once confirmed to be non-radioactive, via a radiation detector, is piped to a drain. According to some other embodiments, circuit 300 may be configured so that the waste may be used to purge air from the tubing lines thereof and/or to perform the bypass

flush that was described above, preferably after the radioactivity of the waste drops below a critical threshold.

FIGS. 1A and 1C further illustrate a pair of relatively shallow external recesses 190, which are formed in upper surface 131 of shell 13, for example, in order to catch any spills from the infusion system; one of recesses 190 is shown located in proximity to post, or hanger 141, which holds reservoir 15, and in proximity to opening 133, through which tubing line 301 passes. Another recess 192 is shown formed in upper surface 131; a width and depth of recess 192 may accommodate storage of technical documentation associated with infusion system 10, for example, a technical manual and/or maintenance records, or printouts from printer 117 (FIG. 1B). With reference to FIG. 1C, upper surface 131 of shell 13 is shown to also include additional recesses 101, which are each sized to hold a shielded test vial, which contains samples from infusion system 10, for example, for breakthrough testing and/or calibration, which will be described in greater detail, below. An exemplary test vial shield is shown in FIG. 1E. The test vial shield of FIG. 1E is preferably formed from Tungsten rather than lead, for example, to reduce exposure to lead, for improved shielding, and to reduce the weight of the shield. FIG. 1E illustrates the test vial shield including a handle to simplify manipulation thereof, but alternative configurations of test vial shields have no handle—for these a sling, or strap, may be employed for handling.

Additional receptacles 180 are shown formed in bin 18, on either side of a handle 182, which facilitates removal of bin 18 away from shell 13. Technical personnel may, thus, conveniently transport bin 18 to a storage area for a collection of supplies, for example, sharps, gloves, tubing lines, etc. . . . , into one or more receptacles 180 thereof, and/or to a waste container where separate receptacles 180 of bin 18 may be emptied of waste, such as packaging for the aforementioned supplies, for example, deposited therein during infusion procedures. According to some embodiments, one or more additional receptacles are formed in one or more disposal containers, for example, to contain sharps and/or radioactive waste (other than that contained in waste bottle 23), which may be integrated into bin 18, or otherwise fitted into, or attached to shell 13, separate from bin 18.

FIG. 2A is a perspective view of shielding assembly 200, according to some embodiments of the present invention. With reference to FIGS. 1C and 2A, together, it may be appreciated that opening 137, in upper surface 131 of shell 13, provides access to a lid or door 221 of a sidewall 201 of shielding assembly 200, which sidewall 201 encloses a compartment sized to contain a radioisotope generator of system 10, for example, generator 21, previously introduced. It should be noted that, according to alternate embodiments, the compartment enclosed by sidewall 201 is large enough to hold more than one generator, for example, to increase system operating efficiency for relatively high volume operation. In some of these alternate embodiments, tubing lines 304 and 305 are each branched for parallel flow through the multiple generators, in which case divergence valves may be employed to alternate the flow through the generators, one at a time. In others of these alternate embodiments, the multiple generators are connected in series between tubing line 304 and tubing line 305. In addition, a reservoir for accumulating eluate may be included in circuit 300, downstream of the generators and upstream of divergence valve 35 WP, in conjunction with a second pump, in some cases. Embodiments including multiple generators and/or an eluate reservoir and second pump can be employed to better manage an activity level of each

dose, or patient injection, for example, as described below, in conjunction with FIGS. 12A-B.

According to the embodiment illustrated in FIG. 2A, opening 137 and door 221 are located at a lower elevation, for example, with respect to platform 113, than are opening 139 and lid 223, which provide access to the compartment being formed by a sidewall 203 of shielding assembly 200 to contain waste bottle 23, as previously described. When panel 132 is separated from shell 13, and door 221 opened, generator 21 may be lifted out from an opening 231 (FIG. 3A) which mates with door 221 of sidewall 201. A weight of generator 21, which includes its own shielding, may be between approximately 23 and approximately 25 pounds, thus, according to some preferred embodiments of the present invention, the elevation of each of openings 137 and 231, with respect to the lowermost portion of the cabinet structure, is between approximately 1 foot and approximately 2 feet, in order to facilitate an ergonomic stance for technical personnel to lift generator 21 out from the compartment. According to an exemplary embodiment, when shielding assembly 200 is contained in the cabinet structure of FIG. 1A, openings 137 and 231 are located at an elevation of approximately 12 inches, with respect to the lower surface of platform 113, or at an elevation of approximately 19 inches, with respect to the ground surface upon which wheels 121, 122 rest. FIG. 1C further illustrates access panel 132 including a security lock 138, which mates with a framework 19 of system 10, shown in FIG. 2B, in order to limit access to generator 21.

FIGS. 1C and 2A further illustrate a lid or a door 225 of another sidewall 205 (FIG. 3A) of shielding assembly 200, which encloses another compartment that is accessible through opening 137 of shell 13, and which is located adjacent the compartment enclosed by sidewall 201. Each of doors 221, 225 are shown being attached by a corresponding hinge H, and another door 227 is shown attached to sidewall 203 by another hinge H. FIG. 2A illustrates each of lid 223 and doors 221, 225, 227 including a handle 232, 212, 252 and 272, respectively, for moving lid 223 and doors 221, 225, 227, in order to provide access to the corresponding compartments, which can be seen in FIGS. 3A-B. FIG. 2A further illustrates optional thumb screws 290, one securing lid 223 to sidewall 203 and another securing door 221 to sidewall 201, or other means for securing the doors, which are known to those skilled in the art, may be incorporated. Each sidewall 201, 203, 205 and the corresponding lid/door 223, 221, 225, 227 thereof may be individually cast from 3% antimony lead, or from other known shielding materials, and then assembled together according to methods known to those skilled in the art.

According to the illustrated embodiment, doors 221, 225 are hinged to open in an upward direction, per arrows D and C, and, with reference back to FIG. 1C, a latch component 191 is provided to hold each of doors 221, 225 in an opened position, thereby, preventing doors 221, 225 from falling closed, which could pinch/crush fingers of technical personnel and/or tubing lines of circuit 300, when in the midst of a maintenance procedure. FIG. 2B is a perspective view of framework 19 of the cabinet structure of system 10, according to some embodiments, to which latch component 191 is mounted; FIG. 2B-1 is an enlarged detailed view of latch component 191, according to some embodiments. FIG. 2B illustrates latch component 191 including a first pin 193, corresponding to door 225, and a second pin 195, corresponding to door 221; each pin 193, 195 includes a lever end 193A, 193B, respectively, and a holding end 193B, 195B, respectively. An edge of each door 221, 225, upon opening

of doors 221, 225, may push past the holding end 195B, 193B of the corresponding pin 195, 193, in a first direction, per arrow F, and then may rest against a respective side S95 and S93 of each end 195B, 193B, until the corresponding lever end 195A, 193A is rotated in a counter-clockwise direction, per arrow cc, thereby moving the corresponding holding end 193B, 195B to make way for the closing of doors 221, 225. Doors 221, 225 being held by latch component 191 in an open position may be seen in FIG. 3A.

With further reference to FIG. 2A, according to some preferred embodiments of the present invention, an edge of door 225 overlaps door 221 to prevent door 221 from being opened, per arrow D, if door 225 is not opened, per arrow C; and an edge of door 227 overlaps an edge of door 225 to prevent door 225 from being opened if door 227 is not opened, per arrow B; and an edge of lid 223 overlaps door 227 to prevent door 227 from being opened if lid 223 is not opened, per arrow A. Thus, access to the compartment enclosed by sidewall 201 and containing generator 21 is only systematically allowed through a sequential opening of lid 223 and doors 227, 225, 221, since, when generator 21 is replaced it is typically desirable to also replace those portions of circuit 300 which are shielded behind lid 223 and doors 227, 225. The routing of these portions of circuit 300 will be described in conjunction with FIGS. 3A-C.

FIG. 3A is another perspective view of shielding assembly 200, according to some embodiments of the present invention. In FIG. 3A, lid 223 and doors 221, 225, and 227 are opened to provide a view into openings 233, 235 and 231 of sidewalls 203, 205 and 201, respectively, and into a passageway 207, which is formed in sidewall 203, opposite the compartment, which contains waste bottle 23. Passageway 207 is shown extending vertically along sidewall 203 and having a grooved extension 213 formed in a perimeter surface of opening 233. An optional retaining member 237, for example, formed from an elongate strip of resilient plastic having a generally c-shape cross-section, is shown being mounted along a length of passageway 207 to hold lines 305_w and 305_p in place within passageway 207. FIG. 3A further illustrates a pair of passageways 251_b and 251_g, which are formed as grooves in a portion of sidewall 205, and another pair of passageways 215_i and 215_o, which are formed as grooves in a portion of sidewall 201. A routing of portions of tubing circuit 300 (FIG. 1D) through passageways 207, 251_b, 251_c, 215_i and 215_o is shown in FIG. 3B.

FIG. 3B illustrates tubing line 304 being routed through passageways 251_g and 215_i, eluate tubing line 305 being routed through passageway 215_o, and both waste line 305_w and patient line 305_p being routed along passageway 207. Waste line 305_w further extends through grooved extension 213 to waste bottle 23, and patient line 305_p further extends outward from shielding assembly 200, for example, to extend out through opening 135 in upper surface 131 of shell 13 (FIG. 1A). According to the illustrated embodiment, each passageway formed in shielding assembly 200, by being accessible along a length thereof, can facilitate a relatively easy routing of the corresponding tubing line therethrough, when the corresponding lid/door is open, and a depth of each passageway prevents pinching and/or crushing of the corresponding tubing line routed therethrough, when the corresponding lid/door is closed down thereover. With further reference to FIGS. 3A-B, it may be appreciated that the compartment formed by sidewall 201 may have a shape matching an exterior contour of generator 21, such that generator 21 is 'keyed' to the compartment, for example, to prevent installation of an improper generator into system 10, and/or to facilitate the proper orientation of generator 21

within the compartment for the proper routing of tubing lines. Alternately, or in addition, according to alternate embodiments, if system 10 includes a reader of encoded information in communication with computer 17, a unique identification and/or data associated with each generator may be provided, for example, in a bar code label or a radiofrequency identification (RFID) tag that is attached to each generator, so that the reader may transfer the information to computer 17, when a generator is installed, in order to either enable system operation or to provide an indication to the user that an incorrect generator has been installed. Of course a user of system 10 may, alternately, manually enter information, that is provided on a generator label or marking, into computer 17, in order to either enable system 10, or to receive feedback from computer 17 that the incorrect generator is installed.

FIG. 3A further illustrates sidewall 205 including a valve actuator receptacle 253, into which divergence valve 35WP is mounted, to be controlled by one of the servomotors (not shown) of system 10, and an opening 325 for activity detector 25. Activity detector 25 is mounted in a shielded well 255 that extends downward from opening 325 (shown in FIG. 3B), and, with reference to FIG. 3B, tubing line 305 passes over opening 325 so that detector 25 can detect an activity of the eluate, which passes therethrough. According to some embodiments, the positioning, within the compartment enclosed by sidewall 205, of the components of the portion of infusion circuit 300 which are shown routed therein, is facilitated by providing the components mounted in a frame 39 as a disposable subassembly 390, an embodiment of which is illustrated by FIGS. 3C-D.

FIG. 3C is a perspective view of subassembly 390, and FIG. 3D is a perspective view of frame 39. According to the embodiment illustrated by FIG. 3D, frame 39 is formed from mating trays 39A, 39B, for example, formed from a thermoformed plastic, which fit together to capture, therebetween, and hold, in fixed relation to a perimeter edge of frame 39, divergence valve 35WP and portions of eluant tubing line 304, by-pass tubing line 303, eluate tubing line 305, waste line 305_w and patient line 305_p. FIG. 3C illustrates the perimeter edge divided into a first side 391, a second side 392, opposite first side 391, a third side 393, extending between first and second sides 391, 392, and a fourth side 394, opposite third side 393. Although FIG. 3D shows trays 39A, 39B individually formed for fitting together, according to alternate embodiments, mating trays of frame 39 may be parts of a continuous sheet of plastic folded over on itself.

According to the illustrated embodiment, an end 404A, of eluant line 304, and an end 403, of by-pass line 303 extend from third side 393 of frame 39 to couple with divergence valve 35BG and an upstream section of eluant tubing line 302. FIG. 3C further illustrates an opposite end 404B of eluant line extending from first side 391 of frame 39, alongside a similarly extending end 405 of eluate line 305, and ends 406 and 407 of patient line 305_p and waste line 305_w, respectively, extending from second side 392 of frame 39. Although ends 406, 407 are shown extending upward from tray 39a, as they would within shielding assembly 200, it should be appreciated that the tubing lines of circuit 300 are preferably flexible and would drop down under their own weight rather than extending upward, as shown, if not supported. Referring back to FIG. 1D, in conjunction with FIG. 3C, it can be seen that the aforementioned fittings are provided for coupling subassembly 390 into circuit 300: first fitting 311 couples the section of eluant line 302 to filter 37; second fitting 312 couples eluant line 304 to an inlet port of

generator 21; third fitting 313, which may incorporate a check valve, couples eluate line 305 to an outlet port of generator 21; fourth fitting 314 couples waste line 305_w to waste bottle 23; and fifth fitting 315 couples patient line 305_p to an extension thereof, which extends outside shell 13 (designated by the dotted line). Each of the fittings 311, 312, 313, 314, 315 may be of the Luer type, may be a type suitable for relatively high pressure applications, or may be any other suitable type that is known to those skilled in the art.

As previously mentioned, when generator 21 is replaced, it is typically desirable to also replace those portions of circuit 300 which are shielded behind lid 223 and doors 227, 225, and, in those instances wherein system 10 is moved to a new site each day, these portions may be replaced daily. Thus, according to the illustrated embodiment, these portions are conveniently held together by frame 39, as subassembly 390, in order to facilitate relatively speedy removal and replacement, while assuring a proper assembly orientation, via registration with features formed in sidewall 205 (FIG. 3A), for example: registration of divergence valve 35WP with valve actuator receptacle 253, registration of tubing line ends 403 and 404A with passageways 251_b and 251_g, respectively, registration of tubing line ends 404B and 405 with passageways 215_i and 215_o, respectively, and registration of tubing line ends 406 and 407 with passage-way 207.

With further reference to FIG. 3B, other portions of tubing circuit 300 are shown. FIG. 3B illustrates eluant tubing line 301 extending from reservoir 15, outside of shell 13 (FIG. 1A), to syringe pump 33, which is mounted to an actuating platform 433. According to the illustrated embodiment, platform 433 is actuated by another servomotor (not shown) of system 10, which is controlled by the controller and computer 17 of system 10, to cause a plunger of pump 33 to move, per arrow I, so as to draw in eluant, from reservoir 15, through tubing line 301, and then to cause the plunger to move in the opposite direction so as to pump the eluant, through tubing line 302, to either generator 21 or to by-pass line 303. Although the illustrated embodiment includes syringe pump 33, other suitable pumps, known to those skilled in the art, may be substituted for pump 33, in order to draw eluant from reservoir 15 and to pump the eluant throughout circuit 300. Although not shown, it should be appreciated that divergence valve 35BG is fitted into another valve actuating receptacle mounted within shell 13 and coupled to yet another servomotor (not shown) of system 10.

FIG. 3B further illustrates a filter holder 317 that is mounted alongside an interior surface of shell 13 to hold filter 37 (FIG. 1D) of tubing line 302. Filter holder 317, like frame 39 for subassembly 390, may be formed from a thermoformed plastic sheet; holder 317 may have a clam-shell structure to enclose filter 37 in an interior space, yet allow tubing line 302, on either side of filter 37, to extend out from the interior space, in between opposing sides of the clam-shell structure. Holder 317 is shown including an appendage 307 for hanging holder 317 from a structure (not shown) inside shell 13.

Turning now to FIGS. 4-9C details concerning computer-facilitated operation of system 10 will be described, according to some embodiments of the present invention. As previously mentioned, and with reference back to FIG. 1A, computer 17 of system 10 includes monitor 172, which, preferably, not only displays indications of system operation to inform a user of system 10, but is also configured as a touch screen to receive input from the user. It should be understood that computer 17 is coupled to the controller of

system 10, which may be mounted within the interior space surrounded by shell 13. Although FIG. 1A shows computer 17 mounted to post 142 of system 10, for direct hardwiring to the controller of system 10, according to some alternate embodiments, computer 17 is coupled to the controller via a flexible lead that allows computer 17 to be positioned somewhat remotely from those portions of system 10, from which radioactive radiation may emanate; or, according to some other embodiments, computer 17 is wirelessly coupled, for example, via two-way telemetry, to the controller of system 10, for even greater flexibility in positioning computer 17, so that the operation of system 10 may be monitored and controlled remotely, away from radioactive radiation.

According to some preferred embodiments, computer 17 is pre-programmed to guide the user, via monitor 172, through procedures necessary to maintain system 10, to perform quality control tests on system 10, and to operate system 10 for patient infusions, as well as to interact with the user, via the touch-screen capability of monitor 172, according to preferred embodiments, in order to track volumes of eluant and eluate contained within system 10, to track a time from completion of each elution performed by system 10, to calculate one or more system parameters for the quality control tests, and to perform various data operations. Computer 17 may also be pre-programmed to interact with the controller of system 10 in order to keep a running tally or count of elutions per unit time, for a given generator employed by the system, and may further categorize each of the counted elutions, for example, as being generated either as a sample, for quality control testing, or as a dose, for patient injection. The elution count and categorization, along with measurements made on each sample or dose, for example, activity level, volume, flow rate, etc. . . . , may be maintained in a stored record on computer 17. All or a portion of this stored information can be compiled in a report, to be printed locally, and/or to be electronically transferred to a remote location, for example, via an internet connection to technical support personnel, suppliers, service providers, etc. . . . , as previously described. Computer 17 may further interact with the user and/or a reader of encoded information, for example, a bar code reader or a radiofrequency identification (RFID) tag reader, to store and organize product information collected from product labels/tags, thereby facilitating inventory control, and/or confirming that the proper components, for example, of the tubing circuit, and/or accessories, and/or solutions are being used in the system.

It should be understood that screen shots shown in FIGS. 4-9C are exemplary in nature and are presented to provide an outline of some methods of the present invention in which computer 17 facilitates the aforementioned procedures, without limiting the scope of the invention to any particular computer interface format. Computer 17 may also include a pre-programmed user manual, which may be viewed on monitor 172, either independent of system operation or in conjunction with system operation, for example, via pop-up help screens. Although the English language is employed in the screen shots of FIGS. 4-9C, it should be understood that, according to some embodiments, computer 17 is pre-programmed to provide guidance in multiple languages.

FIG. 4 is a screen shot of a main menu 470, which is presented by computer 17 on monitor 172, according to some embodiments. Main menu 470 includes a listing of each computer-facilitated operation that may be selected by the user, once the user has logged on. According to some

multi-lingual embodiments, computer 17 presents a list of languages from which the user may select, prior to presenting main menu 470.

FIG. 5A is a schematic showing a series of screen shots which includes a log in screen 570. According to some embodiments, when the user touch-selects the data entry fields of screen 570 or 571, or of any of the other screens presented herein, below, a virtual keyboard is displayed for touch-select data entry into the selected data entry field; alternately, computer 17 may be augmented with another type of device for user data entry, examples of which include, without limitation, a peripheral keyboard device, a storage medium (i.e. disk) reader, a scanner, a bar code reader (or other reader of encoded information), a hand control (i.e. mouse, joy stick, etc. . . .). Although not shown, according to some embodiments, screen 570 may further include another data entry field in which the user is required to enter a license key related to the generator employed by system 10 in order to enable operation of system 10; the key may be time sensitive, related to generator contract terms. Of course any number of log in requirements may be employed, according to various embodiments, and may be presented on multiple sequentially appearing screens rather than on a single log in screen.

After the user enters the appropriate information into data entry fields of log in screen 570, computer 17 presents a request for the user to confirm the volume of eluant that is within reservoir 15 (e.g. saline in saline bag), via a screen 571, and then brings up main menu 470. If the user determines that the volume of eluant/saline is insufficient, the user selects a menu item 573, to replace the saline bag. If system 10 includes an encoded information reader, such as a bar code or RFID tag reader, confirmation that the selected reservoir is proper, i.e., contains the proper saline solution, may be carried out by computer 17, prior to connecting the reservoir into circuit 300, by processing information read from a label/tag attached to the reservoir. Alternatively, or in addition, tubing line 301 of circuit 300 may be provided with a connector which only mates with the proper type of reservoir 15. According to some embodiments, system 10 may further include an osmolarity or charge detector, which is located just downstream of reservoir 15 and is linked to computer 17, so that an error message may be presented on monitor 172 stating that the wrong osmolarity or charge is detected in the eluant supplied by reservoir, indicating an improper solution. One example of a charge detector that may be employed by system 10 is the SciCon™ Conductivity Sensor (available from SciLog, Inc. of Middleton, Wis.).

Once the reservoir/saline bag is successfully replaced, computer 17 prompts the user to enter a quantity of saline contained by the new saline bag, via a screen 574. Alternately, if system 10 includes the aforementioned reader, and the saline bag includes a tag by which volume information is provided, the reader may automatically transfer the quantity information to computer 17. Thus, computer 17 uses either the confirmed eluant/saline volume, via screen 571, or the newly entered eluant/saline volume as a baseline from which to track depletion of reservoir volume, via activations of pump 33, in the operation of system 10. With reference to FIG. 5B, during the operation of system 10, when computer 17 detects that the eluant reservoir/saline bag has been depleted to a predetermined volume threshold, computer 17 warns the user, via a screen 577. If the user has disregarded screen 577 and continues to deplete the saline bag, computer 17 detects when the saline bag is empty and provides indication of the same to the user, via a screen 578. To

replenish the reservoir/saline bag, the user may either refill the reservoir/bag or replace the empty reservoir/bag with a full reservoir/bag. According to some embodiments, system 10 automatically precludes any further operation of the system until the reservoir is replenished. It should be noted that, as previously mentioned, system 10 can include a fluid level sensor coupled to the eluant reservoir in order to detect when the level of saline drops below a certain level.

In addition to tracking the volume of eluant in reservoir 15, computer 17 also tracks a volume of the eluate which is discharged from generator 21 into waste bottle 23. With reference to FIG. 5C, an item 583 is provided in main menu 470, to be selected by the user when the user empties waste bottle 23. When the user selects item 583, computer 17 presents a screen 584, by which the user may effectively command computer 17 to set a waste bottle level indicator to zero, once the user has emptied waste bottle 23. Typically, the user, when powering up system 10 for operation, each day, will either empty waste bottle 23, or confirm that waste bottle 23 was emptied at the end of operation the previous day, and utilize screen 584 to set the waste bottle level indicator to zero. Thus, computer 17, can track the filling of waste bottle 23 via monitoring of the operation of pump 33 and divergence valve 35WP, and provide an indication to the user when waste bottle 23 needs to be emptied, for example, via presentation of screen 584, in order to warn the user that, unless emptied, the waste bottle will overflow. According to some embodiments, system 10 automatically precludes any further operation of the system until the waste bottle is emptied. According to some alternative embodiments, a fluid level sensor may be coupled to waste bottle 23, for example, as mentioned above in conjunction with FIG. 1D, in order to automatically detect when waste bottle 23 is filled to a predetermined level and to provide, via computer 17, an indication to the user that waste bottle 23 needs to be emptied and/or to automatically preclude operation of system 10 until the waste bottle is emptied.

In addition to the above maintenance steps related to eluant and eluate volumes of system 10, the user of system 10 will typically perform quality control tests each day, prior to any patient infusions. With reference to FIG. 6, according to preferred methods, prior to performing the quality control tests (outlined in conjunction with FIGS. 7A-C and 8A-B), the user may select an item 675 from main menu 470, in order to direct system 10 to wash the column of generator 21. During the generator column wash, which is performed by pumping a predetermined volume of eluant, for example, approximately 50 milliliters, through generator 21 and into waste bottle 23, computer 17 provides an indication, via a screen 676, that the wash is in progress. Also, during the generator column wash, the system may provide a signal to indicate that eluate it being diverted to waste bottle 23, for example, light projector 100 (FIG. 1C) may project a flashing light signal, as previously described.

FIG. 6 further illustrates a screen 677, which is presented by computer 17 upon completion of the column wash, and which provides an indication of a time lapse since the completion of the wash, in terms of a time countdown, until a subsequent elution process may be effectively carried out. While screen 677 is displayed, system 10 may be refilling, from reservoir 15, pump 33, which has a capacity of approximately 55 milliliters, according to some embodiments. According to some preferred embodiments of the present invention, computer 17 starts a timer once any elution process is completed and informs the user of the time lapse, either in terms of the time countdown (screen 677), or in terms of a time from completion of the elution, for

example, as will be described in conjunction with FIG. 7B. According to an exemplary embodiment, wherein generator 21 is the CardioGen-82® that yields a saline solution of Rubidium-82, produced by the decay of Strontium-82, via the elution, a time required between two effective elution processes is approximately 10 minutes.

Once the appropriate amount of time has lapsed, after the elution process of generator column wash, a first quality control test may be performed. With reference to FIG. 7A, the user may select, from main menu 470, an item 773A, which directs computer 17 to begin a sequence for breakthrough testing. According to some embodiments, in conjunction with the selection of item 773A, the user attaches a needle to an end of patient line 305p and inserts the needle into a test vial, for the collection of an eluate sample therefrom, and, according to FIG. 7A, computer 17 presents a screen 774, which instructs the user to insert the test vial into a vial shield, which may be held in recess 101 of shell 13 (FIG. 1C).

FIG. 7A further illustrates a subsequent screen 775, by which computer 17 receives input, from the user, for system 10 to start the breakthrough elution, followed by a screen 776, which provides both an indication that the elution is in progress and an option for the user to abort the elution. As previously described, the system may provide a signal to indicate that elution is in progress, for example, light projector 100 (FIG. 1C) may project a flashing light signal during that portion of the elution process when eluate is diverted from generator 21 through waste line 305w and into waste bottle 23, and then a steady light signal during that portion of the elution process when the eluate is diverted from generator 21 through patient line 305p and into the test vial, for example, once activity detector 25 detects a dose rate of approximately 1.0 mCi/sec in the eluate discharged from generator 21. Another type of light signal, for example, the more rapidly flashing light, as previously described, may be projected when a peak bolus of radioactivity is detected in the eluate.

Upon completion of the elution process for breakthrough testing, computer 17 presents a screen 777, shown in FIG. 7B, which, like screen 677, provides an indication of a time lapse since the completion of the elution, but now in terms of a time since completion of the breakthrough elution process. When the user transfers the vial containing the sample of eluate into a dose calibrator, to measure the activity of the sample, the user may make a note of the time lapse indicated on screen 777. With further reference to FIG. 7B, once the user has received the activity measure from the dose calibrator, the user proceeds to a screen 778, which includes data entry fields for the activity measure and the time between that at which the dose calibrator measured the activity of the sample and that at which the elution was completed. The user may enter the data via the touch-screen interface of monitor 172, or via any of the other aforementioned devices for user data entry. According to some alternate embodiments, computer 17 may receive the data, electronically, from the dose calibrator, either via wireless communication or a cable connection.

After the data is entered by the user, computer 17 presents screen 779, from which the user moves back to main menu 470 to perform a system calibration, for example, as will be described in conjunction with FIGS. 8A-B, although the breakthrough testing is not completed. With reference back to FIG. 7A, an item 773B is shown in main menu 470; item 773B may only be effectively selected following the completion of steps for item 773A, so as to perform a second stage of breakthrough testing. In the second stage, the

breakthrough of the sample of eluate collected in the test vial for the breakthrough testing is measured, at a time of approximately 60 minutes from the completion of the elution that produced the sample. With reference to FIG. 7C, after the user has selected item 773B from main menu 470, in order to direct computer 17 to provide breakthrough test results, a screen 781 is displayed. Screen 781 includes, for reference, the values previously entered by the user in screen 778, along with another pair of data entry fields into which the user is instructed to enter the breakthrough reading of the sample at 60 minutes and the background radiation reading, respectively. After the user enters this remaining information, as described above, computer 17 may calculate and then display, on a screen 782, the breakthrough test results. According to the illustrated embodiment, computer 17 also displays on screen 782 pre-programmed allowable limits for the results, so that the user may verify that the breakthrough test results are in compliance with acceptable limits, before moving on to a patient infusion. According to some embodiments, system 10 will not allow an infusion if the results exceed the acceptable limits, and may present a screen explaining that the results are outside the acceptable limits; the screen may further direct the user to contact the generator supplier, for example, to order a replacement generator.

With reference to FIG. 8A, during the aforementioned 60 minute time period, while waiting to complete the breakthrough testing, the user may perform calibration by selecting item 873 from main menu 470. Upon selection of item 873, computer 17 presents a screen 874, which instructs the user to insert a new test vial into an elution vial shield. In addition to placing the vial in the shield, the user, preferably, replaces patient line 305p with a new patient line, and then attaches a needle to the end of the new patient line for insertion into the test vial, in order to collect an eluate sample therefrom. After performing these steps, the user may move to screen 875, wherein a plurality of data entry fields are presented; all or some of the fields may be filled in with pre-programmed default parameters, which the user has an option to change, if necessary. Once the user confirms entry of desired parameters for the calibration, the user may enter a command, via interaction with a subsequent screen 876, to start the calibration elution.

With reference to FIG. 8B, after computer 17 starts the elution process, a screen 87 informs the user that the calibration elution is in progress and provides an option to abort the elution. As previously described, the system may provide an indication that elution is in progress, for example, light projector 100 (FIG. 1C) may project a flashing light signal during that portion of the elution process when eluate is diverted from generator 21 through waste line 305w and into waste bottle 23, and then a steady light signal during that portion of the elution process when activity detector 25 has detected that a prescribed dose rate threshold is reached, for example, 1.0 mCi/sec, and the eluate is being diverted from generator 21, through the new patient line, and into the test vial. Another type of light signal, for example, the more rapidly flashing light, as previously described, may be projected when a peak bolus of radioactivity is detected in the eluate. Upon completion of the elution process for calibration, computer 17 presents a screen 878, which provides an indication of a time lapse since the completion of the elution, in terms of a time since completion of the calibration elution process. When the user transfers the vial containing the sample of eluate into the dose calibrator, to measure the activity of the sample, the user may make a note of the time lapse indicated on screen 878. With further reference to FIG. 8B, once the user has received the activity

measure from the dose calibrator, the user proceeds to a screen 879, which includes data entry fields for the activity measure and the time, with respect to the completion of elution, at which the dose calibrator measured the activity of the sample. Once the data is input by the user, as described above, the computer calculates a calibration coefficient, or ratio, and presents the ratio on a screen 880. According to FIG. 8B, screen 880 further provides an indication of a desirable range for the calibration ratio and presents an option for the user to reject the calculated ratio, in which case, the user may instruct computer 17 to recalculate the ratio.

As previously mentioned, some alternate embodiments of the present invention include an on board dose calibrator so that the entire sequence of sample collection and calculation steps, which are described above, in conjunction with FIGS. 6-8B, for the quality control procedures, may be automated. This automated alternative preferably includes screen shots, similar to some of those described above, which provide a user of the system with information at various stages over the course of the automated procedure and that provide the user with opportunities to modify, override and/or abort one or more steps in the procedure. Regardless of the embodiment (i.e. whether system 10 employs an on board dose calibrator or not), computer 17 may further collect all quality control test parameters and results into a stored record and/or compile a report including all or some of the parameters and results for local print out and/or electronic transfer to a remote location.

With reference to FIG. 9A, upon completion of the above-described quality control tests, the user may select an item 971, from main menu 470, in order to direct system 10 to begin a procedure for the generation and automatic infusion of a radiopharmaceutical into a patient. As previously described, system 10 infuses the patient with the radiopharmaceutical so that nuclear diagnostic imaging equipment, for example, a PET scanner, can create images of an organ of the patient, which absorbs the radiopharmaceutical, via detection of radioactive radiation therefrom. According to FIG. 9A, upon selection of item 971, computer 17 presents a screen 972 which includes a data entry field for a patient identification number. This identification number that is entered by the user is retained by computer 17, in conjunction with the pertinent system parameters associated with the patient's infusion. After the user enters the patient identification number, computer 17 directs, per a screen 973, the user to attach a new patient line and to purge the patient line of air. A subsequent screen 974 presented by computer 17 includes data entry fields by which the user may establish parameters for the automatic infusion; all or some of the fields may be filled in with pre-programmed default parameters, which the user has an option to change, if necessary.

With reference to FIG. 9B, if pump 33 does not contain enough eluant/saline for the patient infusion, computer 17 will present a warning, via a screen 901, which includes an option for the user to direct the refilling of pump 33, via a subsequent screen 902. Once pump 33 has been filled, computer 17 presents an indication to the user, via a screen 903. According to some embodiments, if the user does not re-fill pump 33, yet attempts to proceed with an infusion, system 10 will preclude the infusion and present another screen, that communicates to the user that no infusion is possible, if the pump is not refilled, and asking the user to refill the pump, as in screen 901. When pump 33 contains a sufficient volume of eluant for the patient infusion, computer 17 presents a screen 975, which is shown in FIG. 9C, and allows the user to enter a command for system 10 to start the

patient infusion. During the infusion, computer 17 provides the user with an indication that the infusion is in process and with an option for the user to abort the infusion, via a screen 976. As previously described, the system may provide an indication that an elution is in progress, for example, light projector 100 (FIG. 1C) may project a flashing light signal during that portion of the elution process when eluate is diverted from generator 21 through waste line 305_w and into waste bottle 23, and then a steady light signal during that portion of the elution process when activity detector 25 has detected that a prescribed dose rate threshold is reached, for example, 1.0 mCi/sec, and the eluate is being diverted from generator 21, through the new patient line for infusion into the patient. Another type of light signal, for example, the more rapidly flashing light, previously described, may be projected when a peak bolus of radioactivity is detected in the eluate. At the completion of the infusion, a screen 977 is displayed by computer 17 to inform the user of the completion of the infusion and a time since the completion. Computer 17 also displays a summary of the infusion, per screen 978.

With further reference to FIG. 9C, screen 976 shows an exemplary activity profile (activity—mCi/sec, on y-axis, versus time—sec, on x-axis) for the infusion/injected dose (designated between the two vertical lines). Those skilled in the art will appreciate that the shape of this profile depends upon the infusion flow rate, for a given volume of the dose, which flow rate is controlled, for example, by the speed at which pump 33 drives flow through the patient line, and upon the amount of Strontium-82 remaining in the generator. In the absence of flow rate control, activity profiles may change over the life of the generator. Furthermore, the peak bolus of radioactivity, particularly for injected doses from a relatively new generator, may exceed a saturation level of the imaging equipment, i.e. PET scanner. According to some preferred methods of the present invention, in order to maintain relatively consistent, and desirable/effective, activity profiles for patient injections, over the life of the generator, the operating speed of pump 33 may be varied (both over the course of a single injection and from injection to injection), according to feedback from activity detector 25. Such a method may be implemented via incorporation of another quality control test in which pump 33 is operated to drive flow through the generator at a constant rate, in order to collect, into computer, a plurality of activity measurements from activity detector 25; the plurality of measurements comprise a characteristic, or baseline activity profile from which the computer 17 may calculate an appropriate flow rate profile to control a speed of pump 33, in order to achieve the desirable/effective activity profile. In general, at the start of generator life, when Strontium-82 is plentiful, the pump is controlled to drive infusion flow at relatively lower rates, and, then, toward the end of generator life, when much of the Strontium-82 has been depleted, the pump is controlled to drive infusion flow at relatively higher rates. As was described above, in conjunction with FIG. 1D, if a desired infusion/injection flow rate is relatively high, that is, high enough to create too much back pressure, via flow through the column of generator 21, by-pass line 303 may be employed by adjusting divergence valve 35BG to divert a flow of eluant therethrough after a sufficient volume has been pumped through generator at a lower flow rate. According to this method, once a dose of eluate, from generator 21, has flowed into patient line 305_p, divergence valve 35BG is set to divert the flow of eluant through by-pass line 303, and then pump speed is increased to pump eluant at a higher flow

rate in order to push the dose out from patient line 305_p, for injection at the higher flow rate.

Consistency of activity profiles among injected doses can greatly facilitate the use of PET scanning for the quantification of flow, for example, in coronary perfusion studies. Alternative infusion circuit configurations, operable according to alternative methods, to achieve consistency of activity profiles among injected doses, as well as a more uniform level of radioactivity across each individual dose, will be described below, in conjunction with FIGS. 12A-C.

Printer 117 (FIG. 1B) may be activated to print out a hard copy of the infusion summary, on which the patient identification number and pertinent infusion and system parameters are also printed, for reference. Alternatively, or in addition, according to some embodiments, the summary may be downloaded onto a computer readable storage device to be electronically transferred to one or more remote computers and/or the summary may be automatically transferred to the one or more remote computers, via wireless communication or a cable connection, for example, over an intranet network and/or the internet. In order to protect private patient information, the files may be encrypted for transmission over the internet. The one or more remote computers may be included, for example, in a hospital information system, and/or a billing system, and/or in a medical imaging system. Infusion parameters, for example, corresponding to the activity profile, may also be collected and electronically transferred for analysis in conjunction with captured images, for example, in order to quantify coronary flow, via a software package that is loaded into a system that includes the PET scanner.

With reference back to FIG. 9A the user may select an item 995, from main menu 470, in order have system 10 perform data operations, such as, archiving a data base of patient infusion information and quality control test results, transmitting patient infusion summary records to USB mass storage devices, and various types of data filtering, for example, according to date ranges and/or patient identification numbers, for example, to search for a particular set of data and/or to compile a summary report of related sets of data. Additionally, certain information, which is collected by computer 17 over the course of system operation, and which defines system operation, may be transmitted to a local or remote computerized inventory system and/or to computers of technical support personnel, maintenance/service providers and/or suppliers of infusion circuit elements/components, thereby facilitating more efficient system operation and maintenance.

Turning now to FIG. 10, an item 981 for computer-facilitated purging of the tubing lines of system 10 is shown included in main menu 470. When a user selects item 981, computer 17 guides the user to select either an air purge or a saline purge. The direction provided by computer 17 is not explicitly laid out herein, for a saline purge, as procedures for saline purging should be readily apparent to those skilled in the art, with reference to the schematic of infusion circuit 300 shown in FIG. 1D. A saline purge of circuit 300 is desired to assure that all the air is removed from circuit 300 when a new generator and/or a new complete or partial tubing set is installed. An air purge of the tubing lines of circuit 300 may be performed after removing reservoir 15, by-passing generator 21, by connecting tubing line 304 to tubing line 305, and coupling patient line 305_p to a vial, for example, as is directed by the computer interface, in screens 983 and 984 shown in FIG. 10. The air purge is desirable for blowing out the tubing lines, thereby removing all remaining eluate and eluate, prior to installing a new generator and/or

prior to transporting system 10 from one site to another. If generator 21 is not depleted and will be used in system 10 at the new site, it is important to by-pass the generator prior to purging the tubing lines of circuit 300 with air, so that air is not blown across the generator, since air through generator 21 may compromise both the function and the aseptic nature of generator 21.

According to preferred embodiments, once the user has followed the instructions presented in screens 983 and 984 and selects to start the air purge, for example, via screen 985, computer 17 directs the controller of system 10 to carry out a complete air purge, in which pump 33 and divergence valves 35BG and 35WP are automatically controlled. The automated air purge preferably includes the following steps, which may be best understood with reference to tubing circuit 300 in FIG. 1D: pumping any remaining volume of eluate left in pump 33, through lines 302, 304, 305 and 305_w, to waste bottle 23; refilling pump 33 with air and pumping the air through lines 302, 304, 305 and 305_w, into waste bottle 23 (lines 304 and 305 have been previously connected directly to one another, in order to by-pass generator 21; if generator 21 is depleted and will be replaced with a new generator, pumping air through generator 21 may be acceptable); refilling pump 33 with air and then pumping a portion of the air through lines 302, 304, 305 and 305_p, into the vial, and then a remaining portion of the air through lines 302, 304, 303 and 305_p, into the vial. With reference to FIG. 1D and the previous description of divergence valves 35BG, 35WP, it should be understood how divergence valves 35BG, 35WP are automatically controlled to carry out the above steps.

The purge operations, which are facilitated by selecting item 981 from main menu 470, may also be accessed via the selection of an item 991 for generator setup. When the user selects item 991, computer 17 may present an option for guidance in removing an old, depleted, generator and a set of tubing lines, prior to installing the new generator, or an option to just be guided in the installation of the new generator.

According to some embodiments, computer 17 is pre-programmed to calculate an amount of activity left in a depleted generator, for example, by tracking activity of eluate over a life of the generator. At an end of the life of the generator, computer 17 may further compile this information, along with other pertinent generator information, into a report that may accompany a declaration of dangerous goods for shipping the depleted generator out for disposal or, in some cases, back to the manufacturer for investigation. An example of such a report is shown in FIG. 11. According to those embodiments of system 10 that include an encoded information reader, computer 17 may confirm that the new generator is proper by processing information that is read from an encoded label/tag attached thereto.

FIGS. 12A-B are schematics of alternative infusion circuits 1300A, 1300B that may be employed by system 10, in place of circuit 300 (FIG. 1D), according to some additional embodiments of the present invention. Circuits 1300A, 1300B are configured to allow for alternative methods of operation, to that previously described for circuit 300, when a relatively even, or uniform level of activity over each injected dose, along with the relatively consistent level of activity from injection to injection is desired, for example, in order to facilitate a quantification of coronary artery blood flow via PET scanning. FIG. 12C is a schematic illustrating activity profiles 1200A, 1200B for two injected doses, wherein profile 1200B has a more uniform level of activity

than profile 1200A; profile 1200B may be achieved via the operation of circuits 1300A, 1300B as described below.

Similar to circuit 300 (FIG. 1D), dashed lines are shown in each of FIGS. 12A-B to indicate a general boundary of a shielding assembly for portions of each circuit 1300A, 1300B. The shielding assembly for each of circuits 1300A, 1300B may be very similar, in most respects, to shielding assembly 200, which is described above for system 10, and the elements of each of circuits 1300A, 1300B may be arranged with respect to their respective shielding and with respect to shell 13 of system 10 in a similar manner to that described above for circuit 300.

FIG. 12A illustrates circuit 1300A including, like the previously described circuit 300, eluant reservoir 15, pump 33, radioisotope generator 21, through which the filtered eluant is pumped to create the radioactive eluate, activity detector 25, and waste bottle 23. FIG. 12A further illustrates two filters 37 and two pressure transducers 1334 included in circuit 1300A. Circuit 1300A further includes by-pass tubing line 303, which is located downstream of divergence valve 35BG, like in circuit 300, and which accommodates the previously described eluant/saline flush. However, in contrast to circuit 300, circuit 1300A further includes a linear/proportional valve 1335 integrated into by-pass/flush line 303 so that circuit 1300A may be operated, for example, according to pre-programmed parameters of computer 17, in conjunction with feedback of information from activity detector 25, for a controlled by-pass of generator 21 in order to mix eluant with eluate and, thereby, achieve a relatively uniform level of activity over each patient injection, for example, according to profile 1200B of FIG. 12C. It should be noted that, in addition to the controlled mixing, a flow rate of each injection may be varied, if necessary, in order to maintain a consistent activity level.

FIG. 12B illustrates circuit 1300B including, like the previously described circuit 300, eluant reservoir 15, pump 33, radioisotope generator 21, activity detector 25, and waste bottle 23, as well as the two filters 37 and two pressure transducers 1334, as in circuit 1300A. In contrast to circuits 300 and 1300A, circuit 1300B further includes an eluate reservoir 1350, which is shown located downstream of generator 21, in between first and second segments 305A, 305B of the eluate tubing line. It should be noted that a pump is combined with reservoir 1350, for example, similar to syringe pump 33, such that, when a divergence valve 1335IO is set to allow fluid communication between reservoir 1350 and tubing line segment 305A, the associated pump may be operated to draw in a volume of eluate, and, then, when divergence valve 1335IO is set to allow fluid communication between reservoir 1350 and tubing line segment 305B, the pump may be operated to push the volume of eluate out through tubing line segment 305B for a patient injection, when divergence valve 35WP is set to direct flow into patient line 305p. With reference back to FIGS. 3A-B, sidewall 205 of shielding assembly 200 may be enlarged to further enclose eluate reservoir 1350. For example, another shielded well, to house the eluate reservoir, may extend alongside well 255, in which activity detector 25 is described as being mounted. Furthermore, sidewall 205 may include another valve actuator receptacle for divergence valve 1335IO, similar to receptacle 253, shown in FIG. 3A for divergence valve 35WP.

Collection of discrete volumes of eluate, in reservoir 1350, may help to achieve a more uniform activity level over each injection, for example, like that of profile 1200B in FIG. 12C, and, according to preferred methods, feedback from activity detector 25 may be used to control the pump

associated with reservoir 1350, in order to vary injection flow rate and, thereby, maintain a relatively consistent activity level across multiple injections, and, when necessary, to vary injection flow rate over an individual injection to maintain the uniform activity level. Feedback from the pressure transducer 1334, that is downstream from detector 25, and/or from a flow meter (not shown) of circuit 1300B may also be used to control the varying of injection flow rate.

With further reference to FIGS. 12A-B, it should be noted that alternative circuits may be configured to employ a combination of the methods described for circuits 1300A and 1300B. Furthermore, some infusion circuits of the present invention may employ multiple generators 21, as mentioned above, in conjunction with FIG. 2A, to help maintain the relatively uniform level of activity over each injection and the relatively consistent level of activity from injection to injection.

In the foregoing detailed description, the invention has been described with reference to specific embodiments. However, it may be appreciated that various modifications and changes can be made without departing from the scope of the invention as set forth in the appended claims.

The invention claimed is:

1. A method of building an infusion system to deliver a rubidium radioactive eluate comprising:

installing a first shielding compartment, a second shielding compartment, and a shielded well on a platform of a cart, wherein:

the first shielding compartment has a first opening facing vertically upwardly,

the first opening is configured for a strontium-rubidium radioisotope generator to be inserted into and removed from the first shielding compartment,

the second shielding compartment has a second opening facing vertically upwardly,

the second opening is configured for a waste bottle to be inserted into and removed from the second shielding compartment,

the first opening is located at a lower elevation than the second opening, and

the shielded well is configured to receive an eluate reservoir that is configured to receive a sample of the rubidium radioactive eluate;

configuring a computer with a touch screen display for the infusion system to:

fill the eluate reservoir in the shielded well on-board the cart with the sample of the rubidium radioactive eluate by pumping saline from a saline reservoir into the strontium-rubidium radioisotope generator via a saline tubing line thereby generating the rubidium radioactive eluate that is discharged through an eluate tubing line,

determine a strontium breakthrough test result on the sample of the rubidium radioactive eluate filled into the eluate reservoir in the shielded well on-board the cart while the eluate reservoir remains in the shielded well on-board the cart, and

not allow a patient infusion if the strontium breakthrough test result is greater than or equal to an allowed limit.

2. The method of claim 1, further comprising configuring the computer to:

measure a radioactivity of the sample of the rubidium radioactive eluate while the sample is flowing through the eluate tubing line to the eluate reservoir;

25

measure a calibration radioactivity of the sample while the sample remains in the eluate reservoir in the shielded well on-board the cart; and

compare the radioactivity of the sample measured while flowing through the eluate tubing line with the calibration radioactivity of the sample measured in the eluate reservoir in the shielded well on-board the cart.

3. The method of claim 2, further comprising installing a dose calibrator in the shielded well on-board the cart, wherein the dose calibrator is in communication with the computer to measure the strontium breakthrough test result and the calibration radioactivity of the sample pumped into the eluate reservoir.

4. The method of claim 2, further comprising configuring the computer to allow a user to:

log into the computer by entering a user login credential on the touch screen display, transfer a patient infusion record via a USB port, and

print a document concerning the patient infusion or a quality control test result via a printer.

5. The method of claim 2, further comprising configuring the computer to allow a user to:

initiate a purging process through the touch screen display to purge a patient tubing line of air, wherein the patient tubing line is in fluid communication with the eluate tubing line.

6. The method of claim 2, further comprising configuring the computer to present on the touch screen display a screen reminding a user to insert the eluate reservoir in the shielded well on-board the cart.

7. The method of claim 2, further comprising configuring the computer to present on the touch screen display a screen for starting the patient infusion by touching a button on the touch screen display.

8. The method of claim 2, further comprising configuring the computer to present on the touch screen display a screen indicating that the patient infusion is in process, wherein the screen indicates that the patient infusion is in process displays a stop button to abort the patient infusion.

9. The method of claim 2, further comprising configuring the computer to:

present on the touch screen display a screen for starting the patient infusion by touching a button on the touch screen display;

present on the touch screen display a screen reminding a user to insert the eluate reservoir in the shielded well on-board the cart;

present on the touch screen display a screen indicating that the patient infusion is in process, wherein the screen indicating that the patient infusion is in process displays a stop button to abort the patient infusion; and present on the touch screen display the strontium breakthrough test result.

10. The method of claim 9, further comprising configuring the computer to allow the user to:

log into the computer by entering a user login credential on the touch screen display,

enter a patient ID on the touch screen display,

enter a patient dose on the touch screen display, and

enter a flow rate on the touch screen display.

11. The method of claim 10, further comprising configuring the computer to:

track time passed from completion of pumping the sample of the rubidium radioactive eluate into the eluate reservoir to measuring the strontium breakthrough test result,

26

track a volume of saline remaining in the saline reservoir, provide an alert via the touch screen display when the volume of saline remaining in the saline reservoir is below a predetermined volume threshold,

track a volume of the rubidium radioactive eluate discharged from the strontium-rubidium radioisotope generator to the waste bottle, and

present on the touch screen display a screen reminding the user to empty the waste bottle.

12. The method of claim 11, further comprising configuring the computer to allow the user to:

initiate a generator column wash through the touch screen display, wherein a predetermined amount of saline is pumped through the strontium-rubidium radioisotope generator and directed to the waste bottle during the generator column wash, and

initiate a purging process through the touch screen display to purge a patient tubing line of air, wherein the patient tubing line is in fluid communication with the eluate tubing line.

13. The method of claim 12, wherein the infusion system is configured for the saline tubing line and the eluate tubing line to be routed through two tubing passageways formed in a perimeter surface of the first opening, wherein each of the two tubing passageways has a depth configured to prevent pinching or crushing of a corresponding tubing line routed therethrough when a first door is closed over the first opening.

14. The method of claim 13, wherein the infusion system further comprises:

an exterior shell extending upwardly above the platform, wherein the platform and the exterior shell collectively define an interior space of a cabinet structure,

a handle configured for the user to grasp in order to move the infusion system, and

four wheels mounted to an underside of the platform of the cabinet structure.

15. The method of claim 14, further comprising configuring the computer to:

project a first light signal from a light projector mounted on a top end of a vertical post extending above the cabinet structure to indicate that an elution is taking place, and

project a second light signal from the light projector to indicate that a peak bolus of radioactivity is detected.

16. The method of claim 15, wherein the cabinet structure has a lowermost portion and the platform has a lower surface,

the first opening is at a first elevation,

the second opening is at a second elevation,

the first elevation is between approximately 1 foot and approximately 2 feet, with respect to the lowermost portion of the cabinet structure, and

the second elevation is between approximately 2 feet and approximately 3 feet, with respect to the lower surface of the platform.

17. The method of claim 14, wherein the infusion system further comprises a dose calibrator in the shielded well on-board the cart and wherein the dose calibrator is in communication with the computer to measure the strontium breakthrough test result.

18. The method of claim 17, wherein

the cabinet structure has a lowermost portion and the platform has a lower surface,

the first opening is at a first elevation,

the second opening is at a second elevation,

the first elevation is between approximately 1 foot and approximately 2 feet, with respect to the lowermost portion of the cabinet structure, and the second elevation is between approximately 2 feet and approximately 3 feet, with respect to the lower surface of the platform.

19. The method of claim 1, further comprising configuring the computer to:

control a fluid communication between the strontium-rubidium radioisotope generator and the saline reservoir,

control a fluid communication between the eluate tubing line and the eluate reservoir,

control a fluid communication between the eluate tubing line and the waste bottle,

place the eluate tubing line in fluid communication with a patient,

pump a dose of the rubidium radioactive eluate to the patient; and

flush the rubidium radioactive eluate remaining in at least a portion of the eluate tubing line into the patient by pumping saline from the saline reservoir to the eluate tubing line through a by-pass line that by-passes the strontium-rubidium radioisotope generator.

20. The method of claim 1, further comprising installing an exterior shell extending upwardly above the platform, wherein:

the exterior shell comprises a front side; a rear side; two sidewalls; and a top surface,

the platform and the exterior shell collectively define an interior space of a cabinet structure,

the cabinet structure has a lowermost portion and the platform has a lower surface,

the first opening is at a first elevation,

the second opening is at a second elevation, the first elevation is between approximately 1 foot and approximately 2 feet, with respect to the lowermost portion of the cabinet structure, and

the second elevation is between approximately 2 feet and approximately 3 feet, with respect to the lower surface of the platform.

21. The method of claim 20, further comprising installing a light projector on a top end of a vertical post extending above the cabinet structure to:

project a first light signal from the light projector to indicate that an elution is taking place, and

project a second light signal from the light projector to indicate that a peak bolus of radioactivity is detected.

22. The method of claim 20, wherein the saline reservoir is located outside of the interior space of the cabinet structure.

23. The method of claim 20, wherein the infusion system further comprises:

a handle configured for a user to grasp in order to move the infusion system, and

four wheels mounted to an underside of the platform of the cabinet structure.

24. The method of claim 1, wherein the infusion system is configured for the saline tubing line and the eluate tubing line to be routed through two tubing passageways formed in a perimeter surface of the first opening, wherein each of the two tubing passageways has a depth configured to prevent pinching or crushing of a corresponding tubing line routed therethrough when a first door is closed over the first opening.

25. The method of claim 1, further comprising configuring the computer to:

track a volume of saline remaining in the saline reservoir, and

provide an alert via the touch screen display when the volume of saline remaining in the saline reservoir is below a predetermined volume threshold.

26. The method of claim 1, further comprising configuring the computer to:

track a volume of the rubidium radioactive eluate discharged from the strontium-rubidium radioisotope generator to the waste bottle, and

present on the touch screen display a screen reminding a user to empty the waste bottle.

27. The method of claim 1, wherein the infusion system is configured to pump saline through the strontium-rubidium radioisotope generator at a rate less than approximately 70 ml/min.

28. The method of claim 1, further comprising configuring the computer to allow a user to:

initiate a generator column wash through the touch screen display, wherein a predetermined amount of saline is pumped through the strontium-rubidium radioisotope generator and directed to the waste bottle during the generator column wash.

29. The method of claim 1, further comprising configuring the computer to track time passed from completion of pumping the sample of the rubidium radioactive eluate into the eluate reservoir to measuring the strontium breakthrough test result.

30. The method of claim 1, further comprising configuring the computer to allow a user to:

enter a patient ID on the touch screen display, enter a patient dose on the touch screen display, and enter a flow rate on the touch screen display.

* * * * *




EXHIBIT 2

A 7667315



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME;

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 08, 2018

**THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON
JUNE 15, 2017.**

**By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office**




R GLOVER
Certifying Officer

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4461109

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
STEPHEN E. HIDEM	04/28/2010
AARON M. FONTAINE	04/28/2010
JANET L. GELBACH	04/20/2010
PATRICK M. MCDONALD	04/16/2010
KATHRYN M. HUNTER	04/12/2010
ROLF E. SWENSON	04/13/2010
JULIUS P. ZODDA	04/13/2010
RECEIVING PARTY DATA	
Name:	BRACCO DIAGNOSTICS INC.
Street Address:	107 COLLEGE ROAD EAST
City:	PRINCETON
State/Country:	NEW JERSEY
Postal Code:	08540
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15620320
CORRESPONDENCE DATA	
Fax Number:	(612)492-7077
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	612-492-7000
Email:	IP@fredlaw.com
Correspondent Name:	PAUL J. LAVANWAY, JR.
Address Line 1:	200 SOUTH SIXTH STREET
Address Line 2:	SUITE 4000
Address Line 4:	MINNEAPOLIS, MINNESOTA 55402
ATTORNEY DOCKET NUMBER:	56782.4.3
NAME OF SUBMITTER:	PAUL J. LAVANWAY, JR.
SIGNATURE:	/Paul J. LaVanway, Jr./
DATE SIGNED:	06/15/2017

504414409

PATENT
REEL: 042715 FRAME: 0831

Total Attachments: 7

source=56782.4.3_Executed Assignment#page1.tif

source=56782.4.3_Executed Assignment#page2.tif

source=56782.4.3_Executed Assignment#page3.tif

source=56782.4.3_Executed Assignment#page4.tif

source=56782.4.3_Executed Assignment#page5.tif

source=56782.4.3_Executed Assignment#page6.tif

source=56782.4.3_Executed Assignment#page7.tif

PATENT
REEL: 042715 FRAME: 0832

ASSIGNMENT

We, Stephen E. Hidem, residing at 4710 Juneau Lane North, Plymouth, Minnesota 55446, Aaron M. Fontaine, residing at 5663 West Bavarian Pass, Fridley, Minnesota 55432, Janet L. Gelbach, residing at 4204 Shetland Court, New Albany, Indiana 47150, Patrick M. McDonald, residing at 15395 Nicholas Street, Omaha, Nebraska 68154, Kathryn M. Hunter, residing at 1312 Judy Reagan Lane, Knoxville, Tennessee 37931, Rolf E. Swenson, residing at 35 Fieldston Road, Princeton, New Jersey 08540 and Julius P. Zodda, residing at 3 Tigers Court, Mercerville, New Jersey 08619 ("Assignor"), have made invention(s) for which United States and foreign patents and patent applications have been filed and are identified on the attached Schedule 1;

Whereas, Bracco Diagnostics Inc., a Delaware corporation having a place of business at 107 College Road East, Princeton, NJ 08540 ("Assignee"), desires to acquire the entire right, title and interest in and to the United States and foreign patents and patent applications identified on the attached Schedule 1 and in and to the inventions described and claimed therein (the "Patents"); and

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby assigns to Assignee, and its successors and assigns the following:

- (1) The entire right, title and interest to the Patents including the inventions described or claimed therein, and to each U.S. and foreign patent application and patent from which the Patents claim priority to, in whole or in part, and to which the Patents claim priority; and
- (2) The entire right, title and interest to any United States or foreign patents that may issue with respect to the inventions described or claimed in the Patents;
- (3) The entire right, title and interest to any renewals, reissues, extensions, substitutions, continuations, continuations-in-part, or divisions of the Patents, and all foreign applications based thereon;
- (4) The right to apply for patents in foreign countries in its own name and to claim any priority rights to which such foreign applications are entitled under international conventions, treaties or otherwise; and
- (5) The right to enforce patent rights to such Patents as fully and entirely as the same would have been held and enjoyed by the Assignors if this assignment had not been made; together with all claims by Assignors for damages by reason of past infringement or for provisional rights and including the right to sue for, and collect the same for its own use and benefit, and for the use and benefit of its successors, assigns, and other legal representatives.

Assignor further agrees for himself and for his successors and assigns to execute and deliver without further consideration any further applications, assignments or other documents and to perform such other lawful acts as Assignee its successors and assigns may deem necessary to fully secure, maintain and enforce its rights, title or interest as outlined herein.

Assignor hereby authorizes and requests the Commissioner of Patents to issue to Assignee any patents that may be granted in accordance with this Assignment.

We hereby authorize attorneys associated with Customer No. 22859, of 200 South Sixth Street, Suite 4000, Minneapolis, Minnesota, 55402-1425, to insert the Application Nos. and Filing Dates of said application when known.

This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement. The signatures from each counterpart may be combined with a copy of the Agreement to constitute the entire Agreement.

Date: 4/28/2010

[Signature]
Stephen E. Hidem

Subscribed to and sworn to before
me this 28 day of APRIL, 2010.

[Signature]
Notary Public

Notary Seal




Date: 4/28/2010

[Signature]
Aaron M. Fontaine

Subscribed to and sworn to before
me this 28 day of APRIL, 2010.

[Signature]
Notary Public

Notary Seal



Date: 4-20-2010

Janet L. Gelbach
Janet L. Gelbach

Witnessed by: Esther B. Paris on 4-20-10
(Signature) (Date)

Esther B. Paris
(Name)

4204 Sretland Ct. New Albany, IN 47150
(Address)

Date: _____

Patrick M. McDonald

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: _____

Kathryn M. Hunter

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: _____
Janet L. Gelbach

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: 16-APR-2010 _____
Patrick M. McDonald

Witnessed by: Renee McDonald on 4-16-10
(Signature) (Date)

Renee McDonald
(Name)

15395 NICHOLAS ST. OMAHA, NE 68154
(Address)

Date: _____
Kathryn M. Hunter

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: _____
Janet L. Gelbach

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: _____
Patrick M. McDonald

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: April 12, 2010 Kathryn M. Hunter
Kathryn M. Hunter

Witnessed by: [Signature] on April 12, 2010
(Signature) (Date)
JIM CLAIR
(Name)
1312 GUDY REAGAN LANE KNOXVILLE, TN 37931
(Address)

Date: 4/13/10

Rolf E. Swenson
Rolf E. Swenson

Witnessed by: Patricia Bussiere on 4/13/2010
(Signature) (Date)

Patricia Bussiere
(Name)

10 Garfield Court, Dayton, NJ 08810
(Address)

Date: Apr. 13, 2010

Julius P. Zodda
Julius P. Zodda

Witnessed by: Patricia Bussiere on April 13, 2010
(Signature) (Date)

Patricia Bussiere
(Name)

10 Garfield Court, Dayton NJ 08810
(Address)

SCHEDULE 1US Patent Applications

Patent App. No.	Date Filed	Title	Attorney Docket No.
12/137,356	6/11/2008	SHIELDING ASSEMBLIES FOR INFUSION SYSTEMS	56782.1.5
12/137,363	6/11/2008	INFUSION SYSTEM CONFIGURATIONS	56782.1.6
12/137,364	6/11/2008	INFUSION SYSTEMS INCLUDING COMPUTER-FACILITATED MAINTENANCE AND/OR OPERATION AND METHODS OF USE	56782.1.7
12/137,377	6/11/2008	CABINET STRUCTURE CONFIGURATIONS FOR INFUSION SYSTEMS	56782.1.8
12/808,467	6/16/2010	INFUSION SYSTEMS INCLUDING COMPUTER-FACILITATED MAINTENANCE AND/OR OPERATION AND METHODS OF USE	56782.1.7.2
15/389,200	12/22/2016	INTEGRATED STRONTIUM-RUBIDIUM RADIOISOTOPE INFUSION SYSTEMS	56782.4.1
15/620,320	6/12/2017	INTEGRATED STRONTIUM-RUBIDIUM RADIOISOTOPE INFUSION SYSTEMS	56782.4.3

US Patents

Patent No.	Date Issued	Title

Foreign and International Patent Applications

Country	Patent App. No.	Date Filed	Title	Attorney Docket No.
WO	PCT/US09/47031	6/11/2009	INFUSION SYSTEMS INCLUDING COMPUTER-FACILITATED MAINTENANCE AND/OR OPERATION AND METHODS OF USE	56782.1.7.1

Foreign Patents

Country	Patent No.	Date of Issue	Title

4661175_1.DOC





EXHIBIT 3

U 7667315



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

February 12, 2018

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THIS OFFICE OF:

U.S. PATENT: 9,750,869

ISSUE DATE: *September 05, 2017*

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office



P. R. GRANT
Certifying Officer



US009750869B2

(12) **United States Patent**
Hidem et al.

(10) **Patent No.:** **US 9,750,869 B2**
(45) **Date of Patent:** ***Sep. 5, 2017**

(54) **INTEGRATED STRONTIUM-RUBIDIUM
RADIOISOTOPE INFUSION SYSTEMS**

(71) Applicant: **Bracco Diagnostics Inc.**, Monroe
Township, NJ (US)

(72) Inventors: **Stephen E. Hidem**, Edina, MN (US);
Aaron M. Fontaine, Minneapolis, MN
(US); **Janet L. Gelbach**, Rolling
Meadows, IL (US); **Patrick M.
McDonald**, Omaha, NE (US); **Kathryn
M. Hunter**, Knoxville, TN (US); **Rolf
E. Swenson**, Silver Spring, MD (US);
Julius P. Zodda, Mercerville, NJ (US)

(73) Assignee: **Bracco Diagnostics, Inc.**, Monroe
Township, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **15/389,200**

(22) Filed: **Dec. 22, 2016**

(65) **Prior Publication Data**

US 2017/0100535 A1. Apr. 13, 2017

Related U.S. Application Data

(63) Continuation of application No. 12/808,467, filed as
application No. PCT/US2009/047031 on Jun. 11,
(Continued)

(51) **Int. Cl.**
A61M 5/00 (2006.01)
A61N 5/10 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC **A61M 5/007** (2013.01); **A61B 6/037**
(2013.01); **A61B 6/107** (2013.01); **A61B 6/481**
(2013.01);
(Continued)

(58) **Field of Classification Search**
CPC .. A61N 5/1001; A61N 5/1002; A61N 5/1007;
A61N 5/1014-5/1017;

(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,483,867 A 12/1969 Markovitz
3,535,085 A 10/1970 Shumate

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2913373 A1 4/2008
CN 1968653 A 5/2007

(Continued)

OTHER PUBLICATIONS

Alvarez-Diez et al. "Manufacture of strontium-82/rubidium-82 gen-
erators and quality control of rubidium-82 chloride for myocardial
perfusion imaging in patients using positron emission tomography,"
Applied Radiation and Isotopes, 1999, pp. 1015-1023.

(Continued)

Primary Examiner — Charles A Marmor, II


Assistant Examiner — Carrie R Dorna

(74) *Attorney, Agent, or Firm* — Fredrikson & Byron,
P.A.

(57) **ABSTRACT**

Methods for setting up, maintaining and operating a radio-
pharmaceutical infusion system, that includes a radioisotope
generator, are facilitated by a computer of the system. The
computer may include pre-programmed instructions and a
computer interface, for interaction with a user of the system,
for example, in order to track contained volumes of eluant
and/or eluate, and/or to track time from completion of an
elution performed by the system, and/or to calculate one or
more system and/or injection parameters for quality control,
and/or to perform purges of the system, and/or to facilitate
diagnostic imaging.

30 Claims, 27 Drawing Sheets



Related U.S. Application Data

2009, now Pat. No. 9,607,722, which is a continuation of application No. 12/137,356, filed on Jun. 11, 2008, now Pat. No. 8,317,674, and a continuation of application No. 12/137,363, filed on Jun. 11, 2008, now Pat. No. 7,862,534, and a continuation of application No. 12/137,377, filed on Jun. 11, 2008, now Pat. No. 8,708,352, and a continuation of application No. 12/137,364, filed on Jun. 11, 2008, now Pat. No. 9,597,053.

(51) Int. Cl.

A61B 90/00 (2016.01)
A61M 5/14 (2006.01)
G21F 7/00 (2006.01)
G21G 1/00 (2006.01)
A61B 6/00 (2006.01)
A61B 6/10 (2006.01)
A61M 5/142 (2006.01)
G21F 3/00 (2006.01)
A61K 51/00 (2006.01)
G21G 4/08 (2006.01)
A61B 6/03 (2006.01)
A61M 5/168 (2006.01)
A61B 50/13 (2016.01)
A61M 5/145 (2006.01)
A61M 5/158 (2006.01)
G06F 21/31 (2013.01)
A61B 50/10 (2016.01)
B62B 3/00 (2006.01)

(52) U.S. Cl.

CPC *A61B 6/507* (2013.01); *A61B 50/13* (2016.02); *A61B 90/39* (2016.02); *A61K 51/00* (2013.01); *A61M 5/14* (2013.01); *A61M 5/142* (2013.01); *A61M 5/1409* (2013.01); *A61M 5/1452* (2013.01); *A61M 5/158* (2013.01); *A61M 5/16854* (2013.01); *A61M 5/16881* (2013.01); *A61N 5/1001* (2013.01); *A61N 5/1007* (2013.01); *A61N 5/1075* (2013.01); *G06F 21/31* (2013.01); *G21F 3/00* (2013.01); *G21F 7/00* (2013.01); *G21G 1/001* (2013.01); *G21G 1/0005* (2013.01); *G21G 4/08* (2013.01); *A61B 2050/105* (2016.02); *A61B 2090/392* (2016.02); *A61M 2005/1403* (2013.01); *A61M 2205/18* (2013.01); *A61M 2205/276* (2013.01); *A61M 2205/50* (2013.01); *A61M 2205/505* (2013.01); *A61M 2205/52* (2013.01); *A61M 2209/084* (2013.01); *A61N 2005/1021* (2013.01); *A61N 2005/1022* (2013.01); *A61N 2005/1074* (2013.01); *A61N 2005/1094* (2013.01); *B62B 3/005* (2013.01); *G21G 2001/0031* (2013.01)

(58) Field of Classification Search

CPC .. *A61N 5/1027*; *A61N 5/1028*; *A61N 5/1071*; *A61N 2005/1021*; *A61M 5/007*; *A61M 5/14*; *A61M 5/142*; *G06F 19/3468*; *G21G 4/08*; *A61B 2050/105*
 See application file for complete search history.

(56)

References Cited

U.S. PATENT DOCUMENTS

3,543,752 A 12/1970 Hesse et al.
 3,565,376 A 2/1971 Viers
 3,576,998 A 5/1971 Deutsch et al.

3,710,118 A 1/1973 Holgate et al.
 3,714,429 A 1/1973 McAfee et al.
 3,774,036 A 11/1973 Gerhart
 3,847,138 A 11/1974 Gollub
 3,861,380 A 1/1975 Chassagne et al.
 3,953,567 A 4/1976 Grant et al.
 3,991,960 A 11/1976 Tanaka
 3,997,784 A 12/1976 Picunko et al.
 4,096,859 A 6/1978 Agarwal et al.
 4,160,910 A 7/1979 Thornton et al.
 4,212,303 A 7/1980 Nolan
 4,241,728 A 12/1980 Mirell
 4,286,169 A 8/1981 Rossem
 4,336,036 A 6/1982 Leeke et al.
 4,406,877 A 9/1983 Neirinckx et al.
 4,466,888 A 8/1984 Verkaart
 4,562,829 A 1/1986 Bergner
 4,585,009 A 4/1986 Barker et al.
 4,585,941 A 4/1986 Bergner
 4,597,951 A 7/1986 Gennaro et al.
 4,623,102 A 11/1986 Hough et al.
 4,625,118 A 11/1986 Kriwetz et al.
 4,656,697 A 4/1987 Naslund
 4,674,403 A 6/1987 Bryant et al.
 4,679,142 A 7/1987 Lee
 4,755,679 A 7/1988 Wong
 4,759,345 A 7/1988 Mistry
 4,769,008 A 9/1988 Hessel
 4,853,546 A 8/1989 Abe et al.
 4,994,056 A 2/1991 Ikeda
 5,039,863 A 8/1991 Matsuno et al.
 5,092,834 A 3/1992 Bradshaw et al.
 5,166,526 A 11/1992 Dietzel
 5,254,328 A 10/1993 Herscheid
 5,258,906 A 11/1993 Kroll et al.
 5,274,239 A 12/1993 Lane et al.
 5,395,320 A 3/1995 Padda et al.
 5,468,355 A 11/1995 Shefer et al.
 5,475,232 A 12/1995 Powers et al.
 5,485,831 A 1/1996 Holdsworth et al.
 5,580,541 A 12/1996 Wells et al.
 5,590,648 A 1/1997 Mitchell et al.
 5,674,404 A 10/1997 Kenley et al.
 5,681,285 A 10/1997 Ford et al.
 5,702,115 A 12/1997 Pool et al.
 5,739,508 A 4/1998 Uber et al.
 5,765,842 A 6/1998 Phaneuf
 5,827,429 A 10/1998 Ruschke et al.
 5,840,026 A 11/1998 Uber, III et al.
 5,885,216 A 3/1999 Evans, III et al.
 6,058,718 A 5/2000 Forsberg et al.
 6,157,036 A 12/2000 Whiting et al.
 6,220,554 B1 4/2001 Daoud
 6,267,717 B1 7/2001 Stoll et al.
 6,269,810 B1 8/2001 Brooker et al.
 6,327,895 B1 12/2001 Jeppsson et al.
 6,347,711 B1 2/2002 Goebel et al.
 6,442,418 B1 8/2002 Evans, III et al.
 6,450,936 B1 9/2002 Smith, III et al.
 6,454,460 B1 9/2002 Ramanathan et al.
 6,558,125 B1 5/2003 Futterknecht
 6,626,862 B1 9/2003 Duchon et al.
 6,639,237 B2 10/2003 Pedersen et al.
 6,758,975 B2 7/2004 Peabody et al.
 6,767,319 B2 7/2004 Reilly et al.
 6,773,686 B1 8/2004 Herscheid et al.
 6,870,175 B2 3/2005 Dell
 6,901,283 B2 5/2005 Evans, III et al.
 6,908,598 B2 6/2005 Sylvester
 6,931,327 B2 8/2005 Goode et al.
 7,091,494 B2 8/2006 Weisner et al.
 7,125,166 B2 10/2006 Eck et al.
 7,163,031 B2 1/2007 Graves et al.
 7,169,135 B2 1/2007 Duchon et al.
 7,204,797 B2 4/2007 Reilly et al.
 7,256,888 B2 8/2007 Stachr et al.
 7,286,867 B2 10/2007 Schlyer et al.
 7,413,123 B2 8/2008 Ortenzi
 7,476,377 B2 1/2009 Moller et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

7,504,646 B2 3/2009 Balestracci et al.
 7,522,952 B2 4/2009 Krieg et al.
 7,586,102 B2 9/2009 Mourtada et al.
 7,605,384 B2 10/2009 Sonnenhol et al.
 7,608,831 B2 10/2009 Lamb et al.
 7,612,999 B2 11/2009 Clark et al.
 7,712,491 B2 5/2010 Tochon-Danguy et al.
 7,734,331 B2 6/2010 Dhawale et al.
 7,737,415 B2 6/2010 Casale et al.
 7,780,352 B2 8/2010 Fox et al.
 7,813,841 B2 10/2010 deKemp et al.
 7,825,372 B2 11/2010 Allberg
 7,862,534 B2 1/2011 Quirico et al.
 7,996,068 B2 8/2011 Telischak et al.
 8,058,632 B2 11/2011 Balestracci et al.
 8,071,959 B2 12/2011 deKemp
 8,198,599 B2 6/2012 Bouton et al.
 8,216,181 B2 7/2012 Balestracci
 8,216,184 B2 7/2012 Balestracci
 8,295,916 B2 10/2012 Shimchuk et al.
 8,317,674 B2 11/2012 Quirico et al.
 8,431,909 B2 4/2013 Horton et al.
 8,439,815 B2 5/2013 Lemer
 8,442,803 B2 5/2013 Chen et al.
 8,708,352 B2 4/2014 Quirico et al.
 2002/0128594 A1 9/2002 Das et al.
 2002/0129471 A1 9/2002 Wang
 2003/0139640 A1 7/2003 Whittacre et al.
 2003/0194894 A1 10/2003 Wariar et al.
 2004/0054319 A1 3/2004 Langley et al.
 2004/0104160 A1 6/2004 Scagliarini et al.
 2004/0260143 A1 12/2004 Reilly et al.
 2005/0085682 A1 4/2005 Sasaki et al.
 2005/0187515 A1 8/2005 Varrichio et al.
 2005/0277833 A1 12/2005 Williams
 2005/0278066 A1 12/2005 Graves et al.
 2006/0015056 A1 1/2006 Ellingboe et al.
 2006/0151048 A1 7/2006 Tochon-Danguy et al.
 2006/0164093 A1 7/2006 Ooe et al.
 2006/0173419 A1 8/2006 Malcolm
 2007/0080223 A1 4/2007 Japuntich
 2007/0140958 A1 6/2007 deKemp
 2007/0226175 A1 9/2007 Resnic et al.
 2007/0232980 A1 10/2007 Felt et al.
 2007/0260213 A1 11/2007 Williams et al.
 2007/0282263 A1 12/2007 Kalafut et al.
 2008/0015794 A1 1/2008 Eiler et al.
 2008/0071219 A1 3/2008 Rhinehart et al.
 2008/0093564 A1 4/2008 Tartaglia et al.
 2008/0166292 A1 7/2008 Levin et al.
 2008/0177126 A1 7/2008 Tate et al.
 2008/0191148 A1 8/2008 Gibson
 2008/0200747 A1 8/2008 Wagner et al.
 2008/0203318 A1 8/2008 Wagner et al.
 2008/0237502 A1 10/2008 Fago
 2008/0242915 A1 10/2008 Jackson et al.
 2008/0260580 A1 10/2008 Helle et al.
 2009/0112478 A1 4/2009 Mueller, Jr. et al.
 2009/0155167 A1 6/2009 Powell et al.
 2009/0224171 A1 9/2009 Verbokkem
 2009/0312630 A1 12/2009 Hidem et al.
 2010/0312039 A1 12/2010 Quirico et al.
 2011/0071392 A1 3/2011 Quirico et al.
 2011/0172524 A1 7/2011 Hidem et al.
 2011/0178359 A1 7/2011 Hirschman et al.
 2011/0209764 A1 9/2011 Uber et al.
 2012/0098671 A1 4/2012 Wieczorek et al.
 2012/0305730 A1 12/2012 Balestracci
 2012/0310031 A1 12/2012 Quirico et al.
 2012/0312980 A1 12/2012 Whitehouse
 2013/0300109 A1 11/2013 Balestracci et al.
 2014/0084187 A1 3/2014 Quirico et al.
 2014/0175959 A1 6/2014 Quirico et al.
 2014/0343418 A1 11/2014 Quirico et al.

2014/0374614 A1 12/2014 Hidem et al.
 2014/0374615 A1 12/2014 Hidem et al.
 2015/0260855 A1 9/2015 McQuaid et al.

FOREIGN PATENT DOCUMENTS

EP 102121 A1 3/1984
 EP 310148 A2 4/1989
 EP 317114 A1 5/1989
 EP 160303 A2 2/1991
 EP 319148 A2 2/1994
 EP 1421960 A1 5/2004
 EP 919249 A1 1/2005
 EP 1772157 A1 4/2007
 EP 1820730 A1 8/2007
 EP 2011126 A2 1/2009
 EP 2492920 A2 8/2012
 FR 2867084 A1 9/2005
 JP 2000350783 A 12/2000
 JP 2003520780 A 7/2003
 JP 2006325826 A 12/2006
 KR 960003726 B1 3/1996
 RU 2131273 C1 6/1999
 RU 2288755 C1 12/2006
 SU 244513 A1 12/1969
 WO 9615337 A1 5/1996
 WO 9956117 A1 11/1999
 WO 02096335 A2 12/2002
 WO 03034444 A1 4/2003
 WO 2004004787 A2 1/2004
 WO 2004059661 A1 7/2004
 WO 2004080523 A2 9/2004
 WO 2005002971 A1 1/2005
 WO 2006007750 A1 1/2006
 WO 2006026603 A2 3/2006
 WO 2006074473 A2 7/2006
 WO 2006129301 A2 12/2006
 WO 2006135374 A2 12/2006
 WO 2007016170 A1 2/2007
 WO 2007016173 A1 2/2007
 WO 2007030249 A2 3/2007
 WO 2007041017 A1 4/2007
 WO 2007071022 A1 6/2007
 WO 2007082093 A2 7/2007
 WO 2007104133 A1 9/2007
 WO 2007149108 A2 12/2007
 WO 2008028165 A2 3/2008
 WO 2008037939 A2 4/2008
 WO 2008066586 A2 6/2008
 WO 2008082966 A2 7/2008
 WO 2008140351 A1 11/2008
 WO 2009152320 A2 12/2009
 WO 2010020596 A1 2/2010
 WO 2011126522 A2 10/2011

OTHER PUBLICATIONS

Brochure, "IV and Liquid Filters: Speedflow Adult 0.2 um Positive", <http://www.gvs.it/flex/FixedPages/UK/LiquidFilters.php/L/UK/ID/Speedflow%20Adjust%...> Retrieved from URL on Nov. 11, 2008.
 Bracco Brochure, "Rubidium 82 Infusion System, Easy to Operate... Automated... Complete", © Bracco Diagnostics, Inc., 0605-002NA, Jun. 2001, (2 pages).
 "CardioGen-82 Infusion System User's Guide," Medical Product Service GmbH, Jul. 3, 2007, 53 pages.
 Imaging Technology News, web exclusive: "FDG-PET Injector Thrusts New Life into Molecular Imaging", Apr. 2008, 2 pages.
 Neil J. Epstein, "A Rb82 infusion system for quantitative perfusion imaging with 3D PET" Applied Radiation and Isotopes, vol. 60, Feb. 9, 2004, pp. 921-927, XP002557544 DOI:10.1016/j.apradiso.2004.02.002.
 R. Klein, "Precision controlled elution of a Sr82/Rb82 generator for cardiac perfusion imaging with positron emission tomography" Physics in Medicine and Biology, vol. 52, Jan. 11, 2007, pp. 659-673, XP002557545 DOI:10.1088/0031-9155/52/3/009.

(56)

References Cited

OTHER PUBLICATIONS

International Search Report and Written Opinion for International Patent Application No. PCT/US2009/047027, dated Feb. 25, 2010, 22 pages.

International Search Report and Written Opinion for International Patent Application No. PCT/US2009/047030, dated Feb. 17, 2010, 17 pages.

International Search Report and Written Opinion for International Patent Application No. PCT/US2009/047031, dated Mar. 1, 2010, 20 pages.

International Search Report and Written Opinion for International Patent Application No. PCT/US2009/047034, dated Feb. 25, 2010, 15 pages.

International Search Report and Written Opinion for International Patent Application No. PCT/US2009/063788, dated Apr. 1, 2010, 13 pages.

Lerner Pax, POSIJET® Integrated FDG dispensing and infusion system, www.lernerpax.com (copyright date May 2008).

R. Klein, "Precise 82RB infusion system for cardiac perfusion measurement using 3D positron emission tomography", Ottawa-Carleton Institute for Electrical and Computer Engineering School

of Information Technology and Engineering (Electrical & Computer Engineering), Feb. 2005, 147 pages.

R. Klein, "Precision control of eluted Activity from a Sr/Rb generator for cardiac positron emission tomography", Proceedings of the 26th Annual International Conference of the IEEE EMBS San Francisco, CA, USA, Sep. 1-5, 2004, 4 pages.

Machine translation of abstract of RU2307378 dated Sep. 27, 2007.

Kost, "Preventing Medical Errors in Point-of-Care Testing," Archives of Pathology & Laboratory Medicine, vol. 125, No. 10, Oct. 2001, pp. 1307-1315.

Leveson, "Medical Devices: The Therac-25," Appendix of: Safeware: System Safety and Computers, 1995, 49 pages.

"Medfusion 3000 Series Technical Service Manual," Smiths Medical, 2010, 184 pages.

"BodyGuard 323 Infusion Pump System Operator Manual," Caesarea Medical Electronics Ltd, Mar. 2009, 81 pages.

"Alaris GH Syringe Pump Directions for Use," Cardinal Health, Oct. 2005, 34 pages.

"Auto Syringe AS40A: Model AS40A Infusion Pump Operation Manual," Baxter, Aug. 1993, 84 pages.

"CardioGen-82 Rubidium Rb 82 Generator for Elution of Rubidium Chloride Rb 82 Injection," Bracco Diagnostics, May 2000, 13 pages.

English Abstract and Machine Translation for European Publication No. 1772157 A1, dated Apr. 11, 2007, 20 pgs.

Fig. 1A




Fig. 1B




Fig. 1C




Fig. 1D





Fig. 1E








Fig. 3A






Fig. 3B




Fig. 4




Fig. 5A




Fig. 5B






Fig. 5C








Fig. 7A






Fig. 7C









Fig. 8B







Fig. 9B







Fig. 11

CARDIOGEN-82 GENERATOR MONTHLY RECEIPT/RETURN WORKSHEET																							
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">GENERATOR RECEIPT</th> </tr> <tr> <td style="width: 50%;">DATE OF DELIVERY:</td> <td>11/9/2008</td> </tr> <tr> <td>DATE OF CALIBRATION:</td> <td>11/10/2008</td> </tr> <tr> <td>LOT NUMBER:</td> <td></td> </tr> <tr> <td>Sr-82 ACTIVITY:</td> <td>100 mCi</td> </tr> <tr> <td>TOTAL ACTIVITY:</td> <td>256 mCi</td> </tr> <tr> <td>Sr-85 ACTIVITY:</td> <td>156 mCi</td> </tr> </table>	GENERATOR RECEIPT		DATE OF DELIVERY:	11/9/2008	DATE OF CALIBRATION:	11/10/2008	LOT NUMBER:		Sr-82 ACTIVITY:	100 mCi	TOTAL ACTIVITY:	256 mCi	Sr-85 ACTIVITY:	156 mCi	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">RECEIPT SURVEY</th> </tr> <tr> <td style="width: 50%;">SURFACE:</td> <td>10.0 mrem/hr (MUST BE < 50 mrem/hr)</td> </tr> <tr> <td>1 METER:</td> <td>0.6 mrem/hr (MUST BE < 1 mrem/hr)</td> </tr> <tr> <td>SURFACE WIPE:</td> <td>1599 dpm (MUST BE < 2200 dpm/100 cm²)</td> </tr> </table>	RECEIPT SURVEY		SURFACE:	10.0 mrem/hr (MUST BE < 50 mrem/hr)	1 METER:	0.6 mrem/hr (MUST BE < 1 mrem/hr)	SURFACE WIPE:	1599 dpm (MUST BE < 2200 dpm/100 cm ²)
GENERATOR RECEIPT																							
DATE OF DELIVERY:	11/9/2008																						
DATE OF CALIBRATION:	11/10/2008																						
LOT NUMBER:																							
Sr-82 ACTIVITY:	100 mCi																						
TOTAL ACTIVITY:	256 mCi																						
Sr-85 ACTIVITY:	156 mCi																						
RECEIPT SURVEY																							
SURFACE:	10.0 mrem/hr (MUST BE < 50 mrem/hr)																						
1 METER:	0.6 mrem/hr (MUST BE < 1 mrem/hr)																						
SURFACE WIPE:	1599 dpm (MUST BE < 2200 dpm/100 cm ²)																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">GENERATOR RETURN</th> </tr> <tr> <td style="width: 50%;">DATE OF RETURN:</td> <td>12/27/2008</td> </tr> <tr> <td>DAYS SINCE CALIBRATION DATE:</td> <td>47</td> </tr> </table>	GENERATOR RETURN		DATE OF RETURN:	12/27/2008	DAYS SINCE CALIBRATION DATE:	47	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">RETURN SURVEY</th> </tr> <tr> <td style="width: 50%;">SURFACE:</td> <td>5.6 mrem/hr (MUST BE < 50 mrem/hr)</td> </tr> <tr> <td>1 METER:</td> <td>0.2 mrem/hr (MUST BE < 1 mrem/hr)</td> </tr> <tr> <td>SURFACE WIPE:</td> <td>1278 dpm (MUST BE < 2200 dpm/100 cm²)</td> </tr> </table>	RETURN SURVEY		SURFACE:	5.6 mrem/hr (MUST BE < 50 mrem/hr)	1 METER:	0.2 mrem/hr (MUST BE < 1 mrem/hr)	SURFACE WIPE:	1278 dpm (MUST BE < 2200 dpm/100 cm ²)								
GENERATOR RETURN																							
DATE OF RETURN:	12/27/2008																						
DAYS SINCE CALIBRATION DATE:	47																						
RETURN SURVEY																							
SURFACE:	5.6 mrem/hr (MUST BE < 50 mrem/hr)																						
1 METER:	0.2 mrem/hr (MUST BE < 1 mrem/hr)																						
SURFACE WIPE:	1278 dpm (MUST BE < 2200 dpm/100 cm ²)																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">Sr-82 RETURN CALCULATIONS</th> </tr> <tr> <td style="width: 50%;">INITIAL Sr-82 ACTIVITY:</td> <td>100 mCi</td> </tr> <tr> <td>DECAY FACTOR:</td> <td>0.2718</td> </tr> <tr> <td>REMAINING Sr-82 IN mCi:</td> <td>27.18 mCi</td> </tr> <tr> <td>REMAINING Sr-82 IN GBq:</td> <td>1.01 GBq</td> </tr> </table>	Sr-82 RETURN CALCULATIONS		INITIAL Sr-82 ACTIVITY:	100 mCi	DECAY FACTOR:	0.2718	REMAINING Sr-82 IN mCi:	27.18 mCi	REMAINING Sr-82 IN GBq:	1.01 GBq	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">SUMMARY</th> </tr> <tr> <td style="width: 50%;">TOTAL Sr-82/Sr-85 ACTIVITY:</td> <td>120.95 mCi</td> </tr> <tr> <td>TOTAL Sr-82/Sr-85 ACTIVITY:</td> <td>4.48 GBq</td> </tr> <tr> <td>TRANSPORT INDEX:</td> <td>0.2</td> </tr> </table>	SUMMARY		TOTAL Sr-82/Sr-85 ACTIVITY:	120.95 mCi	TOTAL Sr-82/Sr-85 ACTIVITY:	4.48 GBq	TRANSPORT INDEX:	0.2				
Sr-82 RETURN CALCULATIONS																							
INITIAL Sr-82 ACTIVITY:	100 mCi																						
DECAY FACTOR:	0.2718																						
REMAINING Sr-82 IN mCi:	27.18 mCi																						
REMAINING Sr-82 IN GBq:	1.01 GBq																						
SUMMARY																							
TOTAL Sr-82/Sr-85 ACTIVITY:	120.95 mCi																						
TOTAL Sr-82/Sr-85 ACTIVITY:	4.48 GBq																						
TRANSPORT INDEX:	0.2																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">Sr-85 RETURN CALCULATIONS</th> </tr> <tr> <td style="width: 50%;">INITIAL Sr-85 ACTIVITY:</td> <td>156 mCi</td> </tr> <tr> <td>DECAY FACTOR:</td> <td>0.6011</td> </tr> <tr> <td>REMAINING Sr-85 IN mCi:</td> <td>93.77 mCi</td> </tr> <tr> <td>REMAINING Sr-85 IN GBq:</td> <td>3.47 GBq</td> </tr> </table>	Sr-85 RETURN CALCULATIONS		INITIAL Sr-85 ACTIVITY:	156 mCi	DECAY FACTOR:	0.6011	REMAINING Sr-85 IN mCi:	93.77 mCi	REMAINING Sr-85 IN GBq:	3.47 GBq													
Sr-85 RETURN CALCULATIONS																							
INITIAL Sr-85 ACTIVITY:	156 mCi																						
DECAY FACTOR:	0.6011																						
REMAINING Sr-85 IN mCi:	93.77 mCi																						
REMAINING Sr-85 IN GBq:	3.47 GBq																						

Fig. 12A



1300B

Fig. 12B





Fig. 12C



INTEGRATED STRONTIUM-RUBIDIUM RADIOISOTOPE INFUSION SYSTEMS

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/808,467, filed Jun. 16, 2010, which is a 371 National Stage of International Application No. PCT/US09/47031, filed Jun. 11, 2009, which in turn is a continuation of the following four patent applications: U.S. patent application Ser. No. 12/137,356, filed Jun. 11, 2008, now U.S. Pat. No. 8,317,674, issued Nov. 27, 2012; U.S. patent application Ser. No. 12/137,363, filed Jun. 11, 2008, now U.S. Pat. No. 7,862,534, issued Jan. 4, 2011; U.S. patent application Ser. No. 12/137,364, filed Jun. 11, 2008; and U.S. patent application Ser. No. 12/137,377, filed Jun. 11, 2008, now U.S. Pat. No. 8,708,352, issued Apr. 29, 2014. The entire contents of all of these applications are incorporated herein by reference.

TECHNICAL FIELD

The present invention pertains to systems that generate and infuse radiopharmaceuticals, and, more particularly, to systems including computer-facilitated maintenance and/or operation.

BACKGROUND

Nuclear medicine employs radioactive material for therapy and diagnostic imaging. Positron emission tomography (PET) is one type of diagnostic imaging, which utilizes doses of radiopharmaceuticals, for example, generated by elution within a radioisotope generator, that are injected, or infused into a patient. The infused dose of radiopharmaceutical is absorbed by cells of a target organ, of the patient, and emits radiation, which is detected by a PET scanner, in order to generate an image of the organ. An example of a radioactive isotope, which may be used for PET, is Rubidium-82 (produced by the decay of Strontium-82); and an example of a radioisotope generator, which yields a saline solution of Rubidium-82, via elution, is the CardioGen-82® available from Bracco Diagnostics Inc. (Princeton, N.J.). A PET scanner in combination with infused doses of radiopharmaceuticals may also be employed to quantify blood flow rate, for example, through the coronary arteries of a patient.

Set up, maintenance and operational procedures for infusion systems that both generate and inject doses of radiopharmaceuticals are relatively involved in order to assure the safety and efficacy of each injected dose for the patient. Efficiency in carrying out these procedures is highly desirable for technical personnel, who work with these systems on a routine basis and would like to avoid unnecessarily prolonged exposure to radioactive radiation. Thus there is a need for new system configurations that facilitate more efficient set up, maintenance and operation.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings are illustrative of particular embodiments of the present invention and therefore do not limit the scope of the invention. The drawings are not to scale (unless so stated) and are intended for use in conjunction with the explanations in the following detailed description. Embodiments of the present invention will hereinafter

be described in conjunction with the appended drawings, wherein like numerals denote like elements.

FIG. 1A is a first perspective view of an infusion system, according to some embodiments of the present invention.

FIG. 1B is another perspective view of a portion of a cabinet structure of the system shown in FIG. 1A, according to some embodiments.

FIG. 1C is a second perspective view of the system shown in FIG. 1A, according to some embodiments.

FIG. 1D is a schematic of an infusion circuit, according to some embodiments of the present invention.

FIG. 1E is a perspective view of exemplary sample vial shielding that may be employed in conjunction with the infusion system of FIG. 1A.

FIG. 2A is a perspective view of a shielding assembly for an infusion system, such as that shown in FIGS. 1A-C, according to some embodiments of the present invention.

FIG. 2B is a perspective view of a framework of the system, according to some embodiments, and FIG. 2B-1 is an enlarged detailed view of a component of the system, according to some embodiments.

FIG. 3A is another perspective view of the shielding assembly shown in FIG. 2A.

FIG. 3B is a perspective view of the infusion circuit, shown in FIG. 1C, configured and routed, according to some embodiments.

FIG. 3C is a perspective view of a disposable infusion circuit subassembly, according to some embodiments.

FIG. 3D is a frame for the subassembly shown in FIG. 3C, according to some embodiments.

FIG. 4 is a main menu screen shot from an interface of a computer, which may be included in systems of the present invention, according to some embodiments.

FIG. 5A is a schematic showing a first group of successive screen shots from the computer interface, according to some embodiments.

FIG. 5B is a pair of screen shots from the computer interface, which provide indications related to eluant volume levels in a reservoir of the system, according to some embodiments.

FIG. 5C is a schematic showing a second group of successive screen shots from the computer interface, according to some embodiments.

FIG. 6 is a schematic showing a third group of successive screen shots from the computer interface, according to some embodiments.

FIGS. 7A-C are schematics showing a fourth group of successive screen shots from the computer interface, according to some embodiments.

FIGS. 8A-B are schematics showing a fifth group of successive screen shots from the computer interface, according to some embodiments.

FIGS. 9A-C are schematics showing a sixth group of successive screen shots from the computer interface, according to some embodiments.

FIG. 10 is a schematic showing a seventh group of successive screen shots from the computer interface, according to some embodiments.

FIG. 11 is an exemplary report which may be generated by the computer included in infusion systems, according to some embodiments.

FIGS. 12A-B are schematics of alternative infusion circuits that may be employed by embodiments of the present invention.

FIG. 12C is a schematic illustrating exemplary activity profiles of injected doses of a radiopharmaceutical.

DETAILED DESCRIPTION

The following detailed description is exemplary in nature and is not intended to limit the scope, applicability, or configuration of the invention in any way. Rather, the following description provides practical illustrations for implementing exemplary embodiments. Utilizing the teaching provided herein, those skilled in the art will recognize that many of the examples have suitable alternatives that can be utilized.

FIG. 1A is a first perspective view of an infusion system 10, according to some embodiments of the present invention, wherein system 10 is shown supported by a cabinet structure, which includes a platform 113 (seen better in FIG. 2B) and a shell 13; shell 13 extends upward from a skirt 11, that surrounds platform 113, to surround an interior space in which a portion of infusion system 10 is contained (seen in FIG. 1C). Shell 13 may be formed from panels of injection-molded polyurethane fitted together according to methods known to those skilled in the art. FIG. 1A illustrates the cabinet structure of system 10 including a grip or handle 14, which extends laterally from shell 13, in proximity to an upper surface 131 thereof, and a post 142, which extends upward from shell 13, and to which a work surface, or tray 16 and a computer 17 are, preferably, attached, via an ergonomic, positionable mount. According to some embodiments, computer 17 is coupled to a controller of system 10, which is mounted within the interior space surrounded by shell 13; and, a monitor 172 of computer 17 not only displays indications of system operation for a user of system 10, but also serves as a device for user input (e.g. touch screen input). However, according to alternate embodiments, another type of user input device, known to those skilled in the art, may be employed by computer 17. Other types of user input devices may be included, for example, a keyboard, a series of control buttons or levers, a bar code reader (or other reader of encoded information), a scanner, a computer readable medium containing pertinent data, etc. The user input device may be mounted on the cabinet structure of system 10, as shown, or may be tethered thereto; alternatively the user input device may be remote from system 10, for example, located in a separate control room. According to some additional embodiments, another user input device, for example, in addition to a touch screen of computer 17, may be remote from system 10 and used to start and stop infusions, as well as to monitor system operation both during quality control infusions and during patient infusions. Operation of system 10, which is facilitated by computer 17, will be described below, in conjunction with FIGS. 4-9C.

FIG. 1A further illustrates two pairs of wheels 121, 122, mounted to an underside of platform 113, to make system 10 mobile; handle 14 is shown located at an elevation suitable for a person to grasp in order to maneuver system 10, from one location to another, upon pairs of wheels 121, 122. According to some preferred embodiments, one or both pairs of wheels 121, 122, are casters, allowing for rotation in a horizontal plane (swivel), in order to provide additional flexibility for maneuvering system 10 in relatively tight spaces.

FIG. 1B is a perspective view of a portion of system 10, on a side 111 of the cabinet structure, which is in proximity to wheels 121, 122. FIG. 1B illustrates a lever or pedal 125, which is located for activation by a foot of the person, who

grasps handle 14 to maneuver system 10. In a neutral position, pedal 125 allows wheels 121, 122 to rotate, and, if embodied as casters, to swivel freely. Pedal 125 may be depressed to a first position which prevents a swiveling of wheels 121, 122, according to those embodiments in which wheels 121, 122 are casters, and may be further depressed to brake wheels 121, 122 from rolling and swiveling, upon reaching a desired location. According to some embodiments, braking may be designed to slow system 10, for example, when rolling down an incline, and, according to yet further embodiments, system 10 may include a motor to power movement thereof.

FIG. 1B further illustrates: a rear access panel 174 of shell 13, for example, providing access to circuit boards of the aforementioned controller contained within the interior space that is surrounded by shell 13; an optional lock 184, to secure panel 174; a power jack 118, for connecting system 10 to a power source; and a printer 117 for providing documentation of each patient infusion carried out by system 10, and of system quality control test results. In some embodiments, system 10 may further include a power strip by which auxiliary equipment may be powered, and one or more additional electrical connectors, or ports (not shown), which are supported by platform 113 and may be integrated into shell 13, for example, in proximity to jack 118 or printer 117; these electrical connectors/ports allow system 10 to communicate with, other devices used for nuclear imaging procedures, for example, a PET scanner/camera, and/or for coupling to an intranet network, and/or to the internet, for example, to link up with software programs for various types of data analysis, and/or to link to computers of consulting clinicians/physicians, and/or to link into service providers and/or component suppliers data bases for enhanced maintenance and inventory management.

FIG. 1A further illustrates upper surface 131 of shell 13 including several openings 133, 135, 139 formed therein. FIG. 1C is a partially exploded perspective view of system 10, wherein a removable access panel 132 is shown as a contoured portion of upper surface 131, which, when exposed, by lifting away a bin 18, that mates therewith, may be removed from another opening 137 formed in upper surface 131. FIG. 1C also provides a better view of another panel 134 which may be lifted away from opening 139. According to the illustrated embodiment, openings 139 and 137 provide a user of system 10 with independent access to separate portions of infusion system 10, which are contained within shell 13, for example, to set up and maintain system 10; and openings 133 and 135 provide passageways for tubing lines to pass through shell 13. FIG. 1C further illustrates an optional switch 102, which in case of an emergency, may be activated to abort function of system 10. With reference to FIGS. 1A and 1C, it may be appreciated that an arrangement of features formed in upper surface 131 of shell 13, in conjunction with bin 18, tray 16 and computer 17, provide a relatively ergonomic and organized work area for technical personnel who operate system 10.

Turning now to FIG. 1D, a schematic of an infusion circuit 300, which may be incorporated by system 10, is shown. FIG. 1D illustrates circuit 300 generally divided into a first part 300A, which includes components mounted outside shell 13, and a second part 300B, which includes components mounted within the interior space surrounded by shell 13. (Parts 300A and 300B are delineated by dotted lines in FIG. 1D.) FIG. 1D further illustrates second part 300B of circuit 300 including a portion contained within a shielding assembly 200, which is designated schematically as a dashed line. Some embodiments of shielding assembly

200 will be described in greater detail, in conjunction with FIGS. 2A-B and 3A-B, below.

According to the illustrated embodiment, circuit 300 includes: an eluant reservoir 15, for example, a bag, bottle or other container, containing saline as the eluant, which is shown hanging from a post, or hanger 141 above upper surface 131 of shell 13 in FIG. 1A; a syringe pump 33, for pumping the eluant from reservoir 15, and a pressure syringe 34 (or other device or sensor), for monitoring pumping pressure; a filter 37, which may also serve as a bubble trap, for the pumped eluant; a radioisotope generator 21, through which the filtered eluant is pumped to create a radioactive eluate, for example an eluate carrying Rubidium-82 that is generated by the decay of Strontium-82, via elution, within a column of generator 21; and an activity detector 25, for measuring the activity of the eluate discharged from generator 21, in order to provide feedback for directing the flow of the eluate, via a divergence valve 35WP, either to a waste bottle 23 or through a patient line 305_p, for example, to inject a dose of the radiopharmaceutical eluate into a patient. With reference back to FIG. 1A, patient line 305_p is shown extending out from shell 13, through opening 135, to a distal end thereof, which, according to some embodiments, includes a filter. Patient line 305_p may be coupled to another line that includes a patient injection needle (not shown). Alternatively, patient line 305_p may be coupled to another line (not shown), which extends from a source of another active substance, for example, a stress agent; the other line is coupled to the line that includes the patient injection needle, in order to permit injection of the additional active substance.

FIG. 1D illustrates an eluant tubing line 301 coupled to reservoir 15 and to pump 33, and, with reference to FIGS. 1A-B, it may be appreciated that opening 133 provides the passageway for tubing line 301 to enter the interior space surrounded by shell 13. According to some preferred embodiments, opening 133 includes a grommet-type seal that prevents leakage of eluant, which may spill from reservoir 15, into the interior space through opening 133, while allowing a user to assemble tubing line 301 through opening 133. Likewise opening 135, which provides a passageway for patient line 305_p, may include a grommet-type seal. According to some embodiments, shell 13 further supports holders to safely hold, for example, during transport of system 10, portions of tubing lines that extend outward therefrom, for example, line 301 and/or line 305_p.

FIG. 1D further illustrates another eluant tubing line 302 coupled to pump 33 and a divergence valve 35BG, which may either direct pumped eluant through a tubing line 304, to generator 21, or direct the pumped eluant through a by-pass tubing line 303, directly to patient line 305_p. Divergence valve 35BG, as well as divergence valve 35WP, which directs eluate from an eluate tubing line 305 either to a waste line 305_w or to patient line 305_p, may each be automatically operated by a corresponding servomotor (not shown), coupled to the controller (not shown) of system 10, which controller receives feedback from activity detector 25. When system 10 is operating for automatic infusion, to deliver a dose of radiopharmaceutical to a patient, for example, Rubidium-82 for diagnostic imaging, divergence valve 35BG is initially set to direct eluant to generator 21 and divergence valve 35WP is set to direct eluate from the generator into waste bottle 23, until activity detector 25 detects the desired activity of the eluate, at which time the feedback from activity detector 25 causes the controller to direct the corresponding servo-motor to re-set valve 35WP for diverting the flow of eluate into patient line 305_p.

According to some embodiments, once a prescribed volume of the eluate has passed through patient line 305_p, the controller directs the corresponding servomotor to re-set divergence valve 35BG for diverting the flow of eluant through by-pass line 303 and into patient line 305_p in order to flush, or push any eluate remaining in patient line 305_p into the patient. According to some embodiments, the controller may also direct the corresponding servomotor to re-set divergence valve 35WP back toward waste bottle 23, prior to the flush through by-pass line 303, in order to prevent back flow of eluant, through line 305, toward generator 21. According to some preferred methods of operation, in certain situations, which will be described in greater detail below, eluant is pumped through by-pass line 303 immediately following the flow of the prescribed volume of eluate into patient line 305_p, at a higher speed, in order to push the eluate in patient line 305, thereby increasing a flow rate of the injection of eluate out from patient line 305_p and into the patient. For example, once the prescribed volume of eluate has flowed into patient line 305_p, and once divergence valve 35BG is set to divert flow through by-pass line 303, the speed of pump 33 may be adjusted to increase the flow rate of eluant to between approximately 70 mL/min and approximately 100 mL/min. This method for increasing the injection flow rate, is desirable, if a relatively high flow rate is desired for patient injection and a flow rate through generator 21 is limited, for example, to below approximately 70 mL/min, maximum (typical flow rate may be approximately 50 mL/min), in order to avoid an excessive back pressure created by the column of generator 21 in upstream portions of tubing circuit 300; the excessive back pressure could damage filter 37 or otherwise impede flow through eluant tubing line 302.

Although not shown in FIG. 1D, a number of sensors, for example, to measure pressure and/or flow velocity, may be incorporated into circuit 300, according to some alternate embodiments, in order to monitor for flow anomalies, for example, related to occlusions/plugs in circuit 300 and/or leaks, and/or to provide feedback for control of an activity level of infused doses of radiopharmaceutical. Suitable sensors for any of the above purposes are known to those skilled in the art. Examples of flow meters that may be incorporated into circuit 300, include the Innova-Sonic® Model 205 Transit-Time Ultrasonic Liquid Flow Meter that employs digital signal processing (available from Sierra Instruments, Inc.) and the Flocat LA10-C differential pressure flow meter. One example of a pressure sensor that may be employed to detect infusion circuit occlusions is the PRO/Pressure-Occlusion Detector (available from INTROTEK® of Edgewood, N.Y., a subsidiary of Magnetrol of Downers Grove, Ill.), which employs pulse-type ultrasound; this sensor detects subtle changes in positive and negative air pressure and produces a corresponding passive resistive output signal, which may be routed to the system controller and/or computer 17. One or more of this type of sensor may be incorporated into infusion circuit 300 by simply fitting the sensor around any of the tubing lines of infusion circuit 300; in fact, the PRO/Pressure-Occlusion Detector may be a suitable alternative to pressure syringe 34 of circuit 300. Other types of pressure sensors, for example, similar to those known in the art for blood pressure monitoring, may be employed in infusion circuit 300.

System 10 may further include sensors to detect fluid levels in eluant reservoir 15 and waste bottle 23. Some examples of such sensors, which also employ the aforementioned pulse-type ultrasound, are the Drip Chamber Liquid Level Sensor and the CLD/Continuous Level Detector (both

available from INTROTEK®); alternatively, for example, an HPQ-T pipe mounted, self-contained liquid sensor (available from Yamatake Sensing Control, Ltd.), or an SL-630 Non-Invasive Disposable/Reusable Level Switch (available from Cosense, Inc. of Hauppauge, N.Y.) may be employed to detect the fluid levels. Alternately or in addition, system 10 can include additional radiation and/or moisture detection sensors, which can detect leaks. With reference to FIG. 1D, such sensors are preferably located in proximity to fittings 311, 312, 313, 314 and 315 that join portions of circuit 300 to one another. Some examples of leak detection sensors include, without limitation, those in the HPQ-D leak detection sensor family, and the HPF-D040 fiberoptic leak detector (all available from Yamatake Sensing Control, Ltd.). System 10 may further include additional sensors to detect contaminants and/or air bubbles within the tubing lines of circuit; examples of such sensors include the Point-air Detection (PAD) Sensor, that employs pulse-type ultrasound for air bubble detection, and the Blood Component Detector that employs optical sensing technology to perform Colorimetry-based fluid detection of unwanted elements in the tubing lines (both available from INTROTEK®).

According to those embodiments that include any of the above sensors, the sensors are linked into the controller of system 10 and/or computer 17, either of which may provide a signal to a user of system 10, when a flow anomaly is detected, and/or information to the user, via monitor 172, concerning fluid levels, pressure and/or flow through circuit 300. Computer 17 may be pre-programmed to display, for example, on monitor 172, a graphic of infusion circuit 300 wherein each zone of the circuit, where an anomaly has been detected, is highlighted, and/or to provide guidance, to the system user, for correcting the anomaly. It should be noted that the alternative infusion circuits illustrated in FIGS. 12A-B, which will be described below, may also include any or all of these types of sensors.

With further reference to FIG. 1D, it may be appreciated that shielding assembly 200 encloses those portions of circuit 300 from which radioactive radiation may emanate, with the exception of that portion of patient line 305_p, which must extend out from shielding assembly 200 in order to be coupled to the patient for injection, or in order to be coupled to shielded sample vials, as will be described below. Thus, technical personnel, who operate system 10, are protected from radiation by shielding assembly 200, except at those times when an infusion is taking place, or when quality control tests require collection of eluate into sample vials. During infusions and quality control test sample collection, all technical personnel are typically in another room, or otherwise distanced from system 10, in order to avoid exposure to radiation during the infusion, and, according to some preferred embodiments of the present invention, system 10 includes at least one means for informing technical personnel that an infusion is about to take place or is taking place. With reference back to FIGS. 1A and 1C, system 10 is shown including a light projector 100, mounted on post 142. According to the illustrated embodiment, projector 100, projects a light signal upward, for maximum visibility, when pump 33 is pumping eluant and elution is taking place within generator 21, or at all times when pump 33 is pumping eluant. According to some embodiments, the light signal flashes on and off when the eluate is being diverted from generator 21 into waste bottle 23, and the light signal shines steadily when the eluate is being diverted through patient line 305_p, or visa versa. According to other embodiments, a projector 100 shines a light having a first color, to indicate that eluate is being diverted to waste bottle 23, and then

shines a light having a second, different color, to indicate that eluate is being directed to patient line 305_p for infusion. Light projector 100 may further project a more rapidly flashing light, for example, for approximately five seconds, once a peak bolus of radioactivity is detected in the eluate, to provide further information to technical personnel. Alternative means of informing technical personnel that an infusion is taking place may also be incorporated by system 10, for example, including audible alarms or other types of visible or readable signals that are apparent at a distance from system 10, including in the control room.

It should be noted that, according to alternate embodiments, system 10 includes an 'on board' dose calibrator for quality control tests, and circuit 300 is expanded to include elements for an automated collection of eluate samples for activity measurements, via the on board dose calibrator. According to a first set of these alternate embodiments, a sample collection reservoir is integrated into circuit 300, downstream of divergence valve 35WP and in communication with tubing line 305P, in order to receive quality control test samples of eluate, via tubing line 305P, and both the reservoir and the dose calibrator are located in a separate shielded well. According to a second set of these alternate embodiments, waste bottle 23 is configured to receive the quality control test samples of eluate, via tubing line 305W, and a dose calibrator is integrated into shielding assembly 200. Quality control procedures will be described in greater detail below, in conjunction with FIGS. 6-8B.

When maintenance of system 10 requires the emptying waste bottle 23, relatively easy access to waste bottle 23 is provided through opening 139 in top surface 131 of shell 13. It should be noted that technical personnel are preferably trained to empty waste bottle 23 at times when the eluate, contained in waste bottle 23, has decayed sufficiently to ensure that the radioactivity thereof has fallen below a threshold to be safe. Opening 139 is preferably located at an elevation of between approximately 2 feet and approximately 3 feet; for example, opening 139 may be at an elevation of approximately 24 inches, with respect to a lower surface of platform 113, or at an elevation of approximately 32 inches, with respect to a ground surface upon which wheels 121, 122 rest. According to the illustrated embodiment, opening 139 is accessed by lifting panel 134; just within opening 139, a shielded lid or door 223 (FIG. 2A) may be lifted away from a compartment of shielding assembly 200 that contains waste bottle 23. With further reference to FIG. 1C, it may be appreciated that opening 137 provides access to other portions of circuit 300 for additional maintenance procedures, such as changing out generator 21 and/or other components of circuit 300, as will be described below.

For those embodiments of system 10 in which automated quality control tests are performed and/or when system 10 is employed for relatively high volume operation, management of waste may become burdensome, even though access to waste bottle 23 is greatly facilitated, as described above. Thus, in order to facilitate waste management, some embodiments of system 10 may employ a separation system to separate salts, including radioactive elements, from water, for example, via evaporation or reverse osmosis. In an evaporation type system, the water component of the waste is evaporated, while in a reverse osmosis type system the water is separated from the salts, and, then, once confirmed to be non-radioactive, via a radiation detector, is piped to a drain. According to some other embodiments, circuit 300 may be configured so that the waste may be used to purge air from the tubing lines thereof and/or to perform the bypass

flush that was described above, preferably after the radioactivity of the waste drops below a critical threshold.

FIGS. 1A and 1C further illustrate a pair of relatively shallow external recesses 190, which are formed in upper surface 131 of shell 13, for example, in order to catch any spills from the infusion system; one of recesses 190 is shown located in proximity to post, or hanger 141, which holds reservoir 15, and in proximity to opening 133, through which tubing line 301 passes. Another recess 192 is shown formed in upper surface 131; a width and depth of recess 192 may accommodate storage of technical documentation associated with infusion system 10, for example, a technical manual and/or maintenance records, or printouts from printer 117 (FIG. 1B). With reference to FIG. 1C, upper surface 131 of shell 13 is shown to also include additional recesses 101, which are each sized to hold a shielded test vial, which contains samples from infusion system 10, for example, for breakthrough testing and/or calibration, which will be described in greater detail, below. An exemplary test vial shield is shown in FIG. 1E. The test vial shield of FIG. 1E is preferably formed from Tungsten rather than lead, for example, to reduce exposure to lead, for improved shielding, and to reduce the weight of the shield. FIG. 1E illustrates the test vial shield including a handle to simplify manipulation thereof, but alternative configurations of test vial shields have no handle—for these a sling, or strap, may be employed for handling.

Additional receptacles 180 are shown formed in bin 18, on either side of a handle 182, which facilitates removal of bin 18 away from shell 13. Technical personnel may, thus, conveniently transport bin 18 to a storage area for a collection of supplies, for example, sharps, gloves, tubing lines, etc . . . , into one or more receptacles 180 thereof, and/or to a waste container where separate receptacles 180 of bin 18 may be emptied of waste, such as packaging for the aforementioned supplies, for example, deposited therein during infusion procedures. According to some embodiments, one or more additional receptacles are formed in one or more disposal containers, for example, to contain sharps and/or radioactive waste (other than that contained in waste bottle 23), which may be integrated into bin 18, or otherwise fitted into, or attached to shell 13, separate from bin 18.

FIG. 2A is a perspective view of shielding assembly 200, according to some embodiments of the present invention. With reference to FIGS. 1C and 2A, together, it may be appreciated that opening 137, in upper surface 131 of shell 13, provides access to a lid or door 221 of a sidewall 201 of shielding assembly 200, which sidewall 201 encloses a compartment sized to contain a radioisotope generator of system 10, for example, generator 21, previously introduced. It should be noted that, according to alternate embodiments, the compartment enclosed by sidewall 201 is large enough to hold more than one generator, for example, to increase system operating efficiency for relatively high volume operation. In some of these alternate embodiments, tubing lines 304 and 305 are each branched for parallel flow through the multiple generators, in which case divergence valves may be employed to alternate the flow through the generators, one at a time. In others of these alternate embodiments, the multiple generators are connected in series between tubing line 304 and tubing line 305. In addition, a reservoir for accumulating eluate may be included in circuit 300, downstream of the generators and upstream of divergence valve 35 WP, in conjunction with a second pump, in some cases. Embodiments including multiple generators and/or an eluate reservoir and second pump can be employed to better manage an activity level of each

dose, or patient injection, for example, as described below, in conjunction with FIGS. 12A-B.

According to the embodiment illustrated in FIG. 2A, opening 137 and door 221 are located at a lower elevation, for example, with respect to platform 113, than are opening 139 and lid 223, which provide access to the compartment being formed by a sidewall 203 of shielding assembly 200 to contain waste bottle 23, as previously described. When panel 132 is separated from shell 13, and door 221 opened, generator 21 may be lifted out from an opening 231 (FIG. 3A) which mates with door 221 of sidewall 201. A weight of generator 21, which includes its own shielding, may be between approximately 23 and approximately 25 pounds, thus, according to some preferred embodiments of the present invention, the elevation of each of openings 137 and 231, with respect to the lowermost portion of the cabinet structure, is between approximately 1 foot and approximately 2 feet, in order to facilitate an ergonomic stance for technical personnel to lift generator 21 out from the compartment. According to an exemplary embodiment, when shielding assembly 200 is contained in the cabinet structure of FIG. 1A, openings 137 and 231 are located at an elevation of approximately 12 inches, with respect to the lower surface of platform 113, or at an elevation of approximately 19 inches, with respect to the ground surface upon which wheels 121, 122 rest. FIG. 1C further illustrates access panel 132 including a security lock 138, which mates with a framework 19 of system 10, shown in FIG. 2B, in order to limit access to generator 21.

FIGS. 1C and 2A further illustrate a lid or a door 225 of another sidewall 205 (FIG. 3A) of shielding assembly 200, which encloses another compartment that is accessible through opening 137 of shell 13, and which is located adjacent the compartment enclosed by sidewall 201. Each of doors 221, 225 are shown being attached by a corresponding hinge H, and another door 227 is shown attached to sidewall 203 by another hinge H. FIG. 2A illustrates each of lid 223 and doors 221, 225, 227 including a handle 232, 212, 252 and 272; respectively, for moving lid 223 and doors 221, 225, 227, in order to provide access to the corresponding compartments, which can be seen in FIGS. 3A-B. FIG. 2A further illustrates optional thumb screws 290, one securing lid 223 to sidewall 203 and another securing door 221 to sidewall 201, or other means for securing the doors, which are known to those skilled in the art, may be incorporated. Each sidewall 201, 203, 205 and the corresponding lid/door 223, 221, 225, 227 thereof may be individually cast from 3% antimony lead, or from other known shielding materials, and then assembled together according to methods known to those skilled in the art.

According to the illustrated embodiment, doors 221, 225 are hinged to open in an upward direction, per arrows D and C, and, with reference back to FIG. 1C, a latch component 191 is provided to hold each of doors 221, 225 in an opened position, thereby, preventing doors 221, 225 from falling closed, which could pinch/crush fingers of technical personnel and/or tubing lines of circuit 300, when in the midst of a maintenance procedure. FIG. 2B is a perspective view of framework 19 of the cabinet structure of system 10, according to some embodiments, to which latch component 191 is mounted; FIG. 2B-1 is an enlarged detailed view of latch component 191, according to some embodiments. FIG. 2B illustrates latch component 191 including a first pin 193, corresponding to door 225, and a second pin 195, corresponding to door 221; each pin 193, 195 includes a lever end 193A, 193B, respectively, and a holding end 193B, 195B, respectively. An edge of each door 221, 225, upon opening

11

of doors 221, 225, may push past the holding end 195B, 193B of the corresponding pin 195, 193, in a first direction, per arrow F, and then may rest against a respective side S95 and S93 of each end 195B, 193B, until the corresponding lever end 195A, 193A is rotated in a counter-clockwise direction, per arrow cc, thereby moving the corresponding holding end 193B, 195B to make way for the closing of doors 221, 225. Doors 221, 225 being held by latch component 191 in an open position may be seen in FIG. 3A.

With further reference to FIG. 2A, according to some preferred embodiments of the present invention, an edge of door 225 overlaps door 221 to prevent door 221 from being opened, per arrow D, if door 225 is not opened, per arrow C; and an edge of door 227 overlaps an edge of door 225 to prevent door 225 from being opened if door 227 is not opened, per arrow B; and an edge of lid 223 overlaps door 227 to prevent door 227 from being opened if lid 223 is not opened, per arrow A. Thus, access to the compartment enclosed by sidewall 201 and containing generator 21 is only systematically allowed through a sequential opening of lid 223 and doors 227, 225, 221, since, when generator 21 is replaced it is typically desirable to also replace those portions of circuit 300 which are shielded behind lid 223 and doors 227, 225. The routing of these portions of circuit 300 will be described in conjunction with FIGS. 3A-C.

FIG. 3A is another perspective view of shielding assembly 200, according to some embodiments of the present invention. In FIG. 3A, lid 223 and doors 221, 225, and 227 are opened to provide a view into openings 233, 235 and 231 of sidewalls 203, 205 and 201, respectively, and into a passageway 207, which is formed in sidewall 203, opposite the compartment, which contains waste bottle 23. Passageway 207 is shown extending vertically along sidewall 203 and having a grooved extension 213 formed in a perimeter surface of opening 233. An optional retaining member 237, for example, formed from an elongate strip of resilient plastic having a generally c-shape cross-section, is shown being mounted along a length of passageway 207 to hold lines 305_w and 305_p in place within passageway 207. FIG. 3A further illustrates a pair of passageways 251_b and 251_g, which are formed as grooves in a portion of sidewall 205, and another pair of passageways 215_i and 215_o, which are formed as grooves in a portion of sidewall 201. A routing of portions of tubing circuit 300 (FIG. 1D) through passageways 207, 251_b, 251_c, 215_i and 215_o is shown in FIG. 3B.

FIG. 3B illustrates tubing line 304 being routed through passageways 251_g and 215_i, eluate tubing line 305 being routed through passageway 215_o, and both waste line 305_w and patient line 305_p being routed along passageway 207. Waste line 305_w further extends through grooved extension 213 to waste bottle 23, and patient line 305_p further extends outward from shielding assembly 200, for example, to extend out through opening 135 in upper surface 131 of shell 13 (FIG. 1A). According to the illustrated embodiment, each passageway formed in shielding assembly 200, by being accessible along a length thereof, can facilitate a relatively easy routing of the corresponding tubing line therethrough, when the corresponding lid/door is open, and a depth of each passageway prevents pinching and/or crushing of the corresponding tubing line routed therethrough, when the corresponding lid/door is closed down thereover. With further reference to FIGS. 3A-B, it may be appreciated that the compartment formed by sidewall 201 may have a shape matching an exterior contour of generator 21, such that generator 21 is 'keyed' to the compartment, for example, to prevent installation of an improper generator into system 10, and/or to facilitate the proper orientation of generator 21

12

within the compartment for the proper routing of tubing lines. Alternately, or in addition, according to alternate embodiments, if system 10 includes a reader of encoded information in communication with computer 17, a unique identification and/or data associated with each generator may be provided, for example, in a bar code label or a radiofrequency identification (RFID) tag that is attached to each generator, so that the reader may transfer the information to computer 17, when a generator is installed, in order to either enable system operation or to provide an indication to the user that an incorrect generator has been installed. Of course a user of system 10 may, alternately, manually enter information, that is provided on a generator label or marking, into computer 17, in order to either enable system 10, or to receive feedback from computer 17 that the incorrect generator is installed.

FIG. 3A further illustrates sidewall 205 including a valve actuator receptacle 253, into which divergence valve 35WP is mounted, to be controlled by one of the servomotors (not shown) of system 10, and an opening 325 for activity detector 25. Activity detector 25 is mounted in a shielded well 255 that extends downward from opening 325 (shown in FIG. 3B), and, with reference to FIG. 3B, tubing line 305 passes over opening 325 so that detector 25 can detect an activity of the eluate, which passes therethrough. According to some embodiments, the positioning, within the compartment enclosed by sidewall 205, of the components of the portion of infusion circuit 300 which are shown routed therein, is facilitated by providing the components mounted in a frame 39 as a disposable subassembly 390, an embodiment of which is illustrated by FIGS. 3C-D.

FIG. 3C is a perspective view of subassembly 390, and FIG. 3D is a perspective view of frame 39. According to the embodiment illustrated by FIG. 3D, frame 39 is formed from mating trays 39A, 39B, for example, formed from a thermoformed plastic, which fit together to capture, therebetween, and hold, in fixed relation to a perimeter edge of frame 39, divergence valve 35WP and portions of eluant tubing line 304, by-pass tubing line 303, eluate tubing line 305, waste line 305_w and patient line 305_p. FIG. 3C illustrates the perimeter edge divided into a first side 391, a second side 392, opposite first side 391, a third side 393, extending between first and second sides 391, 392, and a fourth side 394, opposite third side 393. Although FIG. 3D shows trays 39A, 39B individually formed for fitting together, according to alternate embodiments, mating trays of frame 39 may be parts of a continuous sheet of plastic folded over on itself.

According to the illustrated embodiment, an end 404A, of eluant line 304, and an end 403, of by-pass line 303 extend from third side 393 of frame 39 to couple with divergence valve 35BG and an upstream section of eluant tubing line 302. FIG. 3C further illustrates an opposite end 404B of eluant line extending from first side 391 of frame 39, alongside a similarly extending end 405 of eluate line 305, and ends 406 and 407 of patient line 305_p and waste line 305_w, respectively, extending from second side 392 of frame 39. Although ends 406, 407 are shown extending upward from tray 39a, as they would within shielding assembly 200, it should be appreciated that the tubing lines of circuit 300 are preferably flexible and would drop down under their own weight rather than extending upward, as shown, if not supported. Referring back to FIG. 1D, in conjunction with FIG. 3C, it can be seen that the aforementioned fittings are provided for coupling subassembly 390 into circuit 300: first fitting 311 couples the section of eluant line 302 to filter 37; second fitting 312 couples eluant line 304 to an inlet port of

generator 21; third fitting 313, which may incorporate a check valve, couples eluate line 305 to an outlet port of generator 21; fourth fitting 314 couples waste line 305_w to waste bottle 23; and fifth fitting 315 couples patient line 305_p to an extension thereof, which extends outside shell 13 (designated by the dotted line). Each of the fittings 311, 312, 313, 314, 315 may be of the Luer type, may be a type suitable for relatively high pressure applications, or may be any other suitable type that is known to those skilled in the art.

As previously mentioned, when generator 21 is replaced, it is typically desirable to also replace those portions of circuit 300 which are shielded behind lid 223 and doors 227, 225, and, in those instances wherein system 10 is moved to a new site each day, these portions may be replaced daily. Thus, according to the illustrated embodiment, these portions are conveniently held together by frame 39, as subassembly 390, in order to facilitate relatively speedy removal and replacement, while assuring a proper assembly orientation, via registration with features formed in sidewall 205 (FIG. 3A), for example: registration of divergence valve 35WP with valve actuator receptacle 253, registration of tubing line ends 403 and 404A with passageways 251b and 251g, respectively, registration of tubing line ends 404B and 405 with passageways 215i and 215o, respectively, and registration of tubing line ends 406 and 407 with passageway 207.

With further reference to FIG. 3B, other portions of tubing circuit 300 are shown. FIG. 3B illustrates eluant tubing line 301 extending from reservoir 15, outside of shell 13 (FIG. 1A), to syringe pump 33, which is mounted to an actuating platform 433. According to the illustrated embodiment, platform 433 is actuated by another servomotor (not shown) of system 10, which is controlled by the controller and computer 17 of system 10, to cause a plunger of pump 33 to move, per arrow I, so as to draw in eluant, from reservoir 15, through tubing line 301, and then to cause the plunger to move in the opposite direction so as to pump the eluant, through tubing line 302, to either generator 21 or to by-pass line 303. Although the illustrated embodiment includes syringe pump 33, other suitable pumps, known to those skilled in the art, may be substituted for pump 33, in order to draw eluant from reservoir 15 and to pump the eluant throughout circuit 300. Although not shown, it should be appreciated that divergence valve 35BG is fitted into another valve actuating receptacle mounted within shell 13 and coupled to yet another servomotor (not shown) of system 10.

FIG. 3B further illustrates a filter holder 317 that is mounted alongside an interior surface of shell 13 to hold filter 37 (FIG. 1D) of tubing line 302. Filter holder 317, like frame 39 for subassembly 390, may be formed from a thermoformed plastic sheet; holder 317 may have a clam-shell structure to enclose filter 37 in an interior space, yet allow tubing line 302, on either side of filter 37, to extend out from the interior space, in between opposing sides of the clam-shell structure. Holder 317 is shown including an appendage 307 for hanging holder 317 from a structure (not shown) inside shell 13.

Turning now to FIGS. 4-9C details concerning computer-facilitated operation of system 10 will be described, according to some embodiments of the present invention. As previously mentioned, and with reference back to FIG. 1A, computer 17 of system 10 includes monitor 172, which, preferably, not only displays indications of system operation to inform a user of system 10, but is also configured as a touch screen to receive input from the user. It should be understood that computer 17 is coupled to the controller of

system 10, which may be mounted within the interior space surrounded by shell 13. Although FIG. 1A shows computer 17 mounted to post 142 of system 10, for direct hardwiring to the controller of system 10, according to some alternate embodiments, computer 17 is coupled to the controller via a flexible lead that allows computer 17 to be positioned somewhat remotely from those portions of system 10, from which radioactive radiation may emanate; or, according to some other embodiments, computer 17 is wirelessly coupled, for example, via two-way telemetry, to the controller of system 10, for even greater flexibility in positioning computer 17, so that the operation of system 10 may be monitored and controlled remotely, away from radioactive radiation.

According to some preferred embodiments, computer 17 is pre-programmed to guide the user, via monitor 172, through procedures necessary to maintain system 10, to perform quality control tests on system 10, and to operate system 10 for patient infusions, as well as to interact with the user, via the touch-screen capability of monitor 172, according to preferred embodiments, in order to track volumes of eluant and eluate contained within system 10, to track a time from completion of each elution performed by system 10, to calculate one or more system parameters for the quality control tests, and to perform various data operations. Computer 17 may also be pre-programmed to interact with the controller of system 10 in order to keep a running tally or count of elutions per unit time, for a given generator employed by the system, and may further categorize each of the counted elutions, for example, as being generated either as a sample, for quality control testing, or as a dose, for patient injection. The elution count and categorization, along with measurements made on each sample or dose, for example, activity level, volume, flow rate, etc. . . . , may be maintained in a stored record on computer 17. All or a portion of this stored information can be compiled in a report, to be printed locally, and/or to be electronically transferred to a remote location, for example, via an internet connection to technical support personnel, suppliers, service providers, etc. . . . , as previously described. Computer 17 may further interact with the user and/or a reader of encoded information, for example, a bar code reader or a radiofrequency identification (RFID) tag reader, to store and organize product information collected from product labels/tags, thereby facilitating inventory control, and/or confirming that the proper components, for example, of the tubing circuit, and/or accessories, and/or solutions are being used in the system.

It should be understood that screen shots shown in FIGS. 4-9C are exemplary in nature and are presented to provide an outline of some methods of the present invention in which computer 17 facilitates the aforementioned procedures, without limiting the scope of the invention to any particular computer interface format. Computer 17 may also include a pre-programmed, user manual, which may be viewed on monitor 172, either independent of system operation or in conjunction with system operation, for example, via pop-up help screens. Although the English language is employed in the screen shots of FIGS. 4-9C, it should be understood that, according to some embodiments, computer 17 is pre-programmed to provide guidance in multiple languages.

FIG. 4 is a screen shot of a main menu 470, which is presented by computer 17 on monitor 172, according to some embodiments. Main menu 470 includes a listing of each computer-facilitated operation that may be selected by the user, once the user has logged on. According to some

multi-lingual embodiments, computer 17 presents a list of languages from which the user may select, prior to presenting main menu 470.

FIG. 5A is a schematic showing a series of screen shots which includes a log in screen 570. According to some embodiments, when the user touch-selects the data entry fields of screen 570 or 571, or of any of the other screens presented herein, below, a virtual keyboard is displayed for touch-select data entry into the selected data entry field; alternately, computer 17 may be augmented with another type of device for user data entry, examples of which include, without limitation, a peripheral keyboard device, a storage medium (i.e. disk) reader, a scanner, a bar code reader (or other reader of encoded information), a hand control (i.e. mouse, joy stick, etc. . . .). Although not shown, according to some embodiments, screen 570 may further include another data entry field in which the user is required to enter a license key related to the generator employed by system 10 in order to enable operation of system 10; the key may be time sensitive, related to generator contract terms. Of course any number of log in requirements may be employed, according to various embodiments, and may be presented on multiple sequentially appearing screens rather than on a single log in screen.

After the user enters the appropriate information into data entry fields of log in screen 570, computer 17 presents a request for the user to confirm the volume of eluant that is within reservoir 15 (e.g. saline in saline bag), via a screen 571, and then brings up main menu 470. If the user determines that the volume of eluant/saline is insufficient, the user selects a menu item 573, to replace the saline bag. If system 10 includes an encoded information reader, such as a bar code or RFID tag reader, confirmation that the selected reservoir is proper, i.e., contains the proper saline solution, may be carried out by computer 17, prior to connecting the reservoir into circuit 300, by processing information read from a label/tag attached to the reservoir. Alternatively, or in addition, tubing line 301 of circuit 300 may be provided with a connector which only mates with the proper type of reservoir 15. According to some embodiments, system 10 may further include an osmolarity or charge detector, which is located just downstream of reservoir 15 and is linked to computer 17, so that an error message may be presented on monitor 172 stating that the wrong osmolarity or charge is detected in the eluant supplied by reservoir, indicating an improper solution. One example of a charge detector that may be employed by system 10 is the SciCon™ Conductivity Sensor (available from SciLog, Inc. of Middleton, Wis.).

Once the reservoir/saline bag is successfully replaced, computer 17 prompts the user to enter a quantity of saline contained by the new saline bag, via a screen 574. Alternately, if system 10 includes the aforementioned reader, and the saline bag includes a tag by which volume information is provided, the reader may automatically transfer the quantity information to computer 17. Thus, computer 17 uses either the confirmed eluant/saline volume, via screen 571, or the newly entered eluant/saline volume as a baseline from which to track depletion of reservoir volume, via activations of pump 33, in the operation of system 10. With reference to FIG. 5B, during the operation of system 10, when computer 17 detects that the eluant reservoir/saline bag has been depleted to a predetermined volume threshold, computer 17 warns the user, via a screen 577. If the user has disregarded screen 577 and continues to deplete the saline bag, computer 17 detects when the saline bag is empty and provides indication of the same to the user, via a screen 578. To

replenish the reservoir/saline bag, the user may either refill the reservoir/bag or replace the empty reservoir/bag with a full reservoir/bag. According to some embodiments, system 10 automatically precludes any further operation of the system until the reservoir is replenished. It should be noted that, as previously mentioned, system 10 can include a fluid level sensor coupled to the eluant reservoir in order to detect when the level of saline drops below a certain level.

In addition to tracking the volume of eluant in reservoir 15, computer 17 also tracks a volume of the eluate which is discharged from generator 21 into waste bottle 23. With reference to FIG. 5C, an item 583 is provided in main menu 470, to be selected by the user when the user empties waste bottle 23. When the user selects item 583, computer 17 presents a screen 584, by which the user may effectively command computer 17 to set a waste bottle level indicator to zero, once the user has emptied waste bottle 23. Typically, the user, when powering up system 10 for operation, each day, will either empty waste bottle 23, or confirm that waste bottle 23 was emptied at the end of operation the previous day, and utilize screen 584 to set the waste bottle level indicator to zero. Thus, computer 17, can track the filling of waste bottle 23 via monitoring of the operation of pump 33 and divergence valve 35WP, and provide an indication to the user when waste bottle 23 needs to be emptied, for example, via presentation of screen 584, in order to warn the user that, unless emptied, the waste bottle will overflow. According to some embodiments, system 10 automatically precludes any further operation of the system until the waste bottle is emptied. According to some alternative embodiments, a fluid level sensor may be coupled to waste bottle 23, for example, as mentioned above in conjunction with FIG. 1D, in order to automatically detect when waste bottle 23 is filled to a predetermined level and to provide, via computer 17, an indication to the user that waste bottle 23 needs to be emptied and/or to automatically preclude operation of system 10 until the waste bottle is emptied.

In addition to the above maintenance steps related to eluant and eluate volumes of system 10, the user of system 10 will typically perform quality control tests each day, prior to any patient infusions. With reference to FIG. 6, according to preferred methods, prior to performing the quality control tests (outlined in conjunction with FIGS. 7A-C and 8A-B), the user may select an item 675 from main menu 470, in order to direct system 10 to wash the column of generator 21. During the generator column wash, which is performed by pumping a predetermined volume of eluant, for example, approximately 50 milliliters, through generator 21 and into waste bottle 23, computer 17 provides an indication, via a screen 676, that the wash is in progress. Also, during the generator column wash, the system may provide a signal to indicate that eluate it being diverted to waste bottle 23, for example, light projector 100 (FIG. 1C) may project a flashing light signal, as previously described.

FIG. 6 further illustrates a screen 677, which is presented by computer 17 upon completion of the column wash, and which provides an indication of a time lapse since the completion of the wash, in terms of a time countdown, until a subsequent elution process may be effectively carried out. While screen 677 is displayed, system 10 may be refilling, from reservoir 15, pump 33, which has a capacity of approximately 55 milliliters, according to some embodiments. According to some preferred embodiments of the present invention, computer 17 starts a timer once any elution process is completed and informs the user of the time lapse, either in terms of the time countdown (screen 677), or in terms of a time from completion of the elution, for

17

example, as will be described in conjunction with FIG. 7B. According to an exemplary embodiment, wherein generator 21 is the CardioGen-82® that yields a saline solution of Rubidium-82, produced by the decay of Strontium-82, via the elution, a time required between two effective elution processes is approximately 10 minutes.

Once the appropriate amount of time has lapsed, after the elution process of generator column wash, a first quality control test may be performed. With reference to FIG. 7A, the user may select, from main menu 470, an item 773A, which directs computer 17 to begin a sequence for breakthrough testing. According to some embodiments, in conjunction with the selection of item 773A, the user attaches a needle to an end of patient line 305_p and inserts the needle into a test vial, for the collection of an eluate sample therefrom, and, according to FIG. 7A, computer 17 presents a screen 774, which instructs the user to insert the test vial into a vial shield, which may be held in recess 101 of shell 13 (FIG. 1C).

FIG. 7A further illustrates a subsequent screen 775, by which computer 17 receives input, from the user, for system 10 to start the breakthrough elution, followed by a screen 776, which provides both an indication that the elution is in progress and an option for the user to abort the elution. As previously described, the system may provide a signal to indicate that elution is in progress, for example, light projector 100 (FIG. 1C) may project a flashing light signal during that portion of the elution process when eluate is diverted from generator 21 through waste line 305_w and into waste bottle 23, and then a steady light signal during that portion of the elution process when the eluate is diverted from generator 21 through patient line 305_p and into the test vial, for example, once activity detector 25 detects a dose rate of approximately 1.0 mCi/sec in the eluate discharged from generator 21. Another type of light signal, for example, the more rapidly flashing light, as previously described, may be projected when a peak bolus of radioactivity is detected in the eluate.

Upon completion of the elution process for breakthrough testing, computer 17 presents a screen 777, shown in FIG. 7B, which, like screen 677, provides an indication of a time lapse since the completion of the elution, but now in terms of a time since completion of the breakthrough elution process. When the user transfers the vial containing the sample of eluate into a dose calibrator, to measure the activity of the sample, the user may make a note of the time lapse indicated on screen 777. With further reference to FIG. 7B, once the user has received the activity measure from the dose calibrator, the user proceeds to a screen 778, which includes data entry fields for the activity measure and the time between that at which the dose calibrator measured the activity of the sample and that at which the elution was completed. The user may enter the data via the touch-screen interface of monitor 172, or via any of the other aforementioned devices for user data entry. According to some alternate embodiments, computer 17 may receive the data, electronically, from the dose calibrator, either via wireless communication or a cable connection.

After the data is entered by the user, computer 17 presents screen 779, from which the user moves back to main menu 470 to perform a system calibration, for example, as will be described in conjunction with FIGS. 8A-B, although the breakthrough testing is not completed. With reference back to FIG. 7A, an item 773B is shown in main menu 470; item 773B may only be effectively selected following the completion of steps for item 773A, so as to perform a second stage of breakthrough testing. In the second stage, the

18

breakthrough of the sample of eluate collected in the test vial for the breakthrough testing is measured, at a time of approximately 60 minutes from the completion of the elution that produced the sample. With reference to FIG. 7C, after the user has selected item 773B from main menu 470, in order to direct computer 17 to provide breakthrough test results, a screen 781 is displayed. Screen 781 includes, for reference, the values previously entered by the user in screen 778, along with another pair of data entry fields into which the user is instructed to enter the breakthrough reading of the sample at 60 minutes and the background radiation reading, respectively. After the user enters this remaining information, as described above, computer 17 may calculate and then display, on a screen 782, the breakthrough test results.

According to the illustrated embodiment, computer 17 also displays on screen 782 pre-programmed allowable limits for the results, so that the user may verify that the breakthrough test results are in compliance with acceptable limits, before moving on to a patient infusion. According to some embodiments, system 10 will not allow an infusion if the results exceed the acceptable limits, and may present a screen explaining that the results are outside the acceptable limits; the screen may further direct the user to contact the generator supplier, for example, to order a replacement generator.

With reference to FIG. 8A, during the aforementioned 60 minute time period, while waiting to complete the breakthrough testing, the user may perform calibration by selecting item 873 from main menu 470. Upon selection of item 873, computer 17 presents a screen 874, which instructs the user to insert a new test vial into an elution vial shield. In addition to placing the vial in the shield, the user, preferably, replaces patient line 305_p with a new patient line, and then attaches a needle to the end of the new patient line for insertion into the test vial, in order to collect an eluate sample therefrom. After performing these steps, the user may move to screen 875, wherein a plurality of data entry fields are presented; all or some of the fields may be filled in with pre-programmed default parameters, which the user has an option to change, if necessary. Once the user confirms entry of desired parameters for the calibration, the user may enter a command, via interaction with a subsequent screen 876, to start the calibration elution.

With reference to FIG. 8B, after computer 17 starts the elution process, a screen 87 informs the user that the calibration elution is in progress and provides an option to abort the elution. As previously described, the system may provide an indication that elution is in progress, for example, light projector 100 (FIG. 1C) may project a flashing light signal during that portion of the elution process when eluate is diverted from generator 21 through waste line 305_w and into waste bottle 23, and then a steady light signal during that portion of the elution process when activity detector 25 has detected that a prescribed dose rate threshold is reached, for example, 1.0 mCi/sec, and the eluate is being diverted from generator 21, through the new patient line, and into the test vial. Another type of light signal, for example, the more rapidly flashing light, as previously described, may be projected when a peak bolus of radioactivity is detected in the eluate. Upon completion of the elution process for calibration, computer 17 presents a screen 878, which provides an indication of a time lapse since the completion of the elution, in terms of a time since completion of the calibration elution process. When the user transfers the vial containing the sample of eluate into the dose calibrator, to measure the activity of the sample, the user may make a note of the time lapse indicated on screen 878. With further reference to FIG. 8B, once the user has received the activity

measure from the dose calibrator, the user proceeds to a screen 879, which includes data entry fields for the activity measure and the time, with respect to the completion of elution, at which the dose calibrator measured the activity of the sample. Once the data is input by the user, as described above, the computer calculates a calibration coefficient, or ratio, and presents the ratio on a screen 880. According to FIG. 8B, screen 880 further provides an indication of a desirable range for the calibration ratio and presents an option for the user to reject the calculated ratio, in which case, the user may instruct computer 17 to recalculate the ratio.

As previously mentioned, some alternate embodiments of the present invention include an on board dose calibrator so that the entire sequence of sample collection and calculation steps, which are described above, in conjunction with FIGS. 6-8B, for the quality control procedures, may be automated. This automated alternative preferably includes screen shots, similar to some of those described above, which provide a user of the system with information at various stages over the course of the automated procedure and that provide the user with opportunities to modify, override and/or abort one or more steps in the procedure. Regardless of the embodiment (i.e. whether system 10 employs an on board dose calibrator or not), computer 17 may further collect all quality control test parameters and results into a stored record and/or compile a report including all or some of the parameters and results for local print out and/or electronic transfer to a remote location.

With reference to FIG. 9A, upon completion of the above-described quality control tests, the user may select an item 971, from main menu 470, in order to direct system 10 to begin a procedure for the generation and automatic infusion of a radiopharmaceutical into a patient. As previously described, system 10 infuses the patient with the radiopharmaceutical so that nuclear diagnostic imaging equipment, for example, a PET scanner, can create images of an organ of the patient, which absorbs the radiopharmaceutical, via detection of radioactive radiation therefrom. According to FIG. 9A, upon selection of item 971, computer 17 presents a screen 972 which includes a data entry field for a patient identification number. This identification number that is entered by the user is retained by computer 17, in conjunction with the pertinent system parameters associated with the patient's infusion. After the user enters the patient identification number, computer 17 directs, per a screen 973, the user to attach a new patient line and to purge the patient line of air. A subsequent screen 974 presented by computer 17 includes data entry fields by which the user may establish parameters for the automatic infusion; all or some of the fields may be filled in with pre-programmed default parameters, which the user has an option to change, if necessary.

With reference to FIG. 9B, if pump 33 does not contain enough eluant/saline for the patient infusion, computer 17 will present a warning, via a screen 901, which includes an option for the user to direct the refilling of pump 33, via a subsequent screen 902. Once pump 33 has been filled, computer 17 presents an indication to the user, via a screen 903. According to some embodiments, if the user does not re-fill pump 33, yet attempts to proceed with an infusion, system 10 will preclude the infusion and present another screen, that communicates to the user that no infusion is possible, if the pump is not refilled, and asking the user to refill the pump, as in screen 901. When pump 33 contains a sufficient volume of eluant for the patient infusion, computer 17 presents a screen 975, which is shown in FIG. 9C, and allows the user to enter a command for system 10 to start the

patient infusion. During the infusion, computer 17 provides the user with an indication that the infusion is in process and with an option for the user to abort the infusion, via a screen 976. As previously described, the system may provide an indication that an elution is in progress, for example, light projector 100 (FIG. 1C) may project a flashing light signal during that portion of the elution process when eluate is diverted from generator 21 through waste line 305w and into waste bottle 23, and then a steady light signal during that portion of the elution process when activity detector 25 has detected that a prescribed dose rate threshold is reached, for example, 1.0 mCi/sec, and the eluate is being diverted from generator 21, through the new patient line for infusion into the patient. Another type of light signal, for example, the more rapidly flashing light, previously described, may be projected when a peak bolus of radioactivity is detected in the eluate. At the completion of the infusion, a screen 977 is displayed by computer 17 to inform the user of the completion of the infusion and a time since the completion. Computer 17 also displays a summary of the infusion, per screen 978.

With further reference to FIG. 9C, screen 976 shows an exemplary activity profile (activity—mCi/sec, on y-axis, versus time—sec, on x-axis) for the infusion/injected dose (designated between the two vertical lines). Those skilled in the art will appreciate that the shape of this profile depends upon the infusion flow rate, for a given volume of the dose, which flow rate is controlled, for example, by the speed at which pump 33 drives flow through the patient line, and upon the amount of Strontium-82 remaining in the generator. In the absence of flow rate control, activity profiles may change over the life of the generator. Furthermore, the peak bolus of radioactivity, particularly for injected doses from a relatively new generator, may exceed a saturation level of the imaging equipment, i.e. PET scanner. According to some preferred methods of the present invention, in order to maintain relatively consistent, and desirable/effective, activity profiles for patient injections, over the life of the generator, the operating speed of pump 33 may be varied (both over the course of a single injection and from injection to injection), according to feedback from activity detector 25. Such a method may be implemented via incorporation of another quality control test in which pump 33 is operated to drive flow through the generator at a constant rate, in order to collect, into computer, a plurality of activity measurements from activity detector 25; the plurality of measurements comprise a characteristic, or baseline activity profile from which the computer 17 may calculate an appropriate flow rate profile to control a speed of pump 33, in order to achieve the desirable/effective activity profile. In general, at the start of generator life, when Strontium-82 is plentiful, the pump is controlled to drive infusion flow at relatively lower rates, and, then, toward the end of generator life, when much of the Strontium-82 has been depleted, the pump is controlled to drive infusion flow at relatively higher rates. As was described above, in conjunction with FIG. 1D, if a desired infusion/injection flow rate is relatively high, that is, high enough to create too much back pressure, via flow through the column of generator 21, by-pass line 303 may be employed by adjusting divergence valve 35BG to divert a flow of eluant therethrough after a sufficient volume has been pumped through generator at a lower flow rate. According to this method, once a dose of eluate, from generator 21, has flowed into patient line 305p, divergence valve 35BG is set to divert the flow of eluant through by-pass line 303, and then pump speed is increased to pump eluant at a higher flow

rate in order to push the dose out from patient line 305_p, for injection at the higher flow rate.

Consistency of activity profiles among injected doses can greatly facilitate the use of PET scanning for the quantification of flow, for example, in coronary perfusion studies. Alternative infusion circuit configurations, operable according to alternative methods, to achieve consistency of activity profiles among injected doses, as well as a more uniform level of radioactivity across each individual dose, will be described below, in conjunction with FIGS. 12A-C.

Printer 117 (FIG. 1B) may be activated to print out a hard copy of the infusion summary, on which the patient identification number and pertinent infusion and system parameters are also printed, for reference. Alternatively, or in addition, according to some embodiments, the summary may be downloaded onto a computer readable storage device to be electronically transferred to one or more remote computers and/or the summary may be automatically transferred to the one or more remote computers, via wireless communication or a cable connection, for example, over an intranet network and/or the internet. In order to protect private patient information, the files may be encrypted for transmission over the internet. The one or more remote computers may be included, for example, in a hospital information system, and/or a billing system, and/or in a medical imaging system. Infusion parameters, for example, corresponding to the activity profile, may also be collected and electronically transferred for analysis in conjunction with captured images, for example, in order to quantify coronary flow, via a software package that is loaded into a system that includes the PET scanner.

With reference back to FIG. 9A the user may select an item 995, from main menu 470, in order have system 10 perform data operations, such as, archiving a data base of patient infusion information and quality control test results, transmitting patient infusion summary records to USB mass storage devices, and various types of data filtering, for example, according to date ranges and/or patient identification numbers, for example, to search for a particular set of data and/or to compile a summary report of related sets of data. Additionally, certain information, which is collected by computer 17 over the course of system operation, and which defines system operation, may be transmitted to a local or remote computerized inventory system and/or to computers of technical support personnel, maintenance/service providers and/or suppliers of infusion circuit elements/components, thereby facilitating more efficient system operation and maintenance.

Turning now to FIG. 10, an item 981 for computer-facilitated purging of the tubing lines of system 10 is shown included in main menu 470. When a user selects item 981, computer 17 guides the user to select either an air purge or a saline purge. The direction provided by computer 17 is not explicitly laid out herein, for a saline purge, as procedures for saline purging should be readily apparent to those skilled in the art, with reference to the schematic of infusion circuit 300 shown in FIG. 1D. A saline purge of circuit 300 is desired to assure that all the air is removed from circuit 300 when a new generator and/or a new complete or partial tubing set is installed. An air purge of the tubing lines of circuit 300 may be performed after removing reservoir 15, by-passing generator 21, by connecting tubing line 304 to tubing line 305, and coupling patient line 305_p to a vial, for example, as is directed by the computer interface, in screens 983 and 984 shown in FIG. 10. The air purge is desirable for blowing out the tubing lines, thereby removing all remaining eluant and eluate, prior to installing a new generator and/or

prior to transporting system 10 from one site to another. If generator 21 is not depleted and will be used in system 10 at the new site, it is important to by-pass the generator prior to purging the tubing lines of circuit 300 with air, so that air is not blown across the generator, since air through generator 21 may compromise both the function and the aseptic nature of generator 21.

According to preferred embodiments, once the user has followed the instructions presented in screens 983 and 984 and selects to start the air purge, for example, via screen 985, computer 17 directs the controller of system 10 to carry out a complete air purge, in which pump 33 and divergence valves 35BG and 35WP are automatically controlled. The automated air purge preferably includes the following steps, which may be best understood with reference to tubing circuit 300 in FIG. 1D: pumping any remaining volume of eluant left in pump 33, through lines 302, 304, 305 and 305_w, to waste bottle 23; refilling pump 33 with air and pumping the air through lines 302, 304, 305 and 305_w, into waste bottle 23 (lines 304 and 305 have been previously connected directly to one another, in order to by-pass generator 21; if generator 21 is depleted and will be replaced with a new generator, pumping air through generator 21 may be acceptable); refilling pump 33 with air and then pumping a portion of the air through lines 302, 304, 305 and 305_p, into the vial, and then a remaining portion of the air through lines 302, 304, 303 and 305_p, into the vial. With reference to FIG. 1D and the previous description of divergence valves 35BG, 35WP, it should be understood how divergence valves 35BG, 35WP are automatically controlled to carry out the above steps.

The purge operations, which are facilitated by selecting item 981 from main menu 470, may also be accessed via the selection of an item 991 for generator setup. When the user selects item 991, computer 17 may present an option for guidance in removing an old, depleted, generator and a set of tubing lines, prior to installing the new generator, or an option to just be guided in the installation of the new generator. According to some embodiments, computer 17 is pre-programmed to calculate an amount of activity left in a depleted generator, for example, by tracking activity of eluate over a life of the generator. At an end of the life of the generator, computer 17 may further compile this information, along with other pertinent generator information, into a report that may accompany a declaration of dangerous goods for shipping the depleted generator out for disposal or, in some cases, back to the manufacturer for investigation. An example of such a report is shown in FIG. 11. According to those embodiments of system 10 that include an encoded information reader, computer 17 may confirm that the new generator is proper by processing information that is read from an encoded label/tag attached thereto.

FIGS. 12A-B are schematics of alternative infusion circuits 1300A, 1300B that may be employed by system 10, in place of circuit 300 (FIG. 1D), according to some additional embodiments of the present invention. Circuits 1300A, 1300B are configured to allow for alternative methods of operation, to that previously described for circuit 300, when a relatively even, or uniform level of activity over each injected dose, along with the relatively consistent level of activity from injection to injection is desired, for example, in order to facilitate a quantification of coronary artery blood flow via PET scanning FIG. 12C is a schematic illustrating activity profiles 1200A, 1200B for two injected doses, wherein profile 1200B has a more uniform level of activity than profile 1200A; profile 1200B may be achieved via the operation of circuits 1300A, 1300B as described below.

Similar to circuit 300 (FIG. 1D), dashed lines are shown in each of FIGS. 12A-B to indicate a general boundary of a shielding assembly for portions of each circuit 1300A, 1300B. The shielding assembly for each of circuits 1300A, 1300B may be very similar, in most respects, to shielding assembly 200, which is described above for system 10, and the elements of each of circuits 1300A, 1300B may be arranged with respect to their respective shielding and with respect to shell 13 of system 10 in a similar manner to that described above for circuit 300.

FIG. 12A illustrates circuit 1300A including, like the previously described circuit 300, eluant reservoir 15, pump 33, radioisotope generator 21, through which the filtered eluant is pumped to create the radioactive eluate, activity detector 25, and waste bottle 23. FIG. 12A further illustrates two filters 37 and two pressure transducers 1334 included in circuit 1300A. Circuit 1300A further includes by-pass tubing line 303, which is located downstream of divergence valve 35BG, like in circuit 300, and which accommodates the previously described eluant/saline flush. However, in contrast to circuit 300, circuit 1300A further includes a linear/proportional valve 1335 integrated into by-pass/flush line 303 so that circuit 1300A may be operated, for example, according to pre-programmed parameters of computer 17, in conjunction with feedback of information from activity detector 25, for a controlled by-pass of generator 21 in order to mix eluant with eluate and, thereby, achieve a relatively uniform level of activity over each patient injection, for example, according to profile 1200B of FIG. 12C. It should be noted that, in addition to the controlled mixing, a flow rate of each injection may be varied, if necessary, in order to maintain a consistent activity level.

FIG. 12B illustrates circuit 1300B including, like the previously described circuit 300, eluant reservoir 15, pump 33, radioisotope generator 21, activity detector 25, and waste bottle 23, as well as the two filters 37 and two pressure transducers 1334, as in circuit 1300A. In contrast to circuits 300 and 1300A, circuit 1300B further includes an eluate reservoir 1350, which is shown located downstream of generator 21, in between first and second segments 305A, 305B of the eluate tubing line. It should be noted that a pump is combined with reservoir 1350, for example, similar to syringe pump 33, such that, when a divergence valve 1335IO is set to allow fluid communication between reservoir 1350 and tubing line segment 305A, the associated pump may be operated to draw in a volume of eluate, and, then, when divergence valve 1335IO is set to allow fluid communication between reservoir 1350 and tubing line segment 305B, the pump may be operated to push the volume of eluate out through tubing line segment 305B for a patient injection, when divergence valve 35WP is set to direct flow into patient line 305p. With reference back to FIGS. 3A-B, sidewall 205 of shielding assembly 200 may be enlarged to further enclose eluate reservoir 1350. For example, another shielded well, to house the eluate reservoir, may extend alongside well 255, in which activity detector 25 is described as being mounted. Furthermore, sidewall 205 may include another valve actuator receptacle for divergence valve 1335IO, similar to receptacle 253, shown in FIG. 3A for divergence valve 35WP.

Collection of discrete volumes of eluate, in reservoir 1350, may help to achieve a more uniform activity level over each injection, for example, like that of profile 1200B in FIG. 12C, and, according to preferred methods, feedback from activity detector 25 may be used to control the pump associated with reservoir 1350, in order to vary injection flow rate and, thereby, maintain a relatively consistent

activity level across multiple injections, and, when necessary, to vary injection flow rate over an individual injection to maintain the uniform activity level. Feedback from the pressure transducer 1334, that is downstream from detector 25, and/or from a flow meter (not shown) of circuit 1300B may also be used to control the varying of injection flow rate.

With further reference to FIGS. 12A-B, it should be noted that alternative circuits may be configured to employ a combination of the methods described for circuits 1300A and 1300B. Furthermore, some infusion circuits of the present invention may employ multiple generators 21, as mentioned above, in conjunction with FIG. 2A, to help maintain the relatively uniform level of activity over each injection and the relatively consistent level of activity from injection to injection.

In the foregoing detailed description, the invention has been described with reference to specific embodiments. However, it may be appreciated that various modifications and changes can be made without departing from the scope of the invention as set forth in the appended claims.

The invention claimed is:

1. An infusion system on-board a cart comprising:
 - a cabinet structure that comprises:
 - a platform,
 - an exterior shell that extends upwardly above the platform and has a front side; a rear side; two sidewalls connecting the front side to the rear side; and a top surface; wherein the platform and the exterior shell collectively define an interior space of the cabinet structure and wherein the interior space of the cabinet structure is configured to receive a strontium-rubidium radioisotope generator having an inlet tubing port configured to receive saline and an outlet tubing port configured to discharge a rubidium radioactive eluate,
 - an opening through the exterior shell configured to provide access to the strontium-rubidium radioisotope generator within the interior space of the cabinet structure, and
 - an opening through the top surface of the exterior shell configured to provide access for inserting a waste bottle into or removing the waste bottle from the interior space of the cabinet structure;
 - a computer with a touch screen display configured to receive an input from a user for controlling operation of the infusion system, wherein the touch screen display is mounted on a vertical post having a top end extending above the cabinet structure;
 - a first shielding compartment in the interior space of the cabinet structure having a first opening facing vertically upwardly through which the strontium-rubidium radioisotope generator can be inserted into and removed from the first shielding compartment;
 - a first door accessible via the opening through the exterior shell, the first door being configured to provide access to the first shielding compartment and to close over the first opening;
 - a second shielding compartment having a second opening facing vertically upwardly through which the waste bottle can be inserted into and removed from the second shielding compartment;
 - a second door accessible via the opening through the top surface of the exterior shell, the second door being configured to provide access to the second shielding compartment and to close over the second opening;

25

wherein the first opening is located at a lower elevation than the second opening;
 a radioactivity detector positioned to measure radioactivity of the rubidium radioactive eluate flowing through an eluate tubing line in fluid communication with the outlet tubing port of the strontium-rubidium radioisotope generator;
 a shielded well on-board the cart configured to receive an eluate reservoir, wherein the eluate reservoir is configured to receive a test sample; and
 wherein the computer of the infusion system is configured to:

- provide a stop button on the touch screen display to abort a function of the infusion system in response to a user input activating the stop button,
- pump saline from a saline reservoir positioned outside of the interior space of the cabinet structure into the strontium-rubidium radioisotope generator through the inlet tubing port of the strontium-rubidium radioisotope generator thereby generating the rubidium radioactive eluate that is discharged through the outlet tubing port,
- fill the eluate reservoir in the shielded well on-board the cart with the test sample of the rubidium radioactive eluate,
- determine a strontium breakthrough test result on the test sample filled into the eluate reservoir in the shielded well on-board the cart while the eluate reservoir remains in the shielded well on-board the cart, and
- not allow a patient infusion if the strontium breakthrough test result is greater than or equal to an allowed limit.

2. The infusion system of claim 1, further comprising: the strontium-rubidium radioisotope generator in the first shielding compartment in the interior space of the cabinet structure, and the eluate reservoir located in the shielded well on-board the cart and in fluid communication with the eluate tubing line.

3. The infusion system of claim 2, wherein the cabinet structure has a lowermost portion and the platform has a lower surface, the first opening is at a first elevation, the second opening is at a second elevation, the first elevation is between approximately 1 foot and approximately 2 feet, with respect to the lowermost portion of the cabinet structure, and the second elevation is between approximately 2 feet and approximately 3 feet, with respect to the lower surface of the platform.

4. The infusion system of claim 1, wherein the first shielding compartment comprises two tubing passageways formed in a perimeter surface of the first opening, and each of the two tubing passageways has a depth configured to prevent pinching or crushing of a corresponding tubing line routed therethrough when the first door is closed thereover.

5. The infusion system of claim 1, wherein the opening through the exterior shell configured to provide access to the strontium-rubidium radioisotope generator within the interior space of the cabinet structure is through the front side of the exterior shell.

6. The infusion system of claim 1, further comprising: a handle configured for the user to grasp in order to move the infusion system, and four wheels mounted to an underside of the platform of the cabinet structure.

26

7. The infusion system of claim 1, wherein access to an operation of the computer is regulated through a user login credential.

8. The infusion system of claim 1, wherein the infusion system is configured to determine the strontium breakthrough test result on the test sample at least once a day.

9. The infusion system of claim 1, wherein the function of the infusion system aborted in response to the user input activating the stop button is a patient infusion procedure.

10. The infusion system of claim 1, further comprising a waste tubing line and a valve, wherein the waste tubing line is in fluid communication with the eluate tubing line and the waste bottle, and the valve is configured to control fluid flow between the eluate tubing line and the waste bottle via the waste tubing line.

11. The infusion system of claim 1, further comprising a hanger configured to hold the saline reservoir at an elevation above the top surface of the exterior shell.

12. The infusion system of claim 1, wherein the cabinet structure has a lowermost portion and the platform has a lower surface, the first opening is at a first elevation, the second opening is at a second elevation, the first elevation is between approximately 1 foot and approximately 2 feet, with respect to the lowermost portion of the cabinet structure, and the second elevation is between approximately 2 feet and approximately 3 feet, with respect to the lower surface of the platform.

13. The infusion system of claim 1, further comprising a dose calibrator in the shielded well on-board the cart and in communication with the computer to determine the strontium breakthrough test result.

14. The infusion system of claim 1, wherein the computer of the infusion system is further configured to track a volume of the saline remaining in the saline reservoir and to alert the user via the touch screen display when the volume of the saline remaining in the saline reservoir is below a predetermined volume threshold.

15. The infusion system of claim 1, wherein the strontium breakthrough test result is for at least one of strontium-82 and strontium-85.

16. The infusion system of claim 1, wherein the computer of the infusion system is further configured to track a volume of the rubidium radioactive eluate discharged from the strontium-rubidium radioisotope generator to the waste bottle and to control the touch screen display to display a user screen guiding the user to empty the waste bottle.

17. The infusion system of claim 1, wherein the first door is mounted via a hinge and configured to open in an upward direction.

18. The infusion system of claim 1, further comprising: a USB port to transfer data and a power inlet port for connecting the infusion system to a power source, and a printer configured to print a document concerning a patient infusion or a quality control test result generated by the infusion system.

19. The infusion system of claim 1, further comprising a light projector mounted on the top end of the vertical post extending above the cabinet structure, wherein the light projector is configured to:

- project a first light signal to indicate that an elution is taking place, and
- project a second light signal to indicate that a peak bolus of radioactivity is detected.

20. The infusion system of claim 1, wherein the exterior shell further includes a saline tubing opening configured for

27

a saline tubing line to pass from the saline reservoir outside of the exterior shell to the interior space of the cabinet structure.

21. The infusion system of claim 1, wherein the computer of the infusion system is further configured to pump saline through the strontium-rubidium radioisotope generator at a rate less than approximately 70 ml/min.

22. The infusion system of claim 1, further comprising an electrical connector port accessible through an electrical connector port opening on the exterior shell and configured to place the infusion system in communication with at least one of an intranet network, an internet network, and a device used for a nuclear imaging procedure.

23. The infusion system of claim 1, further comprising: a front cover that is movable relative to the exterior shell to close the opening through the exterior shell configured to provide access to the strontium-rubidium radioisotope generator, and a top cover that is movable relative to the exterior shell to close the opening through the top surface of the exterior shell.

24. The infusion system of claim 1, further comprising: a hanger configured to hold the saline reservoir at an elevation above the top surface of the exterior shell, a handle configured for the user to grasp in order to move the infusion system, four wheels mounted to an underside of the platform, a power inlet port for connecting the infusion system to a power source, and a printer configured to print a document concerning a patient infusion or a quality control test result generated by the infusion system;

wherein:

the first shielding compartment comprises two tubing passageways formed in a perimeter surface of the first opening, each of the two tubing passageways has a depth configured to prevent pinching or crushing of a corresponding tubing line routed therethrough when the first door is closed thereover, the first door is mounted via a hinge, access to an operation of the computer is regulated through a user login credential, the strontium breakthrough test result is for at least one of strontium-82 and strontium-85, and the exterior shell further includes a saline tubing opening configured for a saline tubing line to pass from the saline reservoir outside of the exterior shell to the interior space of the cabinet structure; and

wherein the computer of the infusion system is further configured to: determine the strontium breakthrough test result on the test sample at least once a day, pump saline through the strontium-rubidium radioisotope generator at a rate less than approximately 70 ml/min, track a volume of the rubidium radioactive eluate discharged from the strontium-rubidium radioisotope generator to the waste bottle and to control the touch screen display to display a user screen guiding the user to empty the waste bottle, and track a volume of the saline remaining in the saline reservoir and to alert the user via the touch screen display when the volume of the saline remaining in the saline reservoir is below a predetermined volume threshold.

28

25. The infusion system of claim 24, wherein the infusion system further comprises:

the strontium-rubidium radioisotope generator with the inlet tubing port configured to receive saline and the outlet tubing port configured to discharge the rubidium radioactive eluate;

a light projector mounted on the top end of the vertical post extending above the cabinet structure, wherein the light projector is configured to:

project a first light signal to indicate that an elution is taking place, and

project a second light signal to indicate that a peak bolus of radioactivity is detected;

the eluate reservoir located inside the shielded well on-board the cart and in fluid communication with the eluate tubing line;

a waste tubing line in fluid communication with the eluate tubing line and the waste bottle;

a valve configured to control fluid flow between the eluate tubing line and the waste bottle via the waste tubing line; and

a pedal configured to brake at least one of the four wheels when the pedal is depressed.

26. The infusion system of claim 25, wherein the cabinet structure has a lowermost portion and the platform has a lower surface, the first opening is at a first elevation, the second opening is at a second elevation, the first elevation is between approximately 1 foot and approximately 2 feet, with respect to the lowermost portion of the cabinet structure, and the second elevation is between approximately 2 feet and approximately 3 feet, with respect to the lower surface of the platform.

27. The infusion system of claim 24, further comprising a dose calibrator located in the shielded well on-board the cart and in communication with the computer, wherein the dose calibrator is configured to determine the strontium breakthrough test result; and

wherein the opening through the exterior shell configured to provide access to the strontium-rubidium radioisotope generator within the interior space of the cabinet structure is through the front side of the exterior shell.

28. The infusion system of claim 27, further comprising: the strontium-rubidium radioisotope generator with the inlet tubing port configured to receive saline and the outlet tubing port configured to discharge the rubidium radioactive eluate,

the eluate reservoir located inside the shielded well on-board the cart and in fluid communication with the eluate tubing line,

a waste tubing line in fluid communication with the eluate tubing line and the waste bottle, and

a valve configured to control fluid flow between the eluate tubing line and the waste bottle via the waste tubing line.


29. The infusion system of claim 28, wherein the computer of the infusion system is configured to:

measure an activity of the test sample filled into the eluate reservoir in the shielded well on-board the cart while the eluate reservoir remains in the shielded well on-board the cart, wherein the activity is measured with the dose calibrator in the shielded well on-board the cart, and

calibrate the infusion system based on the activity measured by the dose calibrator.

30. The infusion system of claim 29, wherein
the cabinet structure has a lowermost portion and the
platform has a lower surface,
the first opening is at a first elevation,
the second opening is at a second elevation, 5
the first elevation is between approximately 1 foot and
approximately 2 feet, with respect to the lowermost
portion of the cabinet structure, and
the second elevation is between approximately 2 feet and
approximately 3 feet, with respect to the lower surface 10
of the platform.

* * * * *



PTO-1683
(Rev. 7-96)

EXHIBIT 4

A 7667315



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 08, 2018

**THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON
MARCH 13, 2017.**

**By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office**

**R GLOVER
Certifying Officer**



PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4315106

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
STEPHEN E HIDEM	04/28/2010
AARON M. FONTAINE	04/28/2010
JANET L. GELBACH	04/20/2010
PATRICK M. MCDONALD	04/16/2010
KATHRYN M. HUNTER	04/12/2010
ROLF E. SWENSON	04/13/2010
JULIUS P. ZODDA	04/13/2010
RECEIVING PARTY DATA	
Name:	BRACCO DIAGNOSTICS INC.
Street Address:	107 COLLEGE ROAD EAST
City:	PRINCETON
State/Country:	NEW JERSEY
Postal Code:	08540
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15389200
CORRESPONDENCE DATA	
Fax Number:	(612)492-7077
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	612-492-7000
Email:	IP@fredlaw.com
Correspondent Name:	PAUL J. LAVANWAY, JR.
Address Line 1:	200 SOUTH SIXTH STREET
Address Line 2:	SUITE 4000
Address Line 4:	MINNEAPOLIS, MINNESOTA 55402
ATTORNEY DOCKET NUMBER:	56782.4.1
NAME OF SUBMITTER:	PAUL J. LAVANWAY, JR.
SIGNATURE:	/Paul J. LaVarway, Jr./
DATE SIGNED:	03/13/2017

504268426

PATENT
REEL: 041553 FRAME: 0019

Total Attachments: 7

source=56782.4.1_Executed_Assignment#page1.tif

source=56782.4.1_Executed_Assignment#page2.tif

source=56782.4.1_Executed_Assignment#page3.tif

source=56782.4.1_Executed_Assignment#page4.tif

source=56782.4.1_Executed_Assignment#page5.tif

source=56782.4.1_Executed_Assignment#page6.tif

source=56782.4.1_Executed_Assignment#page7.tif

PATENT
REEL: 041553 FRAME: 0020

ASSIGNMENT

We, Stephen E. Hidem, residing at 4710 Juneau Lane North, Plymouth, Minnesota 55446, Aaron M. Fontaine, residing at 5663 West Bavarian Pass, Fridley, Minnesota 55432, Janet L. Gelbach, residing at 4204 Shetland Court, New Albany, Indiana 47150, Patrick M. McDonald, residing at 15395 Nicholas Street, Omaha, Nebraska 68154, Kathryn M. Hunter, residing at 1312 Judy Reagan Lane, Knoxville, Tennessee 37931, Rolf E. Swenson, residing at 35 Fieldston Road, Princeton, New Jersey 08540 and Julius P. Zodda, residing at 3 Tigers Court, Mercerville, New Jersey 08619 ("Assignor"), have made invention(s) for which United States and foreign patents and patent applications have been filed and are identified on the attached Schedule 1;

Whereas, Bracco Diagnostics Inc., a Delaware corporation having a place of business at 107 College Road East, Princeton, NJ 08540 ("Assignee"), desires to acquire the entire right, title and interest in and to the United States and foreign patents and patent applications identified on the attached Schedule 1 and in and to the inventions described and claimed therein (the "Patents"); and

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby assigns to Assignee, and its successors and assigns the following:

- (1) The entire right, title and interest to the Patents including the inventions described or claimed therein, and to each U.S. and foreign patent application and patent from which the Patents claim priority to, in whole or in part, and to which the Patents claim priority; and
- (2) The entire right, title and interest to any United States or foreign patents that may issue with respect to the inventions described or claimed in the Patents;
- (3) The entire right, title and interest to any renewals, reissues, extensions, substitutions, continuations, continuations-in-part, or divisions of the Patents, and all foreign applications based thereon;
- (4) The right to apply for patents in foreign countries in its own name and to claim any priority rights to which such foreign applications are entitled under international conventions, treaties or otherwise; and
- (5) The right to enforce patent rights to such Patents as fully and entirely as the same would have been held and enjoyed by the Assignors if this assignment had not been made; together with all claims by Assignors for damages by reason of past infringement or for provisional rights and including the right to sue for, and collect the same for its own use and benefit, and for the use and benefit of its successors, assigns, and other legal representatives.

Assignor further agrees for himself and for his successors and assigns to execute and deliver without further consideration any further applications, assignments or other documents and to perform such other lawful acts as Assignee its successors and assigns may deem necessary to fully secure, maintain and enforce its rights, title or interest as outlined herein.

Assignor hereby authorizes and requests the Commissioner of Patents to issue to Assignee any patents that may be granted in accordance with this Assignment.

We hereby authorize attorneys associated with Customer No. 22859, of 200 South Sixth Street, Suite 4000, Minneapolis, Minnesota, 55402-1425, to insert the Application Nos. and Filing Dates of said application when known.

This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement. The signatures from each counterpart may be combined with a copy of the Agreement to constitute the entire Agreement.

Date: 4/28/2010

[Signature]
Stephen E. Hidem

Subscribed to and sworn to before me this 28 day of APRIL, 2010.

[Signature]
Notary Public

Notary Seal



Date: 4/28/2010

[Signature]
Aaron M. Fontaine

Subscribed to and sworn to before me this 28 day of APRIL, 2010.

[Signature]
Notary Public

Notary Seal



Date: 4-20-2010

Janet L. Gelbach
Janet L. Gelbach

Witnessed by: Esther B. Paris on 4-20-10
(Signature) (Date)

Esther B. Paris
(Name)

4201 Sretland Ct. New Albany, IN 47150
(Address)

Date: _____

Patrick M. McDonald

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: _____

Kathryn M. Hunter

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: _____

Janet L. Gelbach

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: 16-APR-2010

Patrick M. McDonald
Patrick M. McDonald

Witnessed by: Renee McDonald on 4-16-10
(Signature) (Date)

Renee McDonald
(Name)

15395 NICHOLAS ST. OMAHA, NE 68154
(Address)

Date: _____

Kathryn M. Hunter

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: _____
Janet L. Gelbach

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: _____
Patrick M. McDonald

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: April 12, 2010 Kathryn M. Hunter
Kathryn M. Hunter

Witnessed by: [Signature] on April 12, 2010
(Signature) (Date)
Jim CLAIR
(Name)
1312 Gudy Reagan Lane Knoxville, TN 37931
(Address)

Date: 4/13/10

Rolf E. Swenson
Rolf E. Swenson

Witnessed by: Patricia Bussiere on 4/13/2010
(Signature) (Date)

Patricia Bussiere
(Name)

10 Garfield Court, Dayton, NJ 08810
(Address)

Date: Apr. 13, 2010

Julius P. Zodda
Julius P. Zodda

Witnessed by: Patricia Bussiere on April 13, 2010
(Signature) (Date)

Patricia Bussiere
(Name)

10 Garfield Court, Dayton NJ 08810
(Address)

SCHEDULE 1US Patent Applications

Patent App. No.	Date Filed	Title	Attorney Docket No.
12/137,356	6/11/2008	SHIELDING ASSEMBLIES FOR INFUSION SYSTEMS	56782.1.5
12/137,363	6/11/2008	INFUSION SYSTEM CONFIGURATIONS	56782.1.6
12/137,364	6/11/2008	INFUSION SYSTEMS INCLUDING COMPUTER-FACILITATED MAINTENANCE AND/OR OPERATION AND METHODS OF USE	56782.1.7
12/137,377	6/11/2008	CABINET STRUCTURE CONFIGURATIONS FOR INFUSION SYSTEMS	56782.1.8
12/808,467	6/16/2010	INFUSION SYSTEMS INCLUDING COMPUTER-FACILITATED MAINTENANCE AND/OR OPERATION AND METHODS OF USE	56782.1.7.2
15/389,200	12/22/2016	INTEGRATED STRONTIUM-RUBIDIUM RADIOISOTOPE INFUSION SYSTEMS	56782.4.1

US Patents


Patent No.	Date Issued	Title

Foreign and International Patent Applications

Country	Patent App. No.	Date Filed	Title	Attorney Docket No.
WO	PCT/US09/47031	6/11/2009	INFUSION SYSTEMS INCLUDING COMPUTER-FACILITATED MAINTENANCE AND/OR OPERATION AND METHODS OF USE	56782.1.7.1

Foreign Patents

Country	Patent No.	Date of Issue	Title



PTO-1683
(Rev. 7-96)

EXHIBIT 5

U 7667315



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME;

**UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office**

February 12, 2018

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THIS OFFICE OF:**

**U.S. PATENT: 9,750,870
ISSUE DATE: *September 05, 2017***

**By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office**




**P. R. GRANT
Certifying Officer**



US009750870B2

(12) **United States Patent**
Hidem et al.

(10) **Patent No.:** **US 9,750,870 B2**
(45) **Date of Patent:** ***Sep. 5, 2017**

(54) **INTEGRATED STRONTIUM-RUBIDIUM
RADIOISOTOPE INFUSION SYSTEMS**

(71) Applicant: **Bracco Diagnostics Inc.**, Monroe
Township, NJ (US)

(72) Inventors: **Stephen E. Hidem**, Edina, MN (US);
Aaron M. Fontaine, Minneapolis, MN
(US); **Janet L. Gelbach**, Rolling
Meadows, IL (US); **Patrick M.
McDonald**, Omaha, NE (US); **Kathryn
M. Hunter**, Knoxville, TN (US); **Rolf
E. Swenson**, Silver Spring, MD (US);
Julius P. Zodda, Mercerville, NJ (US)

(73) Assignee: **Bracco Diagnostics, Inc.**, Monroe
Township, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **15/490,484**

(22) Filed: **Apr. 18, 2017**

(65) **Prior Publication Data**

US 2017/0224908 A1 Aug. 10, 2017

Related U.S. Application Data

(63) Continuation of application No. 15/389,200, filed on
Dec. 22, 2016, which is a continuation of application
(Continued)

(51) **Int. Cl.**
A61M 5/00 (2006.01)
A61B 50/13 (2016.01)
(Continued)

(52) **U.S. Cl.**
CPC **A61M 5/007** (2013.01); **A61B 50/13**
(2016.02); **A61M 5/1409** (2013.01);
(Continued)

(58) **Field of Classification Search**
CPC **A61M 5/007**; **A61M 5/14**; **A61M 5/142**;
A61N 5/1001; **A61N 5/1002**;
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,483,867 A 12/1969 Markovitz
3,535,085 A 10/1970 Shumate

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2913373 A1 4/2008
CN 1968653 A 5/2007

(Continued)

OTHER PUBLICATIONS

Alvarez-Diez et al. "Manufacture of strontium-82/rubidium-82 gen-
erators and quality control of rubidium-82 chloride for myocardial
perfusion imaging in patients using positron emission tomography,"
Applied Radiation and Isotopes, 1999, pp. 1015-1023.

(Continued)

Primary Examiner — Charles A Marmor, II


Assistant Examiner — Carrie R Dorna

(74) *Attorney, Agent, or Firm* — Fredrikson & Byron,
P.A.

(57) **ABSTRACT**

Methods for setting up, maintaining and operating a radio-
pharmaceutical infusion system, that includes a radioisotope
generator, are facilitated by a computer of the system. The
computer may include pre-programmed instructions and a
computer interface, for interaction with a user of the system,
for example, in order to track contained volumes of eluant
and/or eluate, and/or to track time from completion of an
elution performed by the system, and/or to calculate one or
more system and/or injection parameters for quality control,
and/or to perform purges of the system, and/or to facilitate
diagnostic imaging.

30 Claims, 27 Drawing Sheets



Related U.S. Application Data

No. 12/808,467, filed as application No. PCT/US2009/047031 on Jun. 11, 2009, now Pat. No. 9,607,722, which is a continuation of application No. 12/137,377, filed on Jun. 11, 2008, now Pat. No. 8,708,352, and a continuation of application No. 12/137,363, filed on Jun. 11, 2008, now Pat. No. 7,862,534, and a continuation of application No. 12/137,356, filed on Jun. 11, 2008, now Pat. No. 8,317,674, and a continuation of application No. 12/137,364, filed on Jun. 11, 2008, now Pat. No. 9,597,053.

(51) Int. Cl.

A61M 5/14 (2006.01)
A61M 5/145 (2006.01)
A61M 5/168 (2006.01)
A61M 5/36 (2006.01)
G21F 7/00 (2006.01)
G21G 1/00 (2006.01)
G21G 4/08 (2006.01)
G06F 19/00 (2011.01)
A61B 50/10 (2016.01)

(52) U.S. Cl.

CPC *A61M 5/1452* (2013.01); *A61M 5/16854* (2013.01); *A61M 5/16881* (2013.01); *A61M 5/365* (2013.01); *G06F 19/3468* (2013.01); *G21F 7/00* (2013.01); *G21G 1/001* (2013.01); *G21G 1/0005* (2013.01); *G21G 4/08* (2013.01); *A61B 2050/105* (2016.02); *A61M 2005/1403* (2013.01); *A61M 2205/18* (2013.01); *A61M 2205/3375* (2013.01); *A61M 2205/50* (2013.01); *A61M 2205/505* (2013.01); *A61M 2205/52* (2013.01); *A61M 2205/584* (2013.01); *A61M 2205/587* (2013.01); *A61M 2205/6009* (2013.01); *A61M 2205/6054* (2013.01); *A61M 2205/6072* (2013.01); *A61M 2205/70* (2013.01); *A61M 2205/75* (2013.01); *G21G 2001/0031* (2013.01)

(58) Field of Classification Search

CPC .. A61N 5/1007; A61N 5/1014-5/1017; A61N 5/1027; A61N 5/1028; A61N 5/1071; A61N 2005/1021; G21G 1/0005; G21G 4/08

See application file for complete search history.

(56)

References Cited

U.S. PATENT DOCUMENTS

3,543,752 A 12/1970 Hesse et al.
 3,565,376 A 2/1971 Viers
 3,576,998 A 5/1971 Deutsch et al.
 3,710,118 A 1/1973 Holgate et al.
 3,714,429 A 1/1973 McAfee et al.
 3,774,036 A 11/1973 Gerhart
 3,847,138 A 11/1974 Gollub
 3,861,380 A 1/1975 Chassagne et al.
 3,953,567 A 4/1976 Grant et al.
 3,991,960 A 11/1976 Tanaka
 3,997,784 A 12/1976 Picunko et al.
 4,096,859 A 6/1978 Agarwal et al.
 4,160,910 A 7/1979 Thornton et al.
 4,212,303 A 7/1980 Nolan
 4,241,728 A 12/1980 Mirell
 4,286,169 A 8/1981 Rossem
 4,336,036 A 6/1982 Leeke et al.
 4,406,877 A 9/1983 Neirinckx et al.
 4,466,888 A 8/1984 Verkaart

4,562,829 A 1/1986 Bergner
 4,585,009 A 4/1986 Barker et al.
 4,585,941 A 4/1986 Bergner
 4,597,951 A 7/1986 Gennaro et al.
 4,623,102 A 11/1986 Hough et al.
 4,625,118 A 11/1986 Kriwetz et al.
 4,656,697 A 4/1987 Naslund
 4,674,403 A 6/1987 Bryant et al.
 4,679,142 A 7/1987 Lee
 4,755,679 A 7/1988 Wong
 4,759,345 A 7/1988 Mistry
 4,769,008 A 9/1988 Hessel
 4,853,546 A 8/1989 Abe et al.
 4,994,056 A 2/1991 Ikeda
 5,039,863 A 8/1991 Matsuno et al.
 5,092,834 A 3/1992 Bradshaw et al.
 5,166,526 A 11/1992 Dietzel
 5,254,328 A 10/1993 Herscheid
 5,258,906 A 11/1993 Kroll et al.
 5,274,239 A 12/1993 Lane et al.
 5,395,320 A 3/1995 Padda et al.
 5,468,355 A 11/1995 Shefer et al.
 5,475,232 A 12/1995 Powers et al.
 5,485,831 A 1/1996 Holdsworth et al.
 5,580,541 A 12/1996 Wells et al.
 5,590,648 A 1/1997 Mitchell et al.
 5,674,404 A 10/1997 Kenley et al.
 5,681,285 A 10/1997 Ford et al.
 5,702,115 A 12/1997 Pool et al.
 5,739,508 A 4/1998 Uber
 5,765,842 A 6/1998 Phaneuf
 5,827,429 A 10/1998 Ruschke et al.
 5,840,026 A 11/1998 Uber, III et al.
 5,885,216 A 3/1999 Evans, III et al.
 6,058,718 A 5/2000 Forsberg et al.
 6,157,036 A 12/2000 Whiting et al.
 6,220,554 B1 4/2001 Daoud
 6,267,717 B1 7/2001 Stoll et al.
 6,269,810 B1 8/2001 Brooker et al.
 6,327,895 B1 12/2001 Jeppsson et al.
 6,347,711 B1 2/2002 Goebel et al.
 6,442,418 B1 8/2002 Evans, III et al.
 6,450,936 B1 9/2002 Smith, III et al.
 6,454,460 B1 9/2002 Ramanathan et al.
 6,558,125 B1 5/2003 Futterknecht
 6,626,862 B1 9/2003 Duchon et al.
 6,639,237 B2 10/2003 Pedersen et al.
 6,758,975 B2 7/2004 Peabody et al.
 6,767,319 B2 7/2004 Reilly et al.
 6,773,686 B1 8/2004 Herscheid et al.
 6,870,175 B2 3/2005 Dell et al.
 6,901,283 B2 5/2005 Evans, III et al.
 6,908,598 B2 6/2005 Sylvester
 6,931,327 B2 8/2005 Goode et al.
 7,091,494 B2 8/2006 Weisner et al.
 7,125,166 B2 10/2006 Eck et al.
 7,163,031 B2 1/2007 Graves et al.
 7,169,135 B2 1/2007 Duchon et al.
 7,204,797 B2 4/2007 Reilly et al.
 7,256,888 B2 8/2007 Staehr et al.
 7,286,867 B2 10/2007 Schlyer et al.
 7,413,123 B2 8/2008 Ortenzi
 7,476,377 B2 1/2009 Moller et al.
 7,504,646 B2 3/2009 Balestracci et al.
 7,522,952 B2 4/2009 Krieg et al.
 7,586,102 B2 9/2009 Mourtada et al.
 7,605,384 B2 10/2009 Sonnenhol et al.
 7,608,831 B2 10/2009 Lamb et al.
 7,612,999 B2 11/2009 Clark et al.
 7,712,491 B2 5/2010 Tochon-Danguy et al.
 7,734,331 B2 6/2010 Dhawale et al.
 7,737,415 B2 6/2010 Casale et al.
 7,780,352 B2 8/2010 Fox et al.
 7,813,841 B2 10/2010 deKemp et al.
 7,825,372 B2 11/2010 Allberg
 7,862,534 B2 1/2011 Quirico et al.
 7,996,068 B2 8/2011 Telischak et al.
 8,058,632 B2 11/2011 Balestracci et al.
 8,071,959 B2 12/2011 dekemp

(56)

References Cited

U.S. PATENT DOCUMENTS

8,198,599 B2 6/2012 Bouton et al.
 8,216,181 B2 7/2012 Balestracci
 8,216,184 B2 7/2012 Balestracci
 8,295,916 B2 10/2012 Shimchuk et al.
 8,317,674 B2 11/2012 Quirico et al.
 8,431,909 B2 4/2013 Horton et al.
 8,439,815 B2 5/2013 Lemer
 8,442,803 B2 5/2013 Chen et al.
 8,708,352 B2 4/2014 Quirico et al.
 2002/0128594 A1 9/2002 Das et al.
 2002/0129471 A1 9/2002 Wang
 2003/0139640 A1 7/2003 Whittacre et al.
 2003/0194894 A1 10/2003 Warriar et al.
 2004/0054319 A1 3/2004 Langley et al.
 2004/0104160 A1 6/2004 Scagliarini et al.
 2004/0260143 A1 12/2004 Reilly et al.
 2005/0085682 A1 4/2005 Sasaki et al.
 2005/0187515 A1 8/2005 Varrichio et al.
 2005/0277833 A1 12/2005 Williams
 2005/0278066 A1 12/2005 Graves et al.
 2006/0015056 A1 1/2006 Ellingboe et al.
 2006/0151048 A1 7/2006 Tochon-Danguy et al.
 2006/0164093 A1 7/2006 Ooe et al.
 2006/0173419 A1 8/2006 Malcolm
 2007/0080223 A1 4/2007 Japuntich
 2007/0140958 A1 6/2007 deKemp
 2007/0226175 A1 9/2007 Resnic et al.
 2007/0232980 A1 10/2007 Felt et al.
 2007/0260213 A1 11/2007 Williams et al.
 2007/0282263 A1 12/2007 Kalafut et al.
 2008/0015794 A1 1/2008 Eiler et al.
 2008/0071219 A1 3/2008 Rhinehart et al.
 2008/0093564 A1 4/2008 Tartaglia et al.
 2008/0166292 A1 7/2008 Levin et al.
 2008/0177126 A1 7/2008 Tate et al.
 2008/0191148 A1 8/2008 Gibson
 2008/0200747 A1 8/2008 Wagner et al.
 2008/0203318 A1 8/2008 Wagner et al.
 2008/0237502 A1 10/2008 Fago
 2008/0242915 A1 10/2008 Jackson et al.
 2008/0260580 A1 10/2008 Helle et al.
 2009/0112478 A1 4/2009 Mueller, Jr. et al.
 2009/0155167 A1 6/2009 Powell et al.
 2009/0224171 A1 9/2009 Verbokkem
 2009/0312630 A1 12/2009 Hidem et al.
 2010/0312039 A1 12/2010 Quirico et al.
 2011/0071392 A1 3/2011 Quirico et al.
 2011/0172524 A1 7/2011 Hidem et al.
 2011/0178359 A1 7/2011 Hirschman et al.
 2011/0209764 A1 9/2011 Uber et al.
 2012/0098671 A1 4/2012 Wieczorek et al.
 2012/0305730 A1 12/2012 Balestracci
 2012/0310031 A1 12/2012 Quirico et al.
 2012/0312980 A1 12/2012 Whitehouse
 2013/0300109 A1 11/2013 Balestracci et al.
 2014/0084187 A1 3/2014 Quirico et al.
 2014/0175959 A1 6/2014 Quirico et al.
 2014/0343418 A1 11/2014 Quirico et al.
 2014/0374614 A1 12/2014 Hidem et al.
 2014/0374615 A1 12/2014 Hidem et al.
 2015/0260855 A1 9/2015 McQuaid et al.

FOREIGN PATENT DOCUMENTS

EP 102121 A1 3/1984
 EP 310148 A2 4/1989
 EP 317114 A1 5/1989
 EP 160303 A2 2/1991
 EP 319148 A2 2/1994
 EP 1421960 A1 5/2004
 EP 319249 A1 1/2005
 EP 1772157 A1 4/2007
 EP 1820730 A1 8/2007
 EP 2011126 A2 1/2009
 EP 2492920 A2 8/2012

FR 2867084 A1 9/2005
 JP 2000350783 A 12/2000
 JP 2003520780 A 7/2003
 JP 2006325826 A 12/2006
 KR 960003726 B1 3/1996
 RU 2131273 C1 6/1999
 RU 2288755 C1 12/2006
 SU 244513 A1 12/1969
 WO 9615337 A1 5/1996
 WO 9956117 A1 11/1999
 WO 02096335 A2 12/2002
 WO 03034444 A1 4/2003
 WO 2004004787 A2 1/2004
 WO 2004059661 A1 7/2004
 WO 2004080523 A2 9/2004
 WO 2005002971 A1 1/2005
 WO 2006007750 A1 1/2006
 WO 2006026603 A2 3/2006
 WO 2006074473 A2 7/2006
 WO 2006129301 A2 12/2006
 WO 2006135374 A2 12/2006
 WO 2007016170 A1 2/2007
 WO 2007016173 A1 2/2007
 WO 2007030249 A2 3/2007
 WO 2007041017 A1 4/2007
 WO 2007071022 A1 6/2007
 WO 2007082093 A2 7/2007
 WO 2007104133 A1 9/2007
 WO 2007149108 A2 12/2007
 WO 2008028165 A2 3/2008
 WO 2008037939 A2 4/2008
 WO 2008066586 A2 6/2008
 WO 2008082966 A2 7/2008
 WO 2008140351 A1 11/2008
 WO 2009152320 A2 12/2009
 WO 2010020596 A1 2/2010
 WO 2011126522 A2 10/2011

OTHER PUBLICATIONS

Brochure, "IV and Liquid Filters: Speedflow Adult 0.2 um Positive", <http://www.gvs.it/flex/FixedPages/UK/LiquidFilters.php/L/UK/ID/Speedflow%20Adjust%...> Retrieved from URL on Nov. 11, 2008.
 Bracco Brochure, "Rubidium 82 Infusion System, Easy to Operate... Automated... Complete", © Bracco Diagnostics, Inc., 0605-002NA, Jun. 2001, (2 pages).
 "CardioGen-82 Infusion System User's Guide," Medical Product Service GmbH, Jul. 3, 2007, 53 pages.
 Imaging Technology News, web exclusive: "FDG-PET Injector Thrusts New Life into Molecular Imaging", Apr. 2008, 2 pages.
 Neil J. Epstein, "A Rb82 infusion system for quantitative perfusion imaging with 3D PET" Applied Radiation and Isotopes, vol. 60, Feb. 9, 2004, pp. 921-927, XP002557544 DOI:10.1016/j.apradiso.2004.02.002.
 R. Klein, "Precision controlled elution of a Sr82/Rb82 generator for cardiac perfusion imaging with positron emission tomography" Physics in Medicine and Biology, vol. 52, Jan. 11, 2007, pp. 659-673, XP002557545 DOI:10.1088/0031-9155/52/3/009.
 International Search Report and Written Opinion for International Patent Application No. PCT/US2009/047027, dated Feb. 25, 2010, 22 pages.
 International Search Report and Written Opinion for International Patent Application No. PCT/US2009/047030, dated Feb. 17, 2010, 17 pages.
 International Search Report and Written Opinion for International Patent Application No. PCT/US2009/047031, dated Mar. 1, 2010, 20 pages.
 International Search Report and Written Opinion for International Patent Application No. PCT/US2009/047034, dated Feb. 25, 2010, 15 pages.
 International Search Report and Written Opinion for International Patent Application No. PCT/US2009/063788, dated Apr. 1, 2010, 13 pages.

(56)

References Cited

OTHER PUBLICATIONS

Lerner Pax, Posijet® Integrated FDG dispensing and infusion system, www.lernerpax.com (copyright date May 2008).

R. Klein, "Precise 82Rb infusion system for cardiac perfusion measurement using 3D positron emission tomography", Ottawa-Carleton Institute for Electrical and Computer Engineering School of Information Technology and Engineering (Electrical & Computer Engineering), Feb. 2005, 147 pages.

R. Klein, "Precision control of eluted activity from a Sr/Rb generator for cardiac positron emission tomography", Proceedings of the 26th Annual International Conference of the IEEE EMBS San Francisco, CA, USA, Sep. 1-5, 2004, 4 pages.

Machine translation of abstract of RU2307378 published Sep. 27, 2007.

Kost, "Preventing Medical Errors in Point-of-Care Testing," Archives of Pathology & Laboratory Medicine, vol. 125, No. 10, Oct. 2001, pp. 1307-1315.

Leveson, "Medical Devices: The Therac-25*," Appendix of Safeware: System Safety and Computers, 1995, 49 pages.

"Medfusion 3000 Series Technical Service Manual," Smiths Medical, 2010, 184 pages.

"BodyGuard 323 Infusion Pump System Operator Manual," Caesarea Medical Electronics Ltd, Mar. 2009, 81 pages.

"Alaris GH Syringe Pump Directions for Use," Cardinal Health, Oct. 2005, 34 pages.

"Auto Syringe AS40A: Model AS40A Infusion Pump Operation Manual," Baxter, Aug. 1993, 84 pages.

"CardioGen-82 Rubidium Rb 82 Generator for Elution of Rubidium Chloride Rb 82 Injection," Bracco Diagnostics, May 2000, 13 pages.

English Abstract and Machine Translation for European Publication No. 1772157 A1, published Apr. 11, 2007, 20 pgs.

Fig. 1A





Fig. 1B







Fig. 1E








Fig. 3A






Fig. 4




Fig. 5A




Fig. 5B







Fig. 5C














Fig. 7C












Fig. 9B




Fig. 9C




Fig. 11

CARDIOGEN-82 GENERATOR MONTHLY RECEIPT/RETURN WORKSHEET																							
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center;">GENERATOR RECEIPT</td> </tr> <tr> <td>DATE OF DELIVERY:</td> <td>11/9/2008</td> </tr> <tr> <td>DATE OF CALIBRATION:</td> <td>11/10/2008</td> </tr> <tr> <td>LOT NUMBER:</td> <td></td> </tr> <tr> <td>Sr-82 ACTIVITY:</td> <td>100 mCi</td> </tr> <tr> <td>TOTAL ACTIVITY:</td> <td>256 mCi</td> </tr> <tr> <td>Sr-85 ACTIVITY:</td> <td>156 mCi</td> </tr> </table>	GENERATOR RECEIPT		DATE OF DELIVERY:	11/9/2008	DATE OF CALIBRATION:	11/10/2008	LOT NUMBER:		Sr-82 ACTIVITY:	100 mCi	TOTAL ACTIVITY:	256 mCi	Sr-85 ACTIVITY:	156 mCi	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center;">RECEIPT SURVEY</td> </tr> <tr> <td>SURFACE:</td> <td>10.0 mrem/hr (MUST BE < 50 mrem/hr)</td> </tr> <tr> <td>1 METER:</td> <td>0.6 mrem/hr (MUST BE < 1 mrem/hr)</td> </tr> <tr> <td>SURFACE WIPE:</td> <td>1899 dpm (MUST BE < 2200 dpm/100 cm²)</td> </tr> </table>	RECEIPT SURVEY		SURFACE:	10.0 mrem/hr (MUST BE < 50 mrem/hr)	1 METER:	0.6 mrem/hr (MUST BE < 1 mrem/hr)	SURFACE WIPE:	1899 dpm (MUST BE < 2200 dpm/100 cm ²)
GENERATOR RECEIPT																							
DATE OF DELIVERY:	11/9/2008																						
DATE OF CALIBRATION:	11/10/2008																						
LOT NUMBER:																							
Sr-82 ACTIVITY:	100 mCi																						
TOTAL ACTIVITY:	256 mCi																						
Sr-85 ACTIVITY:	156 mCi																						
RECEIPT SURVEY																							
SURFACE:	10.0 mrem/hr (MUST BE < 50 mrem/hr)																						
1 METER:	0.6 mrem/hr (MUST BE < 1 mrem/hr)																						
SURFACE WIPE:	1899 dpm (MUST BE < 2200 dpm/100 cm ²)																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center;">GENERATOR RETURN</td> </tr> <tr> <td>DATE OF RETURN:</td> <td>12/27/2008</td> </tr> <tr> <td>DAYS SINCE CALIBRATION DATE:</td> <td>47</td> </tr> </table>	GENERATOR RETURN		DATE OF RETURN:	12/27/2008	DAYS SINCE CALIBRATION DATE:	47	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center;">RETURN SURVEY</td> </tr> <tr> <td>SURFACE:</td> <td>5.6 mrem/hr (MUST BE < 50 mrem/hr)</td> </tr> <tr> <td>1 METER:</td> <td>0.2 mrem/hr (MUST BE < 1 mrem/hr)</td> </tr> <tr> <td>SURFACE WIPE:</td> <td>1278 dpm (MUST BE < 2200 dpm/100 cm²)</td> </tr> </table>	RETURN SURVEY		SURFACE:	5.6 mrem/hr (MUST BE < 50 mrem/hr)	1 METER:	0.2 mrem/hr (MUST BE < 1 mrem/hr)	SURFACE WIPE:	1278 dpm (MUST BE < 2200 dpm/100 cm ²)								
GENERATOR RETURN																							
DATE OF RETURN:	12/27/2008																						
DAYS SINCE CALIBRATION DATE:	47																						
RETURN SURVEY																							
SURFACE:	5.6 mrem/hr (MUST BE < 50 mrem/hr)																						
1 METER:	0.2 mrem/hr (MUST BE < 1 mrem/hr)																						
SURFACE WIPE:	1278 dpm (MUST BE < 2200 dpm/100 cm ²)																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center;">Sr-82 RETURN CALCULATIONS</td> </tr> <tr> <td>INITIAL Sr-82 ACTIVITY:</td> <td>100 mCi</td> </tr> <tr> <td>DECAY FACTOR:</td> <td>0.2718</td> </tr> <tr> <td>REMAINING Sr-82 IN mCi:</td> <td>27.18 mCi</td> </tr> <tr> <td>REMAINING Sr-82 IN GBq:</td> <td>1.01 GBq</td> </tr> </table>	Sr-82 RETURN CALCULATIONS		INITIAL Sr-82 ACTIVITY:	100 mCi	DECAY FACTOR:	0.2718	REMAINING Sr-82 IN mCi:	27.18 mCi	REMAINING Sr-82 IN GBq:	1.01 GBq	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center;">SUMMARY</td> </tr> <tr> <td>TOTAL Sr-82/Sr-85 ACTIVITY:</td> <td>120.95 mCi</td> </tr> <tr> <td>TOTAL Sr-82/Sr-85 ACTIVITY:</td> <td>4.48 GBq</td> </tr> <tr> <td>TRANSPORT INDEX:</td> <td>0.2</td> </tr> </table>	SUMMARY		TOTAL Sr-82/Sr-85 ACTIVITY:	120.95 mCi	TOTAL Sr-82/Sr-85 ACTIVITY:	4.48 GBq	TRANSPORT INDEX:	0.2				
Sr-82 RETURN CALCULATIONS																							
INITIAL Sr-82 ACTIVITY:	100 mCi																						
DECAY FACTOR:	0.2718																						
REMAINING Sr-82 IN mCi:	27.18 mCi																						
REMAINING Sr-82 IN GBq:	1.01 GBq																						
SUMMARY																							
TOTAL Sr-82/Sr-85 ACTIVITY:	120.95 mCi																						
TOTAL Sr-82/Sr-85 ACTIVITY:	4.48 GBq																						
TRANSPORT INDEX:	0.2																						
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center;">Sr-85 RETURN CALCULATIONS</td> </tr> <tr> <td>INITIAL Sr-85 ACTIVITY:</td> <td>156 mCi</td> </tr> <tr> <td>DECAY FACTOR:</td> <td>0.6011</td> </tr> <tr> <td>REMAINING Sr-85 IN mCi:</td> <td>93.77 mCi</td> </tr> <tr> <td>REMAINING Sr-85 IN GBq:</td> <td>3.47 GBq</td> </tr> </table>	Sr-85 RETURN CALCULATIONS		INITIAL Sr-85 ACTIVITY:	156 mCi	DECAY FACTOR:	0.6011	REMAINING Sr-85 IN mCi:	93.77 mCi	REMAINING Sr-85 IN GBq:	3.47 GBq													
Sr-85 RETURN CALCULATIONS																							
INITIAL Sr-85 ACTIVITY:	156 mCi																						
DECAY FACTOR:	0.6011																						
REMAINING Sr-85 IN mCi:	93.77 mCi																						
REMAINING Sr-85 IN GBq:	3.47 GBq																						

Fig. 12A




Fig. 12B





Fig. 12C



1
**INTEGRATED STRONTIUM-RUBIDIUM
 RADIOISOTOPE INFUSION SYSTEMS**

CROSS REFERENCE TO RELATED
 APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/389,200, filed Dec. 22, 2016, which is a continuation of U.S. patent application Ser. No. 12/808,467, filed Jun. 16, 2010, now U.S. Pat. No. 9,607,722, issued Mar. 28, 2017, which is a 371 National Stage of International Application No. PCT/US09/47031, filed Jun. 11, 2009, which in turn is a continuation of the following four patent applications: U.S. patent application Ser. No. 12/137,356, filed Jun. 11, 2008, now U.S. Pat. No. 8,317,674, issued Nov. 27, 2012; U.S. patent application Ser. No. 12/137,363, filed Jun. 11, 2008, now U.S. Pat. No. 7,862,534, issued Jan. 4, 2011; U.S. patent application Ser. No. 12/137,364, filed Jun. 11, 2008, now U.S. Pat. No. 9,597,053, issued Mar. 21, 2017; and U.S. patent application Ser. No. 12/137,377, filed Jun. 11, 2008, now U.S. Pat. No. 8,708,352, issued Apr. 29, 2014. The entire contents of all of these applications are incorporated herein by reference.

TECHNICAL FIELD

The present invention pertains to systems that generate and infuse radiopharmaceuticals, and, more particularly, to systems including computer-facilitated maintenance and/or operation.

BACKGROUND

Nuclear medicine employs radioactive material for therapy and diagnostic imaging. Positron emission tomography (PET) is one type of diagnostic imaging, which utilizes doses of radiopharmaceuticals, for example, generated by elution within a radioisotope generator, that are injected, or infused into a patient. The infused dose of radiopharmaceutical is absorbed by cells of a target organ, of the patient, and emits radiation, which is detected by a PET scanner, in order to generate an image of the organ. An example of a radioactive isotope, which may be used for PET, is Rubidium-82 (produced by the decay of Strontium-82); and an example of a radioisotope generator, which yields a saline solution of Rubidium-82, via elution, is the CardioGen-82® available from Bracco Diagnostics Inc. (Princeton, N.J.). A PET scanner in combination with infused doses of radiopharmaceuticals may also be employed to quantify blood flow rate, for example, through the coronary arteries of a patient.

Set up, maintenance and operational procedures for infusion systems that both generate and inject doses of radiopharmaceuticals are relatively involved in order to assure the safety and efficacy of each injected dose for the patient. Efficiency in carrying out these procedures is highly desirable for technical personnel, who work with these systems on a routine basis and would like to avoid unnecessarily prolonged exposure to radioactive radiation. Thus there is a need for new system configurations that facilitate more efficient set up, maintenance and operation.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings are illustrative of particular embodiments of the present invention and therefore do not limit the scope of the invention. The drawings are not to

2

scale (unless so stated) and are intended for use in conjunction with the explanations in the following detailed description. Embodiments of the present invention will hereinafter be described in conjunction with the appended drawings, wherein like numerals denote like elements.

FIG. 1A is a first perspective view of an infusion system, according to some embodiments of the present invention.

FIG. 1B is another perspective view of a portion of a cabinet structure of the system shown in FIG. 1A, according to some embodiments.

FIG. 1C is a second perspective view of the system shown in FIG. 1A, according to some embodiments.

FIG. 1D is a schematic of an infusion circuit, according to some embodiments of the present invention.

FIG. 1E is a perspective view of exemplary sample vial shielding that may be employed in conjunction with the infusion system of FIG. 1A.

FIG. 2A is a perspective view of a shielding assembly for an infusion system, such as that shown in FIGS. 1A-C, according to some embodiments of the present invention.

FIG. 2B is a perspective view of a framework of the system, according to some embodiments, and FIG. 2B-1 is an enlarged detailed view of a component of the system, according to some embodiments.

FIG. 3A is another perspective view of the shielding assembly shown in FIG. 2A.

FIG. 3B is a perspective view of the infusion circuit, shown in FIG. 1C, configured and routed, according to some embodiments.

FIG. 3C is a perspective view of a disposable infusion circuit subassembly, according to some embodiments.

FIG. 3D is a frame for the subassembly shown in FIG. 3C, according to some embodiments.

FIG. 4 is a main menu screen shot from an interface of a computer, which may be included in systems of the present invention, according to some embodiments.

FIG. 5A is a schematic showing a first group of successive screen shots from the computer interface, according to some embodiments.

FIG. 5B is a pair of screen shots from the computer interface, which provide indications related to eluant volume levels in a reservoir of the system, according to some embodiments.

FIG. 5C is a schematic showing a second group of successive screen shots from the computer interface, according to some embodiments.

FIG. 6 is a schematic showing a third group of successive screen shots from the computer interface, according to some embodiments.

FIGS. 7A-C are schematics showing a fourth group of successive screen shots from the computer interface, according to some embodiments.

FIGS. 8A-B are schematics showing a fifth group of successive screen shots from the computer interface, according to some embodiments.

FIGS. 9A-C are schematics showing a sixth group of successive screen shots from the computer interface, according to some embodiments.

FIG. 10 is a schematic showing a seventh group of successive screen shots from the computer interface, according to some embodiments.

FIG. 11 is an exemplary report which may be generated by the computer included in infusion systems, according to some embodiments.

FIGS. 12A-B are schematics of alternative infusion circuits that may be employed by embodiments of the present invention.

FIG. 12C is a schematic illustrating exemplary activity profiles of injected doses of a radiopharmaceutical.

DETAILED DESCRIPTION

The following detailed description is exemplary in nature and is not intended to limit the scope, applicability, or configuration of the invention in any way. Rather, the following description provides practical illustrations for implementing exemplary embodiments. Utilizing the teaching provided herein, those skilled in the art will recognize that many of the examples have suitable alternatives that can be utilized.

FIG. 1A is a first perspective view of an infusion system 10, according to some embodiments of the present invention, wherein system 10 is shown supported by a cabinet structure, which includes a platform 113 (seen better in FIG. 2B) and a shell 13; shell 13 extends upward from a skirt 11, that surrounds platform 113, to surround an interior space in which a portion of infusion system 10 is contained (seen in FIG. 1C). Shell 13 may be formed from panels of injection-molded polyurethane fitted together according to methods known to those skilled in the art. FIG. 1A illustrates the cabinet structure of system 10 including a grip or handle 14, which extends laterally from shell 13, in proximity to an upper surface 131 thereof, and a post 142, which extends upward from shell 13, and to which a work surface, or tray 16 and a computer 17 are, preferably, attached, via an ergonomic, positionable mount. According to some embodiments, computer 17 is coupled to a controller of system 10, which is mounted within the interior space surrounded by shell 13; and, a monitor 172 of computer 17 not only displays indications of system operation for a user of system 10, but also serves as a device for user input (e.g. touch screen input). However, according to alternate embodiments, another type of user input device, known to those skilled in the art, may be employed by computer 17. Other types of user input devices may be included, for example, a keyboard, a series of control buttons or levers, a bar code reader (or other reader of encoded information), a scanner, a computer readable medium containing pertinent data, etc. The user input device may be mounted on the cabinet structure of system 10, as shown, or may be tethered thereto; alternatively the user input device may be remote from system 10, for example, located in a separate control room. According to some additional embodiments, another user input device, for example, in addition to a touch screen of computer 17, may be remote from system 10 and used to start and stop infusions, as well as to monitor system operation both during quality control infusions and during patient infusions. Operation of system 10, which is facilitated by computer 17, will be described below, in conjunction with FIGS. 4-9C.

FIG. 1A further illustrates two pairs of wheels 121, 122, mounted to an underside of platform 113, to make system 10 mobile; handle 14 is shown located at an elevation suitable for a person to grasp in order to maneuver system 10, from one location to another, upon pairs of wheels 121, 122. According to some preferred embodiments, one or both pairs of wheels 121, 122, are casters, allowing for rotation in a horizontal plane (swivel), in order to provide additional flexibility for maneuvering system 10 in relatively tight spaces.

FIG. 1B is a perspective view of a portion of system 10, on a side 111 of the cabinet structure, which is in proximity to wheels 121, 122. FIG. 1B illustrates a lever or pedal 125, which is located for activation by a foot of the person, who

grasps handle 14 to maneuver system 10. In a neutral position, pedal 125 allows wheels 121, 122 to rotate, and, if embodied as casters, to swivel freely. Pedal 125 may be depressed to a first position which prevents a swiveling of wheels 121, 122, according to those embodiments in which wheels 121, 122 are casters, and may be further depressed to brake wheels 121, 122 from rolling and swiveling, upon reaching a desired location. According to some embodiments, braking may be designed to slow system 10, for example, when rolling down an incline, and, according to yet further embodiments, system 10 may include a motor to power movement thereof.

FIG. 1B further illustrates: a rear access panel 174 of shell 13, for example, providing access to circuit boards of the aforementioned controller contained within the interior space that is surrounded by shell 13; an optional lock 184, to secure panel 174; a power jack 118, for connecting system 10 to a power source; and a printer 117 for providing documentation of each patient infusion carried out by system 10, and of system quality control test results. In some embodiments, system 10 may further include a power strip by which auxiliary equipment may be powered, and one or more additional electrical connectors, or ports (not shown), which are supported by platform 113 and may be integrated into shell 13, for example, in proximity to jack 118 or printer 117; these electrical connectors/ports allow system 10 to communicate with, other devices used for nuclear imaging procedures, for example, a PET scanner/camera, and/or for coupling to an intranet network, and/or to the internet, for example, to link up with software programs for various types of data analysis, and/or to link to computers of consulting clinicians/physicians, and/or to link into service providers and/or component suppliers data bases for enhanced maintenance and inventory management.

FIG. 1A further illustrates upper surface 131 of shell 13 including several openings 133, 135, 139 formed therein. FIG. 1C is a partially exploded perspective view of system 10, wherein a removable access panel 132 is shown as a contoured portion of upper surface 131, which, when exposed, by lifting away a bin 18, that mates therewith, may be removed from another opening 137 formed in upper surface 131. FIG. 1C also provides a better view of another panel 134 which may be lifted away from opening 139. According to the illustrated embodiment, openings 139 and 137 provide a user of system 10 with independent access to separate portions of infusion system 10, which are contained within shell 13, for example, to set up and maintain system 10; and openings 133 and 135 provide passageways for tubing lines to pass through shell 13. FIG. 1C further illustrates an optional switch 102, which in case of an emergency, may be activated to abort function of system 10. With reference to FIGS. 1A and 1C, it may be appreciated that an arrangement of features formed in upper surface 131 of shell 13, in conjunction with bin 18, tray 16 and computer 17, provide a relatively ergonomic and organized work area for technical personnel who operate system 10.

Turning now to FIG. 1D, a schematic of an infusion circuit 300, which may be incorporated by system 10, is shown. FIG. 1D illustrates circuit 300 generally divided into a first part 300A, which includes components mounted outside shell 13, and a second part 300B, which includes components mounted within the interior space surrounded by shell 13. (Parts 300A and 300B are delineated by dotted lines in FIG. 1D.) FIG. 1D further illustrates second part 300B of circuit 300 including a portion contained within a shielding assembly 200, which is designated schematically as a dashed line. Some embodiments of shielding assembly

200 will be described in greater detail, in conjunction with FIGS. 2A-B and 3A-B, below.

According to the illustrated embodiment, circuit 300 includes: an eluant reservoir 15, for example, a bag, bottle or other container, containing saline as the eluant, which is shown hanging from a post, or hanger 141 above upper surface 131 of shell 13 in FIG. 1A; a syringe pump 33, for pumping the eluant from reservoir 15, and a pressure syringe 34 (or other device or sensor), for monitoring pumping pressure; a filter 37, which may also serve as a bubble trap, for the pumped eluant; a radioisotope generator 21, through which the filtered eluant is pumped to create a radioactive eluate, for example an eluate carrying Rubidium-82 that is generated by the decay of Strontium-82, via elution, within a column of generator 21; and an activity detector 25, for measuring the activity of the eluate discharged from generator 21, in order to provide feedback for directing the flow of the eluate, via a divergence valve 35WP, either to a waste bottle 23 or through a patient line 305p, for example, to inject a dose of the radiopharmaceutical eluate into a patient. With reference back to FIG. 1A, patient line 305p is shown extending out from shell 13, through opening 135, to a distal end thereof, which, according to some embodiments, includes a filter. Patient line 305p may be coupled to another line that includes a patient injection needle (not shown). Alternatively, patient line 305p may be coupled to another line (not shown), which extends from a source of another active substance, for example, a stress agent; the other line is coupled to the line that includes the patient injection needle, in order to permit injection of the additional active substance.

FIG. 1D illustrates an eluant tubing line 301 coupled to reservoir 15 and to pump 33, and, with reference to FIGS. 1A-B, it may be appreciated that opening 133 provides the passageway for tubing line 301 to enter the interior space surrounded by shell 13. According to some preferred embodiments, opening 133 includes a grommet-type seal that prevents leakage of eluant, which may spill from reservoir 15, into the interior space through opening 133, while allowing a user to assemble tubing line 301 through opening 133. Likewise opening 135, which provides a passageway for patient line 305p, may include a grommet-type seal. According to some embodiments, shell 13 further supports holders to safely hold, for example, during transport of system 10, portions of tubing lines that extend outward therefrom, for example, line 301 and/or line 305p.

FIG. 1D further illustrates another eluant tubing line 302 coupled to pump 33 and a divergence valve 35BG, which may either direct pumped eluant through a tubing line 304, to generator 21, or direct the pumped eluant through a by-pass tubing line 303, directly to patient line 305p. Divergence valve 35BG, as well as divergence valve 35WP, which directs eluate from an eluate tubing line 305 either to a waste line 305w or to patient line 305p, may each be automatically operated by a corresponding servomotor (not shown), coupled to the controller (not shown) of system 10, which controller receives feedback from activity detector 25. When system 10 is operating for automatic infusion, to deliver a dose of radiopharmaceutical to a patient, for example, Rubidium-82 for diagnostic imaging, divergence valve 35BG is initially set to direct eluant to generator 21 and divergence valve 35WP is set to direct eluate from the generator into waste bottle 23, until activity detector 25 detects the desired activity of the eluate, at which time the feedback from activity detector 25 causes the controller to direct the corresponding servo-motor to re-set valve 35WP for diverting the flow of eluate into patient line 305p.

According to some embodiments, once a prescribed volume of the eluate has passed through patient line 305p, the controller directs the corresponding servomotor to re-set divergence valve 35BG for diverting the flow of eluant through by-pass line 303 and into patient line 305p in order to flush, or push any eluate remaining in patient line 305p into the patient. According to some embodiments, the controller may also direct the corresponding servomotor to re-set divergence valve 35WP back toward waste bottle 23, prior to the flush through by-pass line 303, in order to prevent back flow of eluant, through line 305, toward generator 21. According to some preferred methods of operation, in certain situations, which will be described in greater detail below, eluant is pumped through by-pass line 303 immediately following the flow of the prescribed volume of eluate into patient line 305p, at a higher speed, in order to push the eluate in patient line 305, thereby increasing a flow rate of the injection of eluate out from patient line 305p and into the patient. For example, once the prescribed volume of eluate has flowed into patient line 305p, and once divergence valve 35BG is set to divert flow through by-pass line 303, the speed of pump 33 may be adjusted to increase the flow rate of eluant to between approximately 70 mL/min and approximately 100 mL/min. This method for increasing the injection flow rate, is desirable, if a relatively high flow rate is desired for patient injection and a flow rate through generator 21 is limited, for example, to below approximately 70 mL/min, maximum (typical flow rate may be approximately 50 mL/min), in order to avoid an excessive back pressure created by the column of generator 21 in upstream portions of tubing circuit 300; the excessive back pressure could damage filter 37 or otherwise impede flow through eluant tubing line 302.

Although not shown in FIG. 1D, a number of sensors, for example, to measure pressure and/or flow velocity, may be incorporated into circuit 300, according to some alternate embodiments, in order to monitor for flow anomalies, for example, related to occlusions/plugs in circuit 300 and/or leaks, and/or to provide feedback for control of an activity level of infused doses of radiopharmaceutical. Suitable sensors for any of the above purposes are known to those skilled in the art. Examples of flow meters that may be incorporated into circuit 300, include the Innova-Sonic® Model 205 Transit-Time Ultrasonic Liquid Flow Meter that employs digital signal processing (available from Sierra Instruments, Inc.) and the Flocat LA10-C differential pressure flow meter. One example of a pressure sensor that may be employed to detect infusion circuit occlusions is the PRO/Pressure-Occlusion Detector (available from INTROTEK® of Edgewood, N.Y., a subsidiary of Magnetrol of Downers Grove, Ill.), which employs pulse-type ultrasound; this sensor detects subtle changes in positive and negative air pressure and produces a corresponding passive resistive output signal, which may be routed to the system controller and/or computer 17. One or more of this type of sensor may be incorporated into infusion circuit 300 by simply fitting the sensor around any of the tubing lines of infusion circuit 300; in fact, the PRO/Pressure-Occlusion Detector may be a suitable alternative to pressure syringe 34 of circuit 300. Other types of pressure sensors, for example, similar to those known in the art for blood pressure monitoring, may be employed in infusion circuit 300.

System 10 may further include sensors to detect fluid levels in eluant reservoir 15 and waste bottle 23. Some examples of such sensors, which also employ the aforementioned pulse-type ultrasound, are the Drip Chamber Liquid Level Sensor and the CLD/Continuous Level Detector (both

available from INTROTEK®); alternatively, for example, an HPQ-T pipe mounted, self-contained liquid sensor (available from Yamatake Sensing Control, Ltd.), or an SL-630 Non-Invasive Disposable/Reusable Level Switch (available from Cosense, Inc. of Hauppauge, N.Y.) may be employed to detect the fluid levels. Alternately or in addition, system 10 can include additional radiation and/or moisture detection sensors, which can detect leaks. With reference to FIG. 1D, such sensors are preferably located in proximity to fittings 311, 312, 313, 314 and 315 that join portions of circuit 300 to one another. Some examples of leak detection sensors include, without limitation, those in the HPQ-D leak detection sensor family, and the HPPF-D040 fiberoptic leak detector (all available from Yamatake Sensing Control, Ltd.). System 10 may further include additional sensors to detect contaminants and/or air bubbles within the tubing lines of circuit; examples of such sensors include the Point-air Detection (PAD) Sensor, that employs pulse-type ultrasound for air bubble detection, and the Blood Component Detector that employs optical sensing technology to perform Colorimetry-based fluid detection of unwanted elements in the tubing lines (both available from INTROTEK®).

According to those embodiments that include any of the above sensors, the sensors are linked into the controller of system 10 and/or computer 17, either of which may provide a signal to a user of system 10, when a flow anomaly is detected, and/or information to the user, via monitor 172, concerning fluid levels, pressure and/or flow through circuit 300. Computer 17 may be pre-programmed to display, for example, on monitor 172, a graphic of infusion circuit 300 wherein each zone of the circuit, where an anomaly has been detected, is highlighted, and/or to provide guidance, to the system user, for correcting the anomaly. It should be noted that the alternative infusion circuits illustrated in FIGS. 12A-B, which will be described below, may also include any or all of these types of sensors.

With further reference to FIG. 1D, it may be appreciated that shielding assembly 200 encloses those portions of circuit 300 from which radioactive radiation may emanate, with the exception of that portion of patient line 305p, which must extend out from shielding assembly 200 in order to be coupled to the patient for injection, or in order to be coupled to shielded sample vials, as will be described below. Thus, technical personnel, who operate system 10, are protected from radiation by shielding assembly 200, except at those times when an infusion is taking place, or when quality control tests require collection of eluate into sample vials. During infusions and quality control test sample collection, all technical personnel are typically in another room, or otherwise distanced from system 10, in order to avoid exposure to radiation during the infusion, and, according to some preferred embodiments of the present invention, system 10 includes at least one means for informing technical personnel that an infusion is about to take place or is taking place. With reference back to FIGS. 1A and 1C, system 10 is shown including a light projector 100, mounted on post 142. According to the illustrated embodiment, projector 100, projects a light signal upward, for maximum visibility, when pump 33 is pumping eluant and elution is taking place within generator 21, or at all times when pump 33 is pumping eluant. According to some embodiments, the light signal flashes on and off when the eluate is being diverted from generator 21 into waste bottle 23, and the light signal shines steadily when the eluate is being diverted through patient line 305p, or visa versa. According to other embodiments, a projector 100 shines a light having a first color, to indicate that eluate is being diverted to waste bottle 23, and then

shines a light having a second, different color, to indicate that eluate is being directed to patient line 305p for infusion. Light projector 100 may further project a more rapidly flashing light, for example, for approximately five seconds, once a peak bolus of radioactivity is detected in the eluate, to provide further information to technical personnel. Alternative means of informing technical personnel that an infusion is taking place may also be incorporated by system 10, for example, including audible alarms or other types of visible or readable signals that are apparent at a distance from system 10, including in the control room.

It should be noted that, according to alternate embodiments, system 10 includes an 'on board' dose calibrator for quality control tests, and circuit 300 is expanded to include elements for an automated collection of eluate samples for activity measurements, via the on board dose calibrator. According to a first set of these alternate embodiments, a sample collection reservoir is integrated into circuit 300, downstream of divergence valve 35WP and in communication with tubing line 305P, in order to receive quality control test samples of eluate, via tubing line 305P, and both the reservoir and the dose calibrator are located in a separate shielded well. According to a second set of these alternate embodiments, waste bottle 23 is configured to receive the quality control test samples of eluate, via tubing line 305W, and a dose calibrator is integrated into shielding assembly 200. Quality control procedures will be described in greater detail below, in conjunction with FIGS. 6-8B.

When maintenance of system 10 requires the emptying waste bottle 23, relatively easy access to waste bottle 23 is provided through opening 139 in top surface 131 of shell 13. It should be noted that technical personnel are preferably trained to empty waste bottle 23 at times when the eluate, contained in waste bottle 23, has decayed sufficiently to ensure that the radioactivity thereof has fallen below a threshold to be safe. Opening 139 is preferably located at an elevation of between approximately 2 feet and approximately 3 feet; for example, opening 139 may be at an elevation of approximately 24 inches, with respect to a lower surface of platform 113, or at an elevation of approximately 32 inches, with respect to a ground surface upon which wheels 121, 122 rest. According to the illustrated embodiment, opening 139 is accessed by lifting panel 134; just within opening 139, a shielded lid or door 223 (FIG. 2A) may be lifted away from a compartment of shielding assembly 200 that contains waste bottle 23. With further reference to FIG. 1C, it may be appreciated that opening 137 provides access to other portions of circuit 300 for additional maintenance procedures, such as changing out generator 21 and/or other components of circuit 300, as will be described below.

For those embodiments of system 10 in which automated quality control tests are performed and/or when system 10 is employed for relatively high volume operation, management of waste may become burdensome, even though access to waste bottle 23 is greatly facilitated, as described above. Thus, in order to facilitate waste management, some embodiments of system 10 may employ a separation system to separate salts, including radioactive elements, from water, for example, via evaporation or reverse osmosis. In an evaporation type system, the water component of the waste is evaporated, while in a reverse osmosis type system the water is separated from the salts, and, then, once confirmed to be non-radioactive, via a radiation detector, is piped to a drain. According to some other embodiments, circuit 300 may be configured so that the waste may be used to purge air from the tubing lines thereof and/or to perform the bypass

flush that was described above, preferably after the radioactivity of the waste drops below a critical threshold.

FIGS. 1A and 1C further illustrate a pair of relatively shallow external recesses 190, which are formed in upper surface 131 of shell 13, for example, in order to catch any spills from the infusion system; one of recesses 190 is shown located in proximity to post, or hanger 141, which holds reservoir 15, and in proximity to opening 133, through which tubing line 301 passes. Another recess 192 is shown formed in upper surface 131; a width and depth of recess 192 may accommodate storage of technical documentation associated with infusion system 10, for example, a technical manual and/or maintenance records, or printouts from printer 117 (FIG. 1B). With reference to FIG. 1C, upper surface 131 of shell 13 is shown to also include additional recesses 101, which are each sized to hold a shielded test vial, which contains samples from infusion system 10, for example, for breakthrough testing and/or calibration, which will be described in greater detail, below. An exemplary test vial shield is shown in FIG. 1E. The test vial shield of FIG. 1E is preferably formed from Tungsten rather than lead, for example, to reduce exposure to lead, for improved shielding, and to reduce the weight of the shield. FIG. 1E illustrates the test vial shield including a handle to simplify manipulation thereof, but alternative configurations of test vial shields have no handle—for these a sling, or strap, may be employed for handling.

Additional receptacles 180 are shown formed in bin 18, on either side of a handle 182, which facilitates removal of bin 18 away from shell 13. Technical personnel may, thus, conveniently transport bin 18 to a storage area for a collection of supplies, for example, sharps, gloves, tubing lines, etc. . . . , into one or more receptacles 180 thereof, and/or to a waste container where separate receptacles 180 of bin 18 may be emptied of waste, such as packaging for the aforementioned supplies, for example, deposited therein during infusion procedures. According to some embodiments, one or more additional receptacles are formed in one or more disposal containers, for example, to contain sharps and/or radioactive waste (other than that contained in waste bottle 23), which may be integrated into bin 18, or otherwise fitted into, or attached to shell 13, separate from bin 18.

FIG. 2A is a perspective view of shielding assembly 200, according to some embodiments of the present invention. With reference to FIGS. 1C and 2A, together, it may be appreciated that opening 137, in upper surface 131 of shell 13, provides access to a lid or door 221 of a sidewall 201 of shielding assembly 200, which sidewall 201 encloses a compartment sized to contain a radioisotope generator of system 10, for example, generator 21, previously introduced. It should be noted that, according to alternate embodiments, the compartment enclosed by sidewall 201 is large enough to hold more than one generator, for example, to increase system operating efficiency for relatively high volume operation. In some of these alternate embodiments, tubing lines 304 and 305 are each branched for parallel flow through the multiple generators, in which case divergence valves may be employed to alternate the flow through the generators, one at a time. In others of these alternate embodiments, the multiple generators are connected in series between tubing line 304 and tubing line 305. In addition, a reservoir for accumulating eluate may be included in circuit 300, downstream of the generators and upstream of divergence valve 35WP, in conjunction with a second pump, in some cases. Embodiments including multiple generators and/or an eluate reservoir and second pump can be employed to better manage an activity level of each

dose, or patient injection, for example, as described below, in conjunction with FIGS. 12A-B.

According to the embodiment illustrated in FIG. 2A, opening 137 and door 221 are located at a lower elevation, for example, with respect to platform 113, than are opening 139 and lid 223, which provide access to the compartment being formed by a sidewall 203 of shielding assembly 200 to contain waste bottle 23, as previously described. When panel 132 is separated from shell 13, and door 221 opened, generator 21 may be lifted out from an opening 231 (FIG. 3A) which mates with door 221 of sidewall 201. A weight of generator 21, which includes its own shielding, may be between approximately 23 and approximately 25 pounds, thus, according to some preferred embodiments of the present invention, the elevation of each of openings 137 and 231, with respect to the lowermost portion of the cabinet structure, is between approximately 1 foot and approximately 2 feet, in order to facilitate an ergonomic stance for technical personnel to lift generator 21 out from the compartment. According to an exemplary embodiment, when shielding assembly 200 is contained in the cabinet structure of FIG. 1A, openings 137 and 231 are located at an elevation of approximately 12 inches, with respect to the lower surface of platform 113, or at an elevation of approximately 19 inches, with respect to the ground surface upon which wheels 121, 122 rest. FIG. 1C further illustrates access panel 132 including a security lock 138, which mates with a framework 19 of system 10, shown in FIG. 2B, in order to limit access to generator 21.

FIGS. 1C and 2A further illustrate a lid or a door 225 of another sidewall 205 (FIG. 3A) of shielding assembly 200, which encloses another compartment that is accessible through opening 137 of shell 13, and which is located adjacent the compartment enclosed by sidewall 201. Each of doors 221, 225 are shown being attached by a corresponding hinge H, and another door 227 is shown attached to sidewall 203 by another hinge H. FIG. 2A illustrates each of lid 223 and doors 221, 225, 227 including a handle 232, 212, 252 and 272, respectively, for moving lid 223 and doors 221, 225, 227, in order to provide access to the corresponding compartments, which can be seen in FIGS. 3A-B. FIG. 2A further illustrates optional thumb screws 290, one securing lid 223 to sidewall 203 and another securing door 221 to sidewall 201, or other means for securing the doors, which are known to those skilled in the art, may be incorporated. Each sidewall 201, 203, 205 and the corresponding lid/door 223, 221, 225, 227 thereof may be individually cast from 3% antimony lead, or from other known shielding materials, and then assembled together according to methods known to those skilled in the art.

According to the illustrated embodiment, doors 221, 225 are hinged to open in an upward direction, per arrows D and C, and, with reference back to FIG. 1C, a latch component 191 is provided to hold each of doors 221, 225 in an opened position, thereby, preventing doors 221, 225 from falling closed, which could pinch/crush fingers of technical personnel and/or tubing lines of circuit 300, when in the midst of a maintenance procedure. FIG. 2B is a perspective view of framework 19 of the cabinet structure of system 10, according to some embodiments, to which latch component 191 is mounted; FIG. 2B-1 is an enlarged detailed view of latch component 191, according to some embodiments. FIG. 2B illustrates latch component 191 including a first pin 193, corresponding to door 225, and a second pin 195, corresponding to door 221; each pin 193, 195 includes a lever end 193A, 193B, respectively, and a holding end 193B, 195B, respectively. An edge of each door 221, 225, upon opening

of doors 221, 225, may push past the holding end 195B, 193B of the corresponding pin 195, 193, in a first direction, per arrow F, and then may rest against a respective side S95 and S93 of each end 195B, 193B, until the corresponding lever end 195A, 193A is rotated in a counter-clockwise direction, per arrow cc, thereby moving the corresponding holding end 193B, 195B to make way for the closing of doors 221, 225. Doors 221, 225 being held by latch component 191 in an open position may be seen in FIG. 3A.

With further reference to FIG. 2A, according to some preferred embodiments of the present invention, an edge of door 225 overlaps door 221 to prevent door 221 from being opened, per arrow D, if door 225 is not opened, per arrow C; and an edge of door 227 overlaps an edge of door 225 to prevent door 225 from being opened if door 227 is not opened, per arrow B; and an edge of lid 223 overlaps door 227 to prevent door 227 from being opened if lid 223 is not opened, per arrow A. Thus, access to the compartment enclosed by sidewall 201 and containing generator 21 is only systematically allowed through a sequential opening of lid 223 and doors 227, 225, 221, since, when generator 21 is replaced it is typically desirable to also replace those portions of circuit 300 which are shielded behind lid 223 and doors 227, 225. The routing of these portions of circuit 300 will be described in conjunction with FIGS. 3A-C.

FIG. 3A is another perspective view of shielding assembly 200, according to some embodiments of the present invention. In FIG. 3A, lid 223 and doors 221, 225, and 227 are opened to provide a view into openings 233, 235 and 231 of sidewalls 203, 205 and 201, respectively, and into a passageway 207, which is formed in sidewall 203, opposite the compartment, which contains waste bottle 23. Passageway 207 is shown extending vertically along sidewall 203 and having a grooved extension 213 formed in a perimeter surface of opening 233. An optional retaining member 237, for example, formed from an elongate strip of resilient plastic having a generally c-shape cross-section, is shown being mounted along a length of passageway 207 to hold lines 305_w and 305_p in place within passageway 207. FIG. 3A further illustrates a pair of passageways 251_b and 251_c, which are formed as grooves in a portion of sidewall 205, and another pair of passageways 215_i and 215_o, which are formed as grooves in a portion of sidewall 201. A routing of portions of tubing circuit 300 (FIG. 1D) through passageways 207, 251_b, 251_c, 215_i and 215_o is shown in FIG. 3B.

FIG. 3B illustrates tubing line 304 being routed through passageways 251_g and 215_i, eluate tubing line 305 being routed through passageway 215_o, and both waste line 305_w and patient line 305_p being routed along passageway 207. Waste line 305_w further extends through grooved extension 213 to waste bottle 23, and patient line 305_p further extends outward from shielding assembly 200, for example, to extend out through opening 135 in upper surface 131 of shell 13 (FIG. 1A). According to the illustrated embodiment, each passageway formed in shielding assembly 200, by being accessible along a length thereof, can facilitate a relatively easy routing of the corresponding tubing line therethrough, when the corresponding lid/door is open, and a depth of each passageway prevents pinching and/or crushing of the corresponding tubing line routed therethrough, when the corresponding lid/door is closed down thereover. With further reference to FIGS. 3A-B, it may be appreciated that the compartment formed by sidewall 201 may have a shape matching an exterior contour of generator 21, such that generator 21 is 'keyed' to the compartment, for example, to prevent installation of an improper generator into system 10, and/or to facilitate the proper orientation of generator 21

within the compartment for the proper routing of tubing lines. Alternately, or in addition, according to alternate embodiments, if system 10 includes a reader of encoded information in communication with computer 17, a unique identification and/or data associated with each generator may be provided, for example, in a bar code label or a radiofrequency identification (RFID) tag that is attached to each generator, so that the reader may transfer the information to computer 17, when a generator is installed, in order to either enable system operation or to provide an indication to the user that an incorrect generator has been installed. Of course a user of system 10 may, alternately, manually enter information, that is provided on a generator label or marking, into computer 17, in order to either enable system 10, or to receive feedback from computer 17 that the incorrect generator is installed.

FIG. 3A further illustrates sidewall 205 including a valve actuator receptacle 253, into which divergence valve 35WP is mounted, to be controlled by one of the servomotors (not shown) of system 10, and an opening 325 for activity detector 25. Activity detector 25 is mounted in a shielded well 255 that extends downward from opening 325 (shown in FIG. 3B), and, with reference to FIG. 3B, tubing line 305 passes over opening 325 so that detector 25 can detect an activity of the eluate, which passes therethrough. According to some embodiments, the positioning, within the compartment enclosed by sidewall 205, of the components of the portion of infusion circuit 300 which are shown routed therein, is facilitated by providing the components mounted in a frame 39 as a disposable subassembly 390, an embodiment of which is illustrated by FIGS. 3C-D.

FIG. 3C is a perspective view of subassembly 390, and FIG. 3D is a perspective view of frame 39. According to the embodiment illustrated by FIG. 3D, frame 39 is formed from mating trays 39A, 39B, for example, formed from a thermoformed plastic, which fit together to capture, therebetween, and hold, in fixed relation to a perimeter edge of frame 39, divergence valve 35WP and portions of eluant tubing line 304, by-pass tubing line 303, eluate tubing line 305, waste line 305_w and patient line 305_p. FIG. 3C illustrates the perimeter edge divided into a first side 391, a second side 392, opposite first side 391, a third side 393, extending between first and second sides 391, 392, and a fourth side 394, opposite third side 393. Although FIG. 3D shows trays 39A, 39B individually formed for fitting together, according to alternate embodiments, mating trays of frame 39 may be parts of a continuous sheet of plastic folded over on itself.

According to the illustrated embodiment, an end 404A, of eluant line 304, and an end 403, of by-pass line 303 extend from third side 393 of frame 39 to couple with divergence valve 35BG and an upstream section of eluant tubing line 302. FIG. 3C further illustrates an opposite end 404B of eluant line extending from first side 391 of frame 39, alongside a similarly extending end 405 of eluate line 305, and ends 406 and 407 of patient line 305_p and waste line 305_w, respectively, extending from second side 392 of frame 39. Although ends 406, 407 are shown extending upward from tray 39a, as they would within shielding assembly 200, it should be appreciated that the tubing lines of circuit 300 are preferably flexible and would drop down under their own weight rather than extending upward, as shown, if not supported. Referring back to FIG. 1D, in conjunction with FIG. 3C, it can be seen that the aforementioned fittings are provided for coupling subassembly 390 into circuit 300: first fitting 311 couples the section of eluant line 302 to filter 37; second fitting 312 couples eluant line 304 to an inlet port of

generator 21; third fitting 313, which may incorporate a check valve, couples eluate line 305 to an outlet port of generator 21; fourth fitting 314 couples waste line 305_w to waste bottle 23; and fifth fitting 315 couples patient line 305_p to an extension thereof, which extends outside shell 13 (designated by the dotted line). Each of the fittings 311, 312, 313, 314, 315 may be of the Luer type, may be a type suitable for relatively high pressure applications, or may be any other suitable type that is known to those skilled in the art.

As previously mentioned, when generator 21 is replaced, it is typically desirable to also replace those portions of circuit 300 which are shielded behind lid 223 and doors 227, 225, and, in those instances wherein system 10 is moved to a new site each day, these portions may be replaced daily. Thus, according to the illustrated embodiment, these portions are conveniently held together by frame 39, as subassembly 390, in order to facilitate relatively speedy removal and replacement, while assuring a proper assembly orientation, via registration with features formed in sidewall 205 (FIG. 3A), for example: registration of divergence valve 35WP with valve actuator receptacle 253, registration of tubing line ends 403 and 404A with passageways 251b and 251g, respectively, registration of tubing line ends 404B and 405 with passageways 215i and 215o, respectively, and registration of tubing line ends 406 and 407 with passageway 207.

With further reference to FIG. 3B, other portions of tubing circuit 300 are shown. FIG. 3B illustrates eluant tubing line 301 extending from reservoir 15, outside of shell 13 (FIG. 1A), to syringe pump 33, which is mounted to an actuating platform 433. According to the illustrated embodiment, platform 433 is actuated by another servomotor (not shown) of system 10, which is controlled by the controller and computer 17 of system 10, to cause a plunger of pump 33 to move, per arrow I, so as to draw in eluant, from reservoir 15, through tubing line 301, and then to cause the plunger to move in the opposite direction so as to pump the eluant, through tubing line 302, to either generator 21 or to by-pass line 303. Although the illustrated embodiment includes syringe pump 33, other suitable pumps, known to those skilled in the art, may be substituted for pump 33, in order to draw eluant from reservoir 15 and to pump the eluant throughout circuit 300. Although not shown, it should be appreciated that divergence valve 35BG is fitted into another valve actuating receptacle mounted within shell 13 and coupled to yet another servomotor (not shown) of system 10.

FIG. 3B further illustrates a filter holder 317 that is mounted alongside an interior surface of shell 13 to hold filter 37 (FIG. 1D) of tubing line 302. Filter holder 317, like frame 39 for subassembly 390, may be formed from a thermoformed plastic sheet; holder 317 may have a clam-shell structure to enclose filter 37 in an interior space, yet allow tubing line 302, on either side of filter 37, to extend out from the interior space, in between opposing sides of the clam-shell structure. Holder 317 is shown including an appendage 307 for hanging holder 317 from a structure (not shown) inside shell 13.

Turning now to FIGS. 4-9C details concerning computer-facilitated operation of system 10 will be described, according to some embodiments of the present invention. As previously mentioned, and with reference back to FIG. 1A, computer 17 of system 10 includes monitor 172, which, preferably, not only displays indications of system operation to inform a user of system 10, but is also configured as a touch screen to receive input from the user. It should be understood that computer 17 is coupled to the controller of

system 10, which may be mounted within the interior space surrounded by shell 13. Although FIG. 1A shows computer 17 mounted to post 142 of system 10, for direct hardwiring to the controller of system 10, according to some alternate embodiments, computer 17 is coupled to the controller via a flexible lead that allows computer 17 to be positioned somewhat remotely from those portions of system 10, from which radioactive radiation may emanate; or, according to some other embodiments, computer 17 is wirelessly coupled, for example, via two-way telemetry, to the controller of system 10, for even greater flexibility in positioning computer 17, so that the operation of system 10 may be monitored and controlled remotely, away from radioactive radiation.

According to some preferred embodiments, computer 17 is pre-programmed to guide the user, via monitor 172, through procedures necessary to maintain system 10, to perform quality control tests on system 10, and to operate system 10 for patient infusions, as well as to interact with the user, via the touch-screen capability of monitor 172, according to preferred embodiments, in order to track volumes of eluant and eluate contained within system 10, to track a time from completion of each elution performed by system 10, to calculate one or more system parameters for the quality control tests, and to perform various data operations. Computer 17 may also be pre-programmed to interact with the controller of system 10 in order to keep a running tally or count of elutions per unit time, for a given generator employed by the system, and may further categorize each of the counted elutions, for example, as being generated either as a sample, for quality control testing, or as a dose, for patient injection. The elution count and categorization, along with measurements made on each sample or dose, for example, activity level, volume, flow rate, etc. . . . , may be maintained in a stored record on computer 17. All or a portion of this stored information can be compiled in a report, to be printed locally, and/or to be electronically transferred to a remote location, for example, via an internet connection to technical support personnel, suppliers, service providers, etc. . . . , as previously described. Computer 17 may further interact with the user and/or a reader of encoded information, for example, a bar code reader or a radiofrequency identification (RFID) tag reader, to store and organize product information collected from product labels/tags, thereby facilitating inventory control, and/or confirming that the proper components, for example, of the tubing circuit, and/or accessories, and/or solutions are being used in the system.

It should be understood that screen shots shown in FIGS. 4-9C are exemplary in nature and are presented to provide an outline of some methods of the present invention in which computer 17 facilitates the aforementioned procedures, without limiting the scope of the invention to any particular computer interface format. Computer 17 may also include a pre-programmed user manual, which may be viewed on monitor 172, either independent of system operation or in conjunction with system operation, for example, via pop-up help screens. Although the English language is employed in the screen shots of FIGS. 4-9C, it should be understood that, according to some embodiments, computer 17 is pre-programmed to provide guidance in multiple languages.

FIG. 4 is a screen shot of a main menu 470, which is presented by computer 17 on monitor 172, according to some embodiments. Main menu 470 includes a listing of each computer-facilitated operation that may be selected by the user, once the user has logged on. According to some

multi-lingual embodiments, computer 17 presents a list of languages from which the user may select, prior to presenting main menu 470.

FIG. 5A is a schematic showing a series of screen shots which includes a log in screen 570. According to some embodiments, when the user touch-selects the data entry fields of screen 570 or 571, or of any of the other screens presented herein, below, a virtual keyboard is displayed for touch-select data entry into the selected data entry field; alternately, computer 17 may be augmented with another type of device for user data entry, examples of which include, without limitation, a peripheral keyboard device, a storage medium (i.e. disk) reader, a scanner, a bar code reader (or other reader of encoded information), a hand control (i.e. mouse, joy stick, etc. . . .). Although not shown, according to some embodiments, screen 570 may further include another data entry field in which the user is required to enter a license key related to the generator employed by system 10 in order to enable operation of system 10; the key may be time sensitive, related to generator contract terms. Of course any number of log in requirements may be employed, according to various embodiments, and may be presented on multiple sequentially appearing screens rather than on a single log in screen.

After the user enters the appropriate information into data entry fields of log in screen 570, computer 17 presents a request for the user to confirm the volume of eluant that is within reservoir 15 (e.g. saline in saline bag), via a screen 571, and then brings up main menu 470. If the user determines that the volume of eluant/saline is insufficient, the user selects a menu item 573, to replace the saline bag. If system 10 includes an encoded information reader, such as a bar code or RFID tag reader, confirmation that the selected reservoir is proper, i.e., contains the proper saline solution, may be carried out by computer 17, prior to connecting the reservoir into circuit 300, by processing information read from a label/tag attached to the reservoir. Alternatively, or in addition, tubing line 301 of circuit 300 may be provided with a connector which only mates with the proper type of reservoir 15. According to some embodiments, system 10 may further include an osmolarity or charge detector, which is located just downstream of reservoir 15 and is linked to computer 17, so that an error message may be presented on monitor 172 stating that the wrong osmolarity or charge is detected in the eluant supplied by reservoir, indicating an improper solution. One example of a charge detector that may be employed by system 10 is the SciCon™ Conductivity Sensor (available from SciLog, Inc. of Middleton, Wis.).

Once the reservoir/saline bag is successfully replaced, computer 17 prompts the user to enter a quantity of saline contained by the new saline bag, via a screen 574. Alternately, if system 10 includes the aforementioned reader, and the saline bag includes a tag by which volume information is provided, the reader may automatically transfer the quantity information to computer 17. Thus, computer 17 uses either the confirmed eluant/saline volume, via screen 571, or the newly entered eluant/saline volume as a baseline from which to track depletion of reservoir volume, via activations of pump 33, in the operation of system 10. With reference to FIG. 5B, during the operation of system 10, when computer 17 detects that the eluant reservoir/saline bag has been depleted to a predetermined volume threshold, computer 17 warns the user, via a screen 577. If the user has disregarded screen 577 and continues to deplete the saline bag, computer 17 detects when the saline bag is empty and provides indication of the same to the user, via a screen 578. To

replenish the reservoir/saline bag, the user may either refill the reservoir/bag or replace the empty reservoir/bag with a full reservoir/bag. According to some embodiments, system 10 automatically precludes any further operation of the system until the reservoir is replenished. It should be noted that, as previously mentioned, system 10 can include a fluid level sensor coupled to the eluant reservoir in order to detect when the level of saline drops below a certain level.

In addition to tracking the volume of eluant in reservoir 15, computer 17 also tracks a volume of the eluate which is discharged from generator 21 into waste bottle 23. With reference to FIG. 5C, an item 583 is provided in main menu 470, to be selected by the user when the user empties waste bottle 23. When the user selects item 583, computer 17 presents a screen 584, by which the user may effectively command computer 17 to set a waste bottle level indicator to zero, once the user has emptied waste bottle 23. Typically, the user, when powering up system 10 for operation, each day, will either empty waste bottle 23, or confirm that waste bottle 23 was emptied at the end of operation the previous day, and utilize screen 584 to set the waste bottle level indicator to zero. Thus, computer 17, can track the filling of waste bottle 23 via monitoring of the operation of pump 33 and divergence valve 35WP, and provide an indication to the user when waste bottle 23 needs to be emptied, for example, via presentation of screen 584, in order to warn the user that, unless emptied, the waste bottle will overflow. According to some embodiments, system 10 automatically precludes any further operation of the system until the waste bottle is emptied. According to some alternative embodiments, a fluid level sensor may be coupled to waste bottle 23, for example, as mentioned above in conjunction with FIG. 1D, in order to automatically detect when waste bottle 23 is filled to a predetermined level and to provide, via computer 17, an indication to the user that waste bottle 23 needs to be emptied and/or to automatically preclude operation of system 10 until the waste bottle is emptied.

In addition to the above maintenance steps related to eluant and eluate volumes of system 10, the user of system 10 will typically perform quality control tests each day, prior to any patient infusions. With reference to FIG. 6, according to preferred methods, prior to performing the quality control tests (outlined in conjunction with FIGS. 7A-C and 8A-B), the user may select an item 675 from main menu 470, in order to direct system 10 to wash the column of generator 21. During the generator column wash, which is performed by pumping a predetermined volume of eluant, for example, approximately 50 milliliters, through generator 21 and into waste bottle 23, computer 17 provides an indication, via a screen 676, that the wash is in progress. Also, during the generator column wash, the system may provide a signal to indicate that eluate is being diverted to waste bottle 23, for example, light projector 100 (FIG. 1C) may project a flashing light signal, as previously described.

FIG. 6 further illustrates a screen 677, which is presented by computer 17 upon completion of the column wash, and which provides an indication of a time lapse since the completion of the wash, in terms of a time countdown, until a subsequent elution process may be effectively carried out. While screen 677 is displayed, system 10 may be refilling, from reservoir 15, pump 33, which has a capacity of approximately 55 milliliters, according to some embodiments. According to some preferred embodiments of the present invention, computer 17 starts a timer once any elution process is completed and informs the user of the time lapse, either in terms of the time countdown (screen 677), or in terms of a time from completion of the elution, for

example, as will be described in conjunction with FIG. 7B. According to an exemplary embodiment, wherein generator 21 is the CardioGen-82® that yields a saline solution of Rubidium-82, produced by the decay of Strontium-82, via the elution, a time required between two effective elution processes is approximately 10 minutes.

Once the appropriate amount of time has lapsed, after the elution process of generator column wash, a first quality control test may be performed. With reference to FIG. 7A, the user may select, from main menu 470, an item 773A, which directs computer 17 to begin a sequence for breakthrough testing. According to some embodiments, in conjunction with the selection of item 773A, the user attaches a needle to an end of patient line 305_p and inserts the needle into a test vial, for the collection of an eluate sample therefrom, and, according to FIG. 7A, computer 17 presents a screen 774, which instructs the user to insert the test vial into a vial shield, which may be held in recess 101 of shell 13 (FIG. 1C).

FIG. 7A further illustrates a subsequent screen 775, by which computer 17 receives input, from the user, for system 10 to start the breakthrough elution, followed by a screen 776, which provides both an indication that the elution is in progress and an option for the user to abort the elution. As previously described, the system may provide a signal to indicate that elution is in progress, for example, light projector 100 (FIG. 1C) may project a flashing light signal during that portion of the elution process when eluate is diverted from generator 21 through waste line 305_w and into waste bottle 23, and then a steady light signal during that portion of the elution process when the eluate is diverted from generator 21 through patient line 305_p and into the test vial, for example, once activity detector 25 detects a dose rate of approximately 1.0 mCi/sec in the eluate discharged from generator 21. Another type of light signal, for example, the more rapidly flashing light, as previously described, may be projected when a peak bolus of radioactivity is detected in the eluate.

Upon completion of the elution process for breakthrough testing, computer 17 presents a screen 777, shown in FIG. 7B, which, like screen 677, provides an indication of a time lapse since the completion of the elution, but now in terms of a time since completion of the breakthrough elution process. When the user transfers the vial containing the sample of eluate into a dose calibrator, to measure the activity of the sample, the user may make a note of the time lapse indicated on screen 777. With further reference to FIG. 7B, once the user has received the activity measure from the dose calibrator, the user proceeds to a screen 778, which includes data entry fields for the activity measure and the time between that at which the dose calibrator measured the activity of the sample and that at which the elution was completed. The user may enter the data via the touch-screen interface of monitor 172, or via any of the other aforementioned devices for user data entry. According to some alternate embodiments, computer 17 may receive the data, electronically, from the dose calibrator, either via wireless communication or a cable connection.

After the data is entered by the user, computer 17 presents screen 779, from which the user moves back to main menu 470 to perform a system calibration, for example, as will be described in conjunction with FIGS. 8A-B, although the breakthrough testing is not completed. With reference back to FIG. 7A, an item 773B is shown in main menu 470; item 773B may only be effectively selected following the completion of steps for item 773A, so as to perform a second stage of breakthrough testing. In the second stage, the

breakthrough of the sample of eluate collected in the test vial for the breakthrough testing is measured, at a time of approximately 60 minutes from the completion of the elution that produced the sample. With reference to FIG. 7C, after the user has selected item 773B from main menu 470, in order to direct computer 17 to provide breakthrough test results, a screen 781 is displayed. Screen 781 includes, for reference, the values previously entered by the user in screen 778, along with another pair of data entry fields into which the user is instructed to enter the breakthrough reading of the sample at 60 minutes and the background radiation reading, respectively. After the user enters this remaining information, as described above, computer 17 may calculate and then display, on a screen 782, the breakthrough test results. According to the illustrated embodiment, computer 17 also displays on screen 782 pre-programmed allowable limits for the results, so that the user may verify that the breakthrough test results are in compliance with acceptable limits, before moving on to a patient infusion. According to some embodiments, system 10 will not allow an infusion if the results exceed the acceptable limits, and may present a screen explaining that the results are outside the acceptable limits; the screen may further direct the user to contact the generator supplier, for example, to order a replacement generator.

With reference to FIG. 8A, during the aforementioned 60 minute time period, while waiting to complete the breakthrough testing, the user may perform calibration by selecting item 873 from main menu 470. Upon selection of item 873, computer 17 presents a screen 874, which instructs the user to insert a new test vial into an elution vial shield. In addition to placing the vial in the shield, the user, preferably, replaces patient line 305_p with a new patient line, and then attaches a needle to the end of the new patient line for insertion into the test vial, in order to collect an eluate sample therefrom. After performing these steps, the user may move to screen 875, wherein a plurality of data entry fields are presented; all or some of the fields may be filled in with pre-programmed default parameters, which the user has an option to change, if necessary. Once the user confirms entry of desired parameters for the calibration, the user may enter a command, via interaction with a subsequent screen 876, to start the calibration elution.

With reference to FIG. 8B, after computer 17 starts the elution process, a screen 87 informs the user that the calibration elution is in progress and provides an option to abort the elution. As previously described, the system may provide an indication that elution is in progress, for example, light projector 100 (FIG. 1C) may project a flashing light signal during that portion of the elution process when eluate is diverted from generator 21 through waste line 305_w and into waste bottle 23, and then a steady light signal during that portion of the elution process when activity detector 25 has detected that a prescribed dose rate threshold is reached, for example, 1.0 mCi/sec, and the eluate is being diverted from generator 21, through the new patient line, and into the test vial. Another type of light signal, for example, the more rapidly flashing light, as previously described, may be projected when a peak bolus of radioactivity is detected in the eluate. Upon completion of the elution process for calibration, computer 17 presents a screen 878, which provides an indication of a time lapse since the completion of the elution, in terms of a time since completion of the calibration elution process. When the user transfers the vial containing the sample of eluate into the dose calibrator, to measure the activity of the sample, the user may make a note of the time lapse indicated on screen 878. With further reference to FIG. 8B, once the user has received the activity

measure from the dose calibrator, the user proceeds to a screen 879, which includes data entry fields for the activity measure and the time, with respect to the completion of elution, at which the dose calibrator measured the activity of the sample. Once the data is input by the user, as described above, the computer calculates a calibration coefficient, or ratio, and presents the ratio on a screen 880. According to FIG. 8B, screen 880 further provides an indication of a desirable range for the calibration ratio and presents an option for the user to reject the calculated ratio, in which case, the user may instruct computer 17 to recalculate the ratio.

As previously mentioned, some alternate embodiments of the present invention include an on board dose calibrator so that the entire sequence of sample collection and calculation steps, which are described above, in conjunction with FIGS. 6-8B, for the quality control procedures, may be automated. This automated alternative preferably includes screen shots, similar to some of those described above, which provide a user of the system with information at various stages over the course of the automated procedure and that provide the user with opportunities to modify, override and/or abort one or more steps in the procedure. Regardless of the embodiment (i.e. whether system 10 employs an on board dose calibrator or not), computer 17 may further collect all quality control test parameters and results into a stored record and/or compile a report including all or some of the parameters and results for local print out and/or electronic transfer to a remote location.

With reference to FIG. 9A, upon completion of the above-described quality control tests, the user may select an item 971, from main menu 470, in order to direct system 10 to begin a procedure for the generation and automatic infusion of a radiopharmaceutical into a patient. As previously described, system 10 infuses the patient with the radiopharmaceutical so that nuclear diagnostic imaging equipment, for example, a PET scanner, can create images of an organ of the patient, which absorbs the radiopharmaceutical, via detection of radioactive radiation therefrom. According to FIG. 9A, upon selection of item 971, computer 17 presents a screen 972 which includes a data entry field for a patient identification number. This identification number that is entered by the user is retained by computer 17, in conjunction with the pertinent system parameters associated with the patient's infusion. After the user enters the patient identification number, computer 17 directs, per a screen 973, the user to attach a new patient line and to purge the patient line of air. A subsequent screen 974 presented by computer 17 includes data entry fields by which the user may establish parameters for the automatic infusion; all or some of the fields may be filled in with pre-programmed default parameters, which the user has an option to change, if necessary.

With reference to FIG. 9B, if pump 33 does not contain enough eluant/saline for the patient infusion, computer 17 will present a warning, via a screen 901, which includes an option for the user to direct the refilling of pump 33, via a subsequent screen 902. Once pump 33 has been filled, computer 17 presents an indication to the user, via a screen 903. According to some embodiments, if the user does not re-fill pump 33, yet attempts to proceed with an infusion, system 10 will preclude the infusion and present another screen, that communicates to the user that no infusion is possible, if the pump is not refilled, and asking the user to refill the pump, as in screen 901. When pump 33 contains a sufficient volume of eluant for the patient infusion, computer 17 presents a screen 975, which is shown in FIG. 9C, and allows the user to enter a command for system 10 to start the

patient infusion. During the infusion, computer 17 provides the user with an indication that the infusion is in process and with an option for the user to abort the infusion, via a screen 976. As previously described, the system may provide an indication that an elution is in progress, for example, light projector 100 (FIG. 1C) may project a flashing light signal during that portion of the elution process when eluate is diverted from generator 21 through waste line 305_w and into waste bottle 23, and then a steady light signal during that portion of the elution process when activity detector 25 has detected that a prescribed dose rate threshold is reached, for example, 1.0 mCi/sec, and the eluate is being diverted from generator 21, through the new patient line for infusion into the patient. Another type of light signal, for example, the more rapidly flashing light, previously described, may be projected when a peak bolus of radioactivity is detected in the eluate. At the completion of the infusion, a screen 977 is displayed by computer 17 to inform the user of the completion of the infusion and a time since the completion. Computer 17 also displays a summary of the infusion, per screen 978.

With further reference to FIG. 9C, screen 976 shows an exemplary activity profile (activity—mCi/sec, on y-axis, versus time—sec, on x-axis) for the infusion/injected dose (designated between the two vertical lines). Those skilled in the art will appreciate that the shape of this profile depends upon the infusion flow rate, for a given volume of the dose, which flow rate is controlled, for example, by the speed at which pump 33 drives flow through the patient line, and upon the amount of Strontium-82 remaining in the generator. In the absence of flow rate control, activity profiles may change over the life of the generator. Furthermore, the peak bolus of radioactivity, particularly for injected doses from a relatively new generator, may exceed a saturation level of the imaging equipment, i.e. PET scanner. According to some preferred methods of the present invention, in order to maintain relatively consistent, and desirable/effective, activity profiles for patient injections, over the life of the generator, the operating speed of pump 33 may be varied (both over the course of a single injection and from injection to injection), according to feedback from activity detector 25. Such a method may be implemented via incorporation of another quality control test in which pump 33 is operated to drive flow through the generator at a constant rate, in order to collect, into computer, a plurality of activity measurements from activity detector 25; the plurality of measurements comprise a characteristic, or baseline activity profile from which the computer 17 may calculate an appropriate flow rate profile to control a speed of pump 33, in order to achieve the desirable/effective activity profile. In general, at the start of generator life, when Strontium-82 is plentiful, the pump is controlled to drive infusion flow at relatively lower rates, and, then, toward the end of generator life, when much of the Strontium-82 has been depleted, the pump is controlled to drive infusion flow at relatively higher rates. As was described above, in conjunction with FIG. 1D, if a desired infusion/injection flow rate is relatively high, that is, high enough to create too much back pressure, via flow through the column of generator 21, by-pass line 303 may be employed by adjusting divergence valve 35BG to divert a flow of eluant therethrough after a sufficient volume has been pumped through generator at a lower flow rate. According to this method, once a dose of eluate, from generator 21, has flowed into patient line 305_p, divergence valve 35BG is set to divert the flow of eluant through by-pass line 303, and then pump speed is increased to pump eluant at a higher flow

rate in order to push the dose out from patient line 305_p, for injection at the higher flow rate.

Consistency of activity profiles among injected doses can greatly facilitate the use of PET scanning for the quantification of flow, for example, in coronary perfusion studies. Alternative infusion circuit configurations, operable according to alternative methods, to achieve consistency of activity profiles among injected doses, as well as a more uniform level of radioactivity across each individual dose, will be described below, in conjunction with FIGS. 12A-C.

Printer 117 (FIG. 1B) may be activated to print out a hard copy of the infusion summary, on which the patient identification number and pertinent infusion and system parameters are also printed, for reference. Alternatively, or in addition, according to some embodiments, the summary may be downloaded onto a computer readable storage device to be electronically transferred to one or more remote computers and/or the summary may be automatically transferred to the one or more remote computers, via wireless communication or a cable connection, for example, over an intranet network and/or the internet. In order to protect private patient information, the files may be encrypted for transmission over the internet. The one or more remote computers may be included, for example, in a hospital information system, and/or a billing system, and/or in a medical imaging system. Infusion parameters, for example, corresponding to the activity profile, may also be collected and electronically transferred for analysis in conjunction with captured images, for example, in order to quantify coronary flow, via a software package that is loaded into a system that includes the PET scanner.

With reference back to FIG. 9A the user may select an item 995, from main menu 470, in order have system 10 perform data operations, such as, archiving a data base of patient infusion information and quality control test results; transmitting patient infusion summary records to USB mass storage devices, and various types of data filtering, for example, according to date ranges and/or patient identification numbers, for example, to search for a particular set of data and/or to compile a summary report of related sets of data. Additionally, certain information, which is collected by computer 17 over the course of system operation, and which defines system operation, may be transmitted to a local or remote computerized inventory system and/or to computers of technical support personnel, maintenance/service providers and/or suppliers of infusion circuit elements/components, thereby facilitating more efficient system operation and maintenance.

Turning now to FIG. 10, an item 981 for computer-facilitated purging of the tubing lines of system 10 is shown included in main menu 470. When a user selects item 981, computer 17 guides the user to select either an air purge or a saline purge. The direction provided by computer 17 is not explicitly laid out herein, for a saline purge, as procedures for saline purging should be readily apparent to those skilled in the art, with reference to the schematic of infusion circuit 300 shown in FIG. 1D. A saline purge of circuit 300 is desired to assure that all the air is removed from circuit 300 when a new generator and/or a new complete or partial tubing set is installed. An air purge of the tubing lines of circuit 300 may be performed after removing reservoir 15, by-passing generator 21, by connecting tubing line 304 to tubing line 305, and coupling patient line 305_p to a vial, for example, as is directed by the computer interface, in screens 983 and 984 shown in FIG. 10. The air purge is desirable for blowing out the tubing lines, thereby removing all remaining eluant and eluate, prior to installing a new generator and/or

prior to transporting system 10 from one site to another. If generator 21 is not depleted and will be used in system 10 at the new site, it is important to by-pass the generator prior to purging the tubing lines of circuit 300 with air, so that air is not blown across the generator, since air through generator 21 may compromise both the function and the aseptic nature of generator 21.

According to preferred embodiments, once the user has followed the instructions presented in screens 983 and 984 and selects to start the air purge, for example, via screen 985, computer 17 directs the controller of system 10 to carry out a complete air purge, in which pump 33 and divergence valves 35BG and 35WP are automatically controlled. The automated air purge preferably includes the following steps, which may be best understood with reference to tubing circuit 300 in FIG. 1D: pumping any remaining volume of eluant left in pump 33, through lines 302, 304, 305 and 305_w, to waste bottle 23; refilling pump 33 with air and pumping the air through lines 302, 304, 305 and 305_w, into waste bottle 23 (lines 304 and 305 have been previously connected directly to one another, in order to by-pass generator 21; if generator 21 is depleted and will be replaced with a new generator, pumping air through generator 21 may be acceptable); refilling pump 33 with air and then pumping a portion of the air through lines 302, 304, 305 and 305_p, into the vial, and then a remaining portion of the air through lines 302, 304, 303 and 305_p, into the vial. With reference to FIG. 1D and the previous description of divergence valves 35BG, 35WP, it should be understood how divergence valves 35BG, 35WP are automatically controlled to carry out the above steps.

The purge operations, which are facilitated by selecting item 981 from main menu 470, may also be accessed via the selection of an item 991 for generator setup. When the user selects item 991, computer 17 may present an option for guidance in removing an old, depleted, generator and a set of tubing lines, prior to installing the new generator, or an option to just be guided in the installation of the new generator. According to some embodiments, computer 17 is pre-programmed to calculate an amount of activity left in a depleted generator, for example, by tracking activity of eluate over a life of the generator. At an end of the life of the generator, computer 17 may further compile this information, along with other pertinent generator information, into a report that may accompany a declaration of dangerous goods for shipping the depleted generator out for disposal or, in some cases, back to the manufacturer for investigation. An example of such a report is shown in FIG. 11. According to those embodiments of system 10 that include an encoded information reader, computer 17 may confirm that the new generator is proper by processing information that is read from an encoded label/tag attached thereto.

FIGS. 12A-B are schematics of alternative infusion circuits 1300A, 1300B that may be employed by system 10, in place of circuit 300 (FIG. 1D), according to some additional embodiments of the present invention. Circuits 1300A, 1300B are configured to allow for alternative methods of operation, to that previously described for circuit 300, when a relatively even, or uniform level of activity over each injected dose, along with the relatively consistent level of activity from injection to injection is desired, for example, in order to facilitate a quantification of coronary artery blood flow via PET scanning. FIG. 12C is a schematic illustrating activity profiles 1200A, 1200B for two injected doses, wherein profile 1200B has a more uniform level of activity than profile 1200A; profile 1200B may be achieved via the operation of circuits 1300A, 1300B as described below.

Similar to circuit 300 (FIG. 1D), dashed lines are shown in each of FIGS. 12A-B to indicate a general boundary of a shielding assembly for portions of each circuit 1300A, 1300B. The shielding assembly for each of circuits 1300A, 1300B may be very similar, in most respects, to shielding assembly 200, which is described above for system 10, and the elements of each of circuits 1300A, 1300B may be arranged with respect to their respective shielding and with respect to shell 13 of system 10 in a similar manner to that described above for circuit 300.

FIG. 12A illustrates circuit 1300A including, like the previously described circuit 300, eluant reservoir 15, pump 33, radioisotope generator 21, through which the filtered eluant is pumped to create the radioactive eluate, activity detector 25, and waste bottle 23. FIG. 12A further illustrates two filters 37 and two pressure transducers 1334 included in circuit 1300A. Circuit 1300A further includes by-pass tubing line 303, which is located downstream of divergence valve 35BG, like in circuit 300, and which accommodates the previously described eluant/saline flush. However, in contrast to circuit 300, circuit 1300A further includes a linear/proportional valve 1335 integrated into by-pass/flush line 303 so that circuit 1300A may be operated, for example, according to pre-programmed parameters of computer 17, in conjunction with feedback of information from activity detector 25, for a controlled by-pass of generator 21 in order to mix eluant with eluate and, thereby, achieve a relatively uniform level of activity over each patient injection, for example, according to profile 1200B of FIG. 12C. It should be noted that, in addition to the controlled mixing, a flow rate of each injection may be varied, if necessary, in order to maintain a consistent activity level.

FIG. 12B illustrates circuit 1300B including, like the previously described circuit 300, eluant reservoir 15, pump 33, radioisotope generator 21, activity detector 25, and waste bottle 23, as well as the two filters 37 and two pressure transducers 1334, as in circuit 1300A. In contrast to circuits 300 and 1300A, circuit 1300B further includes an eluate reservoir 1350, which is shown located downstream of generator 21, in between first and second segments 305A, 305B of the eluate tubing line. It should be noted that a pump is combined with reservoir 1350, for example, similar to syringe pump 33, such that, when a divergence valve 1335IO is set to allow fluid communication between reservoir 1350 and tubing line segment 305A, the associated pump may be operated to draw in a volume of eluate, and, then, when divergence valve 1335IO is set to allow fluid communication between reservoir 1350 and tubing line segment 305B, the pump may be operated to push the volume of eluate out through tubing line segment 305B for a patient injection, when divergence valve 35WP is set to direct flow into patient line 305p. With reference back to FIGS. 3A-B, sidewall 205 of shielding assembly 200 may be enlarged to further enclose eluate reservoir 1350. For example, another shielded well, to house the eluate reservoir, may extend alongside well 255, in which activity detector 25 is described as being mounted. Furthermore, sidewall 205 may include another valve actuator receptacle for divergence valve 1335IO, similar to receptacle 253, shown in FIG. 3A for divergence valve 35WP.

Collection of discrete volumes of eluate, in reservoir 1350, may help to achieve a more uniform activity level over each injection, for example, like that of profile 1200B in FIG. 12C, and, according to preferred methods, feedback from activity detector 25 may be used to control the pump associated with reservoir 1350, in order to vary injection flow rate and, thereby, maintain a relatively consistent

activity level across multiple injections, and, when necessary, to vary injection flow rate over an individual injection to maintain the uniform activity level. Feedback from the pressure transducer 1334, that is downstream from detector 25, and/or from a flow meter (not shown) of circuit 1300B may also be used to control the varying of injection flow rate.

With further reference to FIGS. 12A-B, it should be noted that alternative circuits may be configured to employ a combination of the methods described for circuits 1300A and 1300B. Furthermore, some infusion circuits of the present invention may employ multiple generators 21, as mentioned above, in conjunction with FIG. 2A, to help maintain the relatively uniform level of activity over each injection and the relatively consistent level of activity from injection to injection.

In the foregoing detailed description, the invention has been described with reference to specific embodiments. However, it may be appreciated that various modifications and changes can be made without departing from the scope of the invention as set forth in the appended claims.

The invention claimed is:

1. A method of using an infusion system on-board a cart to deliver a rubidium radioactive eluate comprising:
 - installing a saline reservoir on the infusion system, wherein the infusion system comprises a platform and an exterior shell extending upwardly above the platform, and wherein the platform and the exterior shell collectively define an interior space of a cabinet structure;
 - placing the saline reservoir in fluid communication through a saline tubing line with an inlet tubing port of a strontium-rubidium radioisotope generator located in a first shielding compartment in the interior space of the cabinet structure, wherein the strontium-rubidium radioisotope generator further comprises an outlet tubing port configured to discharge the rubidium radioactive eluate, and wherein the first shielding compartment has a first opening facing vertically upwardly;
 - inserting a waste bottle into a second shielding compartment on-board the cart, wherein the second shielding compartment on-board the cart has a second opening facing vertically upwardly and being at a higher elevation than the first opening;
 - placing the waste bottle in fluid communication with the outlet tubing port of the strontium-rubidium radioisotope generator through an eluate tubing line, wherein a computer on-board the cart is configured to control the fluid communication between the waste bottle and the outlet tubing port, and wherein the computer has a touch screen display mounted on a vertical post with a top end extending above the cabinet structure;
 - inserting an eluate reservoir in a shielded well on-board the cart;
 - placing the eluate reservoir in fluid communication with the eluate tubing line, wherein the computer is further configured to control the fluid communication between the eluate reservoir and the eluate tubing line;
 - pumping a sample of the rubidium radioactive eluate into the eluate reservoir in the shielded well on-board the cart;
 - measuring a radioactivity of the sample of the rubidium radioactive eluate flowing through the eluate tubing line with a radioactivity detector on-board the cart while the sample of the rubidium radioactive eluate is flowing through the eluate tubing line;

measuring a calibration radioactivity of the sample pumped into the eluate reservoir in the shielded well on-board the cart while the eluate reservoir remains in the shielded well on-board the cart;

comparing the radioactivity of the sample of the rubidium radioactive eluate flowing through the eluate tubing line measured by the radioactivity detector on-board the cart while the sample of the rubidium radioactive eluate is flowing through the eluate tubing line with the calibration radioactivity of the sample pumped into the eluate reservoir in the shielded well on-board the cart; and

determining a strontium breakthrough test result on the sample pumped into the eluate reservoir in the shielded well on-board the cart while the eluate reservoir remains in the shielded well on-board the cart, wherein the computer of the infusion system is further configured to not allow a patient infusion if the strontium breakthrough test result is greater than or equal to an allowed limit.

2. The method of claim 1, further comprising: placing the eluate tubing line in fluid communication with a patient, wherein the computer is further configured to control the fluid communication between the eluate tubing line and the patient;

pumping a dose of the rubidium radioactive eluate to the patient; and

flushing the rubidium radioactive eluate remaining in at least a portion of the eluate tubing line into the patient by pumping saline from the saline reservoir to the eluate tubing line through a by-pass line that by-passes the strontium-rubidium radioisotope generator, wherein the computer is further configured to control fluid communication via the by-pass line.

3. The method of claim 2, further comprising: logging into the computer by entering a user login credential on the touch screen display, transferring a patient infusion record via a USB port, and printing a document concerning the patient infusion or a quality control test result via a printer.

4. The method of claim 2, further comprising: initiating a purging process through the touch screen display to purge a patient tubing line of air, wherein the patient tubing line is in fluid communication with the eluate tubing line.

5. The method of claim 2, wherein the computer of the infusion system is further configured to present on the touch screen display a screen reminding a user to insert the eluate reservoir in the shielded well on-board the cart.

6. The method of claim 2, wherein the computer of the infusion system is further configured to present on the touch screen display a screen for starting the patient infusion by touching a button on the touch screen display.

7. The method of claim 2, wherein the computer of the infusion system is further configured to present on the touch screen display a screen indicating that the patient infusion is in process, wherein the screen indicating that the patient infusion is in process displays a stop button to abort the patient infusion.

8. The method of claim 2, wherein the computer of the infusion system is further configured to:

“ present on the touch screen display a screen for starting the patient infusion by touching a button on the touch screen display;

present on the touch screen display a screen reminding a user to insert the eluate reservoir in the shielded well on-board the cart;

present on the touch screen display a screen indicating that the patient infusion is in process, wherein the screen indicating that the patient infusion is in process displays a stop button to abort the patient infusion; and

present on the touch screen display the strontium breakthrough test result.

9. The method of claim 8, further comprising: logging into the computer by entering a user login credential on the touch screen display,

entering a patient ID on the touch screen display, entering a patient dose on the touch screen display, and entering a flow rate on the touch screen display.

10. The method of claim 9, wherein the computer of the infusion system is further configured to:

track a volume of saline remaining in the saline reservoir, provide an alert via the touch screen display when the volume of saline remaining in the saline reservoir is below a predetermined volume threshold, and

present on the touch screen display a screen reminding the user to empty the waste bottle.

11. The method of claim 10, further comprising: initiating a generator column wash through the touch screen display, wherein a predetermined amount of saline is pumped through the strontium-rubidium radioisotope generator and directed to the waste bottle during the generator column wash, and

initiating a purging process through the touch screen display to purge a patient tubing line of air, wherein the patient tubing line is in fluid communication with the eluate tubing line.

12. The method of claim 11, wherein the saline tubing line and the eluate tubing line are routed through two tubing passageways formed in a perimeter surface of the first opening, wherein each of the two tubing passageways has a depth configured to prevent pinching or crushing of a corresponding tubing line routed therethrough when a first door is closed over the first opening.

13. The method of claim 12, wherein the infusion system further comprises:

a handle configured for the user to grasp in order to move the infusion system, and

four wheels mounted to an underside of the platform of the cabinet structure.

14. The method of claim 13, wherein the computer of the infusion system is further configured to:

project a first light signal from a light projector mounted on the top end of the vertical post extending above the cabinet structure to indicate that an elution is taking place, and

project a second light signal from the light projector to indicate that a peak bolus of radioactivity is detected.

15. The method of claim 14, wherein the cabinet structure has a lowermost portion and the platform has a lower surface,

the first opening is at a first elevation,

the second opening is at a second elevation,

the first elevation is between approximately 1 foot and approximately 2 feet, with respect to the lowermost portion of the cabinet structure, and

the second elevation is between approximately 2 feet and approximately 3 feet, with respect to the lower surface of the platform.

16. The method of claim 13, wherein the infusion system further comprises a dose calibrator in the shielded well on-board the cart and in communication with the computer to determine the strontium breakthrough test result.

27

17. The method of claim 16, wherein the cabinet structure has a lowermost portion and the platform has a lower surface, the first opening is at a first elevation, the second opening is at a second elevation, the first elevation is between approximately 1 foot and approximately 2 feet, with respect to the lowermost portion of the cabinet structure, and the second elevation is between approximately 2 feet and approximately 3 feet, with respect to the lower surface of the platform.
18. The method of claim 1, wherein the computer of the infusion system is further configured to present on the touch screen display the strontium breakthrough test result.
19. The method of claim 1, wherein the cabinet structure has a lowermost portion and the platform has a lower surface, the first opening is at a first elevation, the second opening is at a second elevation, the first elevation is between approximately 1 foot and approximately 2 feet, with respect to the lowermost portion of the cabinet structure, and the second elevation is between approximately 2 feet and approximately 3 feet, with respect to the lower surface of the platform.
20. The method of claim 1, wherein the saline tubing line and the eluate tubing line are routed through two tubing passageways formed in a perimeter surface of the first opening, wherein each of the two tubing passageways has a depth configured to prevent pinching or crushing of a corresponding tubing line routed therethrough when a first door is closed over the first opening.
21. The method of claim 1, wherein the infusion system further comprises a dose calibrator in the shielded well on-board the cart, wherein the dose calibrator is in communication with the computer to determine the strontium breakthrough test result.
22. The method of claim 1, wherein the computer of the infusion system is further configured to:
track a volume of saline remaining in the saline reservoir,
and
provide an alert via the touch screen display when the volume of saline remaining in the saline reservoir is below a predetermined volume threshold.

28

23. The method of claim 1, wherein the computer of the infusion system is further configured to:
track a volume of the rubidium radioactive eluate discharged from the strontium-rubidium radioisotope generator to the waste bottle, and
present on the touch screen display a screen reminding a user to empty the waste bottle.
24. The method of claim 1, wherein the computer of the infusion system is further configured to:
project a first light signal from a light projector mounted on the top end of the vertical post extending above the cabinet structure to indicate that an elution is taking place, and
project a second light signal from the light projector to indicate that a peak bolus of radioactivity is detected.
25. The method of claim 1, wherein the computer of the infusion system is further configured to pump saline through the strontium-rubidium radioisotope generator at a rate less than approximately 70 ml/min.
26. The method of claim 1, further comprising:
initiating a generator column wash through the touch screen display, wherein a predetermined amount of saline is pumped through the strontium-rubidium radioisotope generator and directed to the waste bottle during the generator column wash.
27. The method of claim 1, wherein the computer of the infusion system is further configured to track time passed from completion of pumping the sample of the rubidium radioactive eluate into the eluate reservoir to determining the strontium breakthrough test result.
28. The method of claim 1, further comprising:
entering a patient ID on the touch screen display,
entering a patient dose on the touch screen display, and
entering a flow rate on the touch screen display.
29. The method of claim 1, wherein the saline reservoir is located outside of the interior space of the cabinet structure.
30. The method of claim 1, wherein the infusion system further comprises:
a handle configured for a user to grasp in order to move the infusion system, and
four wheels mounted to an underside of the platform of the cabinet structure.

* * * * *





EXHIBIT 6

A 7667315



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 08, 2018

**THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON
APRIL 19, 2017.**

**By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office**




R GLOVER
Certifying Officer

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4375013

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
STEPHEN E. HIDEM	04/28/2010
AARON M. FONTAINE	04/28/2010
JANET L. GELBACH	04/20/2010
PATRICK M. MCDONALD	04/16/2010
KATHRYN M. HUNTER	04/12/2010
ROLF E. SWENSON	04/13/2010
JULIUS P. ZODDA	04/13/2010
RECEIVING PARTY DATA	
Name:	BRACCO DIAGNOSTICS INC.
Street Address:	107 COLLEGE ROAD EAST
City:	PRINCETON
State/Country:	NEW JERSEY
Postal Code:	08540
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15490484
CORRESPONDENCE DATA	
Fax Number:	(612)492-7077
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	612-492-7000
Email:	IP@fredlaw.com
Correspondent Name:	PAUL J. LAVANWAY, JR.
Address Line 1:	200 SOUTH SIXTH STREET
Address Line 2:	SUITE 4000
Address Line 4:	MINNEAPOLIS, MINNESOTA 55402
ATTORNEY DOCKET NUMBER:	56782.4.2
NAME OF SUBMITTER:	PAUL J. LAVANWAY, JR.
SIGNATURE:	/Paul J. LaVarway, Jr./
DATE SIGNED:	04/19/2017

504328327

PATENT
REEL: 042063 FRAME: 0635

Total Attachments: 7

source=56782.4.2_Executed Assignment#page1.tif
source=56782.4.2_Executed Assignment#page2.tif
source=56782.4.2_Executed Assignment#page3.tif
source=56782.4.2_Executed Assignment#page4.tif
source=56782.4.2_Executed Assignment#page5.tif
source=56782.4.2_Executed Assignment#page6.tif
source=56782.4.2_Executed Assignment#page7.tif

PATENT
REEL: 042063 FRAME: 0636

ASSIGNMENT

We, Stephen E. Hidem, residing at 4710 Juneau Lane North, Plymouth, Minnesota 55446, Aaron M. Fontaine, residing at 5663 West Bavarian Pass, Fridley, Minnesota 55432, Janet L. Gelbach, residing at 4204 Shetland Court, New Albany, Indiana 47150, Patrick M. McDonald, residing at 15395 Nicholas Street, Omaha, Nebraska 68154, Kathryn M. Hunter, residing at 1312 Judy Reagan Lane, Knoxville, Tennessee 37931, Rolf E. Swenson, residing at 35 Fieldston Road, Princeton, New Jersey 08540 and Julius P. Zodda, residing at 3 Tigers Court, Mercerville, New Jersey 08619 ("Assignor"), have made invention(s) for which United States and foreign patents and patent applications have been filed and are identified on the attached Schedule 1;

Whereas, Bracco Diagnostics Inc., a Delaware corporation having a place of business at 107 College Road East, Princeton, NJ 08540 ("Assignee"), desires to acquire the entire right, title and interest in and to the United States and foreign patents and patent applications identified on the attached Schedule 1 and in and to the inventions described and claimed therein (the "Patents"); and

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby assigns to Assignee, and its successors and assigns the following:

- (1) The entire right, title and interest to the Patents including the inventions described or claimed therein, and to each U.S. and foreign patent application and patent from which the Patents claim priority to, in whole or in part, and to which the Patents claim priority; and
- (2) The entire right, title and interest to any United States or foreign patents that may issue with respect to the inventions described or claimed in the Patents;
- (3) The entire right, title and interest to any renewals, reissues, extensions, substitutions, continuations, continuations-in-part, or divisions of the Patents, and all foreign applications based thereon;
- (4) The right to apply for patents in foreign countries in its own name and to claim any priority rights to which such foreign applications are entitled under international conventions, treaties or otherwise; and
- (5) The right to enforce patent rights to such Patents as fully and entirely as the same would have been held and enjoyed by the Assignors if this assignment had not been made; together with all claims by Assignors for damages by reason of past infringement or for provisional rights and including the right to sue for, and collect the same for its own use and benefit, and for the use and benefit of its successors, assigns, and other legal representatives.


Assignor further agrees for himself and for his successors and assigns to execute and deliver without further consideration any further applications, assignments or other documents and to perform such other lawful acts as Assignee its successors and assigns may deem necessary to fully secure, maintain and enforce its rights, title or interest as outlined herein.

Assignor hereby authorizes and requests the Commissioner of Patents to issue to Assignee any patents that may be granted in accordance with this Assignment.


We hereby authorize attorneys associated with Customer No. 22859, of 200 South Sixth Street, Suite 4000, Minneapolis, Minnesota, 55402-1425, to insert the Application Nos. and Filing Dates of said application when known.

This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement. The signatures from each counterpart may be combined with a copy of the Agreement to constitute the entire Agreement.

Date: 4/28/2010


Stephen E. Hidem


Subscribed to and sworn to before
me this 28 day of APRIL, 2010.


Notary Public

Notary Seal



Date: 4/28/2010


Aaron M. Fontaine

Subscribed to and sworn to before
me this 28 day of APRIL, 2010.


Notary Public

Notary Seal



Date: 4-20-2010

Janet L. Gelbach
Janet L. Gelbach

Witnessed by: Esther B. Paris on 4-20-10
(Signature) (Date)

Esther B. Paris
(Name)

4204 Sretland Ct. New Albany, IN 47150
(Address)

Date: _____

Patrick M. McDonald

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: _____

Kathryn M. Hunter

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: _____
Janet L. Gelbach

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: 16-APR-2010 _____
Patrick M. McDonald

Witnessed by: Renee McDonald on 4-16-10
(Signature) (Date)
Renee McDonald
(Name)
15395 NICHOLAS ST. OMAHA, NE 68154
(Address)

Date: _____
Kathryn M. Hunter

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: _____

Janet L. Gelbach

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: _____

Patrick M. McDonald

Witnessed by: _____ on _____
(Signature) (Date)

(Name)

(Address)

Date: April 12, 2010

Kathryn M. Hunter
Kathryn M. Hunter

Witnessed by: _____ on April 12, 2010
(Signature) (Date)

Jim CLARK
(Name)

1312 Gudy Reagan Lane Knoxville, TN 37931
(Address)

Date: 4/13/10

Rolf E. Swenson
Rolf E. Swenson

Witnessed by: Patricia Bussiere on 4/13/2010
(Signature) (Date)

Patricia Bussiere
(Name)

10 Garfield Court, Dayton, NJ 08810
(Address)

Date: Apr. 13, 2010

Julius P. Zodda
Julius P. Zodda

Witnessed by: Patricia Bussiere on April 13, 2010
(Signature) (Date)

Patricia Bussiere
(Name)

10 Garfield Court, Dayton NJ 08810
(Address)

SCHEDULE 1US Patent Applications

Patent App. No.	Date Filed	Title	Attorney Docket No.
12/137,356	6/11/2008	SHIELDING ASSEMBLIES FOR INFUSION SYSTEMS	56782.1.5
12/137,363	6/11/2008	INFUSION SYSTEM CONFIGURATIONS	56782.1.6
12/137,364	6/11/2008	INFUSION SYSTEMS INCLUDING COMPUTER-FACILITATED MAINTENANCE AND/OR OPERATION AND METHODS OF USE	56782.1.7
12/137,377	6/11/2008	CABINET STRUCTURE CONFIGURATIONS FOR INFUSION SYSTEMS	56782.1.8
12/808,467	6/16/2010	INFUSION SYSTEMS INCLUDING COMPUTER-FACILITATED MAINTENANCE AND/OR OPERATION AND METHODS OF USE	56782.1.7.2
15/389,200	12/22/2016	INTEGRATED STRONTIUM-RUBIDIUM RADIOISOTOPE INFUSION SYSTEMS	56782.4.1
15/490,484	4/18/2017	INTEGRATED STRONTIUM-RUBIDIUM RADIOISOTOPE INFUSION SYSTEMS	56782.4.2

US Patents

Patent No.	Date Issued	Title


Foreign and International Patent Applications

Country	Patent App. No.	Date Filed	Title	Attorney Docket No.
WO	PCT/US09/47031	6/11/2009	INFUSION SYSTEMS INCLUDING COMPUTER-FACILITATED MAINTENANCE AND/OR OPERATION AND METHODS OF USE	56782.1.7.1

Foreign Patents

Country	Patent No.	Date of Issue	Title

4661175_1.DOC



PTO-1683
(Rev. 7-96)

EXHIBIT 7

WESTLAW

JUBILANT DRAXIMAGE INC.

16751 RTE TRANS-CANADA
KIRKLAND, QUEBEC H9H 4J4

[Home](#) > [Company Investigator](#)

JUBILANT DRAXIMAGE INC.

Location Of Incorporation:	CA, Canada
Incorporation Date:	05/28/2008
Primary SIC Code:	2834
Website Address:	www.draximage.com
Officers/Directors/Contacts:	MICHAEL ROSSI, PRESIDENT & BOARD MEMBER MARCELO MORALES, PRESIDENT ARPITA CHATTERJEE, DIRECTOR SHAHIR GUINDI, DIRECTOR GURPARTAP SINGH SACHDEVA, DIRECTOR

QUICK ANALYSIS FLAGS

OFAC:	No
Global Sanctions:	No
Bankruptcy Debtor or Creditor:	No
MSB:	No
Other Listings Linked to Business	No
Phone:	



Source: Google Maps

[Disclaimers](#) | [Help](#)

Related Information:

[Investext Results](#)

EXHIBIT 8

We've updated our Privacy Statement. Before you continue, please read our new Privacy Statement and familiarize yourself with the terms.

WESTLAW

JUBILANT PHARMA LIMITED

80 RAFFLES PL 26-01 UOB PLZ
048624

[Home](#) > [Company Investigator](#)

JUBILANT PHARMA LIMITED


Location Of Incorporation:	SG, Singapore
NAICS Code:	325411
CIK(s):	0001526258
Officers/Directors/Contacts:	SHANKER IYER, DIRECTOR

QUICK ANALYSIS FLAGS

OFAC:	No
Global Sanctions:	No
Bankruptcy Debtor or Creditor:	No
MSB:	No
Other Listings Linked to Business	No
Phone:	



[Disclaimers](#) | [Help](#)



Map data ©2018 Google, Urban Redevelopment Authority Imagery ©2018, CNES / Airbus, [Report a map error](#)

Source: Google Maps

EXHIBIT 9



News | Careers | Contact Us

Search...



EN ▾

out Disease Products R&D Education Upcoming
Js Events

Innovation

Technological and scientific pioneering, progress and innovation.

News

JDI RECEIVES FDA APPROVAL FOR NEW PULMONARY INDICATIONS FOR DRAXIMAGE® DTPA ▶
DECEMBER 30, 2017

JDI TO ATTEND MIAMI THYROID ONCOLOGY SYMPOSIUM 2018 ▶
NOVEMBER 6, 2017

JUBILANT DRAXIMAGE RECEIVES FDA APPROVAL FOR 12-HOUR SHELF-LIFE FOR DRAXIMAGE® MAA ▶
OCTOBER 27, 2017

About Jubilant DraxImage

We develop, manufacture and commercialize radiopharmaceuticals used for the diagnosis and treatment of diseases. We serve customers and through them patients, globally with high quality and reliable products and services.



Jubilant DraxImage is a subsidiary of Jubilant Pharma.



EXHIBIT 10

JUBILANT DRAXIMAGE RECEIVES FDA APPROVAL FOR RUBY-FILL[®] RUBIDIUM 82 GENERATOR AND ELUTION SYSTEM

RUBY-FILL[®] is an approved cutting edge technology for PET myocardial perfusion imaging (MPI) under rest and pharmacological stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

MONTREAL, Quebec – October 3, 2016 - Jubilant DraxImage Inc., (“DraxImage”) a wholly Owned Subsidiary of Jubilant Pharma Ltd, announced today that the U.S. Food and Drug Administration has approved RUBY-FILL[®], an innovative technology for Positron Emission Tomography (PET) myocardial perfusion imaging (MPI). Comprised of a Rubidium-82 (Rb-82) Generator and precedent setting Elution System, RUBY-FILL[®] is used to produce a personalized patient dose of Rubidium Rb 82 chloride used to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease (CAD) which is an important component of diagnosing CAD.

“We are proud to bring to the US market a groundbreaking, state-of-the-art technology for myocardial perfusion imaging. RUBY-FILL[®] expands DraxImage’s nuclear medicine portfolio and is a part of our commitment to provide healthcare providers and their patients with innovative health care solutions for those with suspected or existing coronary artery disease,” **comments GP Singh, CEO of Jubilant Pharma Ltd.**

“Our knowledge of the role and value of PET nuclear cardiology, specifically Rb- 82 Chloride PET in known or suspected coronary artery disease, advanced significantly as we progressed through the comprehensive and rigorous FDA review process,” **said Norman LaFrance, MD, Chief Medical Officer and Senior VP, Medical & Regulatory Affairs, for Jubilant Pharma and Jubilant DraxImage.** “With its advanced weight based dose accuracy and multiple infusion options, among other product capabilities, RUBY-FILL[®] will enhance the way patients with known or suspected coronary artery disease are both diagnosed and managed.”

Commercial launch plans for RUBY-FILL[®] is expected to be in the October-December 2016 quarter.

RUBY-FILL[®] Rubidium 82 Generator and RUBY Rubidium Elution System

The RUBY-FILL[®] Generator contains an accelerator produced Strontium-82, which decays to Rubidium-82. When the generator is eluted with saline it produces a sterile, non-pyrogenic solution of Rb-82 Chloride.

Due to the short half-life (75 s) of Rb-82, the use of an elution system is required for delivery of the Rb-82 Chloride into a patient for the purposes of performing Myocardial Perfusion Imaging with PET. PET imaging with Rb-82 Chloride may be performed under rest and/or stress conditions.

The Rubidium Elution System has been exclusively designed to be used with the RUBY-FILL[®] generator and to deliver accurate doses of Rb-82 Chloride to patients.

For more information, please contact:

Medical & Regulatory Affairs - medicalaffairs@jdi.jubl.com

or visit <http://www.draximage.com/en/pipeline/cardiovascular-pet.html>

Important Safety Information

WARNING: UNINTENDED STRONTIUM 82 (Sr 82) AND STRONTIUM 85 (Sr 85) RADIATION EXPOSURE

Please see full prescribing information for complete boxed warning

- Unintended radiation exposure occurs when the levels of Sr 82 or Sr 85 in the rubidium Rb 82 chloride injection exceed specific limits.
- Perform generator eluate tests:
 - 1) Determine Rb 82, Sr 82, Sr 85 levels in the eluate:
 - Once daily, prior to any drug administration, and
 - With additional daily tests after detection of an Alert Limit.
 - 2) Stop use of the generator at its Expiration Limit.

About Jubilant DraxImage

Jubilant DraxImage Inc., a wholly Owned Subsidiary of Jubilant Pharma Ltd, which is held by Jubilant Life Sciences Ltd, develops, manufactures and commercializes radiopharmaceuticals used for the diagnosis and treatment of diseases. The company is dedicated to nuclear medicine and serves customers and through them patients, globally, with high quality and reliable products and services. The company is the market leader in North America for I-131 products (diagnosis and treatment of thyroid disorder and cancer, MAA (lung perfusion imaging), DTPA (renal and brain imaging) and MDP (bone imaging), and also markets other products such as Sestamibi, Xenon and Glucaptate. The company has a strong development pipeline of new products and commitment in bringing new products to market. For more info: www.draximage.com

About Jubilant Life Sciences

Jubilant Life Sciences Limited is an integrated global Pharmaceutical and Life Sciences Company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Ltd, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non Sterile products through 6 USFDA approved facilities in India, US and Canada. The Life Science Ingredients segment is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment provides proprietary in-house innovation and collaborative research and partnership for out-licensing through 3 world class research centres in India and US. Jubilant Life Sciences Ltd has a team of around 6,500 multicultural people across the globe and is committed to deliver value to its customers

spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.

EXHIBIT 11

DIAGNOSIS & INTERVENTION

About Us

- ▣ Bracco Diagnostics Inc.
 - Mission Statement
- ▣ History
- ▣ Pharmacovigilance
- ▣ Bracco Injengineering
- ▣ Industrial Footprint
- ▣ Reference Market
- ▣ Corporate Citizenship
 - Business Ethics
 - ▣ Data Protection
 - ▣ Health, Safety and Environment
 - ▣ Responsible Care
 - ▣ Anti-Corruption
 - ▣ Whistleblowing
 - ▣ U.S. Compliance
- ▣ Unique Device Identification (UDI)

Products and Solutions

CT & CT Colonography

- ▣ ISOVUE
- ▣ GASTROGRAFIN
- ▣ E-Z-CAT DRY
- ▣ READI-CAT 2
- ▣ READI-CAT 2 SMOOTHIE
- ▣ TAGITOL V
- ▣ VoLumen
- ▣ PROTOCO₂L TOUCH
- ▣ Related CT & CT Colonography

Associated products

EmpowerCTA⁺
 CT Exprès
 NEXO
 NEXO [DOSE]

Magnetic Resonance Imaging

- ▣ MultiHance
- ▣ ProHance
- ▣ Related Magnetic Resonance Imaging

Associated products

EmpowerMR

Injectors & Informatics

- ▣ CT Exprès
- ▣ EmpowerCTA⁺
- ▣ EmpowerMR
- ▣ NEXO
- ▣ NEXO [DOSE]
- ▣ Related Injectors & Informatics

Nuclear Medicine & Radiopharmaceuticals

- ▣ CardioGen-82
- ▣ Kinevac
- ▣ Choletec
- ▣ Related Nuclear Medicine & Radiopharmaceuticals

Cardiac Catheterization and Interventional Radiology

- ▣ ACIST CVi
- ▣ ISOVUE
- ▣ Related Cardiac Catheterization and Interventional Radiology

Fluoroscopy

- E-Z-DISK
- E-Z-HD
- E-Z-PASTE
- E-Z-PAQUE
- Liquid E-Z-PAQUE
- Liquid POLIBAR PLUS
- VARIBAR
- SINOGRAFIN
- CYSTOGRAFIN
- Related Fluoroscopy

Associated products
NEXO [DOSE]

Contrast Enhanced Ultrasound

- LUMASON
- related Contrast Enhanced Ultrasound

Myelography

- ISOVUE-M
- Related Myelography

Products and Solutions

R & D

R&D Centers and Partnerships

- Bracco Imaging R&D objectives

- R&D Pipeline
- Clinical Development

Reimbursement

Congresses

- Past Events
- Upcoming Events

Education

Educational Portfolio

- National MDCT Symposium
- Diagnostic Industry Support
- Professional Societies
- Upcoming Events

- Careers

Press Room

Contacts



Bracco Diagnostics Inc. Launches Web Site on CardioGen-82® (Rubidium Rb 82 Generator)

Princeton, NJ , 05/28/2005

"www.CardioGen.com" to Feature Updated Information on Cardiac PET

Bracco Diagnostics Inc. announced today the launch of a new Web site with content focused on the myocardial perfusion agent CardioGen-82. CardioGen-82 is used for

cardiac PET (Positron Emission Tomography), a diagnostic procedure that detects coronary artery disease.

The new site at www.CardioGen.com features comprehensive product information, related information on PET technology, and other resources for medical professionals. Content will be regularly updated to help users stay in tune with the latest trends and technologies relative to cardiac PET.

About CardioGen-82

CardioGen-82 is the only FDA approved generator-based PET perfusion agent reimbursed for the evaluation of coronary artery disease.

As in the use of any radioactive material, care should be taken to minimize radiation exposure to the patient consistent with proper patient management and to ensure minimum radiation exposure to occupational workers. Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides. Please see full prescribing information available with this release.

About Bracco

The Bracco Group is a world leading provider of global diagnostic imaging solutions, with net sales of about \$1.25 billion. Bracco has operations in 115 countries and about 3,300 employees, around 600 of whom work in R&D. Bracco invests approximately 15% of its annual turnover in R&D and has a portfolio of 1,500 patents worldwide. The Bracco Group is a leader in the diagnostic imaging market with an integrated product offering from a diverse roster of subsidiary companies. While Bracco is recognized internationally as a definitive market leader in its core business of contrast media, Bracco also markets key diagnostic imaging resources through the following companies: Esaote, which is one of the world's primary producers of magnetic resonance and ultrasound imaging systems; ACIST Medical Systems, a manufacturer of advanced contrast media injection systems; EBIT-AET, which creates and markets medical application software, and Singapore-based Volume Interactions, which also produces advanced medical software.

Bracco also operates a high-level international research network, with three centers (Milan, Geneva, and Princeton). These centers develop products of the latest-generation diagnostic techniques, from X-ray and computed tomography (CT) to magnetic resonance imaging (MRI) and echocontrast.


This press release may include some products' commercial brands, which are not to be used unless by media addressed to the medical community.

Please click [here](#) for the CardioGen-82 Package Insert.

Kirk Deeter

Bracco Diagnostics Inc. Press Office

303-838-8708

Copyright © 2018 Bracco Diagnostic Inc.. |  for Bracco VPN users

[Privacy Policy](#) | [Terms of Use](#) | [Imprint](#) | **THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY**

The individuals who appear on this website are for illustrative purposes only. All persons depicted are models and not real patients.

MODALITY

[CT & CT Colonography](#)

[Magnetic Resonance Imaging](#)

[Injectors & Informatics](#)

[Nuclear Medicine & Radiopharmaceuticals](#)

MODALITY

[Cardiac Catheterization and Interventional Radiology](#)

[Fluoroscopy](#)

[Contrast Enhanced Ultrasound](#)

[Myelography](#)

R&D

[R&D Centers and Partnerships](#)

[R&D Pipeline](#)

[Clinical Development](#)

CONTACTS

[Local Contacts](#)

[Worldwide Contacts](#)

[Find your Rep](#)

[Find a Wholesaler](#)

EXHIBIT 12

HIGHLIGHTS OF PRESCRIBING INFORMATION
 These highlights do not include all the information needed to use RUBY-FILL safely and effectively. See full prescribing information for RUBY-FILL.
RUBY-FILL (rubidium Rb 82 generator)
 To produce rubidium Rb 82 chloride injection, for intravenous use
 Initial U.S. Approval: 1999

WARNING: UNINTENDED STRONTIUM 82 (Sr 82) AND STRONTIUM 85 (Sr 85)
 Please see full prescribing information for complete boxed warning
 • Unintended radiation exposure occurs when the levels of Sr 82 or Sr 85 in the rubidium Rb 82 chloride injection exceed specific limits. (5.1)
 • Perform generator eluate tests:
 1) Determine Rb 82, Sr 82, Sr 85 levels in the eluate.
 • Once daily, prior to any drug administration, and
 • With additional daily tests after detection of an Alert Limit. (2.6)
 2) Stop use of the generator at its Expiration Limit. (2.7)

INDICATIONS AND USAGE
 RUBY-FILL is a closed system used to produce rubidium Rb 82 chloride injection for intravenous use. Rubidium Rb 82 chloride injection is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease. (1)
DOSE AND ADMINISTRATION
 Use RUBY-FILL with a specific Elution System. (2.4)
 • The recommended weight-based dose of rubidium Rb 82 is between 10-30 Megabecquerels (MBq) (0.27-0.81 millicuries (mCi)). (2.2)
 • Do not exceed a single dose of 2220 MBq (60 mCi) per rest or stress component of a procedure. (2.2)
 • Administer the single dose at a rate of 15-30 mL/minute through a catheter inserted into a large peripheral vein; do not exceed an infusion volume of 60 mL. (2.2)
 • Use the lowest dose necessary to obtain adequate cardiac visualization and individualize the dose depending on multiple factors, including, patient weight, imaging equipment and acquisition type used to perform the procedure. (2.2)
 • Start imaging acquisition 60-90 seconds after completion of the infusion; if a longer circulation time is anticipated, wait for 120 seconds. Acquisition may be started immediately post-injection if dynamic imaging is needed. Image acquisition is typically 3-7 minutes long. (2.3)
 • To obtain rest and stress images, wait 10 minutes after completion of the rest image acquisition then administer the pharmacologic stress agent in accordance with its prescribing information. After administration of the pharmacologic stress agent, infuse the second dose of Rb 82, at the time interval according to the prescribing information of the pharmacological stress agent and complete the stress image acquisition. (2.3)

DOSE FORMS AND STRENGTHS
 RUBY-FILL consists of Sr 82 adsorbed on a hydrous stannic oxide column with an activity of 3145 – 4255 MBq (85 – 115 mCi) Sr 82 at calibration time. (3)

CONTRAINDICATIONS
 None. (4)

WARNINGS AND PRECAUTIONS
 • Unintended radiation exposure occurs when Sr 82 and Sr 85 levels in rubidium Rb 82 chloride injection exceed specified generator eluate limits. (5.1)
 • Pharmacologic induction of cardiovascular stress: May be associated with serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, and cerebrovascular events. Perform testing only in settings where cardiac resuscitation equipment and trained staff are readily available. (5.2)

ADVERSE REACTIONS
 To report SUSPECTED ADVERSE REACTIONS, contact Jabilart, DRAXIMAGE Inc. at 1-888-633-3343 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS
 • Lactation: Do not nurse breastfeeding until at least one hour after completion of RUBY-FILL infusion. (8.2)
PATENT COUNSELING INFORMATION
 See 17 for PATENT COUNSELING INFORMATION.
 Revised: 11/2016

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: UNINTENDED STRONTIUM 82 (Sr 82) AND STRONTIUM 85 (Sr 85) RADIATION EXPOSURE

1 INDICATIONS AND USAGE
2 DOSE AND ADMINISTRATION
 2.1 Radiation Safety – Drug Handling
 2.2 Recommended Dose and Administration Instructions
 2.3 Image Acquisition Guidelines
 2.4 Elution System
 2.5 Directions for Eluting Rubidium Rb 82 Chloride Injection
 2.6 Eluate Testing Protocol
3 WARNINGS AND PRECAUTIONS
 5.1 Unintended Sr 82 and Sr 85 Radiation Exposure
 5.2 Risks Associated with Pharmacologic Stress
 5.3 Volume Overload
 5.4 Cumulative Radiation Exposure: Long-Term Risk of Cancer
6 ADVERSE REACTIONS
 6.1 Clinical Trials Experience
 6.2 Postmarketing Experience
7 DOSE FORMS AND STRENGTHS
8 CONTRAINDICATIONS
9 WARNINGS AND PRECAUTIONS
 11.1 Unintended Sr 82 and Sr 85 Radiation Exposure
 11.2 Risks Associated with Pharmacologic Stress
 11.3 Volume Overload
 11.4 Cumulative Radiation Exposure: Long-Term Risk of Cancer
12 ADVERSE REACTIONS
 12.1 Clinical Trials Experience
 12.2 Postmarketing Experience
13 USE IN SPECIFIC POPULATIONS
 8.1 Pregnancy
 8.2 Lactation
 8.4 Pediatric Use
 8.5 Geriatric Use
14 DESCRIPTION
 11.1 Chemical Characteristics
 11.2 Physical Characteristics
15 CLINICAL PHARMACOLOGY
 12.1 Mechanism of Action
 12.2 Pharmacodynamics
 12.3 Pharmacokinetics
16 NONCLINICAL TOXICOLOGY
 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
17 CLINICAL STUDIES
18 REFERENCES
19 HOW SUPPLIED/STORAGE AND HANDLING
 16.1 How Supplied
 16.2 Storage and Handling
20 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: UNINTENDED STRONTIUM 82 (Sr 82) AND STRONTIUM 85 (Sr 85) RADIATION EXPOSURE

Unintended radiation exposure occurs when the levels of Sr 82 and Sr 85 in the rubidium Rb 82 chloride injection exceed specified limits [see Warnings and Precautions (5.1)]. Perform generator eluate tests:

- 1) The system automatically generates a record and saves the data for each generator eluate volume, including flushing and rest volumes. Total cumulative eluate volumes are also recorded and saved for the life of the generator [see Dosage and Administration (2.5)].
- 2) Determine Rb 82, Sr 82, Sr 85 in the generator eluate:
 - Once a day, prior to any drug administration, and
 - At additional daily tests after detection of an Alert Limit. Alert Limits are:
 - 20 L for the generator's cumulative eluate volume, or
 - An eluate Sr 82 level of 0.004 µCi/ mCi (kBq/MBq) Rb 82, or
 - An eluate Sr 85 level of 0.04 µCi/ mCi (kBq/MBq) Rb 82.
- Perform additional daily tests every 4 patients after detection of an alert limit [see Dosage and Administration (2.6)].
- 3) Stop use of a generator at any of the following Expiration Limits. Expiry Limits are:
 - 30 L for the generator's cumulative eluate volume, or
 - Expiration date of the generator (60 days post-manufacturing)
 - An eluate Sr 82 level of 0.01 µCi /mCi (kBq/MBq) Rb 82, or
 - An eluate Sr 85 level of 0.1 µCi /mCi (kBq/MBq) Rb 82 [see Dosage and Administration (2.7)].

1 INDICATIONS AND USAGE

RUBY-FILL is a closed system used to produce rubidium Rb 82 chloride injection for intravenous administration. Rubidium Rb 82 chloride injection is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

2 DOSE AND ADMINISTRATION

- 2.1 Radiation Safety – Drug Handling
- 2.2 Recommended Dose and Administration Instructions
- 2.3 Image Acquisition Guidelines
- 2.4 Elution System
- 2.5 Directions for Eluting Rubidium Rb 82 Chloride Injection
- 2.6 Eluate Testing Protocol
- 2.7 Recommended Dose and Administration Instructions
 - The recommended weight-based dose of rubidium Rb 82 chloride to be administered per rest or stress component of a PET myocardial perfusion imaging (MPI) procedure is between 10-30 Megabecquerels (MBq) (0.27-0.81 millicuries (mCi)).
 - Do not exceed a single dose of 2220 MBq (60 mCi).
 - Use the lowest dose necessary to obtain adequate cardiac visualization and individualize the weight-based dose depending on multiple factors, including, patient weight, imaging equipment and acquisition type used to perform the procedure. For example, 3D imaging acquisition may require doses at the lower end of the recommended range compared to 2D imaging.
 - Administer the single dose at a rate of 15 – 30 mL/minute through a catheter inserted into a large peripheral vein; do not exceed an infusion volume of 60 mL.
 - Instruct patients to void as soon as a study is completed and as often as possible thereafter for at least one hour.
 - The maximum available activity (delivery limit) will be determined as the generator ages [see Dosage and Administration (2.2)].

3 Image Acquisition Guidelines

- For Rest Imaging:
 - Administer a single ("rest") rubidium Rb 82 chloride dose;
 - Start imaging 60-90 seconds after completion of the infusion of the rest dose and acquire images for 3-7 minutes.
- For Stress Imaging:
 - Begin the study 10 minutes after completion of the resting dose infusion, to allow for sufficient Rb 82 decay.
 - Administer a pharmacologic stress agent in accordance with its prescribing information;
 - After administration of the pharmacologic stress agent, administer the second dose of Rb 82 at the time interval according to the prescribing information of the pharmacological stress agent;
 - Start imaging 60-90 seconds after completion of the stress rubidium Rb 82 chloride dose infusion and acquire images for 3-7 minutes.

4 Elution System

- Use RUBY-FILL Rubidium Rb 82 Generator only with an elution system specifically designed for use with the generator (RUBY Rubidium Elution System) and capable of accurate measurement and delivery of doses of rubidium Rb 82 chloride injection.
- The generator used with the elution system provides ± 10% accuracy for rubidium Rb 82 chloride doses between 370-2220 MBq (10-60 mCi).
- Follow instructions in the RUBY Rubidium Elution System User Manual for the set up and intravenous infusion of rubidium Rb 82 chloride injection dose.

5 Directions for Eluting Rubidium Rb 82 Chloride Injection

- Allow at least 10 minutes between elutions for regeneration of Rb 82.
- Elute with additive-free 0.9% Sodium Chloride Injection (USP only). Additives (particularly calcium ions, to which strontium ions are chemically analogous), may cause the release of substantial amounts of Sr 82 and/or Sr 85 into the eluate regardless of the age or prior use of the generator.
- The system will automatically discard the first 75 mL eluate each day the generator is first eluted.
- The RUBY Rubidium Elution System automatically generates records and saves data of all eluate volumes (from flushing, QC testing, patient infusions), representing the cumulative volume of eluate from the generator.

6 Eluate Testing Protocol

- Elute with additive-free 0.9% Sodium Chloride Injection (USP only).
- Use the ionization chamber-type dose calibrator that is integrated into the elution system (used specifically with the RUBY-FILL Rubidium Rb 82 Generator) for eluate testing.
- Perform **Mandatory Eluate Testing** (i.e. Quality Control test) to determine Rb 82, Sr 82, and Sr 85 levels:
 1. Daily – Before administering rubidium Rb 82 chloride injection to the first patient each day.
 2. Repeat every 4 patients after an Alert Limit has been detected.
- Alert Limits:
 - 20 L total elution volume has passed through the generator column, or
 - Sr 82 level reaches 0.004 µCi per mCi (kBq per MBq) Rb 82, or
 - Sr 85 level reaches 0.04 µCi per mCi (kBq per MBq) Rb 82.
- 3. Immediately after detection of the volume alert limit (20 L).
- The elution system will automatically indicate when alert limits have been reached and require that additional tests be performed.

When the Quality Control test is performed as described in the User Manual, the system automatically performs the following eluate testing:

- 1. The dose calibrator is automatically set for Rb 82 within the Elution System.
- 2. The Quality Control test begins by automatically initiating a generator flush using 75 mL of 0.9% Sodium Chloride Injection USP. This eluate is by default diverted towards the waste container and is ultimately discarded.
- 3. After the generator flush, the system waits approximately 15.2 minutes to accomplish a complete generator recharge of 12 Rb 82 half-lives
- 4. The system then elutes a calibration sample (35 mL of 0.9% Sodium Chloride Injection USP at 20 mL/min). Using the dose calibrator, the system automatically quantifies the activity of Rb 82 in the calibration sample (Rb 82 decay does not need to be corrected for because of a real-time automated measurement).

Strontium Eluate Testing (Strontium Breakthrough)

- 1. Using the calibration sample obtained from the Rb 82 eluate testing, the system allows the sample to stand for 30 minutes to allow for the complete decay of Rb 82.
- 2. The system measures the activity of the sample to automatically determine the total Sr 82 and Sr 85 activity.
- 3. The system automatically determines the ratio (R) on the day (post calibration) of the measurement using the ratio of Sr 85/Sr 82 on the day of calibration provided on the generator label and the Sr 85/Sr 82 ratio factor from the Sr 85/Sr 82 ratio based on generator age using the following equation:

$$R = \frac{[Sr 85]}{[Sr 82]} \times \text{on calibration date Ratio Factor on the day (post-calibration) of measurement}$$
- 4. The system uses a correction factor (F) of 0.48 to compensate for the contribution of Sr 85 to the reading.

5. The system calculates the amount of Sr 82 in the sample using the following equation:

In Empirical Units (µCi):

$$Sr\ 82\ (\mu Ci) = \frac{\text{dose calibration reading } (\mu Ci)}{[1 + (R/F)]}$$
Example: dose calibrator reading (µCi) = 0.8
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (\mu Ci) = \frac{0.8\ \mu Ci}{[1 + (1.148/0.448)]} = 0.47\ \mu Ci$$

In Empirical Units (kBq):

$$Sr\ 82\ (kBq) = \frac{\text{dose calibration reading } (kBq) \times 29.6\ kBq}{[1 + (R/F)]}$$
Example: dose calibrator reading (kBq) = 29.6 kBq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (kBq) = \frac{29.6\ kBq}{[1 + (1.148/0.448)]} = 17.3\ kBq$$

In International Units (Bq):

$$Sr\ 82\ (Bq) = \frac{\text{dose calibration reading } (Bq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (Bq) = 29,600 Bq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (Bq) = \frac{29,600\ Bq}{[1 + (1.148/0.448)]} = 17,300\ Bq$$

In International Units (MBq):

$$Sr\ 82\ (MBq) = \frac{\text{dose calibration reading } (MBq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (MBq) = 29.6 MBq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (MBq) = \frac{29.6\ MBq}{[1 + (1.148/0.448)]} = 17.3\ MBq$$

In International Units (µCi):

$$Sr\ 82\ (\mu Ci) = \frac{\text{dose calibration reading } (\mu Ci) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (µCi) = 0.8 µCi
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (\mu Ci) = \frac{0.8\ \mu Ci \times 1000}{[1 + (1.148/0.448)]} = 470\ \mu Ci$$

In International Units (mCi):

$$Sr\ 82\ (mCi) = \frac{\text{dose calibration reading } (mCi) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (mCi) = 0.0008 mCi
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (mCi) = \frac{0.0008\ mCi \times 1000}{[1 + (1.148/0.448)]} = 0.47\ mCi$$

In International Units (MBq):

$$Sr\ 82\ (MBq) = \frac{\text{dose calibration reading } (MBq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (MBq) = 0.000296 MBq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (MBq) = \frac{0.000296\ MBq \times 1000}{[1 + (1.148/0.448)]} = 0.173\ MBq$$

In International Units (kBq):

$$Sr\ 82\ (kBq) = \frac{\text{dose calibration reading } (kBq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (kBq) = 29.6 kBq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (kBq) = \frac{29.6\ kBq \times 1000}{[1 + (1.148/0.448)]} = 17,300\ kBq$$

In International Units (Bq):

$$Sr\ 82\ (Bq) = \frac{\text{dose calibration reading } (Bq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (Bq) = 29,600 Bq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (Bq) = \frac{29,600\ Bq \times 1000}{[1 + (1.148/0.448)]} = 17,300,000\ Bq$$

In International Units (µCi):

$$Sr\ 82\ (\mu Ci) = \frac{\text{dose calibration reading } (\mu Ci) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (µCi) = 0.8 µCi
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (\mu Ci) = \frac{0.8\ \mu Ci \times 1000}{[1 + (1.148/0.448)]} = 470\ \mu Ci$$

In International Units (mCi):

$$Sr\ 82\ (mCi) = \frac{\text{dose calibration reading } (mCi) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (mCi) = 0.0008 mCi
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (mCi) = \frac{0.0008\ mCi \times 1000}{[1 + (1.148/0.448)]} = 0.47\ mCi$$

In International Units (MBq):

$$Sr\ 82\ (MBq) = \frac{\text{dose calibration reading } (MBq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (MBq) = 0.000296 MBq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (MBq) = \frac{0.000296\ MBq \times 1000}{[1 + (1.148/0.448)]} = 0.173\ MBq$$

In International Units (kBq):

$$Sr\ 82\ (kBq) = \frac{\text{dose calibration reading } (kBq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (kBq) = 29.6 kBq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (kBq) = \frac{29.6\ kBq \times 1000}{[1 + (1.148/0.448)]} = 17,300\ kBq$$

In International Units (Bq):

$$Sr\ 82\ (Bq) = \frac{\text{dose calibration reading } (Bq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (Bq) = 29,600 Bq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (Bq) = \frac{29,600\ Bq \times 1000}{[1 + (1.148/0.448)]} = 17,300,000\ Bq$$

In International Units (µCi):

$$Sr\ 82\ (\mu Ci) = \frac{\text{dose calibration reading } (\mu Ci) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (µCi) = 0.8 µCi
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (\mu Ci) = \frac{0.8\ \mu Ci \times 1000}{[1 + (1.148/0.448)]} = 470\ \mu Ci$$

In International Units (mCi):

$$Sr\ 82\ (mCi) = \frac{\text{dose calibration reading } (mCi) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (mCi) = 0.0008 mCi
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (mCi) = \frac{0.0008\ mCi \times 1000}{[1 + (1.148/0.448)]} = 0.47\ mCi$$

In International Units (MBq):

$$Sr\ 82\ (MBq) = \frac{\text{dose calibration reading } (MBq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (MBq) = 0.000296 MBq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (MBq) = \frac{0.000296\ MBq \times 1000}{[1 + (1.148/0.448)]} = 0.173\ MBq$$

In International Units (kBq):

$$Sr\ 82\ (kBq) = \frac{\text{dose calibration reading } (kBq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (kBq) = 29.6 kBq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (kBq) = \frac{29.6\ kBq \times 1000}{[1 + (1.148/0.448)]} = 17,300\ kBq$$

In International Units (Bq):

$$Sr\ 82\ (Bq) = \frac{\text{dose calibration reading } (Bq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (Bq) = 29,600 Bq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (Bq) = \frac{29,600\ Bq \times 1000}{[1 + (1.148/0.448)]} = 17,300,000\ Bq$$

In International Units (µCi):

$$Sr\ 82\ (\mu Ci) = \frac{\text{dose calibration reading } (\mu Ci) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (µCi) = 0.8 µCi
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (\mu Ci) = \frac{0.8\ \mu Ci \times 1000}{[1 + (1.148/0.448)]} = 470\ \mu Ci$$

In International Units (mCi):

$$Sr\ 82\ (mCi) = \frac{\text{dose calibration reading } (mCi) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (mCi) = 0.0008 mCi
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (mCi) = \frac{0.0008\ mCi \times 1000}{[1 + (1.148/0.448)]} = 0.47\ mCi$$

In International Units (kBq):

$$Sr\ 82\ (kBq) = \frac{\text{dose calibration reading } (kBq) \times 29.6\ kBq}{[1 + (R/F)]}$$
Example: dose calibrator reading (kBq) = 29.6 kBq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (kBq) = \frac{29.6\ kBq}{[1 + (1.148/0.448)]} = 17.3\ kBq$$

In International Units (MBq):

$$Sr\ 82\ (MBq) = \frac{\text{dose calibration reading } (MBq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (MBq) = 0.000296 MBq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (MBq) = \frac{0.000296\ MBq \times 1000}{[1 + (1.148/0.448)]} = 0.173\ MBq$$

In International Units (µCi):

$$Sr\ 82\ (\mu Ci) = \frac{\text{dose calibration reading } (\mu Ci) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (µCi) = 0.8 µCi
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (\mu Ci) = \frac{0.8\ \mu Ci \times 1000}{[1 + (1.148/0.448)]} = 470\ \mu Ci$$

In International Units (mCi):

$$Sr\ 82\ (mCi) = \frac{\text{dose calibration reading } (mCi) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (mCi) = 0.0008 mCi
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (mCi) = \frac{0.0008\ mCi \times 1000}{[1 + (1.148/0.448)]} = 0.47\ mCi$$

In International Units (MBq):

$$Sr\ 82\ (MBq) = \frac{\text{dose calibration reading } (MBq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (MBq) = 0.000296 MBq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (MBq) = \frac{0.000296\ MBq \times 1000}{[1 + (1.148/0.448)]} = 0.173\ MBq$$

In International Units (kBq):

$$Sr\ 82\ (kBq) = \frac{\text{dose calibration reading } (kBq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (kBq) = 29.6 kBq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (kBq) = \frac{29.6\ kBq \times 1000}{[1 + (1.148/0.448)]} = 17,300\ kBq$$

In International Units (Bq):

$$Sr\ 82\ (Bq) = \frac{\text{dose calibration reading } (Bq) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (Bq) = 29,600 Bq
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (Bq) = \frac{29,600\ Bq \times 1000}{[1 + (1.148/0.448)]} = 17,300,000\ Bq$$

In International Units (µCi):

$$Sr\ 82\ (\mu Ci) = \frac{\text{dose calibration reading } (\mu Ci) \times 1000}{[1 + (R/F)]}$$
Example: dose calibrator reading (µCi) = 0.8 µCi
 Sr 85/Sr 82 ratio (R) = 1.148
 correction factor (F) = 0.448

$$Sr\ 82\ (\mu Ci) = \frac{0.8\ \mu Ci \times 1000}{[1 + (1.148/0.448)]} = 470\ \mu Ci$$

2.7 RUBY-FILL Expiration
 Stop use of the RUBY-FILL Rubidium Rb 82 Generator once any one of the following **Expiration Limits** is reached:

- A total elution volume of 30 L has passed through the generator column, or
- Expiration date of the generator (60 days post-manufacturing), or
- An eluate Sr 82 level of 0.01 µCi/mCi (180pMBq) Rb 82, or
- An eluate Sr 85 level of 0.1 µCi/mCi (88pMBq) Rb 82.

2.8 RUBY-FILL Dose Delivery Limit
 The maximum available activity (delivery limits) will decrease as the generator ages. Certain doses, including the maximum recommended dose (60 mCi (2220 MBq)), are not achievable for the entire shelf-life of the generator. Table 3 provides an estimate of the maximum available activity of Rubidium Rb 82 (Delivery Limit) as a function of generator age.

Generator Age (days) ²	Maximum Rubidium Dose (Delivery Limit)
0-17	40 mCi (2220 MBq)
24	50 mCi (1850 MBq)
32	40 mCi (1480 MBq)
42	30 mCi (1110 MBq)
57	20 mCi (740 MBq)

¹ Estimate is based on a 100 mCi (3700 MBq) Sr 82 generator at calibration.
² Generator age at which delivery limit is reached varies with generator activity at release. For example, an 85 mCi (3145 MBq) generator and a 115 mCi (4255 MBq) generator will reach a delivery limit < 60 mCi at > 12 days and > 23 days, respectively.

2.9 Radiation Dose
 The estimated radiation absorbed dose coefficients for Rb 82, Sr 82, and Sr 85 from an intravenous injection of rubidium Rb 82 chloride are shown in Table 4.

Organ	Effective dose per radioisotope activity associated with injection		
	⁸² Rb ¹ (µSv/MBq)	⁸² Sr ² (µSv/MBq)	⁸⁵ Sr ² (µSv/MBq)
Adrenals	2.4	2.9	1.4
Bone surfaces	0.42	29	2.7
Brain	0.14	2.2	0.8
Breast	0.19	1.9	0.5
Gallbladder wall	0.72	2.3	0.8
Gastrointestinal tract			
Esophagus ³	1.5	2.1	0.6
Stomach wall	0.83	2.1	0.6
Small intestine wall	2.0	2.6	1.1
Colon wall	1.1	9.7	1.2
(LL wall)	1.1	6.4	1.0
(RL wall)	1.1	14	1.4
Heart wall	4.0	2.2	0.7
Kidneys	9.3	2.5	0.7
Liver	1.0	2.2	0.7
Lungs	2.6	2.2	0.8
Muscles	0.23	2.2	0.7
Ovaries	0.50	2.8	1.2
Pancreas	2.6	2.5	0.9
Red marrow	0.39	2.5	2.7
Skin	0.18	1.9	0.5
Spleen	0.18	2.2	0.7
Testes	0.26	2.0	0.5
Thymus	1.5	2.1	0.6
Thyroid	0.31	2.2	0.7
Urinary bladder wall	0.18	5.9	0.8
Uterus	1.0	2.5	0.9
Remaining organs	0.31	-	-

Effective dose per unit activity | 1.1 µSv/MBq | 6.3 µSv/MBq | 1.1 µSv/MBq
¹ Rb 82 doses are averages of rest and stress dosimetry data. To calculate organ doses (µGy) from Rb 82, multiply the dose coefficient for each organ by the administered activity in MBq.
² Rb 82 organ doses attributable to Sr 82 and Sr 85, multiply those dose coefficients by the respective isotope activities associated with the injection.
³ The absorbed dose to the thymus is used as a substitute.

3 DOSAGE FORMS AND STRENGTHS
 RUBY-FILL is a closed system used to produce rubidium Rb 82 chloride injection for intravenous use. RUBY-FILL consists of Sr 82 adsorbed on a hydrous stannic oxide column with an activity of 3145-4255 MBq (85-115 mCi) Sr 82 at calibration time.

4 CONTRAINDICATIONS
 None.

5 WARNINGS AND PRECAUTIONS
5.1 Unintended Sr 82 and Sr 85 Radiation Exposure
 Unintended radiation exposure occurs when the Sr 82 and Sr 85 levels in rubidium Rb 82 chloride injections exceed the specified generator eluate limits. To minimize the risk of unintended radiation exposure, strict adherence to a daily eluate testing protocol is required. Stop using the rubidium generator when the expiration limits are reached (see *Dosage and Administration (2.6) and (2.7)*).

5.2 Risks Associated with Pharmacologic Stress
 Pharmacologic induction of cardiovascular stress may be associated with serious adverse reactions such as myocardial infarction, arrhythmia, hypertension, bronchoconstriction, and cerebrovascular events. Perform pharmacologic stress testing in accordance with the pharmacologic stress agent's prescribing information and only in the setting where cardiac resuscitation equipment and trained staff are readily available.

5.3 Radiation Risks
 RUBY-FILL use contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care providers. Encourage patients to void as soon as a study is completed and as often as possible thereafter for at least one hour (see *Dosage and Administration (2.1) and (2.2)*).

6 ADVERSE REACTIONS
 The following serious adverse reaction associated with the use of rubidium Rb 82 chloride was identified in clinical trials or post marketing reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Unintended Sr 82 and Sr 85 Radiation Exposure: Unintended radiation exposure has occurred in some patients who received rubidium Rb 82 chloride injection at clinical sites where generator eluate testing appeared insufficient (see *Bowel Warning, Warnings and Precautions (5.1, Dosage and Administration (2.6))*).

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
 There are no data available on the use of rubidium Rb 82 in pregnant women. Animal reproduction studies with rubidium Rb 82 chloride have not been conducted. However, all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. If considering rubidium Rb 82 chloride injection administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from Rb 82 and the gestational timing of exposure.
 The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

8.2 Lactation
Risk Summary
 There is no information regarding the presence of Rb 82 chloride in human milk, the effects on the breastfed infant or the effects on milk production. Due to the short half-life of Rb 82 chloride (75 seconds), exposure of a breast fed infant through breast milk can be minimized by temporary discontinuation of breastfeeding (See *Clinical Considerations*). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Rb 82, any potential adverse effects on the breastfed child from Rb 82 or from the underlying maternal condition.
Clinical Considerations
Minimizing Exposure
 Exposure to Rb 82 chloride through breast milk can be minimized if breastfeeding is discontinued when Rb 82 chloride injection is administered. Do not resume breastfeeding until at least one hour after completion of RUBY-FILL infusion.

8.4 Pediatric Use
 The safety and effectiveness of rubidium Rb 82 chloride injection in pediatric patients have not been established.

8.5 Geriatric Use
 In elderly patients with a clinically important decrease in cardiac function, lengthen the delay between infusion and image acquisition (see *Dosage and Administration (2.3)*). Observe for the possibility of fluid overload from the infusion.

11 DESCRIPTION
11.1 Chemical Characteristics
 RUBY-FILL Rubidium Rb 82 Generator contains accelerator-produced Sr 82 adsorbed on stannic oxide in a lead-shielded column and provides a means for obtaining sterile non-pyrogenic solutions of rubidium Rb 82 chloride injection. The chemical form of Rb 82 is ⁸²RbCl.
 The amount (mCi) of Rb 82 obtained in each elution will depend on the potency of the generator. When used with the RUBY Rubidium Elution System, the generator provides ± 10% accuracy for rubidium Rb 82 chloride doses between 370-2220 MBq (10-60 mCi).
 When eluted at a rate of 15-30 mL/minute, each generator eluate at the end of elution should not contain more than 0.02 µCi (0.74 kBq) of Sr 82 and not more than 0.2 µCi (7.4 kBq) of Sr 85 per mCi of rubidium Rb 82 chloride injection, and not more than 1 µg of tin per mL of eluate.

Days	Fraction Remaining	Days	Fraction Remaining	Days	Fraction Remaining
0 ¹	1.000	21	0.559	41	0.321
1	0.973	22	0.543	42	0.312
2	0.946	23	0.529	43	0.304
3	0.920	24	0.514	44	0.295
4	0.895	25	0.500	45	0.287
5	0.871	26	0.486	46	0.279
6	0.847	27	0.473	47	0.272
7	0.824	28	0.460	48	0.264
8	0.801	29	0.448	49	0.257
9	0.779	30	0.435	50	0.250
10	0.758	31	0.423	51	0.243
11	0.737	32	0.412	52	0.237
12	0.717	33	0.401	53	0.230
13	0.697	34	0.390	54	0.224
14	0.678	35	0.379	55	0.218
15	0.660	36	0.369	56	0.212
16	0.642	37	0.358	57	0.206
17	0.624	38	0.349	58	0.200
18	0.607	39	0.339	59	0.195
19	0.591	40	0.330	60	0.189
20	0.574				

Radiation	Mean Percent Per Disintegration	Mean Energy (keV)
Annihilation photons (2)	191.01	511 (each)
Gamma rays	13 to 15	776.5

The specific gamma ray constant for Rb-82 is 6.33 R cm² mCi h (1.23 × 10⁻¹² C m² kg MBq h). The first half-value layer is 0.53 cm of lead (Pb). Table 6 shows a range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb. For example, the use of a 6.15 cm thickness of Pb will attenuate the radiation emitted by a factor of about 1,000.

Shield Thickness (Pb) cm	Attenuation Factor
0.53	0.5
1.68	10 ⁻¹
3.55	10 ⁻²
6.15	10 ⁻³
9.3	10 ⁻⁴

Sr 82 (half-life of 25 days; 600 hrs.) decays to Rb 82. To correct for physical decay of Sr 82, Table 7 shows the fractions that remain at selected intervals after the time of calibration.

Days	Fraction Remaining	Days	Fraction Remaining	Days	Fraction Remaining
0	1.000	21	0.559	41	0.321
1	0.973	22	0.543	42	0.312
2	0.946	23	0.529	43	0.304
3	0.920	24	0.514	44	0.295
4	0.895	25	0.500	45	0.287
5	0.871	26	0.486	46	0.279
6	0.847	27	0.473	47	0.272
7	0.824	28	0.460	48	0.264
8	0.801	29	0.448	49	0.257
9	0.779	30	0.435	50	0.250
10	0.758	31	0.423	51	0.243
11	0.737	32	0.412	52	0.237
12	0.717	33	0.401	53	0.230
13	0.697	34	0.390	54	0.224
14	0.678	35	0.379	55	0.218
15	0.660	36	0.369	56	0.212
16	0.642	37	0.358	57	0.206
17	0.624	38	0.349	58	0.200
18	0.607	39	0.339	59	0.195
19	0.591	40	0.330	60	0.189
20	0.574				

* Calibration time
 To correct for physical decay of Rb 82, Table 1 shows the fraction of Rb 82 remaining in all 15 second intervals up to 300 seconds after time of calibration (see *Dosage and Administration (2.6)*).

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action
 Rb 82 is analogous to potassium ion (K⁺) in its biochemical behavior and is rapidly extracted by the myocardium proportional to the blood flow. Rb⁺ participates in the sodium-potassium (Na⁺/K⁺) ion exchange pumps that are present in cell membranes. The intracellular uptake of Rb 82 requires maintenance of ionic gradient across cell membranes. Rb 82 radioactivity in viable myocardium is higher than in infarcted tissue, reflecting intracellular retention.

12.2 Pharmacodynamics
 In human studies, myocardial activity was noted within the first minute after peripheral intravenous injection of Rb 82. When areas of infarction or ischemia are present in the myocardium, they are visualized within 2-7 minutes after injection as photon-deficient, or "cold", areas on the myocardial perfusion scan. In patients with reduced cardiac function, transit of the injected dose from the peripheral infusion site to the myocardium may be delayed.

Blood flow brings Rb 82 to all areas of the body during the first pass of circulation. Accordingly, visible uptake is observed in highly vascularized organs, such as the kidneys, liver, spleen and lungs.

12.3 Pharmacokinetics
 With a physical half-life of 75 seconds, Rb 82 is converted by radioactive decay into stable Kr 82 gas, which is passively exhaled by the lungs.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
 No long-term studies have been performed to evaluate carcinogenic potential, mutagenicity potential, or to determine whether rubidium Rb 82 chloride injection may affect fertility in males or females.

14 CLINICAL STUDIES
 In a descriptive, prospective, blinded image interpretation study of adult patients with known or suspected coronary artery disease, myocardial perfusion defects in stress and rest PET images obtained with amnionia N 13 (n = 111) or Rb 82 (n = 82) were compared to changes in stress flow reserve (SFR) as determined by coronary angiography. PET perfusion defects at rest and stress for seven cardiac regions (anterior, apical, anteroapical, posteroseptal, anterolateral, posterolateral, and inferior walls) were graded on a scale of 0 (normal) to 5 (severe). Values for stenosis flow reserve, defined as flow at maximum

17 PATIENT COUNSELING INFORMATION

Pregnancy
 Advise a pregnant woman of the potential risk to a fetus.

Lactation
 Advise lactating women that exposure to Rb 82 chloride through breast milk can be minimized if breastfeeding is discontinued when Rb 82 chloride injection is administered. Advise lactating women not to resume breastfeeding for at least one hour after completion of rubidium Rb 82 infusion.

General Safety Precautions
 Advise patients to void after completion of each image acquisition session and as often as possible for one hour after completion of the PET scan.

Manufactured by:
 Jubilant DRAXIMAGE Inc.
 16751 TransCanada Highway
 Kirkland, Quebec, Canada
 H9H 4J4
 Version: 1

coronary vasodilatation relative to rest flow, ranged from 0 (total occlusion) to 5 (normal). With increasing impairment of flow reserve, the correlated with PET defect severity increased. A PET defect score of 2 or higher was positively correlated with flow reserve impairment (SFR < 3).

A systematic review of published literature was conducted using pre-defined inclusion/exclusion criteria which resulted in identification of 10 studies evaluating the use of Rb 82 PET myocardial perfusion imaging (MPI) for the identification of coronary artery disease as defined by catheter-based angiography. In these studies, the patient was the unit of analysis and 50% stenosis was the threshold for clinically significant coronary artery disease (CAD). Of these 10 studies, 9 studies were included in a meta-analysis for sensitivity (excluding one study with 100% sensitivity) and 7 studies were included in a meta-analysis of specificity (excluding 3 studies with 100% specificity). A random effects model yielded overall estimates of sensitivity and specificity of 92% (95% CI: 89% to 95%) and 81% (95% CI: 76% to 86%), respectively. The use of meta-analysis in establishing performance characteristics is limited, particularly by the possibility of publication bias (positive results being more likely to be published than negative results) which is difficult to detect especially when based on a limited number of small studies.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied
 RUBY-FILL Rubidium Rb 82 Generator consists of Sr 82 adsorbed on a hydrous stannic oxide column with an activity of 3145-4255 MBq (85-115 mCi) Sr 82 at calibration time. A lead shield encases the generator. The container label provides complete assay data for each generator. Use RUBY-FILL Rubidium Rb 82 Generator only with an appropriate, properly calibrated Elution System (RUBY Rubidium Elution System) labeled for use with the generator.

- 16.2 Storage and Handling**
- Store the generator at 20-25 °C (68-77 °F).
 - Receipt, transfer, possession, storage, disposal or use of this product is subject to the radioactive material regulations and licensing requirements of the U.S. Nuclear Regulatory Commission (NRC), Agreement States or Licensing States as appropriate. Do not dispose of the generator in regular refuse systems.
 - For questions about the disposal of the RUBY-FILL Rubidium Rb 82 Generator, contact Jubilant Draximage Inc. at 1-888-633-5343.

EXHIBIT 13

January 18, 2018

Surajit Pal
surajitpal@plindia.com
+91-22-66322259

Rating	Accumulate
Price	Rs921
Target Price	Rs861
Implied Upside	-6.5%
Sensex	35,082
Nifty	10,789

(Prices as on January 17, 2018)

Trading data

Market Cap. (Rs bn)	142.3
Shares o/s (m)	154.5
3M Avg. Daily value (Rs m)	380.8

Major shareholders

Promoters	56.25%
Foreign	19.38%
Domestic Inst.	5.28%
Public & Other	19.09%


Stock Performance

(%)	1M	6M	12M
Absolute	35.4	29.4	32.8
Relative	30.5	20.0	4.0

How we differ from Consensus

EPS (Rs)	PL	Cons.	% Diff.
2019	52.4	55.3	-5.3
2020	60.7	67.2	-9.6

Price Perf. (RIC: JUBL.BO, BB: JUBILANT IN)



Source: Bloomberg

■ **Ex-Ethanol Sales, EBITDA, PAT in line:** JUBL sales, EBITDA and PAT after adjusting one-off Ethanol sales are more or less in line with our estimates. Ex-ethanol sales were below estimates by 4% YoY while EBITDA and PAT were up 4% and 2% above estimates. Triad sales (post acquisition) of US\$47.5m with 5% operating loss were on expected lines. EBITDA margin was 16.5% vs our estimates of 15.2% as there was improvement in margin in core LSI business. With increase in demand and favourable price in Vitamins, pyridine and acetyls, JUBL's EBITDA margin in LSI business grew to 19% in Q3FY18 from 17.7% in Q2FY18. Ex-Triad, Pharma sales increased by 3% QoQ despite 9% QoQ growth in specialty pharma business in US. The reason for tepid growth in pharma was 11% decline in generic business, driven by channel consolidation in US generics and lower offtake of clients in API business. JUBL secured tender business of Rs3bn for supplying Ethanol to the GOI's petrol-blending program over 12 months with initial supply beginning in Q3FY18.

■ **Ruby-Fill yet to take off:** JUBL completed installation of Ruby-fill (first NDA product) in three sites while management believes that the drug will take longer time before seeing any critical contribution in revenues and operating margin. JOL plans to launch another NDA drug Drax Exametazime in the US in FY19E. We believe Ruby-Fill sales to remain lacklustre in near term due to installation of costly machinery of PET-CT technology.

■ **Valuation-Maintain 'Accumulate', TP increased to Rs861:** While there are improvement seen in LSI, we have reduced sales and EBITDA estimates due to a) lower growth and margin in pharma sales and b) high LSI base in Q4FY17. JUBL's EBITDA margin of Pharma is expected to have lower margin due to addition of low margin business of Traid Isotopes post acquisition. This will result in 11% CAGR in EBITDA during FY17-20E. Net Debt decreased to Rs34.5bn in Q3FY18 from Rs36.6bn in Q2FY18. We roll forward our earnings to FY20E and assigned 12x EV/EBITDA on pharma and 5x of EV/EBITDA on LSI, leading to increase in valuation by 22%. We maintain our recommendation of 'Accumulate' and increase TP to Rs861 (from earlier Rs707)

Key financials (Y/e March)

	2017	2018E	2019E	2020E
Revenues (Rs m)	57,653	71,879	86,362	97,267
Growth (%)	2.1	24.7	20.2	12.6
EBITDA (Rs m)	12,491	13,262	15,459	17,265
PAT (Rs m)	5,756	6,315	8,164	9,457
EPS (Rs)	37.0	40.5	52.4	60.7
Growth (%)	46.6	9.7	29.3	15.8
Net DPS (Rs)	3.1	3.1	3.1	3.1

Profitability & Valuation

	2017	2018E	2019E	2020E
EBITDA margin (%)	21.7	18.5	17.9	17.8
RoE (%)	18.0	17.0	18.6	18.1
RoCE (%)	10.8	10.9	12.6	13.1
EV / sales (x)	3.1	2.5	2.0	1.7
EV / EBITDA (x)	14.4	13.3	11.1	9.7
PE (x)	24.9	22.7	17.6	15.2
P / BV (x)	4.2	3.6	3.0	2.5
Net dividend yield (%)	0.3	0.3	0.3	0.3

Source: Company Data; PL Research

Prabhudas Lilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision.

Please refer to important disclosures and disclaimers at the end of the report

Key takeaways from Conference call

- With major growth in Specialty Pharma Injectables, JUBL's Pharma segment sales were at Rs11bn, grew 40% YoY and 28% QoQ in Q3FY18. Management guided that the Pharma revenues and profitability increased 5% YoY ex-Triad business
- LSI business grew 39% YoY and 28% QoQ to Rs9.2bn. JOL won a new contract which will help generate revenues worth Rs3bn from Dec 2017 to Nov 2018. EBITDA margin for LSI business increased to 22.3% on favourable pricing regime and due to greater availability of molasses with better pricing. Growth in LSI business was driven equally by increase in volumes and prices
- Management soft launched gCardiogen-82 (branded as Ruby-Fill) in Q3FY17 and successfully completed its installation at three sites in USA by Q3FY18. The company expects Ruby-Fill market to expand to US\$250m by FY21E. Management maintained guidance for achieving at least 30-40% market share of the product over 5 years
- Management guided to launch 5 new products in the Radiopharmaceuticals segment in 3-4 years. The company received 2 approvals and filed 4 ANDAs in Q3FY18 in the injectable segment
- JUBL received approval for new indication for Draximage DTPA in US in Q3FY18. Management guided to launch Drax Exametazime in FY19E in US for which it has received approval in Q3FY18
- The company incurred capex of Rs700m in Q3FY18. R&D expenditure was 4.6% of segment sales at Rs510m in Q3FY18. Of which, Rs380m was charged to P/L and balance being capitalized as product development expenditure which will be amortized over a period of 5 years.
- Management guided for capex at Rs4bn (to be financed through internal accruals) and maintained R&D expenses to be at 8.5% of segment sales in FY18E. Management maintained guidance for capitalisation of Rs1.4-1.7bn on R&D expenditures.
- Tax rate is expected to be lower at 25% in FY18E due to reduction in US federal tax rates from 35% to 21%, which has helped JUBL to reduce US\$10m in tax outflow
- Management guided to maintain overall EBITDA margin in a range of 20-21% and to maintain LSI EBITDA margin at 17-18% in H2FY18E
- JOL decreased net debt by Rs1.59bn in Q3FY18. Its current net debt is Rs34.8bn. Going forward, management has guided to maintain focus on reducing debt and improving the return ratios
- Management guided that capacity enhancement for acetic anhydride is underway at SEZ Bharuch facility. With target completion date in FY19, JOL expects to achieve revenues of Rs3bn at full capacity utilization

Exhibit 1: Change in Estimates

Year	Sales (Rs m)			EBITDA (Rs m)			EPS (Rs)		
	Old	New	Diff (%)	Old	New	Diff (%)	Old	New	Diff (%)
FY18E	72,739	71,879	(1.2)	14,177	13,262	(6.5)	44.3	40.5	(8.5)
FY19E	89,764	86,362	(3.8)	16,145	15,459	(4.2)	55.8	52.4	(6.1)

Source: PL Research

Exhibit 2: Q3FY18 Result Overview (Rs m)


Y/e March	Q3FY18	Q3FY17	YoY gr. (%)	Q2FY18	9MFY18	9MFY17	YoY gr. (%)
Net Sales	20,678	14,916	38.6	16,420	53,059	43,649	21.6
Raw Material	9,065	6,058	49.6	7,107	23,310	17,175	35.7
<i>% of Net Sales</i>	<i>43.8</i>	<i>40.6</i>		<i>43.3</i>	<i>43.9</i>	<i>39.3</i>	
Personnel Cost	4,229	3,092	36.8	3,688	11,021	9,065	21.6
<i>% of Net Sales</i>	<i>20.5</i>	<i>20.7</i>		<i>22.5</i>	<i>20.8</i>	<i>20.8</i>	
Others	3,215	2,449	31.3	2,565	8,123	6,668	21.8
<i>% of Net Sales</i>	<i>15.5</i>	<i>16.4</i>		<i>15.6</i>	<i>15.3</i>	<i>15.3</i>	
Total Expenditure	16,509	11,598	42.3	13,360	42,453	32,908	29.0
EBITDA	4,168	3,318	25.6	3,061	10,605	10,742	(1.3)
<i>Margin (%)</i>	<i>20.2</i>	<i>22.2</i>		<i>18.6</i>	<i>20.0</i>	<i>24.6</i>	
Depreciation	818	727	12.6	790	2,333	2,162	7.9
EBIT	3,350	2,592	29.3	2,271	8,272	8,580	(3.6)
Other Income	32	51	(37.1)	71	171	143	19.5
Interest	771	982	(21.5)	660	2,118	2,609	(18.8)
PBT	2,612	1,661	57.2	1,681	6,325	6,114	(3.5)
Minority Interest	(3)	13	(123.3)	(28)	(59)	(2)	
Total Taxes	483	480	0.7	427	1,505	1,520	(1.0)
<i>ETR (%)</i>	<i>18.5</i>	<i>28.9</i>		<i>25.4</i>	<i>23.8</i>	<i>24.9</i>	
Reported PAT	2,125	1,194	78.0	1,283	4,879	4,596	(6.2)
Other Comprehensive Income	(409)	(98)		802	787	(216)	
Total Comprehensive Income	1,716	1,096	56.6	2,084	5,667	4,380	(29.4)

Source: Company Data, PL Research


Exhibit 3: Major Sources of Revenues (Rs m)

Y/e March	Q3FY18	Q3FY17	YoY gr. (%)	Q2FY18	9MFY18	9MFY17	YoY gr. (%)
Pharmaceuticals	11,007	7,846	40.3	8,593	27,765	23,065	20.4
<i>% of Net Sales</i>	<i>53.2%</i>	<i>52.6%</i>		<i>52.3%</i>	<i>52.3%</i>	<i>52.8%</i>	
Life Science ingredients	9,225	6,633	39.1	7,385	23,993	19,274	24.5
<i>% of Net Sales</i>	<i>44.6%</i>	<i>44.5%</i>		<i>45.0%</i>	<i>45.2%</i>	<i>44.2%</i>	
Drug Discovery Solutions	446	437	2.0	443	1,300	1,311	(0.8)
<i>% of Net Sales</i>	<i>2.2%</i>	<i>2.9%</i>		<i>2.7%</i>	<i>2.5%</i>	<i>3.0%</i>	
Gross Sales	20,678	14,916	38.6	16,420	53,059	43,649	21.6

Source: Company Data, PL Research


Exhibit 4: Pharma sales and growth


Source: Company Data, PL Research

Exhibit 5: LSI Sales and Growth



Source: Company Data, PL Research

Exhibit 6: US Sales and Growth




Source: Company Data, PL Research

Exhibit 7: India Sales and Growth




Source: Company Data, PL Research

Exhibit 8: EU, Japan: Sales and Growth




Source: Company Data, PL Research

Exhibit 9: Overall Sales and Growth




Source: Company Data, PL Research

Exhibit 10: EBITDA and Margin: Pharma and LSI



Source: Company Data, PL Research

Exhibit 11: ROCE: Pharma and LSI



Source: Company Data, PL Research

Income Statement (Rs m)

Y/e March	2017	2018E	2019E	2020E
Net Revenue	57,653	71,879	86,362	97,267
Raw Material Expenses	19,995	27,314	33,250	37,448
Gross Profit	37,657	44,565	53,113	59,819
Employee Cost	12,309	15,454	17,920	20,426
Other Expenses	12,857	15,849	19,734	22,128
EBITDA	12,491	13,262	15,459	17,265
Depr. & Amortization	2,914	3,224	3,547	4,071
Net Interest	3,411	2,803	2,457	2,169
Other Income	1,210	1,184	1,430	1,585
Profit before Tax	7,376	8,420	10,885	12,610
Total Tax	1,630	2,105	2,721	3,152
Profit after Tax	5,746	6,315	8,164	9,457
Ex-Od items / Min. Int.	(10)	—	—	—
Adj. PAT	5,756	6,315	8,164	9,457
Avg. Shares O/S (m)	155.8	155.8	155.8	155.8
EPS (Rs.)	37.0	40.5	52.4	60.7

Cash Flow Abstract (Rs m)

Y/e March	2017	2018E	2019E	2020E
C/F from Operations	12,685	9,808	11,915	10,814
C/F from Investing	(4,504)	(3,478)	(3,478)	(4,478)
C/F from Financing	(6,859)	(7,434)	(6,672)	(6,587)
Inc. / Dec. in Cash	1,322	(1,104)	1,766	(251)
Opening Cash	3,393	4,715	3,611	5,377
Closing Cash	4,715	3,611	5,377	5,125
FCFF	7,790	1,374	5,038	5,141
FCFE	3,310	(2,682)	1,399	1,298

Key Financial Metrics

Y/e March	2017	2018E	2019E	2020E
Growth				
Revenue (%)	2.1	24.7	20.2	12.6
EBITDA (%)	9.1	6.2	16.6	11.7
PAT (%)	46.9	9.7	29.3	15.8
EPS (%)	46.6	9.7	29.3	15.8
Profitability				
EBITDA Margin (%)	21.7	18.5	17.9	17.8
PAT Margin (%)	10.0	8.8	9.5	9.7
RoCE (%)	10.8	10.9	12.6	13.1
RoE (%)	18.0	17.0	18.6	18.1
Balance Sheet				
Net Debt : Equity	1.0	0.8	0.6	0.4
Net Wrkng Cap. (days)	150	129	116	122
Valuation				
PER (x)	24.9	22.7	17.6	15.2
P / B (x)	4.2	3.6	3.0	2.5
EV / EBITDA (x)	14.4	13.3	11.1	9.7
EV / Sales (x)	3.1	2.5	2.0	1.7
Earnings Quality				
Eff. Tax Rate	22.1	25.0	25.0	25.0
Other Inc / PBT	16.4	14.1	13.1	12.6
Eff. Depr. Rate (%)	5.1	5.2	5.3	5.7
FCFE / PAT	57.5	(42.5)	17.1	13.7

Source: Company Data, PL Research.

Balance Sheet Abstract (Rs m)

Y/e March	2017	2018E	2019E	2020E
Shareholder's Funds	34,360	40,100	47,689	56,571
Total Debt	40,453	36,397	32,757	28,913
Other Liabilities	2,817	2,862	2,716	1,754
Total Liabilities	77,631	79,359	83,161	87,238
Net Fixed Assets	57,905	57,081	58,135	58,563
Goodwill	—	—	—	—
Investments	1,027	1,027	1,027	1,027
Net Current Assets	18,124	19,565	23,403	27,039
<i>Cash & Equivalents</i>	4,596	3,611	5,377	5,125
<i>Other Current Assets</i>	24,885	26,925	28,500	32,200
<i>Current Liabilities</i>	11,357	10,970	10,473	10,286
Other Assets	574	585	596	608
Total Assets	77,631	78,259	83,161	87,238

Quarterly Financials (Rs m)

Y/e March	Q4FY17	Q1FY18	Q2FY18	Q3FY18
Net Revenue	16,414	15,961	16,420	20,678
EBITDA	3,050	3,376	3,061	4,168
<i>% of revenue</i>	18.6	21.2	18.6	20.2
Depr. & Amortization	752	725	790	818
Net Interest	802	617	560	571
Other Income	105	(2)	(29)	(168)
Profit before Tax	1,601	2,032	1,681	2,612
Total Tax	111	595	427	483
Profit after Tax	1,501	1,471	1,283	2,125
Adj. PAT	1,501	1,471	1,283	2,125

Key Operating Metrics (Rs m)

Y/e March	2017	2018E	2019E	2020E
Pharmaceuticals	32,987	40,641	51,318	57,820
LSI	27,076	32,165	36,210	40,760

Source: Company Data, PL Research.

EXHIBIT 14



ASNC

2017

22nd Annual Scientific Session
American Society of Nuclear Cardiology

Sept. 14–17, 2017 | Kansas City, Missouri

**KANSAS CITY THE
HEART OF AMERICA**

FINAL PROGRAM



www.asnc.org/ASNC2017

RUBY-FILL® (Rubidium Rb 82 Generator)
and RUBY Rubidium Elution System

Elution Evolution

**LIVE
DEMO**

See for yourself at
ASNC 2017—visit Booth 400

Advancing cardiac PET imaging to be:

Precise

Constant-activity infusion option
Maintains consistent activity rate profiles
throughout the life cycle of the generator¹⁻³

Flexible

Accurate patient-specific dosing
Long shelf life—60 days

Efficient

Automated daily quality control
Built-in safety controls



Leap forward with RUBY-FILL®

Indication and Important Safety Information

RUBY-FILL® Rubidium Rb 82 Generator is a closed system used to produce rubidium Rb 82 chloride injection for intravenous use. Rubidium Rb 82 chloride injection is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

WARNING: UNINTENDED STRONTIUM-82 (Sr-82) AND STRONTIUM-85 (Sr-85) RADIATION EXPOSURE

Please see full prescribing information for complete boxed warning

- Unintended radiation exposure occurs when the levels of Sr-82 or Sr-85 in the rubidium Rb 82 chloride injection exceed specific limits.
- Perform generator eluate tests:
 - 1) Determine Rb-82, Sr-82, Sr-85 levels in the eluate:
 - Once daily, prior to any drug administration, and
 - With additional daily tests after detection of an Alert Limit.
 - 2) Stop use of the generator at its Expiration Limit.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch, or call 1-800-FDA-1088.

References: 1. Epstein JN, Ziadi MC, Benelfassi A, Beanlands RS, deKemp RA. An ⁸²Rb infusion system for quantitative perfusion imaging with 3D PET. *Appl Radiat Isot.* 2004;60(6):921-927. 2. Klein R, Adler A, Beanlands RS, deKemp RA. Precision-controlled elution of a ⁸²Sr/⁸²Rb generator for cardiac perfusion imaging with positron emission tomography. *Phys Med Biol.* 2007;52(3):659-673. 3. Klein R, Renaud JM, Ziadi MC, et al. Intra- and inter-operator repeatability of myocardial blood flow and myocardial flow reserve measurements using rubidium-82 pet and a highly automated analysis program. *J Nucl Cardiol.* 2010;17(4): 600-616.

RUBY RUBIDIUM ELUTION SYSTEM

The risk information provided here is not comprehensive.
Please see full Prescribing Information at www.draximage.com.

RUBY-FILL® is a registered trademark used under license by Jubilant DraxImage, Inc.

RUBY **FILL**®
RUBIDIUM Rb82 GENERATOR



Jubilant DraxImage Inc.
16751 Trans-Canada Highway, Kirkland, Québec, Canada H9H 4J4
Phone: 1.888.633.5343 / 514.630.7080 Fax: 1.866.431.4288 / 514.694.3865
www.draximage.com
DRAXIMAGE® is a registered trademark of Jubilant DraxImage Inc. 2017CARD067

Organizing Committee

Prem Soman, MD, PhD, FASNC, Chair
Brian G. Abbott, MD, MASNC
Firas Al Badarin, MD, FASNC
Karthikeyan Ananthasubramaniam, MD, FASNC
Timothy L. Dunn, CNMT
Raymond R. Russell, MD, PhD, FASNC
Randall C. Thompson, MD, FASNC

Program Committee

Donna M. Polk, MD, MPH, FASNC, Chair
Sharmila Dorbala, MD, FASNC, Vice Chair
James A. Arrighi, MD, MASNC
Rob S.B. Beanlands, MD, FASNC
Jamieson M. Bourque, MD, FASNC
Renee Bullock-Palmer, MD, FASNC
Dennis Calnon, MD, MASNC
Panithaya Chareonthaitawee, MD
Marcelo Di Carli, MD
Andrew J. Einstein, MD, PhD, FASNC
Oliver Gaemperli, MD
Fadi Hage, MD, FASNC
Christopher L. Hansen, MD, FASNC
Matthew E. Harinstein, MD
Gary V. Heller, MD, PhD, MASNC
Edward Hulten, MD, MPH, FASNC
Juhani Knuuti, MD, PhD
April Mann, MBA, CNMT, RT(N), NCT, FASNC
Edward J. Miller, MD, PhD, FASNC
Todd D. Miller, MD
Khurram Nasir, MD, MPH
Robert A. Pagnanelli, CNMT, RT(N)(R), FASNC
Mi-Ae Park, PhD
Matthew Parker, MD
Lawrence M. Phillips, MD, FASNC
Raymonds R. Russell, III, MD, PhD, FASNC
Ibrahim M. Saeed, MD
Maria G. Sciammarella, MD
Nishant R. Shah, MD, MPH
Albert J. Sinusas, MD, FASNC
Mark I. Travin, MD, FASNC
James E. Udelson, MD, MASNC

Table of Contents


President's Welcome	3
Chair's Welcome	3
ASNC2017 Supporters	5
ASNC Education.....	6
Program Tracks.....	7
ASNC2017 Schedule by Track	8
ASNC2017 Schedule by Time	10
ASNC Organized Ancillary Sessions.....	12
2017 Program Schedule	14
ASNC International Partners.....	25
ASNC2017 Mobile App.....	25
General Information.....	26
Exhibitor Listing	27
Exhibitor Floorplan and Index	32
ASNC2018 Save the Date.....	33
ASNC2017 Faculty.....	34
Author/Faculty Index	36
The ASNC Fund	38
Industry Sponsored Satellite Symposia	39



www.asnc.org/ASNC2017

Circling the globe... to bring you TechneLite®

Visit us at
Booth #108



We are Focused on Your Future:

- Globally diversified and balanced supply chain
- Supply agreements with IRE, NTP and ANSTO Mo-99 processors

We are Spearheading Low-Enriched Uranium (LEU)-sourced Mo-99 in the U.S.

- Strategy in place for a consistent and increasing supply of LEU-sourced Mo-99
- First to gain FDA approval to use LEU-sourced Mo-99 in our TechneLite® generator manufacture on June 25, 2009¹
- First to offer a Center for Medicare and Medicaid Services (CMS) compliant LEU manufactured technetium-99m generator (TechneLite®) on January 7, 2013¹

We are committed to Quality and Reliability¹

- LEU TechneLite® generators are equivalent in the elution process and provide the consistent performance you value
- LEU TechneLite® generators are available in our standard sizes

**Brands you know.
Quality you trust.**

TechneLite®
Technetium Tc 99m
Generator

Visit www.TechneLite.com

for additional LEU TechneLite information

To place an order or to speak with Customer Service,
call 1-800-299-3431





Kansas City, Missouri

President's Welcome



As ASNC President, it is my pleasure to welcome you to Kansas City for ASNC2017. Nuclear cardiology continues to play a critical and cost-effective role in the diagnosis of heart disease and risk stratification in our patients. ASNC2017 showcases what nuclear cardiology has to offer in providing the best care for our patients.

This year's program will allow physicians and technologists to refine their diagnostic and technical acumen and to focus on patient-centered imaging – choosing the right test for the right patient and affording the lowest radiation dose possible. Sessions on multimodality imaging will provide an important perspective for attendees, particularly in providing essential diagnostic information in an environment of health care cost containment. State-of-the-art innovations in cardiac PET and SPECT imaging, including perfusion imaging, quantification of myocardial blood flow reserve, and the diagnosis of inflammatory and infiltrative cardiomyopathies, will be highlighted in the meeting. Be sure to attend our first-ever disease-based, rapid-fire abstract session focused on cardiac amyloid during the opening reception.

We are delighted to have world-renowned experts in cardiology in sessions covering a variety of disease-specific imaging topics. In a unique session on heart failure, long-time ASNC member Dr. Rory Hachamovitch will share his perspective as a patient rather than a physician. In addition, we are pleased to have ASNC past president, Dr. Leslee Shaw, deliver the 2017 Verani Lecture "Evolving, Innovating and Revolutionary Changes in Cardiovascular Imaging – We Have Only Begun!"

Our industry partners will exhibit the latest advancements in imaging hardware and software, radiopharmaceuticals, pharmacologic stress agents, and many other products essential to provide high quality patient care. I encourage you to visit the Exhibit Hall to meet with our industry partners and learn more about these exciting advancements.

ASNC's continued growth and success depends on the support of our members, guests, and industry partners. I thank you not only for your attendance, but also for your continued support of ASNC and nuclear cardiology. Enjoy the meeting, have a great time in Kansas City, and don't forget to sample some KC barbecue!

Raymond Russell

Raymond Russell, MD, PhD, FASNC
ASNC2017 President

Chair's Welcome



On behalf of the American Society of Nuclear Cardiology, I would like to welcome you to ASNC2017, the 22nd Annual Scientific Session of ASNC. We are very excited to be visiting Kansas City, the HEART of America. This year's meeting will highlight disease specific sessions (sarcoidosis and amyloidosis), hands on reading with the experts, case-based sessions, new rapid fire ePoster presentations and lots of opportunities for networking and mentorship.

The educational program will consist of several exciting plenary sessions. Dr. Leslee Shaw will deliver the Mario Verani Memorial Lecture at the opening plenary. Dr. Shaw will be speaking on Evolving, Innovating and Revolutionary Changes in Cardiovascular Imaging – We Have Only Begun. Our second plenary will focus on heart failure and will open with the patient perspective (Dr. Rory Hachamovitch): experiencing a heart transplant.

In addition to the diverse plenary sessions there will be several multimodality imaging sessions, practical sessions on how to establish a PET program, PYP imaging, international sessions, and, as always, the engaging Controversies in Cardiology session which will be held in an exciting new format.

NEW for 2017 – be sure to find time to drop in to the Comprehensive Boot Camp for Heart Service Line Administrators, Laboratory Managers, and Nuclear Cardiologists on Thursday afternoon.


So whether this is your first time at an ASNC annual meeting or you are a regular attendee, we have designed an interactive and exciting program that we hope you will enjoy.

I would like to thank the members of the ASNC2017 Program Committee and specifically Vice Chair, Sharmila Dorbala, MD, FASNC for their time and commitment in preparing this program. I would also like to thank all of the individuals who agreed to participate as part of the faculty for ASNC2017.

Donna M. Polk

Donna M. Polk, MD, MPH, FASNC
ASNC2017 Program Chair

American Society of Nuclear Cardiology would like to
thank the International Atomic Energy Agency



IAEA

60 Years

Atoms for Peace and Development

for their generous support of the ASNC2017 Live Streaming
sessions to physicians in developing countries.

Appropriate Use Does Not have to Equal Shrinking Income
Mobile Nuclear Cardiac Imaging Brought to your Office



Nuclear Medicine Professionals, Inc.

- Nuclear Medicine Professionals Inc. Provides Simple Mobile Equipment & Employee Leasing by the Day
- Up to 12 patients in a single Day
- Schedule Services when your patients need them
- Average Cost per patient is \$300 which includes the Radioisotopes, Supplies, Camera & Two Technologists
- NMPI Lease Also Includes: Radioactive Materials Licensure, Nuclear Camera, Treadmill, ECG, Hot-lab, Crash Cart, Accreditation Maintenance, Health Physicist Testing, Personnel, All Equipment Maintenance

*Servicing Florida and Georgia Since 2001



www.MobileNuclear.com

Sales: (352) 327-1000

ASNC2017 Supporters

The American Society of Nuclear Cardiology would like to thank the following companies for their corporate support:

DIAMOND LEVEL



GOLD LEVEL



BRONZE LEVEL



SUPPORTER LEVEL





ASNC Education

Program Design

- A scientific forum featuring panel discussions on focused areas of cutting-edge research
- State-of-the-art reviews of the key aspects of nuclear cardiology by the world's experts
- A basic core curriculum addressing practical issues in the performance of nuclear cardiology procedures to include opportunities for maintenance of certification credit
- Scientific sessions on advances in nuclear cardiology
- Ethics session will offer case-based scenarios dealing with ethical issues
- Educational track dealing with the pathophysiology of multimodality imaging
- Presentations addressing technical issues in nuclear cardiology
- Oral abstracts featuring the latest clinical studies in cardiovascular imaging as well as young investigator presentations
- Abstracts of original investigation programmed as poster presentations
- Commercial exhibits displaying the latest in nuclear cardiology technology and services
- Cost-related information in the practice and business of nuclear cardiology focused on developing a PET program
- Innovations in Technology session to cover expanding horizons for cardiac imaging
- Opportunities to convene and interact with experts in all aspects of nuclear cardiology and cardiovascular imaging

Statement of Need

In order to maintain competence and improve performance, imaging professionals must assimilate and integrate knowledge spanning multiple areas, including clinical data, technical aspects of imaging, and appropriate application of imaging (e.g., clinical guidelines and appropriate use criteria). Each of these areas is constantly evolving, particularly as innovative technologies and novel pharmacologic agents are introduced. ASNC2017 is an educational activity designed to help you and other imaging professionals obtain the latest information in clinical practice and review cutting-edge scientific advances in nuclear cardiology and cardiac imaging.

Disclosure

ASNC is pledged to ensure balance, independence, objectivity, and scientific rigor in all its supported educational activities through disclosure of relationships with commercial companies and resolution of conflict of interest. All planners, reviewers and presenters involved with this activity are expected to disclose financial interests with the manufacturer(s) of any commercial product(s) and/or providers of commercial services discussed in an educational presentation. A complete list of disclosures will be distributed to all attendees on site.

Accreditation and Continuing Education Credit

PHYSICIANS: The American Society of Nuclear Cardiology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Nuclear Cardiology designates this live activity for a maximum of 31.75* AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

TECHNOLOGISTS: The American Society of Nuclear Cardiology is a recognized provider of continuing education credit for technologists. ASNC's Continuing Education (ACE) credit is accepted by both NMTCB and ARRT. ASNC2017 has been approved for a maximum of 20.75* ARRT Category A Credits.

PHYSICIAN ASSISTANTS: The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME.

NURSE PRACTITIONERS: The American Academy of Nurse Practitioners Certification Board (AANPCP) recognizes attendance at CE offerings which provide AMA PRA Category 1 Credits™ for the purpose of recertification.

**Subject to Change*

Target Audience

This course is intended for cardiologists, radiologists, nuclear medicine specialists, practice administrators, nuclear technologists, nurses and other health care professionals with an interest in the field of nuclear cardiology and cardiac CT imaging.



Overall Purpose

The overall goal of the meeting is to improve learner knowledge, competence and skills in applications about appropriate use criteria, radiation safety, reporting, and lab performance in using appropriate guidelines-based treatment.

General Learning Objectives

DEMONSTRATE improved skills in image interpretation and reporting

LEARN how to recognize and minimize technical problems and artifacts that may be associated with cardiac imaging

LEARN the appropriate use of cardiac imaging techniques based on current guidelines

EVALUATE new imaging technologies, software, and stress techniques

UNDERSTAND the role of nuclear and cardiac CT imaging in overall patient care

LEARN the importance of balancing radiation exposure with image quality

DESCRIBE future directions in cardiac PET, CT, and SPECT/CT in order to anticipate training and equipment needs

UNDERSTAND the clinical implication of multimodality cases and recognize the value and limitations in clinical cardiology



Program Tracks

The program will include the following tracks to allow attendees to customize their educational experience:

- PL PLENARY**
Sessions will include keynote presentations from leaders in the field covering areas such as emerging research, new technology, and advances in treatment.
- AR ABSTRACTS/RESEARCH**
To include poster, ePosters, Rapid Fire ePosters and oral abstract presentation including young investigator oral presentations.
- A ADVANCED**
This track includes sessions covering advances in the field of nuclear cardiology and potential clinical applications for these innovations.
- CA CASES WITH THE ACES: INTERACTIVE READING**
Small group sessions on how to read a scan with senior faculty using vendor software to demonstrate cases
- C CORE**
These didactic presentations review topics essential to the effective diagnosis and treatment of heart disease patients using imaging modalities.
- I INTERNATIONAL**
These sessions offer an opportunity to learn about multimodality imaging from the international community and how that view may differ from the US-based approach.
- LL LIFELONG LEARNING**
Participate in a dedicated study session offering the opportunity to weigh in through audience response and discussion with facilitators and fellow participants to identify the most appropriate answers to ABIM approved questions. In addition, many didactic sessions offer MOC. These are designated in the schedule program schedule.
- MI MULTIMODALITY IMAGING**
Sessions include important applications of nuclear cardiology along with other imaging modalities in current practice to deliver optimal care to patients
- O OTHER**
These sessions are general in nature with broad-based interest. They include a boot camp focusing on positioning your lab for the future, an ethics session, choosing wisely challenge and ImageGuide registry update.
- P PET**
These sessions will offer a broad-based review of the clinical value of pharmacologic PET, radiation exposure, modeling cost effectiveness and other areas
- PP POLICY AND PRACTICE**
Managing a cardiology practice has never been more challenging. In each presentation you will find programming that gets to the heart of today's challenges while preparing you for the cardiology practice of tomorrow.
- RE READ WITH THE EXPERTS**
Learn with the best practitioners in the field by walking through cases along with panelists and expert faculty. Audience response opportunities available.
- T TECHNOLOGY AND TECHNIQUES**
Sessions are instructive with regard to nuclear cardiology procedures. Information is intended to provide practical information for providing quality imaging services. These sessions are geared for the nuclear cardiology technologist.

ASNC2017 Schedule by Track

DAY	SESS#	SESSION TITLE	START	END	ROOM
A ADVANCED					
Fri	205	Imaging to Guide Arrhythmia Management	10:30AM	12:00PM	New York
Sat	304	Cutting Edge Technologies	10:30AM	12:00PM	New York
Sat	315	Debate: Clash of the Titans	1:30PM	3:00PM	Exhibit Hall B
Sun	402	Approach to Known or Potential Ischemic Heart Disease	9:45AM	10:45AM	Atlanta
CA CASES WITH THE ACES					
Fri	203	Cases from the Cleveland Clinic	10:00AM	11:30AM	Empire B
Fri	210	Cases from St. Luke's Roosevelt/Mt. Sinai	12:00PM	1:30PM	Empire B
Fri	217	Cases from MMP MaineHealth Cardiology	3:00PM	4:30PM	Empire B
Sat	303	Cases from Brigham & Women's Hospital	10:00AM	11:30AM	Empire B
Sat	310	Cases from Brown University	12:00PM	1:30PM	Empire B
Sat	321	Cases from Mayo Clinic	3:00PM	4:30PM	Empire B
C CORE					
Thu	101	How to Incorporate Test Findings Beyond Perfusion	1:00PM	2:30PM	Chicago
Fri	206	Nuclear Cardiology Lab in 2017	10:30AM	12:00PM	Exhibit Hall B
Sat	305	Cardiac Amyloidosis in 2017	10:30AM	12:00PM	Exhibit Hall B
Sat	316	Patient Centered Myocardial Perfusion Imaging	1:30PM	3:00PM	New York
Sun	404	How Does Radionuclide Imaging Guide Clinical Decision Making?	11:00AM	12:00PM	Atlanta
I INTERNATIONAL					
Fri	225	IAEA Global Initiatives - Part 1	4:00PM	5:00PM	Atlanta
Fri	226	IAEA Global Initiatives - Part 2	5:15PM	6:15PM	Atlanta
LL LIFELONG LEARNING					
Thu	107	ASNC MOC Module 2	7:00PM	9:30PM	New York/Atlanta
MI MULTIMODALITY IMAGING					
Thu	103	CT, PET/CT and PET/MR Imaging to Assess Heart Disease	2:45PM	4:00PM	Chicago
Fri	207	Methods and Value of Cardiotoxicity Assessment in Oncologic Disease	10:30AM	12:00PM	Atlanta
Fri	221	Evaluation of Suspected Coronary Artery Disease in Women	4:00PM	5:30PM	New York
Sun	405	Multimodality Assessment of Complex Cardiovascular Disease	11:00AM	12:00PM	Chicago AB
O OTHER					
Thu	102	Positioning your Nuclear Cardiology Laboratory for Long-term Success - Part 1	1:00PM	2:30PM	Empire BC
Thu	104	Positioning your Nuclear Cardiology Laboratory for Long-term Success - Part 2	2:45PM	4:15PM	Empire BC
Fri	211	Ethics in Nuclear Cardiology: A Focus on Informed Consent	12:15PM	1:15PM	New York
Sat	300	ImageGuide Registry Informational Session	6:30AM	7:45AM	Chicago C
Sat	322	Choosing Wisely Challenge	3:15PM	4:15PM	New York

DAY	SESS#	SESSION TITLE	START	END	ROOM
-----	-------	---------------	-------	-----	------

P PET

Fri	222	How to Establish a Cardiac PET Program	4:00PM	5:30PM	Exhibit Hall B
Sat	306	Imaging in Sarcoidosis (Update on Guidelines)	10:30AM	12:00PM	Atlanta
Sat	317	How to Incorporate PET Myocardial Blood Flow Quantification into Practice	1:30PM	3:00PM	Atlanta
Sat	325	New Directions in Cardiovascular PET	4:00PM	5:30PM	Atlanta

PL PLENARY

Fri	201	Opening Plenary and Verani Lecture	7:45AM	9:30AM	Exhibit Hall B
Fri	215	Multimodality Imaging in the Diagnosis and Management of Heart Failure	1:30PM	3:00PM	Exhibit Hall B
Sat	301	The Emerging Clinical Challenge of Symptomatic Non-obstructive Coronary Artery Disease	7:55AM	9:30AM	Exhibit Hall B
Sun	401	Controversies in Clinical Cardiology and Cardiac Imaging	8:00AM	9:30AM	Atlanta

PP POLICY AND PRACTICE

Thu	105	The Changing Face of Medicare: Considerations in Practice and Payment	4:30PM	6:00PM	Chicago
-----	-----	---	--------	--------	---------

AR ABSTRACTS/RESEARCH

Thu	106	Rapid Fire ePosters: Disease-based - Amyloidosis	6:15PM	7:15PM	Exhibit Hall A
Fri	202a	ePosters: New Developments in Quality and Appropriate Imaging	9:30AM	10:30AM	Exhibit Hall A
Fri	202b	Posters: Advances in PET Imaging	9:30AM	10:30AM	Exhibit Hall A
Fri	218a	ePosters: Advances in PET Imaging	3:00PM	4:00PM	Exhibit Hall A
Fri	218b	Posters: New Techniques in Myocardial Perfusion Imaging	3:00PM	4:00PM	Exhibit Hall A
Sat	302a	ePosters: New Techniques in Myocardial Perfusion Imaging	9:30AM	10:30AM	Exhibit Hall A
Sat	302b	Posters: New Developments in Quality and Appropriate Imaging	9:30AM	10:30AM	Exhibit Hall A
Sat	327	Featured Research Oral Abstracts	4:30PM	5:30PM	New York
Sat	330	Young Investigator Competition	5:45PM	6:45PM	Chicago C

RE READ WITH THE EXPERTS

Fri	208	99mTc-PYP Amyloid Imaging; PET for Inflammation/Infection	10:30AM	12:00PM	Chicago AB
Fri	223	Appropriate Use of Nuclear Stress Imaging	4:00PM	5:30PM	Chicago AB
Sat	307	Imaging for the Detection or Risk Assessment of Stable CAD: Get with the Guidelines	10:30AM	12:00PM	Chicago AB
Sat	318	Viability Assessment (SPECT and PET)	1:30PM	3:00PM	Chicago AB
Sat	326	New Technology in SPECT (Attenuation Correction, CZT)	4:00PM	5:30PM	Chicago AB
Sun	403	PET Perfusion/Myocardial Blood Flow	9:45AM	10:45AM	Chicago AB

T TECHNOLOGY & TECHNIQUES

Fri	209	Not Just Pushing Buttons	10:30AM	12:00PM	Chicago C
Fri	216	Patients are Different - So are Protocols	1:30PM	3:00PM	Chicago C
Fri	224	RWTE for Technologists	4:00PM	5:30PM	Chicago C
Sat	308	Cardiac PET: Focus on Myocardial Perfusion Imaging	10:30AM	12:00PM	Chicago C
Sat	319	Nuclear Cardiology Beyond Plain Myocardial Perfusion Imaging	1:30PM	3:00PM	Chicago C
Sat	328	Multimodality Imaging	4:00PM	5:30PM	Chicago C

ASNC2017 Schedule by Time

TYPE	SESS#	SESSION TITLE	START	END	ROOM
Thursday, September 14, 2017					
C	101	How to Incorporate Test Findings Beyond Perfusion	1:00PM	2:30PM	Chicago
O	102	Positioning your Nuclear Cardiology Laboratory for Long-term Success - Part 1	1:00PM	2:30PM	Empire BC
MI	103	CT, PET/CT and PET/MR Imaging to Assess Heart Disease	2:45PM	4:00PM	Chicago
O	104	Positioning your Nuclear Cardiology Laboratory for Long-term Success - Part 2	2:45PM	4:15PM	Empire BC
PP	105	The Changing Face of Medicare: Considerations in Practice and Payment	4:30PM	6:00PM	Chicago
AR	106	Rapid Fire ePosters: Disease-based - Amyloidosis	6:15PM	7:15PM	Exhibit Hall A
LL	107	ASNC MOC Module 2	7:00PM	9:30PM	New York/Atlanta

Friday, September 15, 2017

PL	201	Opening Plenary and Verani Lecture	7:45AM	9:30AM	Exhibit Hall B
AR	202a	ePosters: New Developments in Quality and Appropriate Imaging	9:30AM	10:30AM	Exhibit Hall A
AR	202b	Posters: Advances in PET Imaging	9:30AM	10:30AM	Exhibit Hall A
CA	203	Cases from the Cleveland Clinic	10:00AM	11:30AM	Empire B
A	205	Imaging to Guide Arrhythmia Management	10:30AM	12:00PM	New York
C	206	Nuclear Cardiology Lab in 2017	10:30AM	12:00PM	Exhibit Hall B
MI	207	Methods and Value of Cardiotoxicity Assessment in Oncologic Disease	10:30AM	12:00PM	Atlanta
RE	208	99mTc-PYP Amyloid Imaging; PET for Inflammation/Infection	10:30AM	12:00PM	Chicago AB
T	209	Not Just Pushing Buttons	10:30AM	12:00PM	Chicago C
CA	210	Cases from St. Luke's Roosevelt/Mt. Sinai	12:00PM	1:30PM	Empire B
O	211	Ethics in Nuclear Cardiology: A Focus on Informed Consent	12:15PM	1:15PM	Chicago AB
PL	215	Multimodality Imaging in the Diagnosis and Management of Heart Failure	1:30PM	3:00PM	Exhibit Hall B
T	216	Patients are Different - So are Protocols	1:30PM	3:00PM	Chicago C
CA	217	Cases from MMP MaineHealth Cardiology	3:00PM	4:30PM	Empire B
AR	218a	ePosters: Advances in PET Imaging	3:00PM	4:00PM	Exhibit Hall A
AR	218b	Posters: New Techniques in Myocardial Perfusion Imaging	3:00PM	4:00PM	Exhibit Hall A
MI	221	Evaluation of Suspected Coronary Artery Disease in Women: A Comparison of the Different Imaging Modalities	4:00PM	5:30PM	New York
P	222	How to Establish a Cardiac PET Program	4:00PM	5:30PM	Exhibit Hall B
RE	223	Appropriate Use of Nuclear Stress Imaging	4:00PM	5:30PM	Chicago AB
T	224	RWTE for Technologists	4:00PM	5:30PM	Chicago C
I	225	IAEA Global Initiatives - Part 1	4:00PM	5:00PM	Atlanta
I	226	IAEA Global Initiatives - Part 2	5:15PM	6:15PM	Atlanta

TYPE	SESS#	SESSION TITLE	START	END	ROOM
------	-------	---------------	-------	-----	------

Saturday, September 17, 2017

O	300	ImageGuide Registry Informational Session	6:30AM	7:45AM	Chicago C
PL	301	The Emerging Clinical Challenge of Symptomatic Non-obstructive Coronary Artery Disease	7:55AM	9:30AM	Exhibit Hall B
AR	302a	ePosters: New Techniques in Myocardial Perfusion Imaging	9:30AM	10:30AM	Exhibit Hall A
AR	302b	Posters: New Developments in Quality and Appropriate Imaging	9:30AM	10:30AM	Exhibit Hall A
CA	303	Cases from Brigham & Women's Hospital	10:00AM	11:30AM	Empire B
A	304	Cutting Edge Technologies	10:30AM	12:00PM	New York
C	305	Cardiac Amyloidosis in 2017	10:30AM	12:00PM	Exhibit Hall B
P	306	Imaging in Sarcoidosis (Update on Guidelines)	10:30AM	12:00PM	Atlanta
RE	307	Imaging for the Detection or Risk Assessment of Stable CAD: Get with the Guidelines	10:30AM	12:00PM	Chicago AB
T	308	Cardiac PET: Focus on Myocardial Perfusion Imaging	10:30AM	12:00PM	Chicago C
CA	310	Cases from Brown University	12:00PM	1:30PM	Empire B
A	315	Debate: Clash of the Titans	1:30PM	3:00PM	Exhibit Hall B
C	316	Patient Centered Myocardial Perfusion Imaging	1:30PM	3:00PM	New York
P	317	How to Incorporate PET Myocardial Blood Flow Quantification into Practice	1:30PM	3:00PM	Atlanta
RE	318	Viability Assessment (SPECT and PET)	1:30PM	3:00PM	Chicago AB
T	319	Nuclear Cardiology Beyond Plain Myocardial Perfusion Imaging	1:30PM	3:00PM	Chicago C
CA	321	Cases from Mayo Clinic	3:00PM	4:30PM	Empire B
O	322	Choosing Wisely Challenge	3:15PM	4:15PM	New York
P	325	New Directions in Cardiovascular PET	4:00PM	5:30PM	Atlanta
RE	326	New Technology in SPECT (Attenuation Correction, CZT)	4:00PM	5:30PM	Chicago AB
AR	327	Featured Research Oral Abstracts	4:30PM	5:30PM	New York
T	328	Multimodality Imaging	4:00PM	5:30PM	Chicago C
AR	330	Young Investigator Competition	5:45PM	6:45PM	Chicago C

Sunday, September 17, 2017

PL	401	Controversies in Clinical Cardiology and Cardiac Imaging	8:00AM	9:30AM	Atlanta
A	402	Approach to Known or Potential Ischemic Heart Disease	9:45AM	10:45AM	Atlanta
RE	403	PET Perfusion/Myocardial Blood Flow	9:45AM	10:45AM	Chicago AB
C	404	How Does Radionuclide Imaging Guide Clinical Decision Making?	11:00AM	12:00PM	Atlanta
MI	405	Multimodality Assessment of Complex Cardiovascular Disease	11:00AM	12:00PM	Chicago AB

ASNC Organized Ancillary Sessions

SATURDAY, SEPTEMBER 16

Saturday, 6:30AM – 7:45AM | Chicago C

ImageGuide Registry Informational Session & Discussion

Join us for an informational session on the latest updates for the ImageGuide Registry and how it can be used to improve quality, demonstrate value, and fulfill requirements under The Merit-based Incentive Payment System (MIPS).

FACULTY: Peter Tilkemeier, MD, FASNC
Georgia Lawrence
Joe Reyes
Emmett Chapital, MD, MBBS, FASNC

Saturday, 3:15PM – 4:15PM | New York

Vote for the Winner of the Nuclear Cardiology Choosing Wisely® Challenge

Come listen to live presentations of the three finalists from ASNC's Choosing Wisely® Challenge. Audience voting will combine with a judging panel to select the top prize winner!

■ **Minimizing Radiation Exposure from Myocardial Perfusion Imaging**

Debra Mahlum, CNMT; Maureen Van der Kooy, CNMT; Steven Port, MD

■ **A Simplified Approach to Stress-first Nuclear Myocardial Perfusion Imaging: Implementation of ASNC Choosing Wisely Recommendations**

Randy Jeffrey MD, David E. Winchester MD, FASNC, David C. Wymer MD, Vicente Taasan MD

■ **Advanced Protocol Planning in Nuclear Cardiology to Enhance Care Delivery**

Sarah Cuddy, MB, BCh, BAO, Yin Ge, MD, Ron Blankstein, MD, FASNC, Marcelo DiCarli, MD, Sharmila Dorbala, MD, MPH, FASNC

FACULTY: Raymond R. Russell, III, MD, PhD, FASNC

JUDGES: Renee Bullock-Palmer, MD, FASNC
Maria G. Sciammarella, MD

This activity is supported by Bracco Diagnostics Inc.